

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019335006 B2**

(54) Title
Dengue vaccine unit dose and administration thereof

(51) International Patent Classification(s)
A61K 39/295 (2006.01) **A61K 39/125** (2006.01)
A61K 39/00 (2006.01) **A61K 39/29** (2006.01)
A61K 39/12 (2006.01)

(21) Application No: **2019335006** (22) Date of Filing: **2019.09.05**

(87) WIPO No: **WO20/051334**

(30) Priority Data

(31) Number	(32) Date	(33) Country
18192701.3	2018.09.05	EP
18192711.2	2018.09.05	EP
18192717.9	2018.09.05	EP
18192776.5	2018.09.05	EP
18192787.2	2018.09.05	EP
18192793.0	2018.09.05	EP
18192800.3	2018.09.05	EP
18192814.4	2018.09.05	EP
19154334.7	2019.01.29	EP
19161184.7	2019.03.07	EP
16/295,611	2019.03.07	US

(43) Publication Date: **2020.03.12**

(44) Accepted Journal Date: **2024.07.04**

(71) Applicant(s)
Takeda Vaccines, Inc.

(72) Inventor(s)
WALLACE, Derek;LEFEVRE, Inge

(74) Agent / Attorney
WRAYS PTY LTD, L7 863 Hay St, Perth, WA, 6000, AU

(56) Related Art
JORGE E OSORIO ET AL: LANCET INFECTIOUS DISEASES, vol. 14, no. 9, 1 September 2014 (2014-09-01), US, pages 830 - 838,
SARAH L. GEORGE ET AL: JOURNAL OF INFECTIOUS DISEASES. JID, vol. 212, no. 7, 19 March 2015 (2015-03-19), US, pages 1032 - 1041,
RICHARD RUPP ET AL: VACCINE, vol. 33, no. 46, 1 November 2015 (2015-11-01), AMSTERDAM, NL, pages 6351 - 6359,



(51) International Patent Classification:

A61K 39/295 (2006.01) A61K 39/125 (2006.01)

A61K 39/12 (2006.01) A61K 39/29 (2006.01)

A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2019/049749

(22) International Filing Date:

05 September 2019 (05.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18192701.3 05 September 2018 (05.09.2018) EP

18192711.2 05 September 2018 (05.09.2018) EP

18192717.9 05 September 2018 (05.09.2018) EP

18192776.5 05 September 2018 (05.09.2018) EP

18192787.2 05 September 2018 (05.09.2018) EP

18192793.0 05 September 2018 (05.09.2018) EP

18192800.3 05 September 2018 (05.09.2018) EP

18192814.4 05 September 2018 (05.09.2018) EP

19154334.7 29 January 2019 (29.01.2019) EP

19161184.7 07 March 2019 (07.03.2019) EP

16/295,611 07 March 2019 (07.03.2019) US

(71) Applicant: TAKEDA VACCINES, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: WALLACE, Derek; 20 Adams Street, Brookline, MA 02446 (US). LEFEVRE, Inge; Geissacher 6A, 8126 Zumikon (CH).

(74) Agent: GOLDBERG, Joshua, B.; Nath, Goldberg & Meyer, 112 S. West Street, Alexandria, VA 22314 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF




Figure 1

(57) Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF**FIELD OF THE INVENTION**

[0001] The present invention relates to a safe and effective method of inoculation against dengue disease and a corresponding safe and effective dengue vaccine. In particular the present invention relates to a safe and effective method of inoculation against dengue disease irrespective of serostatus and a corresponding safe and effective dengue vaccine. The present invention relates also to unit doses of a dengue vaccine composition and methods for administering a unit dose of a dengue vaccine composition to a subject or a subject population in a broad age group. The present invention is also related to particular concomitant administration regimes, wherein the unit dose/vaccine composition is administered concomitantly with one or more of: a yellow fever (YF) vaccine, a hepatitis A vaccine, a human papillomavirus (HPV) vaccine, a combined measles, mumps and rubella (MMR) vaccine, a combined tetanus, diphtheria, and pertussis (whooping cough) (Tdap) vaccine, and/or a combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis and *Haemophilus influenzae* type b (DTap/IPV/Hib), or any combination of the concomitant administration regimes mentioned above. The unit dose according to this invention provides immune responses against all serotypes of dengue virus, i.e. DENV-1, DENV-2, DENV-3 and DENV-4.

BACKGROUND OF THE INVENTION

[0002] Vaccines for protection against viral infections have been effectively used to reduce the incidence of human disease. One of the most successful technologies for viral vaccines is to immunize animals or humans with a weakened or attenuated virus strain (a "live attenuated virus"). Due to limited replication after immunization, the attenuated virus strain does not cause disease. However, the limited viral replication is sufficient to express the full repertoire of viral antigens and can generate potent and long-lasting immune responses to the virus. Thus, upon subsequent exposure to a pathogenic virus strain, the immunized individual is protected from the disease. These live attenuated viral vaccines are among the most successful vaccines used in public health.

[0003] Dengue disease is a mosquito-borne disease caused by infection with a dengue virus. Dengue virus infections can lead to debilitating and painful symptoms, including a sudden high fever, headaches, joint and muscle pain, nausea, vomiting and skin rashes. To date, four serotypes of dengue virus have been identified: dengue-1 (DENV-1), dengue-2 (DENV-2), dengue-3 (DENV-3) and dengue-4 (DENV-4). Dengue virus serotypes 1-4 can also cause dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). In the most severe cases, DHF and DSS can be life threatening. Dengue viruses cause 50-100 million cases of debilitating dengue fever, 500,000 cases of DHF/DSS, and more than 20,000 deaths each year, a large portion of which are children. All four dengue virus serotypes are endemic throughout the tropical regions of the world and constitute the most significant mosquito-borne viral threat to humans there. Dengue viruses are transmitted to humans primarily by *Aedes aegypti* mosquitoes, but also by *Aedes albopictus* mosquitoes. Infection with one dengue virus serotype results in life-long protection from re-infection by that serotype, but does not prevent secondary infection by one of the other three dengue virus serotypes. In fact, previous infection with one dengue virus serotype may lead to an increased risk of severe disease (DHF/DSS) upon secondary infection with a different serotype.

[0004] To date, only one vaccine, a tetravalent dengue vaccine based on a yellow fever backbone, CYD-TDV (Dengvaxia®, Sanofi Pasteur, Lyon, France), has been licensed in several countries based on the clinical demonstration of an overall vaccine efficacy (VE) against virologically-confirmed dengue (VCD) of 56–61% in children in Asia and Latin America (Capeding MR et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children

in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet* 2014, 384:1358-65; Villar LA et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. *Pediatr Infect Dis J* 2013, 32:1102-9). However, clinical trials have shown that Dengvaxia® can enhance, rather than reduce, the risk of severe disease due to dengue infection in individuals who had not been previously infected by a dengue virus (seronegative populations). Therefore, Dengvaxia® is only recommended for use in individuals who had been previously infected with at least one dengue virus serotype (seropositive populations). More specifically, according to the European Medicine Agency's European Public Assessment report (EPAR) for the product, Dengvaxia® is only for use in people from 9 to 45 years of age who have been infected with dengue virus before and who live in areas where this infection is endemic. Endemic areas are areas where the disease occurs regularly throughout the year. See also Sridhar S et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. *N Engl J Med* 2018, 379:327-40; and World Health Organization. Dengue vaccine: WHO position paper – September 2018. *Wkly. Epidemiol. Rec.* 2018, 93:457-476. S.R. Hadinegoro et al. report in the *New England Journal of Medicine*, Vol. 373, page 1195, in "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease" a pooled risk of hospitalization for virologically-confirmed dengue disease among those under the age of 9 years of 1.58 indicating an increased risk for the vaccinated group with respect to severe dengue. This leaves a substantial unmet need for an effective vaccine with a good safety profile in both dengue-naïve and seropositive individuals, including those dengue-naïve populations living in endemic areas, younger individuals who may not have developed any seropositive response to dengue or been exposed to dengue, and travelers and individuals from non-endemic regions. There is also a need for outbreak control or travel vaccination, offering a reduction in the risk of dengue after only one dose.

[0005] One further disadvantage of the only currently approved dengue vaccine, Dengvaxia®, is that it must only be given to people who have had a positive test result showing a previous infection with dengue virus (EPAR), i.e. individuals with known serostatus for dengue. Thus, individuals with unknown serostatus for dengue cannot be vaccinated with Dengvaxia®.

[0006] There is hence a need for a dengue vaccine and corresponding method of inoculation that stimulates an immune response to all dengue serotypes, preferably a balanced immune response to all serotypes, and protects against dengue disease of any severity (including DSS, DHF), both in seronegative and seropositive populations, which is safe for a larger group of ages, in particular also for subjects of 9 years and younger. The development of a safe and effective vaccine capable of protecting all populations, including both seronegative and seropositive populations, and in particular children and young adults and elderly subjects in endemic settings and for the purpose of traveling, represents an important approach to the prevention and control of this global disease.

[0007] There is thus a medical need for a dengue vaccine and corresponding method of inoculation which, as well as being safe and efficacious irrespective of serostatus and in a broad age group. There is a need for a dengue vaccine and corresponding method of inoculation that avoids costly and time consuming serostatus tests or seroprevalence considerations. There is a need for a dengue vaccine and corresponding method of inoculation that can be used in an outbreak situation. Furthermore there is a medical need for a dengue vaccine which as well as being safe and effective can also be administered to individuals with unknown dengue serostatus, children under 9 years and seronegative individuals.

[0008] There is also a need for a vaccine that is administered in fewer doses than the current Dengvaxia® dosing schedule of 3 doses, 6 months apart, such as a vaccine that can be administered in only two doses or one dose to be efficacious.

[0009] The above objects are commensurate with the research priorities provided by the WHO in the Dengue Vaccine: WHO position paper – September 2018 (Wkly. Epidemiol. Rec. 2018, 93:457-476).

[0010] Yellow fever (YF) is an acute viral hemorrhagic disease transmitted by infected mosquitoes of the *Aedes aegypti* specie. Symptoms of yellow fever take 3 to 6 days to develop and include fever, headache, jaundice, muscle pain, nausea, vomiting and fatigue. A small proportion of patients (about 15% of people) who contract the virus develop a severe disease that can lead to bleeding, shock, organ failure, and sometimes death. The virus is endemic in tropical areas of Africa and Central and South America.

[0011] Dengue fever and yellow fever (YF) viruses belong to the same family of flaviviridae and share antigenic determinants, which may result in cross-reacting antibodies. They are both transmitted between humans by mosquitoes (primarily *Aedes aegypti*), and are both endemic in tropical areas of Africa and Latin America with a high public health impact.

[0012] Today there exists a yellow fever vaccine (YF-17D vaccine) which is based on a live, attenuated viral strain, and is the only commercially available YF vaccine administered as a single subcutaneous injection. The YF-17D vaccine is highly effective (approaching 100%) and generally safe with the exception of very rare cases of vaccine-associated neurotropic and viscerotropic disease. Vaccination against YF is also required for travelers to certain countries in accordance with the International Health Regulations, and is also recommended by the WHO for all subjects travelling to areas where there is evidence of persistent or periodic YF virus transmission. A YF-17D vaccine is available under the product name YF-VAX® from Sanofi.

[0013] A yellow fever vaccine is recommended for people from nine months of age and older who are living in or traveling to endemic areas, persons travelling to or through countries requiring. A single dose of yellow fever vaccine administered subcutaneously is usually sufficient to confer sustained lifelong protective immunity against yellow fever. However, for people who remain at risk, a booster dose is recommended every 10 years.

[0014] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and yellow fever.

[0015] Hepatitis A is a liver disease caused by the hepatitis A virus (HAV). The virus is primarily spread when an uninfected (and unvaccinated) person ingests food or water that is contaminated with the feces of an infected person. The disease is closely associated with unsafe water or food, inadequate sanitation and poor personal hygiene. The virus can also be transmitted through close physical contact with an infectious person. Unlike hepatitis B and C, hepatitis A infection does not cause chronic liver disease and is rarely fatal, but it can cause debilitating symptoms and fulminant hepatitis (acute liver failure), which is often fatal. Hepatitis A occurs sporadically and in epidemics worldwide, with a tendency for cyclic recurrences.

[0016] The hepatitis A virus is one of the most frequent causes of foodborne infection. Epidemics related to contaminated food or water can erupt explosively, such as the epidemic in Shanghai in 1988 that affected about 300,000 people. Hepatitis A viruses persist in the environment and can withstand food-production processes routinely used to inactivate and/or control bacterial pathogens. The disease can lead to significant economic and social consequences in communities. It can take weeks or months for people recovering from the illness to return to work, school, or daily life. The impact on food establishments identified with the virus, and local productivity in general, can be substantial. In developing countries with poor sanitary conditions and hygienic practices, most children (90%) have been infected with the hepatitis A virus before the age of 10 years.

[0017] The number of people traveling internationally has grown substantially in recent decades. According to the United Nations World Tourism Organization (UNWTO), over 1.1 billion tourists travelled abroad in 2014. The risk of becoming ill during international travel depends on many factors, such as the region of the world visited, the length of the trip, and the diversity of planned activities. Vaccine recommendations are a prominent part of health preparations before international travel. Vaccination against hepatitis A virus is commonly recommended for travelers to at-risk areas around the world including Asia, Africa, and Latin America.

[0018] For routine hepatitis A vaccination, a two-dose schedule is recommended, particularly in travelers at substantial risk of contracting hepatitis A and in immunocompromised individuals. However, in healthy individuals, comparable effectiveness has been achieved with a single dose. The vaccination schedule for children/adolescents (12 months through 18 years of age) as well as for adults (≥ 19 years of age) consists of a primary dose administered intramuscularly, and a further booster dose administered intramuscularly 6 to 18 months later.

[0019] Available hepatitis A vaccines include HAVRIX® and VAQTA®.

[0020] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and hepatitis A.

[0021] Human papillomavirus (HPV) is a common virus that is passed from one person to another through direct skin-to-skin contact during sexual activity. Most sexually active people will be infected with HPV at some time in their lives and the infection is most common in people in their late teens and early 20s. There are about 40 types of HPV that can infect the genital areas of men and women. While most HPV types cause no symptoms and are cleared by the body's immune system, some HPV types are persistent and can cause cervical cancer in women and other less common cancers - like cancers of the anus, penis, vagina, vulva and oropharynx or warts in the genital areas of men and women, called genital warts.

[0022] HPV vaccination prevents HPV-associated cervical cancers as well as HPV-associated cancers of the anus, vulva, vagina, and oropharynx. The vaccination can also prevent HPV-associated genital warts. HPV vaccination is recommended in particular for 11 and 12 year-old girls. It is also recommended for girls and women age 13 through 26 years of age who have not yet been vaccinated or completed the vaccine series. HPV vaccine can also be given to girls beginning at age 9 years. The CDC recommends 11 to 12 year olds girls get two doses of HPV vaccine to protect against cancers caused by HPV. More recently, vaccination of boys in the same age ranges has also been recommended.

[0023] The routine HPV vaccination schedule for adolescents who start the vaccination series before the 15th birthday includes two doses of a HPV vaccine. The two doses are usually separated by 6 to 12 months. The minimum interval between doses is five calendar months. A three dose schedule is recommended for subjects who start the series on or after the 15th birthday and for subjects with certain immunocompromising conditions (such as cancer, HIV infection, or taking immunosuppressive drugs). The second dose is usually given 1 to 2 months after the first dose and the third dose 6 months after the first dose. The minimum interval between the first and second doses of vaccine is usually 4 weeks. The minimum interval between the second and third doses of vaccine is usually 12 weeks. The minimum interval between the first and third doses is usually 5 calendar months. If the vaccination series is interrupted, the series does not need to be restarted.

[0024] Available HPV vaccines include Gardasil® 9, which is a recombinant 9-valent HPV (9vHPV) vaccine for preventing HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. The HPV vaccine does not include any live or inactivated HPV, but the L1 proteins of the respective HPV serotypes.

[0025] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and HPV-associated cancers or genital warts.

[0026] Measles is a highly contagious infectious disease caused by the measles virus, a single-stranded, negative-sense, enveloped (non-segmented) RNA virus of the genus *Morbillivirus* within the family *Paramyxoviridae*.

Complications occur in about 30% of cases and may include diarrhea, blindness, inflammation of the brain, and pneumonia, among others. Encephalitis occurs in approximately one of every 2000 reported cases; survivors often have permanent brain damage and mental retardation. Death, predominantly from respiratory and neurological causes, occurs in one of every 3000 reported measles cases. The risk of death is greater for infants and adults than for children and adolescents. Contracting measles during pregnancy increases fetal risk. Most commonly, this risk involves premature labor and moderately increases rates of spontaneous abortion and of low birth weight. Subacute sclerosing panencephalitis, a slow virus infection of the central nervous system, is associated with measles virus. Measles is an airborne disease which spreads easily through the coughs and sneezes of infected people and may also be spread through contact with saliva or nasal secretions.

[0027] Mumps is an acute disease of children and young adults, caused by the mumps virus, a single-stranded, negative-sense RNA virus of the genus *Rubulavirus* within the family *Paramyxoviridae*. Mumps virus produces no symptoms in about one-third of infected people. In those with a clinical response, glandular and nerve tissue are most often affected and the most common symptoms include fever and swelling of the parotid glands. Complications may include meningitis (15%), pancreatitis (4%), inflammation of the heart, or permanent deafness. Frequent viruria and abnormal renal function suggest that mumps virus may infect the kidneys. Mumps is highly contagious and spreads rapidly among people living closely together by respiratory droplets or direct contact with an infected person.

[0028] Rubella (German measles) is an infection caused by the rubella virus, a single-stranded, positive-sense RNA virus of the genus *Rubivirus* within the family *Togaviridae*. The virus usually results in a mild illness, accompanied by few constitutional symptoms, and occurs most commonly in childhood. If the infection occurs in a woman in early pregnancy however, the virus may cross the placenta to reach the fetus, in which the infection can induce birth defects. These defects may be serious and permanent and include congenital heart disease, cataract formation, deafness and mental retardation. Rubella is usually spread through the air via coughs of people who are infected.

[0029] Combined vaccine for measles, mumps and rubella (MMR) is used widely for the immunization of children in certain regions of the world, because of its advantages over the individual vaccines. Combined vaccine provokes an adequate immune response in children simultaneously for the three infections.

[0030] MMR vaccines are indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older. Individuals first vaccinated at 12 months of age or older should be revaccinated prior to elementary school entry. Revaccination is intended to seroconvert those who do not respond to the first dose. The Advisory Committee on Immunization Practices (ACIP) recommends administration of the first dose at 12 to 15 months of age and administration of the second dose at 4 to 6 years of age.

[0031] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and measles, mumps and rubella.

[0032] Tetanus is caused by an infection with the bacterium *Clostridium tetani* which is commonly found in soil, saliva, dust, and manure. The bacteria generally enter the body through a break in the skin such as a cut or puncture wound by a contaminated object. The bacteria produce toxins that interfere with muscle contractions, resulting in the

typical signs of muscle spasms. It affects the brain and nervous system and causes extremely painful muscle spasms, usually all over the body. Spasms of the jaw can make it impossible to open the mouth, a condition called "lockjaw." Tetanus kills one out of ten people infected with the disease.

[0033] Diphtheria is an infection caused by the bacterium *Corynebacterium diphtheriae* which primarily infects the throat and upper airways, and produces a toxin affecting other organs. Diphtheria has an acute onset and the main characteristics are sore throat, low fever and swollen glands in the neck. The toxin may, in severe cases, cause myocarditis or peripheral neuropathy. The diphtheria toxin causes a membrane of dead tissue to build up over the throat and tonsils, making breathing and swallowing difficult. Diphtheria is a very contagious infection and the bacteria usually spread between people by direct contact or through the air, but it may also be spread by contaminated objects.

[0034] Pertussis, or whooping cough, caused by the bacterium *Bordetella pertussis* is an airborne disease that results in an extremely contagious respiratory infection that can lead to severe breathing problems, especially in infants. Pertussis first appears like an ordinary cold, but then causes intense, uncontrollable coughing spells which can cause difficulty breathing, vomiting, and disturbed sleep. A person may cough so hard that they vomit, break ribs, or become very tired from the effort. Children less than one year old may have little or no cough and instead have periods where they do not breathe. A high-pitched "whoop" noise is heard when the person tries to take a breath after coughing. Complications include pneumonia or death. Pertussis can affect people of all ages, but can be very serious and even deadly, for babies less than a year old.

[0035] Tdap is a combination vaccine that protects against the three potentially life-threatening bacterial diseases tetanus, diphtheria, and pertussis (whooping cough). Tdap stands for tetanus and diphtheria toxoids with acellular pertussis. Tdap is an inactive vaccine produced by using dead bacteria. It is recommended that vaccination against tetanus, diphtheria and pertussis carried out in infancy (in children of less than 7 years of age) is done by using a particular diphtheria toxoid, tetanus toxoid and acellular pertussis absorbed vaccine, such as INFANRIX® from GlaxoSmithKline. A further booster Tdap vaccine is recommended for children of greater than 10 years to ensure that immunity against tetanus, diphtheria and pertussis is maintained into adulthood. A booster Tdap vaccine based on combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) is available under the brand name BOOSTRIX® from GlaxoSmithKline. Tdap vaccination is administered intramuscularly as a single dose.

[0036] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and tetanus, diphtheria, and pertussis.

[0037] In addition to diphtheria, tetanus and pertussis, poliomyelitis, often called polio or infantile paralysis, is a highly infectious viral disease caused by the poliovirus. It invades the nervous system, and can cause total paralysis in a matter of hours. The virus is transmitted by person-to-person spread mainly through the fecal-oral route or, less frequently, by a common vehicle (for example, contaminated water or food) and multiplies in the intestine. Initial symptoms are fever, fatigue, headache, vomiting, stiffness of the neck and pain in the limbs. 1 in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralyzed, 5% to 10% die when their breathing muscles become immobilized. Polio mainly affects children under 5 years of age. There is no cure for polio, it can only be prevented.

[0038] *Haemophilus influenzae* type b (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in children aged less than 5 years. It is transmitted through the respiratory tract from infected to susceptible individuals. Hib also causes potentially severe inflammatory infections of the face, mouth, blood, epiglottis, joints, heart, bones, peritoneum, and trachea. Although this problem occurs worldwide the burden of

Hib disease was considerably higher in resource-poor countries, prior to the introduction of the vaccine into their national immunization programs. In 2000, Hib was estimated to have caused two to three million cases of serious disease, notably pneumonia and meningitis, and 386,000 deaths in young children. Hib disease is observed in all parts of the world but is difficult to confirm because it requires prompt laboratory investigation in patients that have not received prior antibiotic treatment.

[0039] Commercially available combined DTaP/IPV/Hib vaccines include Pentacel®, which is based on combined diphtheria toxoid, tetanus toxoid, acellular pertussis (adsorbed), and inactivated poliovirus in combination with a Hib conjugate vaccine.

[0040] Hence, there is a need for a safe and effective method of simultaneously preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b.

[0041] Furthermore, it has been reported that elderly subjects infected with dengue virus often present atypically, wherein fever may be the only symptom and are less likely to present with typical symptoms and signs of dengue fever which may be defined as fever plus at least one of the following symptoms: bone pain, myalgia, arthralgia, retro-orbital pain, headache and maculopapular rash (Lee et al. (2013) Am. J. Emerg. Med. 31(5): 783-787). Yet, elderly adults are at increased risk of developing severe dengue and DHF/DSS compared to younger subjects (Liu et al. (2008) Am. J. Infect. Dis. 4(1): 10-17; Lin et al. (2012) Emerg. Infect. Dis. 18(10): 2003-1009; Rowe et al. (2014) PloS Negl. Trop. Dis. 8(4)). Several reasons which may contribute to severe disease in the elderly have been discussed, such as impaired physiological and immune functions, an increased probability of acquiring secondary dengue and an increased prevalence of chronic diseases and other comorbidities in the elderly, i.e. above 60 (see the discussion in Lin et al. (2017) Expert Review of Anti-infective Therapy 15(8): 729-735).

OBJECTS AND SUMMARY

[0042] It is an object of the present invention to provide a safe and effective vaccine and corresponding method of inoculation against all serotypes of dengue virus for dengue-endemic and dengue non-endemic populations and for a broad range of ages, in particular for subjects between 2 months and 60 years of age, and independent of previous exposure to dengue virus and corresponding seropositive or seronegative status before vaccination.

[0043] It is an object of the present invention to minimize the risk of DHF and DSS caused by infection with DENV-1, DENV-2, DENV-3 or DENV-4, in particular following vaccination in children of young age and individuals of any age who have never been previously exposed to dengue, or who are seronegative to dengue before vaccination.

[0044] It is an object of the invention to provide a vaccine and corresponding method of inoculating for controlling a dengue outbreak situation.

[0045] It is an object of the invention to provide a vaccine and corresponding method of inoculating which is useful in settings less familiar with clinical management of dengue or in those with fewer resources.

[0046] It is an object of the invention to provide a vaccine and corresponding method of inoculating which avoids testing for individual serostatus before individual inoculation or analysis of seroprevalence rates in areas to be mass vaccinated.

[0047] It is an object of the invention to provide a vaccine and corresponding method of inoculating which reduces and/or avoids the risk for later antibody dependent enhancement.

[0048] It is an object of the invention to provide a vaccine and corresponding method which reduces and/or avoids dengue NS1 toxicosis.

[0049] It is an object of the invention to provide a vaccine and corresponding method of inoculating which induces cross reactive multitypic antibody and/or cell mediated immunity.

5 **[0050]** It is one object of the present invention to provide a safe and effective protection against dengue disease and yellow fever.

[0051] It is another object of the present invention to provide a safe and effective protection against dengue disease and hepatitis A.

10 **[0052]** It is a further object of the present invention to provide a safe and effective protection against dengue disease and HPV-associated cancers or genital warts.

[0053] It is a certain object of the present invention to provide a safe and effective protection against dengue disease and measles, mumps and rubella.

[0054] It is another object of the present invention to provide safe and effective protection against dengue disease and tetanus, diphtheria, and pertussis.

15 **[0055]** It is another object of the present invention to provide a safe and effective protection against dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b.

[0056] It is another object of the present invention to provide safe and effective protection against any combination of the above mentioned diseases.

20 **[0057]** It is another object of the present invention to provide a vaccine which stimulates a balanced immune response to all four dengue serotypes in a subject, in particular in an elderly subject (i.e. more than 60 years of age).

[0058] The present invention is therefore directed in part to a dengue vaccine for a method of mass vaccination without individual testing for serostatus or prior evaluation of seroprevalence rates. This mass vaccination includes endemic regions including outbreak situations as well as in non-endemic regions for travelers.

25 **[0059]** The present invention is therefore directed to a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, wherein preferably the tetravalent dengue virus composition includes a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain, wherein preferably the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 (represented by SEQ ID NO 11) and differs in at least three nucleotides from the wild type as follows:

- 30 a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
 b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
 c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

the three chimeric dengue strains being derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the
 35 following chimeric dengue strains:

- a DENV-2/1 chimera,

- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[0060] The present invention is in particular directed to a composition or lyophilized unit dose which upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- 5 (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[0060a] The present invention is also directed to a unit dose of a dengue vaccine composition comprising:

a tetravalent virus composition including four live attenuated dengue virus serotypes wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- 15 (i) a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a chimeric dengue serotype 2/3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- 20 (iv) a chimeric dengue serotype 2/4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml, wherein

upon said reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii) and (iv) provide a total concentration of pfu/0.5 ml and based on said total concentration of pfu/0.5 ml

- the concentration of (i) in pfu/0.5 ml is at least 1%,
- the concentration of (ii) in pfu/0.5 ml is less than 10%,
- 25 the concentration of (iii) in pfu/0.5 ml is at least 10%, and
- the concentration of (iv) in pfu/0.5 ml is at least 50%,

wherein the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 and differs in at least three nucleotides from the wild type as follows:

- 30 a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
- b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
- c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- 35 - a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[0061] The present invention is also in particular directed to such a composition or unit dose which upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of

pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or preferably at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%.

5 **[0062a]** The present invention is also directed to a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4 when used in a method of preventing dengue disease in a subject 4 to 16 years of age wherein the method comprises a primary vaccination with only two administrations of a unit dose comprising the steps of:

10 administering a first unit dose of the tetravalent dengue virus composition to the subject, and administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose, wherein the tetravalent dengue virus composition is in the form of a lyophilised unit dose which upon reconstitution with 0.5 ml of a pharmaceutically acceptable diluent comprises:

- 15 (i) a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
 (ii) a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
 (iii) a chimeric dengue serotype 2/3 strain, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
 20 (iv) a chimeric dengue serotype 2/4 strain, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml, wherein

upon said reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii) and (iv) provide a total concentration of pfu/0.5 ml and based on said total concentration of pfu/0.5 ml

- 25 the concentration of (i) in pfu/0.5 ml is at least 1%,
 the concentration of (ii) in pfu/0.5 ml is less than 10%,
 the concentration of (iii) in pfu/0.5 ml is at least 10%, and
 the concentration of (iv) in pfu/0.5 ml is at least 50%,

and

30 wherein the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 and differs in at least three nucleotides from the wild type as follows:

- a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
 b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
 c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

35 wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[0062] The present invention is also in particular directed to such method and use wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%.

[0063] The present invention is therefore directed to a method including and corresponding use of a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, the method being directed to inoculating a subject against virologically confirmable dengue disease, wherein in particular the tetravalent dengue virus composition includes a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain, wherein in particular the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 (represented by SEQ ID NO 11) and differs in at least three nucleotides from the wild type as follows:

d) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)

e) NS1-53 Gly-to-Asp (nt-2579 G-to-A)

f) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

the three chimeric dengue strains being derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[0064] The present invention is in particular directed to such method and use wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[Text continued on page 10]

[0065] The present invention is also in particular directed to such method and use wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%, and wherein the subject is preferably 2 to 17 years of age or 4 to 16 years of age.

[0066] The present invention is also in particular directed to such method and use wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%, wherein the subject is 18 to 60 years of age.

[0067] The present invention is therefore directed to a method and corresponding use, the method comprising a primary vaccination with only two administrations of the unit dose comprising the steps of:

- (A) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (B) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose,

wherein preferably the method and use do not include a step of determination whether there was a previous dengue infection in the subject before administration of the unit dose or wherein the serostatus of the subject is unknown before administration of the unit dose or wherein the method and use do not include a step of determination of a previous dengue infection in the subjects preferably at any time before, during or after the steps of administration or wherein the serostatus of the subject is unknown preferably at any time before, during or after the steps of administration.

[0068] According to one embodiment such a method and use do not include the active surveillance with respect to febrile illness of the subject after the administration of the first- and second-unit dose. During active surveillance any subject with febrile illness (defined as fever $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days) will be asked to return to the site for dengue fever evaluation by the Investigator. Subjects/guardians will be contacted at least weekly to ensure robust identification of febrile illness by reminding subjects/guardians of their obligation to return to the site in case of febrile illness. This contact will be implemented through appropriate methods that may differ in each trial site (eg, phone calls, text messaging, home visits, school-based surveillance).

[0069] According to one embodiment such a method and use do not include vaccine immunogenicity analysis including GMTs for dengue neutralizing antibodies.

[0070] According to one embodiment such a method and use do not include a reactogenicity analysis. Such a reactogenicity analysis relates to solicited local AEs (injection site pain, injection site erythema, and injection site swelling) and solicited systemic AEs (child < 6 years: fever, irritability/fussiness, drowsiness and loss of appetite; child ≥ 6 years: asthenia, fever, headache, malaise and myalgia) which will e.g. be assessed for 7 days and 14 days, respectively, following each vaccination (vaccination day included) via collection of diary cards.

[0071] The method according to the invention does not require the testing of the serostatus before vaccination and thus allows immediate treatment and outbreak control. According to certain embodiments the invention is directed to a method and use wherein the subject is exposed to a dengue outbreak. In certain such embodiments the outbreak is due to a dengue serotype 2, and/or due to a serotype 1.

[0072] According to certain embodiments the method of inoculation against the virologically confirmable dengue disease is due to a dengue serotype 2, and/or due to a dengue serotype 1.

- 5 **[0073]** According to one embodiment the method comprises a primary vaccination consisting of the steps of:
- (A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination of a previous dengue infection, and
 - (B) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
 - (C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months
- 10 of administration of the first unit dose.

Therefore the method of inoculating is finalized without determination of a previous dengue infection. The method further optionally comprises at least 1 years after the administration of the second unit dose a booster dose of the unit dose.

- 15 **[0074]** According to one embodiment the method and use is directed to a method of inoculating a subject against virologically confirmable dengue disease with a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, the dengue serotype 2 strain being derived from the wild type virus strain DEN-2 16681 (represented by SEQ ID NO 11) and differing in at least three nucleotides from the wild type as follows:

- 20 a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
 b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
 c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

the three chimeric dengue strains being derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the

- 25 following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera,

the method comprises a primary vaccination consisting of the steps of:

- 30 (A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination whether there was a previous dengue infection, and
- (B) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months
- 35 of administration of the first unit dose.

Therefore the method of inoculating is finalized without determination of a previous dengue infection. The method further optionally comprises at least 1 years after the administration of the second unit dose a booster dose of the unit dose.

- 40 **[0075]** According to the invention the method and use is applicable to subjects of all kinds of ages. The present invention is in particular directed to such a method and use wherein the subject is under 9 years of age, or 4 to 5 years of age, or 6 to 11 years of age, or 12 to 16 years, or 6 to 16 years of age, or 4 to 16 years of age, or 2 to 17 years of age, or 9 years of age, or over 9 years of age, or 9 to 17 years of age, or 18 to 60 years of age, or 18 to 45 years of age, or 46 to 60 years of age, or over 60 years of age.

[0076] In particular the present invention is directed to such use wherein the method is safe.

[0077] In particular the present invention is directed to such use wherein the method provides a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline from first administration of the administration schedule until 12 to 18 months after the last administration of the administration schedule.

[0078] In particular the present invention is directed to such use wherein the method is effective.

[0079] In particular the present invention is directed to such use wherein the method provides a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 14 to 16 years of age, from the first administration of the administration schedule until 18 months after the last administration of the administration schedule.

[0080] The present invention is also directed in part to a reconstituted dengue vaccine composition for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, wherein the dengue vaccine composition is a tetravalent dengue virus composition including four dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, optionally wherein the dengue virus strains are live, attenuated, and wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

- (i) dengue serotype 1 has a concentration of at least 3.3 log₁₀ pfu/0.5 mL and optionally to 5.0 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of at least 2.7 log₁₀ pfu/0.5 mL and optionally to 4.9 log₁₀ pfu/0.5 mL,
- (iii) dengue serotype 3 has a concentration of at least 4.0 log₁₀ pfu/0.5 mL and optionally to 5.7 log₁₀ pfu/0.5 mL,
- and
- (iv) dengue serotype 4 has a concentration of at least 4.5 log₁₀ pfu/0.5 mL and optionally to 6.2 log₁₀ pfu/0.5 mL.

[0081] The present invention is therefore directed in part to a dengue vaccine composition for use in a method of preventing virologically confirmable dengue disease (VCD) in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, and wherein the dengue vaccine composition is a tetravalent dengue virus composition including four live, attenuated dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, wherein the attenuated dengue virus strains comprise chimeric dengue viruses and preferably at least one non-chimeric dengue virus, and wherein the dengue serotype 1 and the dengue serotype 2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL, in particular wherein the dengue serotype 3 is at least about 10% of the total concentration in pfu/0.5 mL and in particular wherein the dengue serotype 4 is at least about 70% of the total concentration in pfu/0.5 mL.

[0082] The present invention is therefore directed in part to a unit dose of a dengue vaccine composition and use thereof, the unit dose comprising:

a tetravalent dengue virus composition including four live attenuated dengue serotypes (e.g. virus strains):

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain),
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain),
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain),
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain),

and one or more pharmaceutically acceptable excipients thereof.

[0083] The present invention is further directed in part to a unit dose of a dengue vaccine composition and use thereof, the unit dose comprising:

a tetravalent virus composition including four live attenuated dengue virus strains:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of at least 4.5 log₁₀ pfu/0.5 ml,

and one or more pharmaceutically acceptable excipients.

[0084] The present invention is further directed in part to a unit dose of a dengue vaccine composition and use thereof, the unit dose comprising:

a tetravalent virus composition including four live attenuated dengue virus strains, wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[0085] The present invention is further directed in part to a unit dose of a dengue vaccine composition and use thereof, wherein said unit dose is lyophilized and obtained by lyophilizing 0.5 mL of a solution comprising:

a tetravalent virus composition including four live attenuated dengue virus strains:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of at least 4.5 log₁₀ pfu/0.5 ml,

and one or more pharmaceutically acceptable excipients.

[0086] The present invention is in particular directed to such unit dose or composition wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%, in particular wherein the concentration of (iii) in pfu/0.5 mL is at least 10%.

[0087] The present invention is in particular directed to such unit dose or composition, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%.

[0088] The present invention is further directed in part to a kit for preparing a reconstituted unit dose and use thereof, the kit comprising the following components:

- a) a lyophilized unit dose of the present invention as described herein, and
- b) a pharmaceutically acceptable diluent for reconstitution.

[0089] The present invention is further directed in part to a container, such as a vial, comprising one to ten unit doses of the present invention as described herein.

[0090] The present invention is further directed to a method of preventing dengue disease in a subject comprising administering to the subject a reconstituted unit dose of a dengue vaccine composition as described herein, for example by subcutaneous injection.

[0091] The present invention is further directed to the use of the reconstituted unit dose of a dengue vaccine composition as described herein for the manufacture of a medicament for preventing dengue disease in a subject, for example by subcutaneous injection.

[0092] The present invention is further directed to the reconstituted unit dose of a dengue vaccine composition as described herein for use in a method of preventing dengue disease in a subject, for example by subcutaneous injection.

[0093] The present invention is further directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of a vaccine composition as described herein, wherein the subject population is seronegative to all dengue serotypes. In said method the geometric mean neutralizing antibody titers (GMTs) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, may provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4 (GMT DENV-2 : GMT DENV-4), and optionally a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1 (GMT DENV-2 : GMT DENV-1), and optionally a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3 (GMT DENV-2 : GMT DENV-3).

[0094] The present invention is further directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of a vaccine composition as described herein, wherein the subject is seronegative to all dengue serotypes. In said method the neutralizing antibody titers when tested in the subject at

5 day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, may provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4, and optionally a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and optionally a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

10 **[0095]** In one preferred embodiment, the methods of preventing dengue disease of the present invention are not associated with an increased likelihood of solicited systemic adverse events, such as in children under 9 or seronegative individuals.

[0096] The present invention is therefore directed in part to a method of preventing dengue disease as well as yellow fever.

[0097] The present invention is therefore directed in part to a method of preventing dengue disease as well as hepatitis A.

15 **[0098]** The present invention is therefore directed in part to a method of preventing dengue disease as well as HPV-associated cancers or genital warts.

[0099] The present invention is therefore directed in part to a method of preventing dengue disease as well as measles, mumps and rubella.

20 **[00100]** The present invention is therefore directed in part to a method of preventing dengue disease as well as tetanus, diphtheria, and pertussis.

[00101] The present invention is therefore directed in part to a method of preventing dengue disease as well as diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b.

25 **[00102]** The present invention is therefore also directed in part to a method of prevention any combination of the above mentioned diseases.

[00103] The present invention is further directed in part to the use of the reconstituted unit dose of a dengue vaccine composition/ tetravalent dengue virus composition as described herein for the manufacture of a medicament for preventing dengue disease in a subject, for example by subcutaneous injection.

30 **[00104]** The present invention is further directed in part to the reconstituted unit dose of a dengue vaccine composition/tetravalent dengue virus composition as described herein for use in a method of preventing dengue disease in a subject, as described herein.

DEFINITIONS

[00105] In describing the present invention, the following terms are to be used as indicated below. As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise.

5 **[00105a]** Throughout the specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

10 **[00106]** As used herein, the terms "unit dose of a dengue vaccine composition", "unit dose" and "unit dose of the invention as described herein" refer to the amount of a dengue vaccine which is administered to a subject in a single dose. In one embodiment, one unit dose is present in a vial and this unit dose is administered to a subject, e.g.

15

20

25

[TEXT CONTINUED ON PAGE 16]

optionally after reconstitution. In one embodiment, more than one unit dose of the dengue vaccine composition may be present in a vial so that with the content of one vial more than one subject can be vaccinated.

[00107] A "lyophilized unit dose" or "unit dose in lyophilized form" refers to the unit dose that is obtained by subjecting a given volume of the liquid dengue vaccine composition, such as 0.5 mL, to lyophilization. Thus, the aqueous formulations of the dengue vaccine composition being produced by combining the pharmaceutically acceptable excipients and the dengue virus composition comprising the four dengue virus strains, preferably TDV-1 to TDV-4, is subjected to lyophilization to obtain the lyophilized unit dose.

[00108] A "reconstituted unit dose" or "unit dose in reconstituted form" is obtained from the lyophilized dose by reconstitution with a pharmaceutically acceptable diluent. The diluent does not contain dengue virus. The reconstituted unit dose is a liquid which can be administered to a subject, for example by injection, such as subcutaneous injection.

[00109] As used herein, the term "upon reconstitution with 0.5 mL" is not limiting the reconstitution to be performed using 0.5 mL of the diluent, but refers to the concentration of the dengue viruses that will be present in the reconstituted unit dose when 0.5 mL diluent are used for reconstitution. While using a different volume for reconstitution (e.g. 0.8 mL) will result in a different concentration of dengue viruses in the reconstituted unit dose, the administration of the total volume of the unit dose (e.g. 0.8 mL) will result in the same total amount of dengue virus being administered.

[00110] As used herein, a "concentration of at least X log₁₀ pfu/0.5 mL" refers to the concentration of a dengue serotype in 0.5 mL, but is not limiting the unit dose to be 0.5 mL. If the unit dose has a volume different than 0.5 mL, or is lyophilized from a volume different than 0.5 mL, or is reconstituted with a volume different than 0.5 mL, said concentration will differ from the "concentration of at least X log₁₀ pfu/0.5 mL". However, if the unit dose has a volume of 0.5 mL, or is lyophilized from a volume of 0.5 mL, or is reconstituted with a volume of 0.5 mL, said concentration will be the "concentration of at least X log₁₀ pfu/0.5 mL". Thus, while the concentration may differ, the total amount of virus in the unit dose remains the same.

[00111] As used herein, the term "dengue serotype" refers to a species of dengue virus which is defined by its cell surface antigens and therefore can be distinguished by serological methods known in the art. At present, four serotypes of dengue virus are known, i.e. dengue serotype 1 (DENV-1), dengue serotype 2 (DENV-2), dengue serotype 3 (DENV-3) and dengue serotype 4 (DENV-4).

[00112] As used herein, the term "tetravalent dengue virus composition" refers to a dengue virus composition comprising four different immunogenic components from the four different dengue serotypes DENV-1, DENV-2, DENV-3 and DENV-4, preferably comprising four different live, attenuated dengue viruses, each representing one dengue serotype, and which aims to stimulate immune responses to all four dengue serotypes.

[00113] As used herein, the term "live attenuated dengue virus" refers to a viable dengue virus which is mutated to provide reduced virulence. The live attenuated dengue virus can be a dengue virus in which all components are derived from the same dengue serotype or it can be a chimeric dengue virus having parts from two or more dengue serotypes.

[00114] A "virus strain" and in particular a "dengue virus strain" is a genetic subtype of a virus, in particular of a dengue virus, which is characterized by a specific nucleic acid sequence. A dengue serotype may comprise different strains with different nucleic acid sequences which have the same cell surface antigens. A dengue virus strain can be a dengue virus in which all components are derived from the same dengue serotype or it can be a chimeric dengue virus having parts from two or more dengue serotypes.

[00115] As used herein, "TDV-2" refers to a molecularly characterized and cloned dengue serotype 2 strain derived from the live attenuated DEN-2 PDK-53 virus strain. The PDK-53 strain is described for example in Bhamarapravati et al. (1987) Bulletin of the World Health Organization 65(2): 189-195. In one embodiment, the TDV-2 strain served as a backbone for the chimeric TDV-1, TDV-3 and TDV-4 strains into which parts from the TDV-1, TDV-3 and TDV-4 strains were introduced.

[00116] A "non-chimeric dengue virus" or "non-chimeric dengue serotype strain" or "non-chimeric dengue strain" comprises only parts from one dengue serotype. In particular, a non-chimeric dengue virus does not include parts from a different flavivirus such as yellow fever virus, Zika virus, West Nile virus, Japanese encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis virus. TDV-2 is an example of a non-chimeric dengue virus.

[00117] A "chimeric dengue virus" or "chimeric dengue serotype strain" or "chimeric dengue strain" comprises parts from at least two different dengue serotypes. As used herein, the chimeric dengue virus does not include parts from a different flavivirus such as yellow fever virus, Zika virus, West Nile virus, Japanese encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis virus. In particular, the chimeric dengue virus described herein does not include parts from the yellow fever virus. As used herein, a "chimeric dengue serotype 2/1 strain" or "DENV-2/1 chimera" or "TDV-1" refers to a dengue virus chimeric construct which comprises parts from both DENV-2 and DENV-1. In particular, in the chimeric dengue serotype 2/1 strain the prM and E proteins from DENV-1 replace the prM and E proteins from DENV-2 as detailed below. As used herein, a "chimeric dengue serotype 2/3 strain" or "DENV-2/3 chimera" or "TDV-3" refers to a dengue virus chimeric construct which comprises parts from both DENV-2 and DENV-3. In particular, in the chimeric dengue serotype 2/3 strain the prM and E proteins from DENV-3 replace the prM and E proteins from DENV-2 as detailed below. As used herein, a "chimeric dengue serotype 2/4 strain" or "DENV-2/4 chimera" or "TDV-4" refers to a dengue virus chimeric construct which comprises parts from both DENV-2 and DENV-4. In particular, in the chimeric dengue serotype 2/4 strain the prM and E proteins from DENV-4 replace the prM and E proteins from DENV-2 as detailed below.

[00118] As used herein, "TDV" refers to a tetravalent live attenuated dengue vaccine that comprises a mixture of the four live attenuated dengue virus strains TDV-1, TDV-2, TDV-3 and TDV-4 expressing surface antigens from the four dengue serotypes DENV-1, DENV-2, DENV-3 and DENV-4, respectively. In one embodiment (e.g. also in the examples), TDV-1 has the nucleotide sequence according to SEQ ID No. 1 and/or the amino acid sequence according to SEQ ID No. 2. In one embodiment, TDV-2 has the nucleotide sequence according to SEQ ID No. 3 and/or the amino acid sequence according to SEQ ID No. 4. In one embodiment, TDV-3 has the nucleotide sequence according to SEQ ID No. 5 and/or the amino acid sequence according to SEQ ID No. 6. In one embodiment, TDV-4 has the nucleotide sequence according to SEQ ID No. 7 and/or the amino acid sequence according to SEQ ID No. 8.

[00119] As used herein, the term "dengue disease" refers to the disease which is caused by infection with dengue virus. Symptoms of dengue disease include sudden high fever, headaches, joint and muscle pain, nausea, vomiting and skin rashes. The term dengue disease also includes the more severe forms of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Symptoms of DHF include increased vascular permeability, hypovolemia and abnormal blood clotting mechanisms. Subjects with DHF may present with severe manifestations of plasma leakage and hemorrhage. When a subject with DHF experiences shock he or she will be categorized as having DSS. Symptoms of DSS include bleeding that may appear as tiny spots of blood on the skin and larger patches of blood under the skin. Prolonged shock is the main factor associated with complications including massive gastrointestinal hemorrhage that can lead to death. As used herein, DHF cases are defined as VCD cases meeting WHO 1997 DHF criteria. In the context of preventing dengue disease in elderly subjects, the term "preventing dengue disease" preferably includes preventing DHF and/or DSS. In the context of preventing dengue disease in elderly subjects, the term "preventing

dengue disease" preferably includes preventing severe end-organ manifestations of dengue such as hepatomegaly and acute renal failure.

[00120] As used herein, "preventing dengue disease" refers to preventing a subject from developing one or more symptoms of dengue disease because of an infection with a dengue virus. In particular, preventing dengue disease is achieved by vaccinating or inoculating a subject with a dengue vaccine composition, such as the reconstituted unit dose described herein. As used herein, the term "prophylactically treating dengue disease" is equivalent to "preventing dengue disease". In a particular embodiment, preventing dengue disease includes preventing DHS and/or DSS.

[00121] As used herein, the terms "virologically-confirmed dengue disease", "VCD case", or "VCD fever" refer to febrile illness or illness clinically suspected to be dengue disease with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). The term "virologically confirmable dengue" disease refers to a subject having febrile illness or illness clinically suspected to be dengue disease, wherein testing the subject, e.g. using RT-PCR, would confirm the presence of at least one dengue serotype. Severe forms of VCD fever will be identified as follows: Dengue Hemorrhagic Fever (DHF) was defined according to the WHO 1997 criteria. Severe dengue was defined through an assessment of an independent Dengue Case Adjudication Committee which will assess all hospitalized VCD cases (severe / non-severe) based on criteria redefined in a charter. All non-hospitalized cases are considered non-severe.

[00122] As used herein, the term "febrile illness" is defined as temperature $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days.

[00123] As used herein, the terms "virologically-confirmed dengue disease with hospitalization", is considered to be a surrogate for severe dengue and the "incidence of virologically-confirmed dengue disease with hospitalization" is used as a safety parameter. As used herein, the "relative risk with respect to virologically-confirmed dengue disease with hospitalization" means the number of events of virologically confirmed dengue disease with hospitalization divided by the number of subjects treated with the unit dose as disclosed herein over the number of events of virologically confirmed dengue disease with hospitalization divided by the number of subjects treated with placebo. If the "relative risk with respect to virologically-confirmed dengue disease with hospitalization" is 1 or lower the vaccine provides for the same or less risk for virologically-confirmed dengue disease with hospitalization as placebo and is considered "safe". In this context the risk of virologically-confirmed dengue disease with hospitalization may be also 0.9 or less, 0.8 or less, 0.7 or less, 0.6 or less, 0.5 or less, 0.4 or less, 0.3 or less, 0.2 or less, or 0.1 or less, in particular when determined from 30 days after a second administration until 12 months after a second administration, in particular when determined in age groups selected from the age group of 4 to 16 year old subjects, the age group of 4 to under 9 year old subjects, the age group of 2 to under 9 year old subjects, the age group of 4 to 5 year old subjects, the age group of 6 to 11 year old subjects, and the age group of 12 to 16 year old subjects.

[00124] As used herein, alternatively a vaccine is considered "safe" when the vaccine efficacy (VE) with respect to virologically-confirmed dengue disease with hospitalization is 0% or higher. This means that the vaccine provides for the same likelihood or less for virologically-confirmed dengue disease with hospitalization as placebo. In particular considered "safe" is the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, in particular when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects (in particular when measured in age groups selected in particular from the age group of 4 to 16 year old subjects, the age group of 4 to under 9 year old subjects, the age group of 2 to under 9 year old subjects, the age group of 4 to 5 year old subjects, the age group of 6 to 11 year old subjects, and the age group of 12 to 16 year old subjects) being seronegative against all serotypes at baseline or being seropositive against at least one serotype at baseline, in particular when said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about from

first administration or from 30 days after the second or last administration of the administration schedule until at least 12 months, until 12 to 18 months, until 12 months, or until 18 months after the second or last administration of the administration schedule. In particular, the lower bound may be more than 30%, more than 40%, more than 50%, more than 60%, more than 65%, more than 66%, more than 67%, more than 68% more than 70%, or more than 75%. In particular, the 2-sided 95% confidence interval of the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes when comparing seropositive and seronegative subjects provides for lower bounds of the 2-sided confidence interval which are within 10% points or within 15% points or within 20% points. In a particular embodiment "safe" means providing a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline from first administration of the administration schedule until 12 to 18 months after the last administration of the administration schedule.

[00125] If one of the criteria as defined above for the term "safe" is fulfilled, the vaccine is considered safe within the meaning of this invention. In this context, safe in particular refers to a vaccine that is safe for all subjects irrespective of their serostatus at baseline. This means that the vaccine can be administered without the need to determine the occurrence of a previous dengue infection in the subject before administration. Preferably, the vaccine is safe as defined above with respect to all age groups starting from 4 years of age and preferably irrespective of the serostatus, in particular from 4 years of age to 60 years of age, or 4 years of age to 16 years of age. Relevant subgroups in this context are under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age and 12 to 16 years of age or any age group within 4 to 16 years of age. For further definitions of VE against virologically-confirmed dengue disease with hospitalization reference is made to the disclosure below with respect to certain methods of treatment.

[00126] As used herein, "vaccine efficacy" or "VE" measure the proportionate reduction in cases among vaccinated persons. Vaccine efficacy (VE) is measured by calculating the risk of disease among vaccinated and unvaccinated persons and determining the percentage reduction in risk of disease among vaccinated persons relative to unvaccinated persons. The greater the percentage reduction of illness in the vaccinated group, the greater the vaccine efficacy. For example, a VE of 90% indicates a 90% reduction in disease occurrence among the vaccinated group, or a 90% reduction from the number of cases you would expect if they have not been vaccinated. The vaccine efficiency is calculated by the formula: $100 * (1 - HR)$, wherein HR is the Hazard Ratio which is defined as the Hazard rate of vaccine (λ_v) divided by the Hazard rate of placebo (λ_c), i.e. $HR = \lambda_v / \lambda_c$. λ_v denote the hazard rate for the subjects vaccinated with a tetravalent dengue vaccine composition as disclosed herein and λ_c denote the hazard rate for unvaccinated subjects, i.e. subjects receiving placebo. The hazard rate ratio HR is estimated from a Cox proportional hazard model with study vaccine as a factor, adjusted for age, and stratified by region. As used herein the term "combined vaccine efficacy against all four serotypes" is defined as the vaccine efficacy in relation to the risk of dengue disease irrespective of the serotype being responsible for the virologically-confirmed dengue disease and the subject baseline serostatus. A vaccine is considered "effective" in case the combined vaccine efficacy is above 30%. In this context the combined vaccine efficacy may be also 40% or more, 50% or more, 60% or more, 70% or more, 72% or more, or 80% or more, in particular when determined from 30 days after a second administration until 12 months after a second administration or 18 months after a second vaccination, in particular when determined in age groups selected from the age group of 4 to 16 year old subjects, the age group of 4 to under 9 year old subjects, the age group of 2 to under 9 year old subjects, the age group of 4 to 5 year old subjects, the age group of 6 to 11 year old subjects, and the age group of 12 to 16 year old subjects. In this context, effective in particular refers to a vaccine that is effective for all subjects irrespective of their serostatus at baseline. Preferably, the vaccine is effective with

respect to all age groups starting from 4 years of age and preferably irrespective of the serostatus, in particular from 4 years of age to 60 years of age or from 4 years of age to 16 years of age and irrespective of the serostatus. Relevant subgroups in this context are under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age and 12 to 16 years of age or any age group within 4 to 16 years of age. In certain embodiments "effective" means providing a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 4 to 16 years of age, from the first administration of the administration schedule until 18 months after the last administration of the administration schedule. Further specific efficacies can be defined. As used herein, "combined vaccine efficacy against all four serotypes in seronegative subjects" refers to the efficacy measured in subjects which are seronegative at baseline. As used herein, "vaccine efficacy against a specific serotype, e.g. serotype 1" refers to the efficacy in relation to a specific serotype being responsible for the virologically-confirmed dengue disease. As used herein, "combined vaccine efficacy against all four serotypes against virologically-confirmed dengue with hospitalization" refers to the efficacy wherein only virologically-confirmed dengue cases with hospitalization are considered. Such vaccine efficacies can be determined with respect to subjects being seronegative or seropositive at baseline and for different age groups.

[00127] As used herein, the "relative risk" means the number of events of virologically confirmed dengue disease divided by the number of subjects treated with the unit dose as disclosed herein over the number of events of virologically confirmed dengue disease divided by the number of subjects treated with placebo. As used herein the term "combined relative risk against all four serotypes" is defined as the relative risk in relation to the risk of dengue disease irrespective of the serotype being responsible for the virologically-confirmed dengue disease and the subject baseline serostatus.

[00128] As used herein, "vaccinating" or "inoculating" refers to the administration of a vaccine to a subject, with the aim to prevent the subject, from developing one or more symptoms of a disease. As used herein, "vaccinating against dengue disease" or "inoculating against dengue disease" refers to the administration of a dengue vaccine composition to a subject, with the aim to prevent the subject, from developing one or more symptoms of dengue disease. In principle the method comprises a primary vaccination and optionally one or more booster vaccinations. The primary vaccination is defined as the primary administration schedule for administering the composition or unit dose as disclosed herein to establish a protective immune response and e.g. consists of two administrations e.g. within three months. Whenever an administration is mentioned within this disclosure such administration refers to the primary vaccination unless it is specified as booster vaccination. The booster vaccination refers to an administration or administration schedule which takes place after the primary vaccination e.g. at least 1 year or even 5 or 10 years after the last administration, e.g. the second administration, of the primary vaccination schedule. The booster administration attempts at enhancing or reestablishing the immune response of the primary vaccination.

[00129] As used herein, the terms "subject" or "subjects" are limited to human subjects (e.g. infants, children or adults). The terms "elderly subject" or "elderly subjects" refer to subjects with an age of more than 60 years, such as 61 years to 100 years, 61 years to 90 years, 61 years to 80 years, 61 years to 75 years, or 61 years to 70 years.

[00130] As used herein, "subject population" refers to a group of subjects. The subject population may refer to least 40 subjects, at least 50 subjects, at least 60 subjects, at least 100 subjects or at least 1000 subjects and is defined by certain parameters. The parameters that may be used to define a subject population include, but are not limited to, the age of the subjects, whether the subjects are from a dengue endemic region or from a dengue non-endemic region and the serostatus of the subjects.

[00131] As used herein, "endemic region" refers to a region where a disease or infectious agent is constantly present and/or usually prevalent in a population within this region. As used herein, "non-endemic region" refers to a region from which the disease is absent or in which it is usually not prevalent. Accordingly, a "dengue endemic region" refers to geographic areas in which an infection with dengue virus is constantly maintained at a baseline level. A "dengue non-endemic region" is a geographic area in which an infection with dengue virus is not constantly maintained at a baseline level. Accordingly, subject populations or subjects "from a dengue endemic region" or "from a dengue non-endemic region" refer to subject populations or subjects living in geographic areas as defined above. Whether a geographic area or a subject population is dengue-endemic or not can be determined by different calculatory methods such as the ones described in Bhatt et al. (2013) *Nature* 496 (7446): 504-507 and supplementary material and in Stanaway et al. (2016) *Lancet Infect Dis.* 16(6): 712-723 and supplementary material. Overviews of dengue endemic regions and dengue epidemiology are regularly published, for example, by the WHO or CDC. Typical dengue-endemic regions are in Latin America, Southeast Asia and the Pacific islands and dengue endemic countries include, but are not limited to, Australia, Brazil, Bangladesh, Colombia, China, Dominican Republic, Indonesia, India, Mexico, Malaysia, Nicaragua, Nigeria, Pakistan, Panama, Philippines, Puerto Rico, Singapore, Sri Lanka, Thailand and Vietnam. The area's force of infection is measured by seroprevalence surveys provided as seroprevalence rate. Areas with very high force of infection are considered to have a seroprevalence rate of more than 80%. As used herein the term "region" when it concerns seroprevalence rates refers to a geographic area where the seroprevalence rate could be determined or is known, e.g. a village, a town, a city, a region, a county, a state, a province or parts of the foregoing or a whole country.

[00132] As used herein, "serostatus" refers to the amount of antibodies a subject has with respect to a certain infectious agent, in particular dengue virus. As used herein, "seronegative" or "seronaive" means that the subject does not have neutralizing antibodies against any one of dengue serotypes DENV-1, DENV-2, DENV-3 and DENV-4 in the serum. A seronegative or seronaive subject or subject population is defined by a neutralizing antibody titer of less than 10 for each one of the four dengue serotypes. A subject or subject population having a neutralizing antibody titer of equal to or more than 10 for at least one dengue serotype is defined as being "seropositive" with respect to said dengue serotype. Serostatus at baseline refers to the serostatus before the administration of a dengue vaccine composition as described herein.

[00133] As used herein, a "neutralizing antibody titer" refers to the amount of antibodies in the serum of a subject that neutralize the respective dengue serotype. The neutralizing antibody titer against DENV-1, DENV-2, DENV-3 and DENV-4 is determined in a serum sample of the subject using known methods such as the plaque reduction neutralization test (PRNT) as described in the WHO Guidelines (World Health Organization Department of Immunization Vaccines Biologicals (2007) Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses, WHO/IVB/07.07) or a microneutralization (MNT50) assay as described herein. As used herein, the "ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4" means that the neutralizing antibody titer of dengue serotype 2 is divided by the neutralizing antibody titer of dengue serotype 4 and that the ratio obtained hereby is no more than 20. In other words, the neutralizing antibody titer of dengue serotype 2 is not more than 20-times higher than the neutralizing antibody titer of dengue serotype 4 in the subject.

[00134] As used herein, the terms "geometric mean neutralizing antibody titer" and "GMT" refer to the geometric mean value of the titer of neutralizing antibodies against the corresponding dengue serotype in the serum of subjects in a subject population. The geometric mean value is calculated by a well-known formula. As used herein, the "ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4" means that the geometric mean neutralizing antibody titer of dengue serotype 2 (GMT DENV-2) is divided by the geometric mean neutralizing antibody

titer of dengue serotype 4 (GMT DENV-4) and that the ratio obtained hereby is no more than 20. In other words, the geometric mean neutralizing antibody titer of dengue serotype 2 is not more than 20-times higher than the geometric mean neutralizing antibody titer of dengue serotype 4 in the subject population.

[00135] As used herein, an "immune response" refers to a subject's response to the administration of the dengue vaccine. In particular, the immune response includes the formation of neutralizing antibodies to one or more dengue serotypes. It may also include the stimulation of a cell-mediated response or the formation of antibodies to non-structural proteins such as NS1. An immune response is stimulated by the administration of a unit dose of the invention as described herein, if the titer of neutralizing antibodies against at least one dengue virus serotype and preferably against all four dengue virus serotypes is increased after said administration of said unit dose. An immune response is stimulated by the administration of a unit dose of the invention as described herein, if the secretion of interferon gamma by peripheral blood mononuclear cells stimulated with peptides from dengue virus proteins is increased after said administration of said unit dose. An immune response is stimulated by the administration of a unit dose of the invention as described herein, if the titer of antibodies to non-structural proteins such as NS1 is increased after said administration of said unit dose. In a particular embodiment, the administration of a reconstituted unit dose of the present invention as described herein stimulates the formation of neutralizing antibodies to one or more dengue serotypes, a cell-mediated response and the formation of antibodies to non-structural proteins such as NS1.

[00136] As used herein, a "balanced immune response" means that the immune response to the four dengue serotypes is sufficient to provide protection against infection by all four dengue serotypes and preferably the immune response to the four dengue serotypes has a similar strength. In particular, the neutralizing antibody titer against the four dengue serotypes at day 180 or day 365 after administration of a first reconstituted unit dose of the invention as described herein is similar, i.e. it differs by less than factor 30, by less than factor 25 or by less than factor 20.

[00137] The „total concentration in pfu/0.5 ml“ which serves as a base value for the calculation of the percentage concentration for each individual component of a tetravalent dengue vaccine is shown for one exemplary tetravalent vaccine composition comprising dengue serotype 1 in a concentration of 3.60 log₁₀pfu/0.5 ml, a dengue serotype 2 concentration of 4.00 log₁₀pfu/0.5 ml, a dengue serotype 3 concentration of 4.60 log₁₀pfu/0.5 ml and a dengue serotype 4 concentration of 5.11 log₁₀pfu/0.5 ml.

Primarily, the logarithmic values of the concentrations are converted into numerical values. The results of this conversion are 4x10³ pfu/0.5 ml for serotype 1, 1x10⁴ pfu/0.5ml for serotype 2, 4x10⁴ pfu/0.5 ml for serotype 3 and 1.3x10⁵ pfu/0.5 ml for serotype 4. The total concentration in pfu/0.5 ml is the sum of the preceding numerical values resulting in 1.84 x10⁵ pfu/0.5 ml.

[00138] The "percentage concentration" for each of the serotypes 1, 2, 3 and 4 is obtained by dividing the numerical concentration value (expressed as pfu/0.5 ml) of an individual serotype by the total concentration (expressed in pfu/0.5 ml) and multiplying the result by 100 i.e.:

Percentage concentration of serotype 1 = $(4 \times 10^3 \text{ pfu/0.5 ml} \div 1.84 \times 10^5 \text{ pfu/0.5 ml}) \times 100 = 2\%$

Percentage concentration of serotype 2 = $(1 \times 10^4 \text{ pfu/0.5ml} \div 1.84 \times 10^5 \text{ pfu/0.5 ml}) \times 100 = 5\%$

Percentage concentration of serotype 3 = $(4 \times 10^4 \text{ pfu/0.5 ml} \div 1.84 \times 10^5 \text{ pfu/0.5 ml}) \times 100 = 22\%$

Percentage concentration of serotype 4 = $(1.3 \times 10^5 \text{ pfu/0.5 ml} \div 1.84 \times 10^5 \text{ pfu/0.5 ml}) \times 100 = 71\%$.

The percentage concentrations are rounded to whole numbers.

[00139] As used herein the "concomitant" administration of vaccines refers to a combined administration of two or more vaccines. In the context of parts of the invention, the combined administration of two or more vaccines refers to

combining the administration schedule of a dengue vaccine, such as the unit dose of the invention, with the administration schedule of a fellow fever vaccine, such as YF-17D, and/or of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, and/or of a HPV vaccine, such as a 9vHPV vaccine, and/or of a combined measles, mumps and rubella (MMR) vaccine, and/or of a combined Tdap vaccine, such as a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, and/or of a DTaP/IPV/HIB vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®.

[00140] As used herein "simultaneous" administration means an administration of at least two different vaccines, such as a dengue vaccine and a fellow fever vaccine, or a dengue vaccine and a hepatitis A vaccine, or a dengue vaccine and a HPV vaccine, or a dengue vaccine and a MMR vaccine, or a dengue vaccine and a Tdap vaccine, or a dengue vaccine and a DTaP/IPV/Hib vaccine on the same day. The simultaneous administration may be administered by the same medical practitioner, such as during the same medical appointment.

[00141] As used herein "sequential" administration means an administration of at least two different vaccines, such as a dengue vaccine and a fellow fever vaccine, or a dengue vaccine and a hepatitis A vaccine, or a dengue vaccine and a HPV vaccine, or a dengue vaccine and a MMR vaccine, or a dengue vaccine and a Tdap vaccine, or a dengue vaccine and a DTaP/IPV/Hib vaccine on subsequent days, such as within 90 days, but in a combined administration schedule including the administration of the dengue vaccine and the fellow fever vaccine.

[00142] As used herein "HPV-associated cancers or genital warts" refers to cancers and genital warts caused by an HPV infection, respectively. The HPV serotypes 16, 18, 45, 31, 33, 52, 58, also referred to as "high-risk" HPV serotypes, are the types most common in cervical cancers, wherein the two HPV serotypes 16 and 18 cause about 70% of cervical cancers worldwide. The HPV serotypes 6 and 11, also referred to as "low-risk" HPV serotypes, cause genital warts.

[00143] As used herein a "9vHPV vaccine" refers to a 9-valent HPV vaccine that provides protection against the HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. In particular, the 9vHPV vaccine is used to prevent cervical, vulvar, vaginal, and anal cancers, precancerous or dysplastic lesions, and genital warts caused by one or more of these HPV serotypes.

[00144] As used herein, a "MMR vaccine" refers to a combined vaccine for measles, mumps and rubella. Several MMR vaccine are known in the prior art and include M-M-R® II, Priorix®, Tresivac®, and Trimovax®.

[00145] As used herein, a "Tdap vaccine" refers to a combined vaccine for tetanus, diphtheria and pertussis. Tdap vaccines known in the prior art include INFANRIX® (for vaccination of children from 6 weeks to 7 years of age), and BOOSTRIX® from GlaxoSmithKline and Adacel from Sanofi Pasteur (both for use in individuals of 10 years of age or older).

[00146] As used herein, "DTaP" refers to diphtheria, tetanus and acellular pertussis.

[00147] As used herein, "IPV" refers to inactivated poliovirus.

[00148] As used herein, "Hib" refers to *Haemophilus influenzae* type b.

[00149] As used herein, a "DTaP/IPV/Hib vaccine" refers to a combined vaccine for diphtheria, tetanus, pertussis, poliomyelitis and *Haemophilus influenzae* type b. A DTaP/IPV/Hib vaccine known in the prior art includes Pentacel® from Sanofi Pasteur.

[00150] As used herein, the term "chronic disease or condition" includes those diseases and conditions which persist in an elderly subject for three months or more. In particular, it includes diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

[00151] As used herein, the term "impaired immune system" means that at least one function of at least one component of the immune system is weaker than in younger subjects, i.e. in subjects with an age of less than 60 years. These functions include a lower antioxidant response of monocytes against oxidative stress induced by dengue virus and lower T cell responses and cytokine production in response to dengue virus infection.

[00152] As used herein, "solicited systemic adverse events" in children under 6 years are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination, and in children of 6 years or more are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.

[00153] As used herein, "solicited local adverse events" are injection site pain, injection site erythema and injection site swelling that occurred within 7 days after each vaccination.

[00154] As used herein, "unsolicited adverse events" are any adverse events (AEs) that are not solicited local or systemic AEs, as defined above.

[00155] As used herein, a "serious adverse event" or "SAE" is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

[00156] The relationship of each AE, including solicited systemic AEs (solicited local AEs are considered as related) to trial vaccine(s) will be assessed using the following categories: As used herein, "IP-Related AE" or "vaccine related AE" means that there is suspicion that there is a relationship between the vaccine and the AE (without determining the extent of probability); there is a reasonable possibility that the vaccine contributed to the AE. As used herein, "Non-IP Related" or "non-vaccine related" means that there is no suspicion that there is a relationship between the vaccine and the AE; there are other more likely causes and administration of the vaccine is not suspected to have contributed to the AE.

[00157] As used herein, a subject or subject population being "2 to 17 years of age" refers to a subject or subject population being 2 to 17 years of age on the first day of the administration of the dengue vaccine composition as described herein.

[00158] As used herein "%-points" refers to the difference of two %-values in a %-value. For example two values in % which are within 5 %-points refers to e.g. one value at 1% and a second value at 6%.

[00159] As used herein, the term "determination of the previous dengue infection in the subject before administration" means that a previous dengue infection has to be assessed before vaccination in that there is a laboratory confirmed history of dengue or through an appropriately validated serological test e.g. by the method as disclosed herein such as the MNT50 test described in Example 2 or any serotesting with adequate performance in terms of specificity and cross reactivity based on the locale disease epidemiology.

[00160] As used herein % w/v refers to % mg/ml wherein e.g. 150 mg/ml are 15% w/v.

BRIEF DESCRIPTION OF THE DRAWINGS

[00161] Figure 1: Genetic structure of the four dengue strains contained in TDV. The solid red triangles indicate the three attenuating mutations present in the 5'NCR, NS1 and NS3 proteins. The TDV-1, TDV-3 and TDV-4 strains are chimeric viruses where the prM and E genes from dengue serotype 1, 3 and 4, respectively, are inserted into the TDV-2 backbone.

[00162] Figure 2: Schematic drawing illustrating the microneutralization test (MNT) used to determine the titer of neutralizing antibodies.

[00163] Figure 3: Percentage of subjects ($\pm$ 95% confidence intervals) who were seropositive (reciprocal neutralizing titer ≥ 10) for each of the dengue serotypes at different time points of the trial in the HD-TDV group (dark colored, left bar) and TDV group (light colored, right bar) throughout the trial. Time points shown are baseline, day 15 (d15), day 30 (d30), day 90 (d90), day 180 (d180) and day 365 (d365). Part A shows the results for participants seropositive (set of graphs on the left) and seronegative (set of graphs on the right) at baseline, per-protocol set. Part B shows the results for the entire trial population (all) per-protocol set

[00164] Figure 4: Geometric mean titers (GMTs) ($\pm$ 95% confidence intervals) of neutralizing antibodies against each of the four dengue serotypes during the course of the trial for HD-TDV (dark line with triangles) and TDV (light line with circles) recipients, for the entire trial population (part B) and for participants seropositive and seronegative at baseline (part A), per-protocol set.

[00165] Figure 5: IFN γ ELISpot analysis of peripheral blood mononuclear cells before vaccination (baseline) and at different time points after administration of TDV. Shown are the response frequencies to the entire DENV-2 proteome. A subject was considered responsive if response to more than one peptide pool from DENV-2 was positive (i.e. $\geq 4x$ mean of negative control and ≥ 50 SFC/ 10^6 PBMCs).

[00166] Figure 6: IFN γ ELISpot analysis of peripheral blood mononuclear cells before vaccination (baseline) and at different time points after administration of TDV. Shown are the response frequencies to peptide pools matching selected DENV-derived proteins as indicated. A subject was considered responsive if response to more than one peptide pool from DENV-2 was positive (i.e. $\geq 4x$ mean of negative control and ≥ 50 SFC/ 10^6 PBMCs). A = DENV-2 C; B = DENV-1 prM + E; C = DENV-2 prM + E; D = DENV-3 prM + E; E = DENV-4 prM + E; F = DENV-2 NS1; G = DENV-2 NS2; H = DENV-2 NS3; I = DENV-2 NS4; J = DENV-2 NS5.

[00167] Figure 7: Effect of sera from a seronegative subject (A) and a seropositive subject (A) to whom TDV was administered on DENV-2 NS1-induced hyperpermeability as determined by TEER. HPMEC were grown on Transwell semi-permeable membranes (0.4 μ m pore size), and serum samples (30 μ l) were added to the apical chamber in the presence or absence of DENV2 NS1 (5 μ g/ml). DENV2 NS1 is depicted as squares; day 0 serum alone is depicted as diamonds; day 120 serum alone is depicted as triangles; day 0 serum + DENV2 NS1, is depicted as upside-down triangles; day 120 serum + DENV2 NS1 is depicted as X's. (^) represents media change. Endothelial permeability was measured at indicated time-points over 48 hours. Relative TEER values from one independent experiment performed in duplicate are plotted. Error bars indicate standard error of the mean (SEM).

[00168] Figure 8: Effect of sera from seronegative and seropositive subjects to which TDV was administered on NS1-induced sialic acid and heparan sulfate degradation. Shown is the quantification of mean fluorescence intensity (MFI) of (A) sialic acid and (B) heparan sulfate expression after staining with sialic acid- and heparan sulfate-specific fluorescent antibodies as visualized by confocal microscopy. Values are normalized to MFI from the NS1 + positive

control serum group (represented by dotted line at 100%) and expressed as percentage of control. Error bars indicate SEM. The left bar for each subject shows the results at day 0 (d0), the right bar for each subject shows the results at day 120 (d120).

[00169] Figure 9: Flow diagram of the clinical trial of Example 6.

5 [00170] Figure 10: Cumulative incidence of A) virologically-confirmed dengue cases and B) hospitalized virologically-confirmed dengue cases over time during Part 1 study period by baseline serostatus (safety set data; data presented truncated at Month 18). Tables show numbers of participants under follow-up at various time points to end of Part 1 study period.

[00171] Figure 11: Study design of phase III study described in example 6

10

DETAILED DESCRIPTION

Dengue virus strains

[00172] The dengue virus is a single stranded, positive sense RNA virus of the family flaviviridae. The taxonomy is outlined in Table 1. The family flaviviridae includes three genera, flavivirus, hepacivirus and pestivirus. The genus flavivirus contains highly pathogenic and potentially hemorrhagic fever viruses, such as yellow fever virus and dengue virus, encephalitic viruses, such as Japanese encephalitis virus, Murray Valley encephalitis virus and West Nile virus, and a number of less pathogenic viruses.

Table 1. Dengue Virus Taxonomy of the GMO Parental Strain

Family	Flaviviridae
Genus	Flavivirus
Species	Dengue virus
Strains	Dengue Serotype 2 (Strain 16681), Strain DEN-2 PDK-53
GMO parent	TDV-2

[00173] The flavivirus genome comprises in 5' to 3' direction (see **Figure 1**):

- a 5'-noncoding region (5'-NCR),
- a capsid protein (C) encoding region,
- a pre-membrane protein (prM) encoding region,
- an envelope protein (E) encoding region,
- a region encoding nonstructural proteins (NSI, NS2A, NS2B, NS3, NS4A, NS4B, NS5) and
- a 3' noncoding region (3'-NCR).

25 [00174] The viral structural proteins are C, prM and E, and the nonstructural proteins are NSI to NS5. The structural and nonstructural proteins are translated as a single polyprotein and processed by cellular and viral proteases.

[00175] The unit dose of the invention as described herein comprises a dengue virus composition that comprises four live attenuated dengue virus strains (tetravalent dengue virus composition) representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4. Preferably the composition comprises chimeric dengue viruses and optionally at least one non-chimeric dengue virus, in particular a molecularly characterized and cloned dengue serotype 2 strain derived from the live attenuated DEN-2 PDK-53 virus strain (TDV-2), and three chimeric

dengue strains derived from the TDV-2 strain by replacing the structural proteins prM and E from TDV-2 with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera (TDV-1),
- a DENV-2/3 chimera (TDV-3) and
- a DENV-2/4 chimera (TDV-4).

[00176] The genetically modified tetravalent dengue vaccine TDV is based on a molecularly characterized and cloned dengue-2 virus strain (TDV-2). This attenuated TDV-2 strain was generated by cDNA cloning of the attenuated laboratory-derived DEN-2 PDK-53 virus strain that was originally isolated at Mahidol University, Bangkok, Thailand (Kinney et al. (1997) Virology 230(2): 300-308). DEN-2 PDK-53 was generated by 53 serial passages in primary dog kidney (PDK) cells at 32°C (Bhamarapravati et al. (1987) Bull. World Health Organ. 65(2): 189-195).

[00177] The attenuated DEN-2 PDK-53 strain (the precursor of TDV-2) was derived from the wild type virus strain DEN-2 16681 (SEQ ID NO 11) and differs in nine nucleotides from the wild type as follows (Kinney et al. (1997) Virology 230(2): 300-308):

- (i) 5'-noncoding region (NCR)-57 (nt-57 C-to-T): major attenuation locus
- (ii) prM-29 Asp-to-Val (nt-524 A-to-T)
- (iii) nt-2055 C-to-T (E gene) silent mutation
- (iv) NS1-53 Gly-to-Asp (nt-2579 G-to-A): major attenuation locus
- (v) NS2A-181 Leu-to-Phe (nt-4018 C-to-T)
- (vi) NS3-250 Glu-to-Val (nt-5270 A-to-T): major attenuation locus
- (vii) nt-5547 (NS3 gene) T-to-C silent mutation
- (viii) NS4A-75 Gly-to-Ala (nt-6599 G-to-C)
- * nt-8571 C-to-T (NS5 gene) silent mutation

[00178] The three nucleotide changes located in the 5' noncoding region (NCR) (nucleotide 57) (mutation (i)), the NS-1 (amino acid 828 of SEQ ID NO. 4) (mutation (iv)) and NS-3 genes (amino acid 1725 of SEQ ID NO. 4) (mutation (vi)) form the basis for the attenuation phenotype of the DEN-2 PDK-53 strain (Butrapet et al. (2000) J. Virol. 74(7): 3111-3119) (Table 2). These three mutations are referred to herein as the "attenuating mutations" and are comprised in TDV-1, TDV-2, TDV-3 and TDV-4.

Table 2. Attenuating mutations in the common genetic backbone of all TDV strains

Location of Mutation	Nucleotide Change in TDV-2	Amino Acid Change in TDV-2
5' Noncoding Region (5'NCR)	57 C to T	Not applicable (silent)
Nonstructural Protein 1 (NS1)	2579 G to A	828 Gly to Asp
Nonstructural Protein 3 (NS3)	5270 A to T	1725 Glu to Val

[00179] In one embodiment, TDV-2 comprises in addition to the three attenuating mutations one or more mutations selected from:

- a) a mutation in the prM gene at nucleotide 524 from adenine to thymidine resulting in an amino acid change at position 143 from asparagine to valine, and/or
- b) a silent mutation in the E gene at nucleotide 2055 from cytosine to thymidine, and/or
- c) a mutation in the NS2A gene at nucleotide 4018 from cytosine to thymidine resulting in an amino acid change at position 1308 from leucine to phenylalanine, and/or
- d) a silent mutation in the NS3 gene at nucleotide 5547 from thymidine to cytosine, and/or

e) a mutation in the NS4A gene at nucleotide 6599 from guanine to cytosine resulting in an amino acid change at position 2168 from glycine to alanine, and/or

f) a silent mutation in the prM gene at nucleotide 900 from thymidine to cytosine.

The silent mutation in the NS5 gene at nucleotide 8571 from cytosine to thymidine of DEN-2 PDK-53 is not present in the TDV-2 strain.

[00180] In another embodiment, TDV-2 comprises in addition to the three attenuating mutations one or more mutations selected from:

g) a mutation in the prM gene at nucleotide 592 from adenine to guanine resulting in an amino acid change at position 166 from lysine to glutamine, and/or

h) a mutation in the NS5 gene at nucleotide 8803 from adenine to guanine resulting in an amino acid change at position 2903 from isoleucine to valine.

[00181] In another embodiment, TDV-2 comprises in addition to the three attenuating mutations the mutations a) and g), preferably the mutations a), g), c), e) and h), more preferably the mutations a), g), c), e), h) and b), even more preferably the mutations a), g), c), e), h), b) and d), and most preferably the mutations a) to h). The nucleotide positions and amino acids positions of TDV-2 refer to the nucleotide sequence as shown in SEQ ID NO. 3 and amino acid sequence as shown in SEQ ID NO. 4.

[00182] The dengue virus structural envelope (E) protein and pre-membrane (prM) protein have been identified as the primary antigens that elicit a neutralizing protective antibody response (Plotkin 2001). For creation of the tetravalent dengue vaccine (TDV), TDV-2 was modified by replacing the nucleic acid sequence encoding the DENV-2 prM and E glycoproteins with the nucleic acid sequence encoding the corresponding wild type prM and E glycoproteins from the DENV-1, DENV-3, and DENV-4 wild type strains DENV-1 16007, DENV-3 16562 or DENV-4 1036 virus, respectively, (see Table 3) using standard molecular genetic engineering methods (Huang et al. (2003) J. Virol. 77(21): 11436-11447).

Table 3. Viral origin of prM/E gene regions of the TDV virus strains

Virus	Strain	Origin	Source	Reference	Nucleotide sequence	Amino acid sequence
DENV-1	16007	Thailand, 1964	DHF/DSS patient	Halstead and Simasthien, 1970	SEQ ID NO. 9	SEQ ID NO. 10
DENV-2	16681	Thailand, 1964	DHF/DSS patient	Halstead and Simasthien, 1970	SEQ ID NO. 11	SEQ ID NO. 12
DENV-3	16562	Philippines, 1966	DHF patient	Halstead and Simasthien, 1970	SEQ ID NO. 13	SEQ ID NO. 14
DENV-4	1036	Indonesia, 1976	DF patient	Gubler et al., 1979	SEQ ID NO. 15	SEQ ID NO. 16

[00183] A diagram of the four TDV strains comprised in the dengue vaccine composition is shown in **Figure 1**.

[00184] The chimeric dengue strains TDV-1, TDV-3 and TDV-4 express the surface antigens prM and E of the DENV-1, DENV-3 or DENV-4 viruses, as depicted in Table 3 respectively, and retain the genetic alterations responsible for the attenuation of TDV-2. Thus, each of the TDV-1, TDV-3 and TDV-4 strains comprises the attenuating mutations described in Table 2.

[00185] In one embodiment, TDV-1 comprises in addition to the three attenuating mutations one or more mutations selected from:

c) a mutation in the NS2A gene at nucleotide 4018 from cytosine to thymidine resulting in an amino acid change at position 1308 from leucine to phenylalanine, and/or

5 d) a silent mutation in the NS3 gene at nucleotide 5547 from thymidine to cytosine, and/or

e) a mutation in the NS4A gene at nucleotide 6599 from guanine to cytosine resulting in an amino acid change at position 2168 from glycine to alanine, and/or

i) a silent mutation in the E gene at nucleotide 1575 from thymidine to cytosine, and/or

10 j) a silent mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotide 453 from adenine to guanine, and/or

k) a mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotides 2381/2382 from thymidine-guanine to cytosine-cytosine resulting in an amino acid change at position 762 from valine to alanine.

15 **[00186]** In another embodiment, TDV-1 comprises in addition to the three attenuating mutations one or more mutations selected from:

l) a mutation in the NS2A gene at nucleotide 3823 from adenine to cytosine resulting in an amino acid change at position 1243 from isoleucine to leucine, and/or

m) a mutation in the NS2B gene at nucleotide 4407 from adenine to thymidine resulting in an amino acid change at position 1437 from glutamine to asparagine, and/or

20 n) a silent mutation in the NS4B gene at nucleotide 7311 from adenine to guanine.

[00187] In another embodiment, the TDV-1 strain comprises in addition to the three attenuating mutations the mutations l) and m), preferably the mutations l), m), c) and e), even more preferably the mutations l), m), c), e), d) and n), and most preferably the mutations l), m), c), e), d), n), i), j) and k). The nucleotide positions and amino acid positions of TDV-1 refer to the nucleotide sequence as shown in SEQ ID NO. 1 and amino acid sequence as shown in
25 SEQ ID NO. 2.

[00188] In one embodiment, TDV-3 comprises in addition to the three attenuating mutations one or more mutations selected from:

c) a mutation in the NS2A gene at nucleotide 4012 from cytosine to thymidine resulting in an amino acid change at position 1306 from leucine to phenylalanine, and/or

30 d) a silent mutation in the NS3 gene at nucleotide 5541 from thymidine to cytosine, and/or

e) a mutation in the NS4A gene at nucleotide 6593 from guanine to cytosine resulting in an amino acid change at position 2166 from glycine to alanine, and/or

j) a silent mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotide 453 from adenine to guanine, and/or

35 k) a mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotides 2375/2376 from thymidine-guanine to cytosine-cytosine resulting in an amino acid change at position 760 from valine to alanine, and/or

o) a silent mutation in the prM gene at nucleotide 552 from cytosine to thymidine, and/or

40 p) a mutation in the E gene at nucleotide 1970 from adenine to thymidine resulting in an amino acid change at position 625 from histidine to leucine.

[00189] In another embodiment, TDV-3 comprises in addition to the three attenuating mutations one or more mutations selected from:

q) a mutation in the E gene at nucleotide 1603 from adenine to thymidine resulting in an amino acid change at position 503 from threonine to serine, and/or

r) a silent mutation in the NS5 gene at nucleotide 7620 from adenine to guanine.

[00190] In another embodiment, TDV-3 comprises in addition to the three attenuating mutations the mutations p) and q), preferably the mutations p), q), c) and e), even more preferably the mutations p), q), c), e), d) and r), and most preferably the mutations p), q), c), e), d), r), j), k) and o). The nucleotide positions and amino acids positions of TDV-3 refer to the nucleotide sequence as shown in SEQ ID NO. 5 and amino acid sequence as shown in SEQ ID NO. 6.

[00191] In one embodiment, TDV-4 comprises in addition to the three attenuating mutations one or more mutations selected from:

c) a mutation in the NS2A gene at nucleotide 4018 from cytosine to thymidine resulting in an amino acid change at position 1308 from leucine to phenylalanine, and/or

d) a silent mutation in the NS3 gene at nucleotide 5547 from thymidine to cytosine, and/or

e) a mutation in the NS4A gene at nucleotide 6599 from guanine to cytosine resulting in an amino acid change at position 2168 from glycine to alanine, and/or

j) a silent mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotide 453 from adenine to guanine, and/or

k) a mutation in the junction site between the prM-E gene and the DEN-2 PDK-53 backbone at nucleotides 2381/2382 from thymidine-guanine to cytosine-cytosine resulting in an amino acid change at position 762 from valine to alanine, and/or

s) a mutation in the C gene at nucleotide 396 from adenine to cytosine resulting in an amino acid change at position 100 from arginine to serine, and/or

t) a silent mutation in the E gene at nucleotide 1401 from adenine to guanine, and/or

u) a mutation in the E gene at nucleotide 2027 from cytosine to thymidine resulting in an amino acid change at position 644 from alanine to valine, and/or

v) a mutation in the E gene at nucleotide 2275 from adenine to cytosine resulting in an amino acid change at position 727 from methionine to leucine.

[00192] In another embodiment, TDV-4 comprises in addition to the three attenuating mutations one or more mutations selected from:

w) a silent mutation in the C gene at nucleotide 225 from adenine to thymidine, and/or

x) a mutation in the NS2A gene at nucleotide 3674 from adenine to guanine resulting in an amino acid change at position 1193 from asparagine to glycine, and/or

y) a mutation in the NS2A gene at nucleotide 3773 from adenine to an adenine/guanine mix resulting in an amino acid change at position 1226 from lysine to a lysine/asparagine mix, and/or

z) a silent mutation in the NS3 gene at nucleotide 5391 from cytosine to thymidine, and/or

aa) a mutation in the NS4A gene at nucleotide 6437 from cytosine to thymidine resulting in an amino acid change at position 2114 from alanine to valine, and/or

bb) a silent mutation in the NS4B gene at nucleotide 7026 from thymidine to a thymidine/cytosine mix, and/or

cc) a silent mutation in the NS5 gene at nucleotide 9750 from adenine to cytosine.

[00193] In another embodiments, TDV-4 comprises in addition to the three attenuating mutations the mutation s), u) and v), preferably the mutations s), u), v), c), e), x), y) and aa), even more preferably the mutations s), u), v), c), e), x), y), aa) and w), even more preferably the mutations s), u), v), c), e), x), y), aa), w), d), z), bb) and cc), and

most preferably the mutations s), u), v), c), e), x), y), aa), w), d), z), bb), cc), jj), k) and t). The nucleotide positions and amino acids positions of TDV-4 refer to the nucleotide sequence as shown in SEQ ID NO. 7 and amino acid sequence as shown in SEQ ID NO. 8.

[00194] In a preferred embodiment, TDV-1 has the nucleotide sequence of SEQ ID NO. 1, TDV-2 has the nucleotide sequence of SEQ ID NO. 3, TDV-3 has the nucleotide sequence of SEQ ID NO. 5, and/or TDV-4 has the nucleotide sequence of SEQ ID NO. 7. In a further preferred embodiment, TDV-1 has the amino acid sequence of SEQ ID NO. 2, TDV-2 has the amino acid sequence of SEQ ID NO. 4, TDV-3 has the amino acid sequence of SEQ ID NO. 6, and TDV-4 has the amino acid sequence of SEQ ID NO. 8. In a further preferred embodiment, TDV-1 has a nucleotide sequence encoding the amino acid sequence of SEQ ID NO. 2, TDV-2 has a nucleotide sequence encoding the amino acid sequence of SEQ ID NO. 4, TDV-3 has a nucleotide sequence encoding the amino acid sequence of SEQ ID NO. 6, and TDV-4 has a nucleotide sequence encoding the amino acid sequence of SEQ ID NO. 8.

Table 4. Sequences of the TDV virus strains

SEQ ID NO.	dengue virus strain	sequence type
SEQ ID NO. 1	TDV-1	nucleotide sequence
SEQ ID NO. 2	TDV-1	amino acid sequence
SEQ ID NO. 3	TDV-2	nucleotide sequence
SEQ ID NO. 4	TDV-2	amino acid sequence
SEQ ID NO. 5	TDV-3	nucleotide sequence
SEQ ID NO. 6	TDV-3	amino acid sequence
SEQ ID NO. 7	TDV-4	nucleotide sequence
SEQ ID NO. 8	TDV-4	amino acid sequence

[00195] Thus, in a particularly preferred embodiment, the unit dose of the invention as described herein comprises the live attenuated dengue virus strains TDV-1, TDV-2, TDV-3 and TDV-4, wherein TDV-1, TDV-3 and TDV-4 are based on TDV-2 and comprise the prM and E regions of DENV-1, -3 and -4, respectively. In another particularly preferred embodiment, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00196] The E protein of DENV-3 has two fewer amino acids than the E protein of DENV-2. Therefore, the nucleotides and encoded amino acid backbone of TDV-2 starting after the E region of DENV-3 at nucleotide 2374 of SEQ ID NO. 5 and amino acid 760 of SEQ ID NO. 6 are 6 nucleotides less and 2 amino acids less than the original TDV-2 nucleotide and amino acid positions, respectively.

Dengue vaccine composition

[00197] The present invention is in part directed to a unit dose of a dengue vaccine composition as described. The dengue vaccine composition comprises a tetravalent dengue virus composition, also referred to as dengue virus composition, and pharmaceutically acceptable excipients.

Dengue virus composition, virus concentrations and %-concentrations

[00198] The present invention is in part directed to a unit dose of a dengue vaccine composition, wherein the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains:

- 5 (i) a dengue serotype 1 preferably in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 preferably in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a dengue serotype 3 preferably in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a dengue serotype 4 preferably strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

[00199] In one embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains:

- 10 (i) a dengue serotype 1 preferably in a concentration of at least 3.3 log₁₀ pfu/0.5 mL to 3.8 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 preferably in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a dengue serotype 3 preferably in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a dengue serotype 4 preferably strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL or 4.6 log₁₀ pfu/0.5 mL, optionally to 6.2 log₁₀ pfu/0.5 mL.

[00200] The present invention is further in part directed to a unit dose of a dengue vaccine composition, wherein the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains:

- 20 (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

[00201] In one embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains:

- 25 (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL to 3.8 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL or at least 4.6 log₁₀ pfu/0.5 mL to optionally 6.2 log₁₀ pfu/0.5 mL.

[00202] Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4.

[00203] In one embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- 35 (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.3 log₁₀ pfu/0.5 mL,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 6.0 log₁₀ pfu/0.5 mL, and

- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.5 log₁₀ pfu/0.5 mL.

[00204] In one such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- 5 (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
 (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
 10 (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
 (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL.

[00205] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- 15 (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose,
 (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/dose ,
 (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to
 20 5.7 log₁₀ pfu/ dose, and
 (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/dose .

[00206] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- 25 (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 4.1 log₁₀ pfu/dose,
 (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 3.6 log₁₀ pfu/dose ,
 (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to
 30 4.7 log₁₀ pfu/dose, and
 (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.3 log₁₀ pfu/dose.

[00207] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- 35 (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 3.6 log₁₀ pfu/0.5 mL,
 (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.0 log₁₀ pfu/0.5 mL,
 (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/0.5 mL
 40 to 4.6 log₁₀ pfu/0.5 mL, and
 (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/0.5 ml or 4.6 log₁₀ pfu/0.5 mL to 5.1 log₁₀ pfu/0.5 mL.

[00208] In another embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 4.3 log₁₀ pfu/0.5 mL to 4.4 log₁₀ pfu/0.5 mL,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 3.7 log₁₀ pfu/0.5 mL to 3.8 log₁₀ pfu/0.5 mL,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.5 log₁₀ pfu/0.5 mL to 5.6 log₁₀ pfu/0.5 mL.

[00209] In a particularly preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 4.4 log₁₀ pfu/0.5 mL,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 3.8 log₁₀ pfu/0.5 mL,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.5 log₁₀ pfu/0.5 mL, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.6 log₁₀ pfu/0.5 mL.

[00210] In another particularly preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.6 log₁₀ pfu/0.5 mL,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 4.0 log₁₀ pfu/0.5 mL,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.6 log₁₀ pfu/0.5 mL, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.1 log₁₀ pfu/0.5 mL.

[00211] In another preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein the arithmetic sum of all four serotypes is less than 6.7 log₁₀ pfu/0.5 mL, preferably less than 5.5 log₁₀ pfu/0.5 mL. In certain such embodiments, the arithmetic sum of all four serotypes is at least 4.6 log₁₀ pfu/0.5 mL. In a preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/0.5 mL to 6.7 log₁₀ pfu/0.5 mL, preferably in the range of 4.6 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL.

[00212] Preferably, in said embodiments the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00213] The present invention is in part directed to a unit dose of a dengue vaccine composition, wherein the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of at least 3.3 log₁₀ pfu/dose,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of at least 2.7 log₁₀ pfu/dose,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of at least 4.0 log₁₀ pfu/dose, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of at least 4.5 log₁₀ pfu/dose.

[00214] In one embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 5.3 log₁₀ pfu/dose,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 6.0 log₁₀ pfu/dose, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 6.5 log₁₀ pfu/dose.

[00215] In one such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/dose,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/dose, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 6.2 log₁₀ pfu/dose.

[00216] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/dose,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/dose, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/dose.

[00217] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 4.1 log₁₀ pfu/dose,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 3.6 log₁₀ pfu/dose,
- 5 (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 4.7 log₁₀ pfu/dose, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.3 log₁₀ pfu/dose.

[00218] In a further such embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 3.6 log₁₀ pfu/dose,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 4.0 log₁₀ pfu/dose,
- 15 (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 4.6 log₁₀ pfu/dose, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose 4.6 log₁₀ pfu/dose to 5.1 log₁₀ pfu/dose.

[00219] In another embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 4.3 log₁₀ pfu/dose to 4.4 log₁₀ pfu/dose,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 3.7 log₁₀ pfu/dose to 3.8 log₁₀ pfu/dose,
- 25 (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.5 log₁₀ pfu/dose to 5.6 log₁₀ pfu/dose.

[00220] In a particularly preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 4.4 log₁₀ pfu/dose,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 3.8 log₁₀ pfu/dose,
- (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.5 log₁₀ pfu/dose, and
- 35 (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.6 log₁₀ pfu/dose.

[00221] In another particularly preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein:

- (i) the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.6 log₁₀ pfu/dose,
- (ii) the dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 4.0 log₁₀ pfu/dose,
- 40 (iii) the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.6 log₁₀ pfu/dose, and
- (iv) the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 5.1 log₁₀ pfu/dose.

[00222] In another preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein the arithmetic sum of all four serotypes is less than 6.7 log₁₀ pfu/dose, preferably less than 5.5 log₁₀ pfu/dose. In certain such embodiments, the arithmetic sum of all four serotypes is at least 4.6 log₁₀ pfu/dose. In a preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains wherein the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/dose to 6.7 log₁₀ pfu/dose, preferably in the range of 4.6 log₁₀ pfu/dose to 5.5 log₁₀ pfu/dose.

[00223] In one embodiment in the composition (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said concentration, the concentration of (iii) at least 10% of the total concentration in pfu/0.5 mL.

[00224] In one embodiment in the composition (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%.

[00225] It is preferred that the concentration in the reconstituted unit dose of (iii) in pfu/0.5 mL is at least 10%.

[00226] In one embodiment in the composition (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%.

[00227] Preferably, in said embodiments the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00228] The concentration of the different dengue viruses is preferably determined by an immuno-focus assay known in the art. For example, the concentration may be determined by an immuno-focus assay wherein serial dilutions of dengue virus are applied to monolayers of adherent cells, such as Vero cells. After a period of time which allows infectious viruses to bind to the cells and to be taken up by the cells, an overlay containing thickening agents, such as agarose or carboxymethylcellulose, is added to prevent diffusion of viruses so that progeny viruses can only infect cells adjacent to the original infected cells. After a period of incubation to allow viral replication, cells are fixed and stained using serotype-specific anti-dengue monoclonal antibodies and a secondary antibody such as an antibody labeled with alkaline phosphatase. The foci are stained by adding a suitable substrate for the enzyme attached to the secondary antibody, such as 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium phosphatase substrate. The number of plaques on the plate corresponds to the plaque forming units of the virus in the solutions applied to the cells. For example, a concentration of 1,000 pfu/μl indicates that 1 μl of the solution applied to the cells contains enough viruses to produce 1,000 plaques in a cell monolayer.

[00229] The dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains, wherein a chimeric dengue serotype 2/1 strain, a dengue serotype 2 strain, a chimeric

dengue serotype 2/3 strain, and a chimeric dengue serotype 2/4 strain provide a total concentration in pfu/0.5 mL. The term "total concentration in pfu/0.5 mL" or "total concentration in pfu/dose" is the sum of the concentrations of the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain), dengue serotype 2 (e.g. the dengue serotype 2 strain), the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) and the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain), preferably the sum of the concentrations of TDV-1, TDV-2, TDV-3 and TDV-4, and is defined as 100% of the dengue virus concentration as determined by pfu (plaque forming units) in 0.5 mL or in a dose.

[00230] In one embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains, wherein a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain), a dengue serotype 2 (e.g. dengue serotype 2 strain), a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain), and a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) provide a total concentration in pfu/0.5 mL, wherein based on said total concentration the concentration of a dengue serotype 2 (e.g. dengue serotype 2 strain) measured in pfu/0.5 mL is less than 10% of the total concentration, or less than 8%, or less than 6% of the total concentration, and wherein the concentration of a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) measured in pfu/0.5 mL is at least 50% or at least 60% or at least 65% of the total concentration. In one embodiment, based on said total concentration the concentration of a dengue serotype 2 (e.g. dengue serotype 2 strain) measured in pfu/0.5 mL is 0.3 to 10% or 0.5 to 8% of the total concentration and the concentration of a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) measured in pfu/0.5 mL is 50% to 90% or 60% to 88% of the total concentration. This means that the concentration of the dengue serotype 2 (e.g. dengue serotype 2 strain) is lower than the concentration of the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain).

[00231] In one such embodiment, the concentration of a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) measured in pfu/0.5 mL is at least 1% of the total concentration, and/or the concentration of a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) measured in pfu/0.5 mL is at least 6% of the total concentration, or at least 7% or 8%, 10%, 12%, 14%, 16% or 18% of the total concentration. In one such embodiment, the concentration of a dengue serotype 2 (e.g. chimeric dengue serotype 2/1 strain) measured in pfu/0.5 mL is 1% to 7% or 2% to 6% or 2.0% to 5.0% of the total concentration, and/or the concentration of a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) measured in pfu/0.5 mL is 6% to 25% or 7% to 25% or 10% to 25% or 18% to 25% of the total concentration. This means that the concentration of the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) is lower than the concentration of the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain).

[00232] In a preferred embodiment, the concentration of a dengue serotype 2 strain, such as TDV-2, measured in pfu/0.5 mL is less than 10% of the total concentration, preferably less than 6% or less than 2%, the concentration of a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain), such as TDV-4, measured in pfu/0.5 mL is at least 50% of the total concentration, preferably at least 65%, the concentration of a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain), such as TDV-1, measured in pfu/0.5 mL is at least 1% of the total concentration, preferably between 1% and 7% or 2.0% to 5.0%, and the concentration of a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain), such as TDV-3, measured in pfu/0.5 mL is at least 6% of the total concentration, preferably between 6% and 25% or 10% to 25% or 18% to 25%.

[00233] In a further preferred embodiment, a dengue virus composition comprising a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain), a dengue serotype 2 (e.g. dengue serotype 2 strain), a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain), and a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain), such as TDV-1, TDV-2, TDV-3 and TDV-4, is provided, wherein the concentration of the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) measured in pfu/0.5 mL is at least 1% of the total concentration, preferably between 1% and 7% or 2.0% and 5.0%, the concentration of the dengue serotype 2 (e.g. dengue serotype 2 strain) measured in

pfu/0.5 mL is less than 10% of the total concentration, preferably less than 6% or less than 2% and the concentration of the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) measured in pfu/0.5 mL is at least 6% of the total concentration, preferably between 6% and 25% or 10% to 25% or 18% to 25%. It is particularly preferred that the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has the highest concentration of all four dengue serotypes.

[00234] In a further preferred embodiment, the dengue vaccine composition comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains, wherein the concentration of the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) measured in pfu/0.5 mL is 1% to 7% of the total concentration, the concentration of the dengue serotype 2 (e.g. dengue serotype 2 strain) measured in pfu/0.5 mL is less than 8% of the total concentration, such as in the range of 1% to 8% of the total concentration, the concentration of the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) measured in pfu/0.5 mL is at least 10% of the total concentration, and the concentration of the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) measured in pfu/0.5 mL is at least 65% of the total concentration, such as in the range of 65% to 80%. In certain such embodiments, the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/0.5 mL to 6.7 log₁₀ pfu/0.5 mL, preferably in the range of 4.6 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL.

[00235] In a further preferred embodiment the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and the dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 is preferably at least about 10% of the total concentration in pfu/0.5 mL and more preferably the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 is at least about 70% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 each represent lower concentrations than the concentration of serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

[00236] Preferably, in said embodiments the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00237] According to a further embodiment, the chimeric dengue serotype 2/4 strain, preferably TDV-4, has the highest concentration in the dengue vaccine composition, followed by the chimeric dengue serotype 2/3 strain, preferably TDV-3, followed by the chimeric dengue serotype 2/1 strain, preferably TDV-1, followed by the dengue serotype 2 strain, preferably TDV-2. It is particularly preferred that the dengue serotype 2 strain has the lowest concentration of the four strains present in the dengue vaccine composition.

[00238] Whenever reference is made to a concentration/0.5ml, this does not limit the volume of the unit dose described herein to 0.5ml. 0.5ml is the reference volume for the determination of the concentrations of the virus strains in the composition in pfu/ml. The volume and/or amount per unit dose is described in the respective chapter.

Pharmaceutically acceptable excipients

5 **[00239]** The present invention is in part directed to a unit dose of a dengue vaccine composition, wherein the dengue vaccine composition comprises one or more pharmaceutically acceptable excipients. In one embodiment, the dengue vaccine composition comprises a non-reducing sugar, a surfactant, a protein and an inorganic salt. Preferably, the non-reducing sugar is trehalose, the surfactant is poloxamer 407, the protein is human serum albumin and the inorganic salt is sodium chloride.

10 **[00240]** In one embodiment, the unit dose of a dengue vaccine composition comprises the following pharmaceutically acceptable excipients:

- from about 10 % w/v to about 20 % w/v α,α -trehalose dihydrate or an equimolar amount of other forms of α,α -trehalose,
- from about 0.5 % w/v to about 1.5 % w/v poloxamer 407,
- 15 - from about 0.05 % w/v to about 2 % w/v human serum albumin, and
- from about 70 mM to 140 mM sodium chloride.

[00241] In one embodiment, the unit dose of a dengue vaccine composition comprises the following pharmaceutically acceptable excipients when measured in 0.5 ml:

- 20 - from about 10 % w/v to about 20 % w/v α,α -trehalose or an equimolar amount of other forms of α,α -trehalose,
- from about 0.5 % w/v to about 1.5 % w/v poloxamer 407,
- from about 0.05 % w/v to about 2 % w/v human serum albumin, and
- from about 70 mM to 140 mM sodium chloride, and preferably
- has a pH of 7 to 8.5.

25 **[00242]** In one embodiment, the unit dose of a dengue vaccine composition comprises the following pharmaceutically acceptable excipients when measured in 0.5ml:

- from about 143 mg/ml to about 185 mg/ml α,α -trehalose dihydrate or an equimolar amount of other forms of α,α -trehalose,
- from about 9.1 mg/ml to about 12.4 mg/ml poloxamer 407,
- 30 - from about 0.88 % mg/ml to about 1.32 mg/ml human serum albumin, and
- from about 70 mM to 140 mM sodium chloride, and preferably
- has a pH of 7 to 8.5.

[00243] In a preferred embodiment, the lyophilized unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients:

- 35 - about 15 % w/v α,α -trehalose dihydrate,
- about 1 % w/v poloxamer 407,
- about 0.1 % w/v human serum albumin, and
- about 100 mM sodium chloride.

[00244] In a preferred embodiment, the lyophilized unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients when measured in 0.5ml:

- about 15 % w/v α,α -trehalose,
- about 1 % w/v poloxamer 407,
- 5 - about 0.1 % w/v human serum albumin, and
- about 100 mM sodium chloride.

[00245] In a preferred embodiment, the lyophilized unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients:

- about 82.9 mg α,α -trehalose dihydrate,
- 10 - about 5 mg poloxamer 407,
- about 0.5 mg human serum albumin, and
- about 50 μ moles sodium chloride.

[00246] In a preferred embodiment, the reconstituted unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients:

- 15 - about 15 % w/v α,α -trehalose dihydrate,
- about 1 % w/v poloxamer 407,
- about 0.1 % w/v human serum albumin, and
- about 137 mM sodium chloride, and preferably
- has a pH of 7 to 8.5

20 **[00247]** In a preferred embodiment, the reconstituted unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients when measured in 0.5 ml:

- about 15 % w/v α,α -trehalose,
- about 1 % w/v poloxamer 407,
- about 0.1 % w/v human serum albumin, and preferably
- 25 - about 137 mM sodium chloride and preferably
- has a pH of 7 to 8.5.

[00248] In a preferred embodiment, the reconstituted unit dose of the invention as described herein comprises the following pharmaceutically acceptable excipients:

- about 82.9 mg α,α -trehalose dihydrate,
- 30 - about 5 mg poloxamer 407,
- about 0.5 mg human serum albumin, and preferably
- about 68.5 μ moles sodium chloride, and preferably
- has a pH of 7 to 8.5.

35 **[00249]** The human serum albumin may be a native or recombinant human serum albumin (rHSA). The poloxamer 407 may be e.g. Pluronic F127.

[00250] In one embodiment, the unit dose further comprises a buffer. The buffer may be phosphate buffered saline (PBS). The buffer may include at least one of sodium chloride (NaCl), monosodium dihydrogen phosphate (NaH_2PO_4), disodium hydrogen phosphate (Na_2HPO_4), potassium chloride (KCl), and potassium dihydrogen phosphate (KH_2PO_4). In a preferred embodiment, the buffer may include disodium hydrogen phosphate (Na_2HPO_4), potassium chloride (KCl), and potassium dihydrogen phosphate (KH_2PO_4). The buffer may have a pH in the range of 7.0 to 8.5 at 25°C.

Unit dose

[00251] The present invention is directed in part to a unit dose of a dengue vaccine composition comprising a tetravalent dengue virus composition as described herein and pharmaceutically acceptable excipients as described herein.

[00252] The present invention is directed in part to a unit dose of a dengue vaccine composition as described above e.g. of

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) with a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) with a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) with a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) with a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

[00253] Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3, and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00254] In one embodiment, the unit dose is lyophilized. In one such embodiment, the lyophilized unit dose is obtained by subjecting a volume of 0.5 mL of the aqueous dengue vaccine composition produced by combining pharmaceutically acceptable excipients as described herein and the dengue vaccine composition as described herein comprising the four dengue virus strains, in particular TDV-1 to TDV-4, to lyophilization. In a preferred embodiment the residual moisture content as determined by Karl Fischer Determination is equal to or less than 5.0%, preferably equal to or less than 3%.

[00255] In another embodiment, the unit dose is reconstituted. The reconstituted unit dose is obtained by subjecting the lyophilized unit dose to reconstitution with a pharmaceutically acceptable diluent, preferably before administration of the dengue vaccine. In one such embodiment, reconstitution will be accomplished by adding a pharmaceutically acceptable diluent, such as water for injection, phosphate buffered saline or an aqueous sodium chloride solution, to the lyophilized unit dose. In one embodiment, an aqueous sodium chloride solution, such as a 37 mM aqueous sodium chloride solution, is added to the lyophilized unit dose for reconstitution. In one such embodiment, the lyophilized unit dose will be reconstituted with 0.3 to 0.8 mL, or 0.4 to 0.7 mL, or 0.5 mL of diluent. In a preferred embodiment, the lyophilized unit dose is reconstituted with 0.3 to 0.8 mL, 0.4 to 0.7 mL or 0.5 mL of 37 mM aqueous sodium chloride solution. In a more preferred embodiment, the lyophilized unit dose is reconstituted with 0.5 mL of 37 mM aqueous sodium chloride solution. The reconstituted unit dose can subsequently be administered subcutaneously.

[00256] It is preferred that the unit dose in lyophilized form is the final product after manufacture of the unit dose and the storage form of the unit dose, wherein the unit dose in reconstituted form is prepared before administration of the unit dose to a subject.

[00257] The present invention is, moreover, directed in part to a unit dose of a dengue vaccine composition comprising:

a tetravalent virus composition including four live attenuated dengue virus strains, wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- 5 (i) a dengue serotype 1, such as a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, such as a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, such as a chimeric dengue serotype 2/3 strain, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- 10 (iv) a dengue serotype 4, such as a chimeric dengue serotype 2/4 strain, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00258] In one embodiment, the reconstituted unit dose has a volume of e.g. 0.5 mL, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said concentration, the concentration of (iii) at least 10% of the total concentration in pfu/0.5 mL.

15

[00259] In another embodiment the reconstituted unit dose has a volume of e.g. 0.5 mL, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%.

20

[00260] It is preferred that the concentration in the reconstituted unit dose of (iii) in pfu/0.5 mL is at least 10%.

[00261] In one embodiment the reconstituted unit dose has a volume of e.g. 0.5 mL, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%.

25

[00262] In one embodiment, the present invention is directed to a lyophilized unit dose of a dengue vaccine composition comprising upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) with a concentration of at least 3.3 log₁₀ pfu/0.5 mL, a dengue serotype 2 (e.g. dengue serotype 2 strain) with a concentration of at least 2.7 log₁₀ pfu/0.5 mL, a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) with a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) with a concentration of at least 4.5 log₁₀ pfu/0.5 mL and pharmaceutically acceptable excipients as described herein, wherein the unit dose is preferably formulated in 0.5 mL before lyophilization. Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably, TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the

30

35

40

amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00263] In one such embodiment, the lyophilized unit dose is obtained by lyophilizing 0.5 mL of a dengue vaccine composition comprising a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/0.5 mL, a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/0.5 mL, a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/0.5 mL, and a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/0.5 mL and pharmaceutically acceptable excipients as described herein. Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4.

[00264] In one such embodiment, the lyophilized unit dose is obtained by lyophilizing 0.5 mL of a dengue vaccine composition comprising a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) in a concentration of 3.3 log₁₀ pfu/0.5 mL to 3.6 log₁₀ pfu/0.5 mL, a dengue serotype 2 (e.g. dengue serotype 2 strain) in a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.0 log₁₀ pfu/0.5 mL, a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) in a concentration of 4.0 log₁₀ pfu/0.5 mL to 4.6 log₁₀ pfu/0.5 mL, and a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) in a concentration of 4.5 log₁₀ pfu/0.5 mL or 4.6 log₁₀ pfu/0.5 mL to 5.1 log₁₀ pfu/0.5 mL and pharmaceutically acceptable excipients as described herein. Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4.

[00265] In certain embodiments, the lyophilized unit dose refers to 0.5 mL before lyophilization, wherein TDV-2 and TDV-4 are present in certain relative amounts, based on the total concentration of TDV-1, TDV-2, TDV-3 and TDV-4 in pfu/0.5 mL, and the concentration of TDV-2 measured in pfu/0.5 mL is less than 10% or less than 8% or less than 6%, and the concentration of TDV-4 measured in pfu/0.5 mL is at least 50% or at least 65%. In some of these embodiments, the concentration of TDV-1 measured in pfu/0.5 mL is at least 1% and/or the concentration of TDV-3 measured in pfu/0.5 mL is at least 6%, 7%, 8%, 10%, 12%, 14%, 16% or at least 18%.

[00266] In certain embodiments, the reconstituted unit dose has a volume of 0.5 mL and TDV-2 and TDV-4 are present in certain relative amounts, based on the total concentration of TDV-1, TDV-2, TDV-3 and TDV-4 in pfu/0.5 mL, and the concentration of TDV-2 measured in pfu/0.5 mL is less than 10% or less than 8% or less than 6%, and the concentration of TDV-4 measured in pfu/0.5 mL is at least 50% or at least 65%. In some of these embodiments, the concentration of TDV-1 measured in pfu/0.5 mL is at least 1% and/or the concentration of TDV-3 measured in pfu/0.5 mL is at least 6%, 7%, 8%, 10%, 12%, 14%, 16% or at least 18%.

[00267] In a further preferred embodiment, the reconstituted unit dose has a volume of 0.5 mL and comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains, wherein the concentration of the dengue serotype 1 (e.g. dengue serotype 2/1 strain) measured in pfu/0.5 mL is 1% to 7% of the total concentration, the concentration of the dengue serotype 2 (e.g. dengue serotype 2 strain) measured in pfu/0.5 mL is less than 8% of the total concentration, such as in the range of 1% to 8% of the total concentration, the concentration of the dengue serotype 3 (e.g. dengue serotype 2/3 strain) measured in pfu/0.5 mL is at least 10% of the total concentration, and the concentration of the dengue serotype 4 (e.g. dengue serotype 2/4 strain) measured in pfu/0.5 mL is at least 65% of the total concentration, such as in the range of 65% to 80%. In certain such embodiments, the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/0.5 mL to 6.7 log₁₀ pfu/0.5 mL, preferably in the range of 4.6 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL.

[00268] In a further preferred embodiment, the reconstituted unit dose has a volume of 0.5 mL and comprises a tetravalent dengue virus composition including four live attenuated dengue virus strains, wherein the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and the dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 is preferably at least about 10% of the total concentration in pfu/0.5 mL and more preferably the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 is at least about 70% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 each represent lower concentrations than the concentration of serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

[00269] The lyophilized unit dose reconstituted in 0.5 mL will provide the above concentrations for the four dengue serotypes. While the unit dose of a dengue vaccine composition as described herein refers to the concentrations of the dengue serotypes in 0.5 mL, the lyophilized unit dose can be reconstituted with other volumes of a pharmaceutically acceptable diluent, such as an aqueous sodium chloride solution, without changing the absolute virus amount administered or the ratios of the viruses to one another.

[00270] In certain embodiments, the lyophilized unit dose of the invention is prepared from a solution comprising a non-reducing sugar, a surfactant, a protein and an inorganic salt.

[00271] In certain embodiments, the lyophilized unit dose of the invention is prepared from a solution comprising trehalose, poloxamer 407, human serum albumin and sodium chloride.

[00272] In certain embodiments, the lyophilized unit dose of the invention is prepared from a solution comprising about 10 % w/v to about 20 % w/v α,α -trehalose dihydrate or an equimolar amount of other forms of α,α -trehalose, from about 0.5 % w/v to about 1.5 % w/v poloxamer 407, from about 0.05 % w/v to about 2 % w/v human serum albumin, and about 70 mM to about 120 mM sodium chloride.

[00273] In preferred embodiments, the lyophilized unit dose of the invention as described herein is prepared from a solution comprising about 15 % w/v α,α -trehalose dihydrate, about 1 % w/v poloxamer 407, about 0.1 % w/v human serum albumin and about 100 mM sodium chloride.

[00274] In one embodiment, the solution from which the lyophilized unit dose is prepared further comprises a buffer. The buffer may be phosphate buffered saline (PBS). The buffer may include at least one of sodium chloride (NaCl), monosodium dihydrogen phosphate (NaH_2PO_4), disodium hydrogen phosphate (Na_2HPO_4), potassium chloride (KCl), and potassium dihydrogen phosphate (KH_2PO_4). In a preferred embodiment, the buffer may include disodium hydrogen phosphate (Na_2HPO_4), potassium chloride (KCl), and potassium dihydrogen phosphate (KH_2PO_4). The buffer may have a pH in the range of about 7.0 to about 8.5 at 25°C or a pH of about 6.8 to about 7.6 at 25°C, preferably a pH of about 7.2 at 25°C.

[00275] In preferred embodiments, the reconstituted unit dose of the invention as described herein comprising about 15 % w/v α,α -trehalose dihydrate, about 1 % w/v poloxamer 407, about 0.1 % w/v human serum albumin and about 137 mM sodium chloride. The reconstituted unit dose may have a pH of about 7.0 to about 8.5 at 25°C, preferably a pH of about 7.2 at 25°C.

5 **[00276]** The unit dose of the invention as described herein activates multiple arms of the immune system – neutralizing antibodies, cellular immunity and anti-NS1 antibodies – in both seronegative and seropositive subject populations or in both seronegative and seropositive subjects. Thus, the unit dose of the invention as described herein protects both dengue seronegative and dengue seropositive subject populations or subjects against dengue disease.

10 **[00277]** In one embodiment, one unit dose is present in a container, preferably a vial, and said unit dose is administered to a subject after reconstitution. In one embodiment, more than one unit dose of the dengue vaccine composition may be present in a container, preferably a vial, so that with the content of one container, preferably a vial, more than one subject can be vaccinated. In one embodiment, the container comprising more than one unit doses of the invention as described herein is used for providing the reconstituted unit dose to be used in the methods of the invention as described herein.

15 **[00278]** The certain embodiments, the container comprising the unit dose of the invention is part of a kit. Thus, the invention is directed in part to a kit for preparing a reconstituted unit dose comprising a lyophilized unit dose of the present invention as described herein, and a pharmaceutically acceptable diluent for reconstitution.

20 **[00279]** In certain embodiments, the diluent for reconstitution provided in a container, preferably a vial, or a pre-filled syringe. In some embodiments, the diluent for reconstitution is selected from water for injection, phosphate buffered saline or an aqueous sodium chloride solution. In a preferred embodiment, the diluent for reconstitution is 30 to 40 mM sodium chloride, such as 37 mM sodium chloride.

25 **[00280]** In certain embodiments, the kit may further comprise a yellow fever vaccine, in particular YF-17D. In some embodiments, the yellow fever vaccine may be in a separate container, such as a vial. In another embodiment, the yellow fever vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/yellow fever vaccine, wherein the unit dose of the invention as described herein is combined with a yellow fever vaccine. Such a combined dengue/yellow fever vaccine comprises the unit dose of the invention as described herein and a yellow fever vaccine, in particular YF-17D, in the same formulation. In certain embodiments, the invention is directed to a kit comprising such a combined dengue/yellow fever vaccine and a unit dose of the invention as described herein.

30 **[00281]** In certain embodiments, the kit may further comprise a hepatitis A vaccine, such as HAVRIX® or VAQTA®. In some embodiments, the hepatitis A vaccine may be in a separate container, such as a vial. In another embodiment, the hepatitis A vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/hepatitis A vaccine, wherein the unit dose of the invention as described herein is combined with a hepatitis A vaccine. Such a combined dengue/hepatitis A vaccine comprises the unit dose of the invention as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, in the same formulation. In certain embodiments, the invention is directed to a kit comprising such a combined dengue/hepatitis A vaccine and a unit dose of the invention as described herein.

[00282] In certain embodiments, the kit may further comprise a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9. In some embodiments, the HPV vaccine may be in a separate container, such as a vial. In another

embodiment, the HPV vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/HPV vaccine, wherein the unit dose of the invention as described herein is combined with a HPV vaccine. Such a combined dengue/HPV vaccine comprises the unit dose of the invention as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, in the same formulation.

5 In certain embodiments, the invention is directed to a kit comprising such a combined dengue/HPV vaccine and a unit dose of the invention as described herein.

[00283] In certain embodiments, the kit may further comprise a MMR vaccine, such as M-M-R® II. In some embodiments, the MMR vaccine may be in a separate container, such as a vial. In another embodiment, the MMR vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/ MMR vaccine, wherein the unit dose of the invention as described herein is combined with a MMR vaccine. Such a combined dengue/ MMR vaccine comprises the unit dose of the invention as described herein and a MMR vaccine, such as M-M-R® II, in the same formulation. In certain embodiments, the invention is directed to a kit comprising such a combined dengue/ MMR vaccine and a unit dose of the invention as described herein.

[00284] In certain embodiments, the kit may further comprise a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®. In some embodiments, the Tdap vaccine may be in a separate container, such as a vial. In another embodiment, the Tdap vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/Tdap vaccine, wherein the unit dose of the invention as described herein is combined with a Tdap vaccine. Such a combined dengue/Tdap vaccine comprises the unit dose of the invention as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, in the same formulation. In certain embodiments, the invention is directed to a kit comprising such a combined dengue/Tdap vaccine and a unit dose of the invention as described herein.

[00285] In certain embodiments, the kit may further comprise a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®. In some embodiments, the DTaP/IPV/Hib vaccine may be in a separate container, such as a vial. In another embodiment, the DTaP/IPV/Hib vaccine and the unit dose of the invention may be in the same container. Thus, the invention is directed in part to a combined dengue/DTaP/IPV/Hib vaccine, wherein the unit dose of the invention as described herein is combined with a DTaP/IPV/Hib vaccine. Such a combined dengue/DTaP/IPV/Hib vaccine comprises the unit dose of the invention as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, in the same formulation. In certain embodiments, the invention is directed to a kit comprising such a combined dengue/DTaP/IPV/Hib vaccine and a unit dose of the invention as described herein.

Yellow Fever vaccine

[00286] YF-VAX®, a yellow fever vaccine from Sanofi, for subcutaneous use, is prepared by culturing the YF-17D strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos. The vaccine contains sorbitol and gelatin as a stabilizer and is lyophilized. No preservative is added. YF-VAX is formulated to contain not less than 4.74 log₁₀ pfu per 0.5 mL dose throughout the life of the product.

Hepatitis A vaccine

[00287] HAVRIX®, a hepatitis A vaccine from GlaxoSmithKline, is a sterile suspension of inactivated virus for intramuscular administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. After removal of

the cell culture medium, the cells are lysed to form a suspension. This suspension is purified through ultrafiltration and gel permeation chromatography procedures. Treatment of this lysate with formalin ensures viral inactivation. Viral antigen activity is referenced to a standard using an enzyme linked immunosorbent assay (ELISA), and is therefore expressed in terms of ELISA Units (EL.U.). Each 1-mL dose for adults (≥ 18 years of age) of vaccine contains 1440 EL.U. of viral antigen, adsorbed on 0.5 mg of aluminum as aluminum hydroxide. Each 0.5-mL dose for children and adolescents (12 months through 18 years of age) of vaccine contains 720 EL.U. of viral antigen, adsorbed onto 0.25 mg of aluminum as aluminum hydroxide. HAVRIX® contains the following excipients: Amino acid supplement (0.3% w/v) in a phosphate-buffered saline solution and polysorbate 20 (0.05 mg/mL). From the manufacturing process, HAVRIX® also contains residual MRC-5 cellular proteins (not more than 5 µg/mL), formalin (not more than 0.1 mg/mL), and neomycin sulfate (not more than 40 ng/mL), an aminoglycoside antibiotic included in the cell growth media. HAVRIX® is formulated without preservatives.

[00288] VAQTA®, a hepatitis A vaccine from Merck Sharp & Dohme Corp., is an inactivated whole virus vaccine derived from hepatitis A virus grown in cell culture in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain, which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, purified by a combination of physical and high performance liquid chromatographic techniques developed at the Merck Research Laboratories, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulfate. VAQTA® is a sterile suspension for intramuscular injection. One milliliter of the vaccine contains approximately 50 U of hepatitis A virus antigen, which is purified and formulated without a preservative. Within the limits of current assay variability, the 50 U dose of VAQTA® contains less than 0.1 µg of non-viral protein, less than 4×10^{-6} µg of DNA, less than 10^{-4} µg of bovine albumin, and less than 0.8 µg of formaldehyde. Other process chemical residuals are less than 10 parts per billion (ppb), including neomycin. Each 0.5-mL pediatric dose contains 25 U of hepatitis A virus antigen and adsorbed onto approximately 0.225 mg of aluminum provided as amorphous aluminum hydroxyphosphate sulfate, and 35 µg of sodium borate as a pH stabilizer, in 0.9% sodium chloride. Each 1-mL adult dose contains 50 U of hepatitis A virus antigen and adsorbed onto approximately 0.45 mg of aluminum provided as amorphous aluminum hydroxyphosphate sulfate, and 70 µg of sodium borate as a pH stabilizer, in 0.9% sodium chloride.

HPV vaccine

[00289] GARDASIL® 9, a HPV vaccine from Merck, is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV serotypes 6, 11, 16, 18, 31, 33, 45, 52, and 58. The L1 proteins are produced by separate fermentations using recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. The fermentation process involves growth of *S. cerevisiae* on chemically-defined fermentation media which include vitamins, amino acids, mineral salts, and carbohydrates. The VLPs are released from the yeast cells by cell disruption and purified by a series of chemical and physical methods. The purified VLPs are adsorbed on preformed aluminum-containing adjuvant (amorphous aluminum hydroxyphosphate sulfate or AAHS). The 9-valent HPV VLP vaccine is a sterile liquid suspension that is prepared by combining the adsorbed VLPs of each HPV serotype and additional amounts of the aluminum-containing adjuvant and the final purification buffer. GARDASIL 9 is a sterile suspension for intramuscular administration. Each 0.5-mL dose contains approximately 30 µg of HPV serotype 6 L1 protein, 40 µg of HPV serotype 11 L1 protein, 60 µg of HPV serotype 16 L1 protein, 40 µg of HPV serotype 18 L1 protein, 20 µg of HPV serotype 31 L1 protein, 20 µg of HPV serotype 33 L1 protein, 20 µg of HPV serotype 45 L1 protein, 20 µg of HPV serotype 52 L1 protein, and 20 µg of HPV serotype 58 L1 protein. Each 0.5-mL dose of the vaccine also contains approximately 500 µg of aluminum (provided as AAHS), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 µg of polysorbate 80, 35 µg of sodium borate.

MMR vaccine

[00290] Several MMR vaccines are known in the prior art and include M-M-R® II, Priorix®, Tresivac®, and Trimovax®.

[00291] M-M-R® II, a MMR vaccine from Merck Sharp & Dohme Corp, is a live virus vaccine for vaccination against measles, mumps and rubella. M-M-R® II is a sterile lyophilized preparation of (1) ATTENUVAX® (measles virus vaccine live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture, (2) MUMPSVAX® (mumps virus vaccine live), the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture, and (3) MERUVAX® II (rubella virus vaccine live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts. The growth medium for measles and mumps is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and recombinant human albumin) as stabilizer and neomycin. The growth medium for rubella is Minimum Essential Medium (MEM) (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests. The cells, virus pools, and fetal bovine serum are all screened for the absence of adventitious agents. The reconstituted vaccine is for subcutaneous administration. Each 0.5 mL dose contains not less than 1,000 TCID₅₀ (tissue culture infectious doses) of measles virus, 12,500 TCID₅₀ of mumps virus, and 1,000 TCID₅₀ of rubella virus. Each dose of the vaccine is calculated to contain sorbitol (14.5 mg), sodium phosphate, sucrose (1.9 mg), sodium chloride, hydrolyzed gelatin (14.5 mg), recombinant human albumin (≤0.3 mg), fetal bovine serum (<1 ppm), other buffer and media ingredients and approximately 25 µg of neomycin. The product contains no preservative. The lyophilized vaccine is reconstituted before administration.

Combined tetanus, diphtheria, and pertussis (Tdap) vaccine

[00292] BOOSTRIX®, a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) (Tdap) vaccine, is a non-infectious, sterile vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated pertussis toxin (iPT) and formaldehyde-treated filamentous hemagglutinin (FHA) and pertactin (PRN)). The antigens are the same as those in INFANRIX®, but BOOSTRIX® is formulated with reduced quantities of these antigens.

[00293] BOOSTRIX® is supplied as a 0.5 mL suspension for injection. Each 0.5 mL dose of BOOSTRIX® is formulated to contain 5 Limits of flocculation (Lf) of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 µg of iPT, 8 µg of formaldehyde treated FHA, and 2.5 µg of PRN (69 kiloDalton outer membrane protein), aluminum hydroxide as adjuvant (not more than 0.39 mg aluminum by assay), 4.5 mg of sodium chloride, ≤100 µg of residual formaldehyde, and ≤100 µg of polysorbate 80 (Tween 80).

[00294] Tetanus toxin is produced by growing *Clostridium tetani* in a modified Latham medium derived from bovine casein. The diphtheria toxin is produced by growing *Corynebacterium diphtheriae* in Fenton medium containing a bovine extract. Both toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration. Tetanus and diphtheria toxoid potency is determined by measuring the amount of neutralizing antitoxin in previously immunized guinea pigs.

[00295] The acellular pertussis antigens (iPT, FHA, and PRN) are isolated from *Bordetella pertussis* culture grown in modified Stainer-Scholte liquid medium. iPT and FHA are isolated from the fermentation broth, PRN is extracted from

the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. iPT is detoxified using glutaraldehyde and formaldehyde. FHA and PRN are treated with formaldehyde. Each antigen is individually adsorbed onto aluminum hydroxide. The potency of the acellular pertussis components (inactivated iPT and formaldehyde-treated FHA and PRN) is determined by enzyme-linked immunosorbent assay (ELISA) on sera from previously immunized mice.

Combined Diphtheria, Tetanus, Pertussis, Poliomyelitis and *Haemophilus influenzae* type b (DTaP/IPV/Hib) Vaccine

[00296] Pentacel®, a combined DTaP/IPV/Hib vaccine, consists of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus (DTaP-IPV) component and an ActHIB® component combined through reconstitution for intramuscular injection. ActHIB® (*Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate)), consists of *Haemophilus influenzae* type b capsular polysaccharide (polyribosyl-ribitol-phosphate (PRP)) covalently bound to tetanus toxoid (PRP-T). The DTaP-IPV component is supplied as a sterile liquid used to reconstitute the lyophilized ActHIB® component to form Pentacel®.

[00297] Each 0.5 mL dose contains 15 Limits of flocculation (Lf) diphtheria toxoid, 5 Lf tetanus toxoid, acellular pertussis antigens (20 µg detoxified pertussis toxin (PT), 20 µg filamentous hemagglutinin (FHA), 3 µg pertactin (PRN), 5 µg fimbriae types 2 and 3 (FIM)), inactivated polioviruses (40 D-antigen units (DU) Type 1 (Mahoney), 8 DU Type 2 (MEF-1), 32 DU Type 3 (Saukett)) and 10 µg PRP of *Haemophilus influenzae* type b covalently bound to 24 µg of tetanus toxoid (PRP-T).

[00298] Other ingredients per 0.5 mL dose include 1.5 mg aluminum phosphate (0.33 mg aluminum) as the adjuvant, polysorbate 80 (approximately 10 ppm by calculation), 42.5 mg sucrose, ≤5 µg residual formaldehyde, <50 ng residual glutaraldehyde, ≤50 ng residual bovine serum albumin, 3.3 mg (0.6 % v/v) 2-phenoxyethanol (not as a preservative), <4 µg of neomycin and <4 µg polymyxin B sulfate.

[00299] *Corynebacterium diphtheriae* is grown in modified Mueller's growth medium. After purification by ammonium sulfate fractionation, the diphtheria toxin is detoxified with formaldehyde and diafiltered.

[00300] *Clostridium tetani* is grown in modified Mueller-Miller casamino acid medium without beef heart infusion. Tetanus toxin is detoxified with formaldehyde and purified by ammonium sulfate fractionation and diafiltration. Diphtheria and tetanus toxoids are individually adsorbed onto aluminum phosphate.

[00301] The acellular pertussis vaccine antigens are produced from *Bordetella pertussis* cultures grown in Stainer-Scholte medium modified by the addition of casamino acids and dimethyl-beta-cyclodextrin. PT, FHA and PRN are isolated separately from the supernatant culture medium. FIM are extracted and co-purified from the bacterial cells. The pertussis antigens are purified by sequential filtration, salt-precipitation, ultrafiltration and chromatography. PT is detoxified with glutaraldehyde. FHA is treated with formaldehyde and the residual aldehydes are removed by ultrafiltration. The individual antigens are adsorbed separately onto aluminum phosphate.

[00302] Poliovirus Type 1, Type 2 and Type 3 are each grown in separate cultures of MRC-5 cells, a line of normal human diploid cells, by the microcarrier method. The cells are grown in CMRL (Connaught Medical Research Laboratories) 1969 medium, supplemented with calf serum. For viral growth, the culture medium is replaced by Medium 199, without calf serum. After clarification and filtration, the viral suspensions are concentrated by ultrafiltration, and purified by liquid chromatography steps. The monovalent viral suspensions are inactivated with formaldehyde. Monovalent concentrates of each inactivated poliovirus are combined to produce a trivalent poliovirus concentrate.

[00303] The adsorbed diphtheria, tetanus and acellular pertussis antigens are combined with aluminum phosphate (as adjuvant), 2-phenoxyethanol (not as a preservative) and water for injection, into an intermediate concentrate. The trivalent poliovirus concentrate is added and the DTaP-IPV component is diluted to its final concentration. The DTaP-IPV component does not contain a preservative.

- 5 **[00304]** Both diphtheria and tetanus toxoids induce at least 2 neutralizing units per mL in the guinea pig potency test. The potency of the acellular pertussis antigens is evaluated by the antibody response of immunized mice to detoxified PT, FHA, PRN and FIM as measured by enzyme-linked immunosorbent assay (ELISA). The potency of inactivated poliovirus antigens is determined by measuring antibody-mediated neutralization of poliovirus in sera from immunized rats.
- 10 **[00305]** PRP, a high molecular weight polymer, is prepared from the *Haemophilus influenzae* type b strain 1482 grown in a semi-synthetic medium. The tetanus toxoid for conjugation to PRP is prepared by ammonium sulfate purification, and formalin inactivation of the toxin from cultures of *Clostridium tetani* (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. The ActHIB® component does not contain a preservative. Potency of the ActHIB® component is specified on each lot by limits on
- 15 the content of PRP polysaccharide and protein per dose and the proportion of polysaccharide and protein that is characterized as high molecular weight conjugate.

Method of preventing and uses, method of inoculating and uses

Method of preventing, method of inoculating

- 20 **[00306]** The present invention is directed in part to a method of preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject, a unit dose/tetravalent dengue virus composition, in particular a reconstituted unit dose of the invention as described herein.

- 25 **[00307]** The present invention is directed in part to a method of preventing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Thus, in certain embodiments the invention is directed to a method of preventing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), comprising administering to the subject a reconstituted unit dose/tetravalent dengue virus composition of the invention as described herein.

- 30 **[00308]** The present invention is therefore directed to a method of inoculating a subject against virologically confirmable dengue disease with a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, wherein in particular the tetravalent dengue virus composition includes a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain, wherein in particular the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 (SEQ ID NO 11) and differs in at least three nucleotides from the wild type as follows:

- 35 a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T): major attenuation locus
 b) NS1-53 Gly-to-Asp (nt-2579 G-to-A): major attenuation locus
 c) NS3-250 Glu-to-Val (nt-5270 A-to-T): major attenuation locus; and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[00309] Further information regarding the serotypes of the tetravalent composition can be derived from section "Dengue virus strains" above.

[00310] The tetravalent dengue virus composition for such a method may be in the form of a unit dose comprising:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00311] The present invention is in particular directed to such a method wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00312] The present invention is also in particular directed to such a method wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%, and wherein preferably the subject is 2 to 17 years of age or 4 to 16 years of age.

[00313] The present invention is also in particular directed to such a method wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6%, wherein preferably the subject is 18 to 60 years of age.

[00314] Further information regarding the tetravalent composition or the unit dose can be derived from section "Dengue vaccine composition" and "Unit dose" above.

[00315] The present invention is therefore directed to a method and corresponding use, the method comprising a primary vaccination with only two administrations of the unit dose comprising the steps of:

- (A) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (B) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

According to this embodiment the administration of only two doses within 3 months is sufficient to provide effective protection against a subsequent dengue infection.

[00316] Such method preferably provides a combined vaccine efficacy against all four serotypes in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than

60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 14 to 16 years of age, from the first administration of the administration schedule until 18 months after the second administration of the administration schedule.

5 **[00317]** Such method also preferably provides a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 45 %, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects seronegative against all serotypes at baseline and 14 to 16 years of age, from 30 days after the second administration of the administration schedule until 18 months after the second administration of the administration schedule.

10

[00318] According to certain embodiments the method of inoculation against the virologically confirmable dengue disease is due to a dengue serotype 2, and/or due to a dengue serotype 1. The method has very high efficacy against dengue serotype 2 and dengue serotype 1 and the highest efficacy against dengue serotype 2.

15

[00319] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 30%, is more than 35% is more than 40%, is more than 45%, is more than 50%, or is more than 54%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line and the lower bound is more than 35%. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 with a 2-sided 95% confidence interval, wherein the lower bounds are within 10 %-points.

20

25

[00320] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 40%, is more than 50%, is more than 60%, or is more than 65%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 which are within 5 %-points.

30

35

[00321] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 85%. In certain such embodiments the subject population of at least 1,500, is seronegative against all serotypes. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 with a 2-sided 95% confidence interval, wherein the lower bounds are within 5 %-points.

40

[00322] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 60%, is more than 70%, is more than 80%, or is more than 90%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 which are within 5 %-points.

[00323] The efficacy of the method is further described in more detail below in this the section.

[00324] In certain embodiments the unit dose is reconstituted and administered by subcutaneous injection. According to some of these embodiments, the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00325] According to one embodiment such a method does not include a step of determination whether there was a previous dengue infection in the subject before administration of the unit dose or wherein the serostatus of the subject is unknown before administration of the unit dose.

[00326] According to one embodiment such a method does not include a step of determination of a previous dengue infection in the subjects preferably at any time before, during or after the steps of administration or wherein the serostatus of the subject is unknown preferably at any time before, during or after the steps of administration.

[00327] The method according to the invention does not require the testing of the serostatus before vaccination and thus allows immediate treatment and outbreak control. According to certain embodiments the use is for a method wherein the subject is exposed to a dengue outbreak. In certain such embodiments the outbreak is due to a dengue serotype 2, and/or due to a serotype 1.

[00328] According to one embodiment such a method the subject is from a region wherein the seroprevalence rate is unknown and/or wherein the seroprevalence rate is below 80%, or below 70%, or below 60%.

[00329] According to one embodiment of such a method the subject is seronegative at baseline and is from a region or travels to a region wherein the seroprevalence rate is high with respect to serotype 1 and/or serotype 2 i.e. 80%, or 90% or above.

[00330] According this embodiment the vaccine and corresponding method is safe for seronegative and seropositive subjects and thus does not require an analysis of the serostatus or a determination of a previous dengue infection or a high seroprevalence rate in the region. Such a method preferably provides a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline, preferably in at least 1,500 healthy 4 to 16 year old subjects seronegative at baseline, from first administration of the administration schedule until 12 to 18 months after the second administration of the administration schedule. Preferably, the 2-sided 95% confidence interval of the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes when comparing seropositive and seronegative subjects provides for lower bounds of the 2-sided confidence interval which are within 10% points or within 15% points or within 20% points. The method is preferably safe with respect to

serotype 1 and serotype 2 which may therefore be used in outbreak situations due to serotype 1 and/or serotype 2 or even for seronegative subjects (e.g. travelers) or subjects with unknown serostatus in regions with very high seroprevalence rates (>80%) due to serotype 1 and/or serotype 2.

[00331] The safety of the method is further described in more detail in the section "method of preventing, method of inoculating".

[00332] According to one embodiment such a method does not include the active surveillance with respect to febrile illness of the subject after the administration of the first- and second-unit dose. During active surveillance any subject with febrile illness (defined as fever $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days) will be asked to return to the site for dengue fever evaluation by the Investigator. Subjects/guardians will be contacted at least weekly to ensure robust identification of febrile illness by reminding subjects/guardians of their obligation to return to the site in case of febrile illness. This contact will be implemented through appropriate methods that may differ in each trial site (eg, phone calls, text messaging, home visits, school-based surveillance).

[00333] According to one embodiment such a method does not include vaccine immunogenicity analysis including GMTs for dengue neutralizing antibodies.

[00334] According to one embodiment such a method does not include a reactogenicity analysis. Such a reactogenicity analysis relates to solicited local AEs (injection site pain, injection site erythema, and injection site swelling) and solicited systemic AEs (child < 6 years: fever, irritability/fussiness, drowsiness and loss of appetite; child ≥ 6 years: asthenia, fever, headache, malaise and myalgia) which will e.g. be assessed for 7 days and 14 days, respectively, following each vaccination (vaccination day included) via collection of diary cards.

[00335] According to one embodiment the method does not include an active surveillance, an immunogenicity analysis and a reactogenicity analysis.

[00336] According to such embodiments the vaccine and the corresponding method of inoculation are safe and therefore do not require further steps of surveillance or analysis.

In view of the above the method according to one embodiment comprises a primary vaccination consisting of the steps of:

- (A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination of a previous dengue infection, and
- (B) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

Therefore the method of inoculating is finalized without determination of a previous dengue infection. The method further optionally comprises at least 1 years after the administration of the second unit dose a booster dose of the unit dose.

Selecting the subject may include all types of considerations but preferably not the determination of a previous dengue infection. The selection may include consideration of the age, health conditions, and threat of infection. The threat of infection includes consideration of the seroprevalence rate in the region in which the subject normally lives or intends to travel, the serotype specific seroprevalence rate and an outbreak situation or serotype specific outbreak situations. The subject may be selected due to its exposure to serotype 1 and/or serotype 2 or due to the fact it requires protection against a specific dengue serotype, i.e. serotype 1 and/or serotype 2.

[00337] According to the invention the method is applicable to subjects of all kinds of ages. According to one embodiment the subject is under 9 years of age, or 4 to 5 years of age, or 6 to 11 years of age or 12 to 16 years, or 6 to 16 years of age or 4 to 16 years of age, or 2 to 17 years of age, or 9 years of age, or over 9 years of age, or 9 to 17 years of age, or 18 to 45 years of age, or 46 to 60 years of age, or over 60 years of age.

[00338] In particular the present invention is directed to such a method wherein the method which is safe.

[00339] In particular the present invention is directed to such a method providing a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline from first administration of the administration schedule until 12 to 18 months after the last administration of the administration schedule.

[00340] In particular the present invention is directed to such a method wherein the method which is effective.

In particular the present invention is directed to such a method providing a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 14 to 16 years of age, from the first administration of the administration schedule until 18 months after the last administration of the administration schedule.

[00341] In certain embodiments, the invention is directed to said methods, wherein the subject is seronegative to all dengue serotypes.

[00342] The present invention is directed in part to a method of preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a unit dose, in particular a reconstituted unit dose of the invention as described herein.

[00343] The present invention is in part directed to said method for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2: GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00344] The present invention is in part directed to said method for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject comprising administering to the subject at least a first reconstituted

unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00345] The geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with the microneutralization test disclosed herein, for example according to the method described in Example 2. Without wishing to be bound to any theory, it is presently understood that a method inducing a more balanced immune response due to the administration of the reconstituted unit dose of the invention as described herein, in terms of less differences between the geometric mean neutralizing antibody titers (GMTs) against the four dengue serotypes or the neutralizing antibody titers against the four dengue serotypes, is beneficial to the subject or subject population to be vaccinated. In particular, it is understood that a much greater response to any one of the four serotypes, such as to DENV-2 in comparison to the other serotypes, is less beneficial.

[00346] The present invention is in part directed to said method for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject or subject population wherein the method provides a seropositivity rate in a subject population of at least 50 subjects including the administration of two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population are seronegative to all dengue serotypes at baseline. In certain such embodiments, at least 80% of the subject population are seropositive for all four dengue serotypes at least one month after administration of the first unit dose, such as at day 30, and/or at least 80% of the subject population are seropositive for all four dengue serotypes before or at the time of the administration of the second unit dose, such as at day 90, and/or at least 80%, or at least 85%, or at least 90%, or at least 95% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 120, and/or at least 80%, or at least 85%, or at least 90% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 270.

[00347] The present invention is in part directed to said method for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject or subject population wherein the method provides a seropositivity rate in a subject population of at least 100 subjects including administration of two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population comprises from 20% to 40% subjects who are seronegative to all dengue serotypes and from 60% to 80% subjects who are seropositive to at least one dengue serotype at base line, wherein at day 120 and/or day 270 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 10%-points and/or wherein at day 120 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 5%-points.

[00348] The present invention is in part directed to a method of preventing virologically confirmable dengue disease in a subject or subject population comprising administering to the subject or subject population a reconstituted unit

dose of a tetravalent dengue virus composition including four live, attenuated dengue serotypes, in particular the virus strains as described herein.

[00349] The present invention is in part directed to a method of preventing virologically confirmable dengue disease with hospitalization in a subject or subject population comprising administering to the subject or subject population a reconstituted unit dose of a tetravalent dengue virus composition including four live, attenuated dengue serotypes, in particular the virus strains as described herein.

[00350] In certain embodiments, the method includes a reconstituted unit dose/tetravalent dengue virus composition of a dengue vaccine composition administered for preventing dengue disease in a subject or a subject population, the reconstituted unit dose comprising: a tetravalent virus composition including four live attenuated dengue virus strains, wherein a unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent the reconstituted unit dose is obtained which comprises:

- (i) a dengue serotype 1, such as a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, such as a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, such as a chimeric dengue serotype 2/3 strain, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (vi) a dengue serotype 4, such as a chimeric dengue serotype 2/4 strain, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00351] It is preferred that the reconstituted unit dose/tetravalent dengue virus composition is used in the method of preventing dengue disease of the present invention, wherein upon reconstitution of the unit dose with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6% and wherein the subject or subject population is of 18 to 60 years of age.

[00352] In another preferred embodiment, the reconstituted unit dose/tetravalent dengue virus composition is used in the method of preventing dengue disease of the present invention, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8% and wherein the subject or subject population is of 2 to 17 years of age.

[00353] In certain embodiments, the invention is directed to said methods, wherein said unit dose comprises a tetravalent dengue virus composition including four live attenuated dengue serotypes, in particular the virus strains described herein wherein the serotypes have certain concentrations as described herein with respect to the virus composition and unit dose such as:

- (i) a dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/dose, or 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL
- (ii) a dengue serotype 2 (e.g. dengue serotype 2 strain) has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/0.5 dose, or 2.7 log₁₀ pfu/0.5ml to 4.9 log₁₀ pfu/0.5ml
- (iii) a dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) has a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/0.5 dose, or 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL and

(iv) a dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) has a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/0.5 dose, or 4.5 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL.

In preferred such embodiments, the subject or subject population is of 2 to 17 years of age, such as 4 to 16 years of age, and preferably less than 9 years of age. In other preferred embodiments, the subject or subject population is 4-5 years of age, 6-11 years of age or 12-16 years of age.

[00354] In certain embodiments, the invention is directed to said methods, wherein said unit dose upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent has a concentration of 3.3 log₁₀ pfu/0.5 mL to 3.6 log₁₀ pfu/0.5 mL for dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain), has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.0 log₁₀ pfu/0.5 mL for dengue serotype 2 (e.g. dengue serotype 2 strain), has a concentration of 4.0 log₁₀ pfu/0.5 mL to 4.6 log₁₀ pfu/0.5 mL for dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) and has a concentration of 4.5 log₁₀ pfu/0.5 mL or 4.6 log₁₀ pfu/0.5 mL to 5.1 log₁₀ pfu/0.5 mL for dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain). In preferred such embodiments, the subject or subject population is of 2 to 17 years of age, such as 4 to 16 years of age, and preferably less than 9 years of age. In other preferred embodiments, the subject or subject population is 4-5 years of age, 6-11 years of age or 12-16 years of age.

[00355] In certain embodiments, the invention is directed to said methods, wherein the concentration of the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) measured in pfu/0.5 mL is 1% to 7% of the total concentration, the concentration of the dengue serotype 2 (e.g. dengue serotype 2 strain) measured in pfu/0.5 mL is less than 8% of the total concentration, such as in the range of 1% to 8% of the total concentration, the concentration of the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) measured in pfu/0.5 mL is at least 10% of the total concentration, and the concentration of the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) measured in pfu/0.5 mL is at least 65% of the total concentration, such as in the range of 65% to 80%. In certain such embodiments, the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/0.5 mL to 6.7 log₁₀ pfu/0.5 mL, preferably in the range of 4.6 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL. Preferably, in said embodiments the subject or subject population is of 2 to 17 years of age, such as 4 to 16 years of age, and even more preferably less than 9 years of age. In other preferred embodiments, the subject or subject population is 4-5 years of age, 6-11 years of age or 12-16 years of age.

[00356] In a further preferred embodiment, the invention is directed to said methods, wherein the dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and the dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 is preferably at least about 10% of the total concentration in pfu/0.5 mL and more preferably the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 is at least about 70% of the total concentration in pfu/0.5 mL. In certain such embodiments the dengue serotype 4 (e.g. chimeric dengue serotype 2/4 strain) such as TDV-4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 (e.g. chimeric dengue serotype 2/1 strain) such as TDV-1 and dengue serotype 2 (e.g. dengue serotype 2 strain) such as TDV-2 each represent lower concentrations than the concentration of serotype 3 (e.g. chimeric dengue serotype 2/3 strain) such as TDV-3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

[00357] Preferably, the chimeric dengue serotype 2/1 strain is TDV-1, the dengue serotype 2 strain is TDV-2, the chimeric dengue serotype 2/3 strain is TDV-3 and the chimeric dengue serotype 2/4 strain is TDV-4. More preferably,

TDV-1 is characterized by the nucleotide sequence according to SEQ ID No. 1 and the amino acid sequence according to SEQ ID No. 2, TDV-2 is characterized by the nucleotide sequence according to SEQ ID No. 3 and the amino acid sequence according to SEQ ID No. 4, TDV-3 is characterized by the nucleotide sequence according to SEQ ID No. 5 and the amino acid sequence according to SEQ ID No. 6 and TDV-4 is characterized by the nucleotide sequence according to SEQ ID No. 7 and the amino acid sequence according to SEQ ID No. 8.

[00358] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection. According to some of these embodiments, the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00359] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose is administered to a subject of unknown serostatus and/or wherein no test has been carried out to determine whether the subject is seropositive or seronegative (before) the unit dose as described herein is administered. In certain embodiments, the invention is directed to said methods which do not include a step of determination of a previous dengue infection in the subject or subjects. In certain embodiments, the invention is directed to said methods which do not include the analysis of the seroprevalence rate in the region or is conducted in a region with a seroprevalence of below 80%, below 70% or below 60%. In certain embodiments the invention is directed to a method wherein the serostatus of the subject is unknown. In such embodiments the serostatus is not determined at any time before and after administration in relation to this method. In certain embodiments of the invention the method is used in an outbreak situation. In certain embodiments, the invention is directed to said methods being conducted outside a clinical trial

[00360] In certain embodiments, the invention is directed to said methods, wherein the subject, or subject population is seronegative to all dengue serotypes.

[00361] In certain embodiments, the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments the two unit doses are administered within 12 months or more, or within six months, or within three months, and optionally at least 4 weeks apart such as at day 0 and day 90 or at day 1 and day 90. According to some of these embodiments, a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00362] In certain embodiments, the method of the invention comprises or consists of a single unit dose of the invention being administered.

[00363] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population that is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00364] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein is administered to a subject or subject population from a dengue endemic region. In some of these embodiments, the subject or subject population is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In a preferred

embodiment, the subject or subject population is from Asia Pacific or from Latin America. In some other of these embodiments, the subject or subject population is from Thailand, Sri Lanka, Philippines, Panama, Nicaragua, Dominican Republic, Colombia or Brazil. In other embodiments, the subject, or subject population is from a dengue non-endemic region. Such a subject population or such a subject may be vaccinated according to the present invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject, or subject population that is from a dengue endemic region or a dengue non-endemic region.

[00365] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population of 2 to 60 years of age. In some embodiments, the subjects or subject population are adults of more than 17 years, or more than 18 years, or 18 to 60 years. In further specific embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age.

[00366] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to children and adolescents of 2 to 17 years of age. In some embodiments, the subjects or subject population are less than 9 years of age, or less than 4 years of age. In some embodiments, the subjects or subject population are from 2 to 9 years of age, or from 2 to 5 years of age, or from 4 to 9 years of age or from 6 to 9 years of age. In other embodiment, the subject or subject population is 4 to 16 years of age. In some such embodiments, the subject or subject population is 4-5 years of age, 6-11 years of age or 12-16 years of age. Optionally, the subject or subject population is seronegative with respect to all dengue serotypes.

[00367] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein is administered to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years or 2 months to 1.5 years or 2 months to 1 year. According to some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00368] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years or 2 months to 1.5 years or 2 months to 1 year, preferably by subcutaneous injection. According to some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00369] In a certain embodiments, the invention is directed to said methods, wherein the subject or subject population is 4-5 years of age and from Asia Pacific, 6-11 years of age and from Asia Pacific, or 12-16 years of age and from Asia Pacific. In other embodiments, the subject or subject population is 4-5 years of age and from Latin America, 6-11 years of age and from Latin America, or 12-16 years of age and from Latin America.

[00370] In a certain embodiments, the invention is directed to said methods, wherein the subject or subject population is 4-5 years of age and seropositive for at least 1 dengue serotype, 6-11 years of age and seropositive for at least 1 dengue serotype, or 12-16 years of age and seropositive for at least 1 dengue serotype. In other embodiments, the subject or subject population is 4-5 years of age and seronegative for all dengue serotypes, 6-11 years of age and seronegative for all dengue serotypes, or 12-16 years of age and seronegative for all dengue serotypes.

[00371] In a certain embodiments, the invention is directed to said methods, wherein the subject or subject population is from Asia Pacific or Latin America and seropositive for at least one dengue serotype at baseline. In other embodiments, the subject or subject population is from Asia Pacific or Latin America and seronegative for at all dengue serotype at baseline.

5 **[00372]** In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is from Asia Pacific, seropositive for at least one dengue serotype at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In other embodiments, the subject or subject population is from Asia Pacific, seronegative for all dengue serotypes at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In yet other
10 embodiments, the subject or subject population is from Latin America, seropositive for at least one dengue serotype at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In other embodiments, the subject or subject population is from America, seronegative for all dengue serotypes at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age.

[00373] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population had prior vaccination against Yellow Fever. In other embodiments, the subject or subject population had prior
15 vaccination against Japanese Encephalitis. In yet other embodiments, the subject or subject population had no prior vaccination against Yellow Fever. In other embodiments, the subject or subject population had no prior vaccination against Japanese Encephalitis. Prior vaccination indicates a vaccination prior to 30 days after a second administration, such as within 4 months after the first administration, with the reconstituted unit dose as described herein. For example
20 for vaccine efficacy (VE) as determined in Example 6 from 30 days post-second vaccination, a prior vaccination of Yellow Fever is defined as a Yellow Fever vaccination occurring before 30 days post-second vaccination. In certain embodiments, the subject or subject population received Dengvaxia® within the administration regimen as described herein or within 4.5 years after administration of the first dose.

[00374] Particularly unbalanced titers of neutralizing antibodies against the four dengue serotypes are observed in seronegative populations or subjects after administration of the commercially available dengue vaccine. The present
25 invention shows that in particular seronegative subjects show a more balanced immune response to the four dengue serotypes after administration of the reconstituted unit dose of the invention as described herein. It is therefore contemplated that the unit dose of the invention as described herein and methods of the present invention as described herein may provide a more robust immune response in a subject population including both seropositive and seronegative subjects. This balanced response and balanced efficacy and safety is required to allow inoculation without
30 prior serostatus analysis which is a major advantage in vaccination programs and in particular in outbreak situations.

[00375] The present invention is directed in part to a method of preventing virologically confirmable dengue disease in a subject comprising administering to the subject a tetravalent dengue virus composition including four dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, wherein the virus strains are optionally live, attenuated dengue virus strains.

35 **[00376]** The present invention is directed in part to a method of preventing virologically confirmable dengue disease in a subject consisting of administering to the subject a tetravalent dengue virus composition including four dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4, wherein the virus strains are optionally live, attenuated dengue virus strains.

[00377] In certain embodiments, the invention is directed to said methods, wherein there is no step of determining
40 the serostatus of the subject at baseline, in other words, said methods do not comprise a determination of a previous

dengue infection of the subject at baseline before the administration of the tetravalent dengue virus composition. In particular, such methods are safe and effective. Thus, in certain such embodiments, the subject has not been tested for the presence a previous dengue infection.

[00378] In certain embodiments, the invention is directed to said methods, wherein the vaccine administration is safe irrespective of whether there is a determination that the subject had a previous dengue infection before the administration of the tetravalent dengue virus composition. In particular, such methods are also effective.

[00379] In certain embodiments, the invention is directed to said methods, wherein the method is safe and/or effective.

[00380] In certain embodiments, the invention is directed to said methods, wherein the composition includes at least one chimeric dengue virus. In certain such embodiments, the invention is directed to said methods, wherein the composition includes at least one non-chimeric dengue virus and at least one chimeric dengue virus, in particular a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain. The details of the composition are described above.

[00381] Therefore, in certain embodiments, the invention is directed to said methods having a vaccine efficacy, preferably a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and e.g. 14 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is administered e.g. at least twice within less than 6 months, such as within 3 months, after first administration or 30 days after the second/last administration until at least 12 to 18 months (e.g. at 12 or at 18 months) after the second/last administration. In embodiments, the invention is directed to said methods having a vaccine efficacy, preferably a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose or tetravalent dengue virus composition as described herein or placebo is administered at least once, until 15 to 21 months (e.g. 15 or 21 months) after the first administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, more than 40%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70% or more than 72%. Preferably said reconstituted unit dose or placebo is administered subcutaneously within about 3 months, such as on days 0 and 90.

[00382] Therefore, in certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is administered e.g. at least twice within less than 6 months, such as within 3 months, after the first administration until 18 months after the last administration. In these embodiments, the lower bound is e.g. more than 62%, more than 64%, more than 66%, more than 68%, or more than 69%.

[00383] In certain embodiments, the invention is directed to said methods having a vaccine efficacy, preferably a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease of more

than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and e.g. 14 to 16 years of age, wherein a reconstituted unit dose or tetravalent dengue virus composition as described herein or placebo is administered at least twice within less than 6 months, such as within 3 months, after first administration or 30 days after the second administration/last administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration/last administration. In certain embodiments, the invention is directed to said methods having a vaccine efficacy, preferably a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose or tetravalent dengue virus composition as described herein or placebo is administered at least once, until 15 months after the first administration of the administration schedule. In certain such embodiments, the vaccine efficacy is more than 40%, more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 78%, more than 79% or about 80%. Preferably said reconstituted unit dose or placebo is administered subcutaneously within about 3 month, such as on days 0 and 90.

[00384] Therefore, in certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease of more than 66%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 14 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is administered e.g. at least twice within less than 6 months, such as within 3 months, after the first administration until 18 months after the last administration. In these embodiments, the vaccine efficacy is e.g. more than 68%, more than 70%, more than 72%, or more than 74%.

[00385] In certain embodiments, the invention is directed to said methods having a vaccine efficacy, preferably a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization with a 2-sided 95% confidence interval, wherein the lower bound is more than 0%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose or tetravalent dengue virus composition as described herein or placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 18 months after the second administration. In certain such embodiments, the lower bound is more than 10%, is more than 20%, is more than 30%, is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 70% or is more than 80%, or more than 90%.

[00386] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes in seronegative subjects with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 50%, or is more than 55%.

[00387] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at

least 1,500 or at least 2,000 or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 30%, is more than 35%, is more than 40%, or is more than 45%.

[00388] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 40%, is more than 45%, is more than 50%, is more than 60%, or is more than 65%.

[00389] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline being or seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the difference between the lower bound provided by the seropositive subjects at baseline and the subjects seronegative against all serotypes at baseline is no more than 15%-points.

[00390] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes in seronegative subjects of more than 30%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against all four dengue serotypes in seronegative subjects is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

[00391] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500 or at least 2,000 or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments the said vaccine efficacy is more than 30%, is more than 40%, is more than 50%, is more than 55%, is more than 60%, or is more than 65%.

[00392] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments the said vaccine efficacy is more than 40%, is more than 50%, is more than 60%, is more than 65%, is more than 70%, or is more than 75%.

[00393] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline being or seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the difference between the lower bound provided by the seropositive subjects at baseline and the subjects seronegative against all serotypes at baseline is no more than 15%-points, or is no more than 10%-points.

[00394] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 4 to 5 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 45%.

[00395] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 4 to 5 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

[00396] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 6 to 11 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such

embodiments, the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, or is more than 70%.

5 **[00397]** In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 6 to 11 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 75%, or is more than 80%.

15 **[00398]** In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 12 to 16 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 68%.

20 **[00399]** In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 12 to 16 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 75%, or is more than 80%.

30 **[00400]** In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 1 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, or is more than 50%.

40 **[00401]** In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days

post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 30%, is more than 35%, is more than 40%, is more than 45%, is more than 50%, or is more than 54%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line and the lower bound is more than 35%. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 with a 2-sided 95% confidence interval, wherein the lower bounds are within 10 %-points.

[00402] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 1 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy against dengue serotype 1 is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

[00403] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the vaccine efficacy is more than 40%, is more than 50%, is more than 60%, or is more than 65%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 which are within 5 %-points.

[00404] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 2 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 50, is more than 60, is more than 70, is more than 80, or is more than 90%.

[00405] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 85%. In certain such embodiments the subject population of at least 1,500, is seronegative against all serotypes.

In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 with a 2-sided 95% confidence interval, wherein the lower bounds are within 5 %-points.

[00406] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 2 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetavalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy against dengue serotype 2 is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80, or is more than 90%.

[00407] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetavalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the vaccine efficacy is more than 60%, is more than 70%, is more than 80%, or is more than 90%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 which are within 5 %-points.

[00408] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 3 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetavalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%.

[00409] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against dengue serotype 3 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose/tetavalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration. In certain such embodiments, the vaccine efficacy against dengue serotype 3 is more than 40%, is more than 50%, is more than 55%, or is more than 60%.

[00410] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetavalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months,

from first administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration, or from 30 days post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 10%, is more than 20%, is more than 30%, is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 66%, is more than 67%, is more than 70%, is more than 75%, is more than 77%, or is more than 80%.

[00411] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from first administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration, or from 30 days post last administration until 12 to 18 months (e.g. at 12 or at 18 months) after the last administration. In certain such embodiments, the vaccine efficacy is more than 70%, is more than 75%, is more than 80%, or is more than 82%, or is more than 85%, more than 88%.

[00412] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 70%, or is more than 75%.

[00413] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 60%, is more than 65%, is more than 66%, is more than 67%, is more than 70%, is more than 75%, is more than 77% or is more than 80%.

[00414] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes of more than 30%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects, healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 90%.

[00415] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the said vaccine efficacy is more than 60%, is more than 65%, is more than 66%, is more than 67%, is more than 70%, is more than 75%, is more than 77%, is more than 80, or is more than 85%.

[00416] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seropositive at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration of the administration schedule. In certain such embodiments, the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 70%, or is more than 80%.

[00417] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the lower bound is more than 60%, is more than 65%, is more than 70%, is more than 75%, or is more than 80%.

[00418] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes of more than 30%, when measured against placebo in a subject population at least 1,500 or of at least 2,000 healthy subjects, healthy subjects being seropositive at baseline, wherein said unit dose/tetravalent dengue virus composition or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 90%.

[00419] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after

the last administration. In certain such embodiments, the vaccine efficacy is more than 75%, is more than 70%, is more than 80%, is more than 85%, or is more than 90%.

[00420] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline being or seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the difference between the lower bound provided by the seropositive subjects at baseline and the subjects seronegative against all serotypes at baseline is no more than 15%-points.

[00421] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with hospitalization, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) being seropositive at baseline being or seronegative against all serotypes at baseline and 4 to 16 years of age, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is e.g. administered at least twice within less than 6 months, such as within 3 months, from 30 days post last administration until 12 to 18 months (e.g. at 12 months or at 18 months) after the last administration. In certain such embodiments, the difference between the vaccine efficacy provided by the seropositive subjects at baseline and the subjects seronegative against all serotypes at baseline is no more than 10%-points or no more than 5%-points.

[00422] In certain embodiments, the invention is directed to said methods having a relative risk, preferably a combined relative risk against all four serotypes, with a 2-sided 95% confidence interval, wherein the upper bound is less than 0.75, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration. In certain such embodiments, the upper bound is less than 0.70, less than 0.65, less than 0.60, less than 0.55, less than 0.50, less than 0.45, less than 0.40, less than 0.35, less than 0.30 or less than 0.28. Preferably said reconstituted unit dose or placebo is administered subcutaneously within about 3 month, such as on days 0 and 90.

[00423] In certain embodiments, the invention is directed to said methods having a relative risk, preferably a combined relative risk against all four serotypes, of less than 0.70, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose/tetravalent dengue virus composition as described herein or placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration. In certain such embodiments, the relative risk is less than 0.65, less than 0.60, less than 0.55, less than 0.50, less than 0.45, less than 0.40, less than 0.35, less than 0.30, less than 0.25 or less than 0.23. Preferably said reconstituted unit dose or placebo is administered subcutaneously within about 3 month, such as on days 0 and 90.

[00424] In certain embodiments, the invention is directed to said methods, wherein virologically confirmable dengue disease occurs in less than 2.5% of the subjects, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline, wherein a reconstituted unit dose/tetavalent dengue virus composition as described herein or placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months or at least 18 months after the second administration. In certain such embodiments, virologically confirmable dengue disease occurs in less than 2.0% of the subjects, less than 1.5% of the subjects, less than 1.0% of the subjects, less than 0.8% of the subjects, or less than 0.6% of the subjects. Preferably said reconstituted unit dose or placebo is administered subcutaneously within about 3 month, such as on days 0 and 90.

[00425] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 61.0%, or more than 65.0 or more than 70.0% or more than 72.0% when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) from endemic irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose/tetavalent dengue virus composition or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 or 13 months after the last administration of the administration schedule.

[00426] In certain embodiments, the invention is directed to said methods having a combined vaccine efficacy against all four serotypes of more than 66 %, or of more than 70%, or of more than 75%, or of more than 77%, or of more than 80.0%, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) from endemic areas irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose/tetavalent dengue virus composition or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 months or 13 month after the last administration of the administration schedule.

[00427] In certain embodiments, the invention is directed to said methods, wherein the combined vaccine efficacy against all four serotypes is measured about 30 days after the last administration of the administration schedule until 12 or 13 months after the last administration of the administration schedule.

[00428] In certain embodiments, the invention is directed to said methods, wherein said unit dose or said placebo is administered at least twice within three months, in particular at about day 1 and about day 90, and wherein the combined vaccine efficacy against all four serotypes is measured 30 days after the second administration until 12 or 13 months after the second administration of the administration schedule.

[00429] In certain embodiments, the invention is directed to said methods, wherein said methods are effective and safe. In some of these embodiments, the subject or subject population is under 9 years of age, under 4 years of age, or under 2 years of age or from 2 to 9 years of age, or from 2 to 5 years of age, or from 4 to 9 years of age or from 6 to 9 years of age. Optionally the subject is seronegative with respect to all dengue serotypes.

[00430] In certain embodiments, the invention is directed to said methods, wherein said methods having a relative risk for virologically confirmed dengue with hospitalization of 1 or less, or 0.8 or less, or 0.6 or less, when measured against placebo in a subject population of at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects). In some of these embodiments, the subject or subject population is under 9 years of age, under 4 years of

age, or under 2 years of age or from 2 to 9 years of age, or from 2 to 5 years of age, or from 4 to 9 years of age or from 6 to 9 years of age. Optionally the subject is seronegative with respect to all dengue serotypes.

5 [00431] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are 4 to 16 years of age. In some of such embodiments, the healthy subjects of the subject population are 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age.

[00432] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are defined as being healthy in view of the exclusion criteria specified in Example 6.

10 [00433] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are from Asia Pacific or Latin America.

[00434] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are seropositive with respect to at least one serotype. In other embodiments, the healthy subjects of the subject population are seronegative with respect to all serotypes.

15 [00435] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are 4-5 years of age and from Asia Pacific, 6-11 years of age and from Asia Pacific, or 12-16 years of age and from Asia Pacific. In other embodiments, the healthy subjects of the subject population are 4-5 years of age and from Latin America, 6-11 years of age and from Latin America, or 12-16 years of age and from Latin America.

20 [00436] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are 4-5 years of age and seropositive for at least 1 dengue serotype, 6-11 years of age and seropositive for at least 1 dengue serotype, or 12-16 years of age and seropositive for at least 1 dengue serotype. In other embodiments, the healthy subjects of the subject population are 4-5 years of age and seronegative for all dengue serotypes, 6-11 years of age and seronegative for all dengue serotypes, or 12-16 years of age and seronegative for all dengue serotypes.

25 [00437] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are from Asia Pacific or Latin America and seropositive for at least one dengue serotype at baseline. In other embodiments, the healthy subjects of the subject population are from Asia Pacific or Latin America and seronegative for at all dengue serotype at baseline.

30 [00438] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population are from Asia Pacific, seropositive for at least one dengue serotype at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In other embodiments, the healthy subjects of the subject population are from Asia Pacific, seronegative for all dengue serotypes at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In yet other embodiments, the healthy subjects of the subject population are from Latin America, seropositive for at least one dengue serotype at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age. In other embodiments, the healthy subjects of the subject population are from America, seronegative for all
35 dengue serotypes at baseline and 4-5 years of age, 6-11 years of age, or 12-16 years of age.

[00439] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population had prior vaccination against Yellow Fever. In other embodiments, the healthy subjects of the subject population had no prior vaccination against Yellow Fever. Prior vaccination indicates a vaccination prior to the first vaccination with the reconstituted unit dose as described herein. For example for vaccine efficacy (VE) as

determined in Example 6 from 30 days post-second vaccination, a prior vaccination of Yellow Fever is defined as a Yellow Fever vaccination occurring before 30 days post-second vaccination.

[00440] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population had prior vaccination against Japanese Encephalitis. In other embodiments, the healthy subjects of the subject population had no prior vaccination against Japanese Encephalitis.

[00441] In certain embodiments, the invention is directed to said methods, wherein the healthy subjects of the subject population received Dengvaxia® within the administration regimen as described herein or within 4.5 years after administration of the first dose. In certain embodiments, the invention is directed to said methods, wherein the occurrence of vaccine related serious adverse events is less than 0.1%.

[00442] In certain embodiments, the invention is directed to said methods, wherein the occurrence of vaccine related unsolicited adverse events occurring within 4 weeks of administration is less than 2%.

[00443] In certain embodiments, the invention is directed to said methods, wherein the occurrence of vaccine related solicited adverse events occurring within 2 weeks of administration is less than 35%.

[00444] In certain embodiments, the invention is directed to said methods, wherein the occurrence of vaccine related solicited local reactions occurring within 1 weeks of administration is less than 40%.

[00445] In certain embodiments, the invention is directed to said methods, wherein the method does not increase the risk of virologically-confirmed dengue with hospitalization in the individual, such as in a seronegative individual.

[00446] In one embodiment, the unit dose is co-administered with a vaccine selected from the group of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, an MMR vaccine, a yellow fever vaccine, in particular YF-17D, an HPV vaccine, in particular a 9vHPV vaccine, a tetanus, diphtheria, and pertussis (Tdap) vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, and a hepatitis A vaccine as described in more detail below.

Unit dose for use in a method of preventing dengue disease

[00447] The present invention is directed in part to the composition or unit dose of the invention as described herein for use in a method of preventing dengue disease (in particular virologically-confirmable dengue, VCD) in a subject.

[00448] The present invention is directed in part to the composition or unit dose of the invention as described herein for use in a method of preventing dengue disease (in particular virologically-confirmable dengue, VCD) in a subject population.

[00449] Inoculating against dengue disease, vaccinating against dengue disease and preventing dengue disease have the same meaning. The present invention is directed in part to a method of preventing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).

[00450] Any method described herein above under the heading "Method of preventing, method of inoculating" is to be understood to be also disclosed as unit dose for use in such a method of preventing dengue disease in a subject or subject population irrespective of being expressly stated below.

[00451] According to a certain aspect the composition or unit dose of the invention is a tetravalent dengue virus composition including a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain. According to certain such aspects the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 (represented by SEQ ID NO 11) and differs in at least three nucleotides from the wild type as follows:

- a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
- b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
- c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

[00452] Further information regarding the serotypes of the tetravalent composition can be derived from section "Dengue virus strains" above.

[00453] The tetravalent dengue virus composition for such use may be in the form of a unit dose comprising:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00454] The tetravalent dengue virus composition for such use may also be in the form of a lyophilized unit dose which upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00455] In the tetravalent dengue virus composition for such use according to one embodiment upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 10%, and the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, and the concentration of (i) in pfu/0.5 mL is preferably at least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 8%, or more preferred at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18% and wherein the subject is preferably 2 to 17 years of age or 4 to 16 years of age.

[00456] In the tetravalent dengue virus composition for such use according to one embodiment upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 2%, the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, the concentration of (i) in pfu/0.5 mL is at preferably least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 6% and wherein the subject preferably is 18 to 60 years of age.

[00457] Further information regarding the tetravalent composition or the unit dose can be derived from section "Dengue vaccine composition" and "Unit dose" above.

[00458] According to one embodiment the unit dose for such use is directed to a method comprising a primary vaccination with only two administrations of the unit dose comprising the steps of:

- (A) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (B) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

According to this embodiment the administration of only two doses within 3 months is sufficient to provide effective protection against a subsequent dengue infection.

[00459] Such method preferably provides a combined vaccine efficacy against all four serotypes in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 14 to 16 years of age, from the first administration of the administration schedule until 18 months after the second administration of the administration schedule.

[00460] Such method also preferably provides a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 45 %, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects seronegative against all serotypes at baseline and 14 to 16 years of age, from 30 days after the second administration of the administration schedule until 18 months after the second administration of the administration schedule.

[00461] According to certain embodiments the use is for a method of inoculation against the virologically confirmable dengue disease is due to a dengue serotype 2, and/or due to a dengue serotype 1. The method has very high efficacy against dengue serotype 2 and dengue serotype 1 and the highest efficacy against dengue serotype 2.

[00462] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 30%, is more than 35% is more than 40%, is more than 45%, is more than 50%, or is more than 54%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line and the lower bound is more than 35%. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 with a 2-sided 95% confidence interval, wherein the lower bounds are within 10 %-points.

[00463] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 40%, is more than 50%, is more than 60%, or is more than 65%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments

the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 which are within 5 %-points.

[00464] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 85%. In certain such embodiments the subject population of at least 1,500, is seronegative against all serotypes. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 with a 2-sided 95% confidence interval, wherein the lower bounds are within 5 %-points.

[00465] In certain embodiments, the invention is directed to said methods having a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 60%, is more than 70%, is more than 80%, or is more than 90%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 which are within 5 %-points.

[00466] The efficacy of the method is further described in more detail in the section "method of preventing, method of inoculating".

[00467] In certain embodiments the unit dose is reconstituted and administered by subcutaneous injection. According to some of these embodiments, the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00468] According to one embodiment such a method does not include a step of determination of a previous dengue infection in the subjects preferably at any time before, during or after the steps of administration or wherein the serostatus of the subject is unknown preferably at any time before, during or after the steps of administration.

[00469] The method according to the invention does not require the testing of the serostatus before vaccination and thus allows immediate treatment and outbreak control. According to certain embodiments the use is for a method wherein the subject is exposed to a dengue outbreak. In certain such embodiments the outbreak is due to a dengue serotype 2, and/or due to a serotype 1.

[00470] According to one embodiment such a method the subject is from a region wherein the seroprevalence rate is unknown and/or wherein the seroprevalence rate is below 80%, or below 70%, or below 60%.

[00471] According to one embodiment of such a method the subject is seronegative at baseline and is from a region or travels to a region wherein the seroprevalence rate is high with respect to serotype 1 and/or serotype 2 i.e. 80%, or 90% or above.

[00472] According this embodiment the vaccine and corresponding method is safe for seronegative and seropositive subjects and thus does not require an analysis of the serostatus or a determination of a previous dengue infection or a high seroprevalence rate in the region. Such a method preferably provides a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline, preferably in at least 1,500 healthy 4 to 16 year old subjects seronegative at baseline, from first administration of the administration schedule until 12 to 18 months after the second administration of the administration schedule. Preferably, the 2-sided 95% confidence interval of the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes when comparing seropositive and seronegative subjects provides for lower bounds of the 2-sided confidence interval which are within 10% points or within 15% points or within 20% points. The method is preferably safe with respect to serotype 1 and serotype 2 which may therefore be used in outbreak situations due to serotype 1 and/or serotype 2 or even for seronegative subjects (e.g. travelers) or subjects with unknown serostatus in regions with very high seroprevalence rates (>80%) due to serotype 1 and/or serotype 2.

[00473] The safety of the method is further described in more detail in the section "method of preventing, method of inoculating".

[00474] According to one embodiment such a method does not include the active surveillance with respect to febrile illness of the subject after the administration of the first- and second-unit dose. During active surveillance any subject with febrile illness (defined as fever $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days) will be asked to return to the site for dengue fever evaluation by the Investigator. Subjects/guardians will be contacted at least weekly to ensure robust identification of febrile illness by reminding subjects/guardians of their obligation to return to the site in case of febrile illness. This contact will be implemented through appropriate methods that may differ in each trial site (eg, phone calls, text messaging, home visits, school-based surveillance).

[00475] According to one embodiment such a method does not include vaccine immunogenicity analysis including GMTs for dengue neutralizing antibodies.

[00476] According to one embodiment such a method does not include a reactogenicity analysis. Such a reactogenicity analysis relates to solicited local AEs (injection site pain, injection site erythema, and injection site swelling) and solicited systemic AEs (child < 6 years: fever, irritability/fussiness, drowsiness and loss of appetite; child ≥ 6 years: asthenia, fever, headache, malaise and myalgia) which will e.g. be assessed for 7 days and 14 days, respectively, following each vaccination (vaccination day included) via collection of diary cards.

[00477] According to one embodiment the method does not include an active surveillance, an immunogenicity analysis and a reactogenicity analysis.

[00478] According to such embodiments the vaccine and the corresponding method of inoculation are safe and therefore do not require further steps of surveillance or analysis.

[00479] In view of the above the method according to one embodiment comprises a primary vaccination consisting of the steps of:

(A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination of a previous dengue infection, and

- (B) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

Therefore the method of inoculating is finalized without determination of a previous dengue infection. The method however further optionally comprises at least 1 years after the administration of the second unit dose a booster dose of the unit dose.

[00480] Selecting the subject may include all types of considerations but preferably not the determination of a previous dengue infection. The selection may include consideration of the age, health conditions, and threat of

infection. The threat of infection includes consideration of the seroprevalence rate in the region in which the subject normally lives or intends to travel, the serotype specific seroprevalence rate and an outbreak situation or serotype specific outbreak situations. The subject may be selected due to its exposure to serotype 1 and/or serotype 2 or due to the fact it requires protection against a specific dengue serotype, i.e. serotype 1 and/or serotype 2.

[00481] According to the invention the method is applicable to subjects of all kinds of ages. According to one embodiment the subject is under 9 years of age, or 4 to 5 years of age, or 6 to 11 years of age or 12 to 16 years, or 6 to 16 years of age or 4 to 16 years of age, or 2 to 17 years of age, or 9 years of age, or over 9 years of age, or 9 to 17 years of age, or 18 to 45 years of age, or 46 to 60 years of age, or over 60 years of age.

[00482] According to certain such embodiments the unit dose of the tetravalent dengue virus composition comprising (i), (ii), (iii), and (iv) upon reconstitution with a pharmaceutically acceptable diluent provides a total concentration of pfu/0.5 mL of (i), (ii), (iii), and (iv) and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 10%, and the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, and the concentration of (i) in pfu/0.5 mL is preferably at least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 8%, or more preferred at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18% and the subject is 2 to 17 years of age or 4 to 16 years of age.

[00483] According to certain such embodiments the unit dose of the tetravalent dengue virus composition comprising (i), (ii), (iii), and (iv) upon reconstitution with a pharmaceutically acceptable diluent provides a total concentration of pfu/0.5 mL of (i), (ii), (iii), and (iv) and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 2%, the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, the concentration of (i) in pfu/0.5 mL is at preferably least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 6% and the subject is 18 to 60 years of age.

[00484] Further specific embodiments are described below.

[00485] The present invention is directed in part to a reconstituted unit dose of a dengue vaccine composition as described herein for use in a method of preventing virologically confirmable dengue disease in a subject comprising administering at least a first unit dose of the dengue vaccine composition to the subject, wherein the dengue vaccine composition is a tetravalent dengue virus composition including four dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, optionally wherein the dengue virus strains are live, attenuated dengue virus strains and/or comprise chimeric dengue viruses and/or at least one non-chimeric dengue virus, and wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

- (i) dengue serotype 1 has a concentration of at least 3.3 log₁₀ pfu/0.5 mL and optionally to 5.0 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of at least 2.7 log₁₀ pfu/0.5 mL and optionally to 4.9 log₁₀ pfu/0.5 mL,

(iii) dengue serotype 3 has a concentration of at least 4.0 log₁₀ pfu/0.5 mL and optionally to 5.7 log₁₀ pfu/0.5 mL, and

(iv) dengue serotype 4 has a concentration of at least 4.5 log₁₀ pfu/0.5 mL and optionally to 6.2 log₁₀ pfu/0.5 mL.

[00486] The present invention is directed in part to a reconstituted unit dose of a dengue vaccine composition as described herein for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, wherein the dengue vaccine composition is a tetravalent dengue virus composition including four dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, optionally wherein the dengue virus strains are live, attenuated, and wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

(v) dengue serotype 1 has a concentration of at least 3.3 log₁₀ pfu/0.5 mL and optionally to 5.0 log₁₀ pfu/0.5 mL,

(vi) dengue serotype 2 has a concentration of at least 2.7 log₁₀ pfu/0.5 mL and optionally to 4.9 log₁₀ pfu/0.5 mL,

(vii) dengue serotype 3 has a concentration of at least 4.0 log₁₀ pfu/0.5 mL and optionally to 5.7 log₁₀ pfu/0.5 mL, and

(viii) dengue serotype 4 has a concentration of at least 4.5 log₁₀ pfu/0.5 mL and optionally to 6.2 log₁₀ pfu/0.5 mL.

[00487] In certain embodiments, the invention is directed to a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, wherein the dengue vaccine composition is a tetravalent dengue virus composition including four dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, optionally wherein the dengue virus strains are live, attenuated, wherein the subject is under 9 years of age and/or when the serostatus of the subject is unknown or seronegative and wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

(i) dengue serotype 1 has a concentration of at least 3.3 log₁₀ pfu/0.5 mL and optionally to 5.0 log₁₀ pfu/0.5 mL,

(ii) dengue serotype 2 has a concentration of at least 2.7 log₁₀ pfu/0.5 mL and optionally to 4.9 log₁₀ pfu/0.5 mL,

(iii) dengue serotype 3 has a concentration of at least 4.0 log₁₀ pfu/0.5 mL and optionally to 5.7 log₁₀ pfu/0.5 mL, and

(iv) dengue serotype 4 has a concentration of at least 4.5 log₁₀ pfu/0.5 mL and optionally to 6.2 log₁₀ pfu/0.5 mL.

[00488] In certain embodiments, the reconstituted unit dose is administered to a subject of unknown serostatus and/or wherein no test has been carried out to determine whether the subject is seropositive or seronegative before the unit dose as described herein is administered.

[00489] In certain embodiments, the subject is under 9 years of age and/or the serostatus of the subject is unknown or seronegative. In certain such embodiments, the subject is under 9 years of age and the serostatus of the subject is unknown or seronegative, preferably seronegative.

[00490] In certain embodiments, the method is safe. In certain such embodiments, the subject is under 9 years of age or from 4 years of age and/or the serostatus of the subject is unknown or seronegative. In certain such

embodiments, the subject is from 4 years of age and the serostatus of the subject is unknown or seronegative, preferably seronegative.

[00491] In certain embodiments, the method is effective. In certain such embodiments, the subject is under 9 years of age and/or the serostatus of the subject is unknown or seronegative. In certain such embodiments, the subject is under 9 years of age and the serostatus of the subject is unknown or seronegative, preferably seronegative.

[00492] In certain embodiments, the dengue serotype 1 and the dengue serotype 2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL. In certain such embodiments, the dengue serotype 3 is at least about 10% of the total concentration in pfu/0.5 mL and/or the dengue serotype 4 is at least about 70% of the total concentration in pfu/0.5 mL.

[00493] In certain embodiments, the dengue serotype 4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 and dengue serotype 2 each represent lower concentrations than the concentration of serotype 3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

[00494] In certain embodiments, the composition includes at least one chimeric dengue virus. In certain such embodiments, the composition includes at least one non-chimeric dengue virus and at least one chimeric dengue virus.

[00495] In certain embodiments, the subject is seronegative to all dengue serotypes at baseline and/or is from 4 years of age, optionally to 60 years of age. In certain such embodiments, the subject is 4 to 16 years of age, under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age. In other embodiments, the subject is seropositive to at least one dengue serotypes at baseline and/or is from 4 years of age, optionally to 60 years of age. In certain such embodiments, the subject is 4 to 16 years of age, under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age.

[00496] In certain embodiments, the method does not comprise a determination of a previous dengue infection in the subject before the administration of the first unit dose of the tetravalent dengue virus composition. Thus, in certain embodiments, the subject has not been tested for the presence a previous dengue infection.

[00497] In certain embodiments, the dengue serotype 1 is a chimeric dengue serotype 2/1 strain, the dengue serotype 2 is a non-chimeric dengue serotype 2 strain, the dengue serotype 3 is a chimeric dengue serotype 2/3 strain and the dengue serotype 4 is a chimeric dengue serotype 2/4 strain and the dengue serotype 1 has the amino acid sequence of SEQ ID NO. 2, the dengue serotype 2 has the amino acid sequence of SEQ ID NO. 4, the dengue serotype 3 has the amino acid sequence of SEQ ID NO. 6, and the dengue serotype 4 has the amino acid sequence of SEQ ID NO. 8.

[00498] In certain embodiments, the unit dose further comprises from about 10 % w/v to about 20 % w/v α,α -trehalose dihydrate or an equimolar amount of other forms of α,α -trehalose, from about 0.5 % w/v to about 1.5 % w/v poloxamer 407, from about 0.05 % w/v to about 2 % w/v human serum albumin, and from about 70 mM to 140 mM sodium chloride when measured in 0.5 mL. In certain such embodiments, the unit dose comprises about 15 %

(w/v) α , α -trehalose dihydrate, about 1 % (w/v) poloxamer 407, about 0.1 % (w/v) human serum albumin, and about 100 mM sodium chloride when measured in 0.5 mL.

[00499] In certain embodiments, the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

5 **[00500]** In certain embodiments, the subject is from a dengue endemic region. In other embodiments, the subject is from a dengue non-endemic region.

[00501] In certain embodiments, the subject is from Asia Pacific or Latin America.

[00502] In certain embodiments, the reconstituted unit dose provides a seropositivity rate when it is administered to a subject population of at least 50 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the
10 subjects of the subject population are seronegative to all dengue serotypes at baseline. In certain such embodiments, at least 80% of the subject population are seropositive for all four dengue serotypes at least one month after administration of the first unit dose, such as at day 30, and/or at least 80% of the subject population are seropositive for all four dengue serotypes before or at the time of the administration of the second unit dose, such as at day 90,
15 and/or at least 80%, or at least 85% or at least 90%, or at least 95% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 120, and/or at least 80%, or at least 85%, or at least 90% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 270. In certain such embodiments, at least 80% of the subject population are seropositive for all four dengue serotypes at least one month after administration of the first unit dose, such as at day 30, and before or at the time of the administration of the second unit dose, such as at day 90, and after
20 the administration of the second unit dose, such as at day 120 and at day 270.

[00503] In certain embodiments, the reconstituted unit dose provides a seropositivity rate, when it is administered to a subject population of at least 100 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population comprises from 20% to 40% subjects who are seronegative to all dengue serotypes
25 and from 60% to 80% subjects who are seropositive to at least one dengue serotype at base line, wherein at day 120 and/or day 270 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 10%-points and/or wherein at day 120 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive
30 part of the subject population do not deviate more than 5%-points.

[00504] In certain particular embodiments, the invention is directed to a dengue vaccine composition as described herein for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at
35 about day 1 and at about day 90, and wherein the dengue vaccine composition is a tetravalent dengue virus composition including four live, attenuated dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, wherein the attenuated dengue virus strains comprise chimeric dengue viruses and at least one non-chimeric dengue virus, and wherein the dengue serotype 1 and the dengue serotype 2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL.
40

[00505] In certain embodiments, the method does not comprise a determination of a previous dengue infection of the subject before the administration of the first unit dose of the tetravalent dengue virus composition and wherein the method is safe and effective. Thus, in certain embodiments, the subject has not been tested for the presence a previous dengue infection.

5 **[00506]** In certain embodiments, the dengue serotype 3 is at least about 10% of the total concentration in pfu/0.5 mL and/or the dengue serotype 4 is at least about 70% of the total concentration in pfu/0.5 mL.

[00507] In certain embodiments, the dengue serotype 4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 and dengue serotype 2 each represent lower concentrations than the concentration of serotype 3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

10 **[00508]** In certain embodiments, the dengue serotype 1 is a chimeric dengue serotype 2/1 strain, the dengue serotype 2 is a non-chimeric dengue serotype 2 strain, the dengue serotype 3 is a chimeric dengue serotype 2/3 strain and the dengue serotype 4 is a chimeric dengue serotype 2/4 strain and the dengue serotype 1 has the amino acid sequence of SEQ ID NO. 2, the dengue serotype 2 has the amino acid sequence of SEQ ID NO. 4, the dengue serotype 3 has the amino acid sequence of SEQ ID NO. 6, and the dengue serotype 4 has the amino acid sequence of SEQ ID NO. 8.

15 **[00509]** In certain embodiments, in the unit dose upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

(i) dengue serotype 1 has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
 (ii) dengue serotype 2 has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
 (iii) dengue serotype 3 has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
 (iv) dengue serotype 4 has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL, and optionally the composition further comprises about 15 % (w/v) α,α-trehalose dihydrate, about 1 % (w/v) poloxamer 407, about 0.1 % (w/v) human serum albumin, and about 100 mM sodium chloride when measured in 0.5 mL.

[00510] In certain embodiments, the unit doses are administered to the deltoid region of the arm.

20 **[00511]** In certain embodiments, the composition is administered without determining the serostatus of the subject at baseline and wherein the administration is safe and effective regardless of the serostatus at base line.

[00512] In certain embodiments, the subject is seronegative to all dengue serotypes at baseline and/or is from 4 years of age, optionally to 60 years of age. In certain such embodiments, the subject is 4 to 16 years of age, under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age. In particular the subject may be under 9 years of age and seronegative to all four dengue serotypes at baseline. In other embodiments, the subject is seropositive to at least one dengue serotypes at baseline and/or is from 4 years of age, optionally to 60 years of age. In certain such embodiments, the subject is 4 to 16 years of age, under 9 years of age, from 2 years of age to under 9 years of age, from 4 years of age to under 9 years of age, 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age. In particular the

subject may be under 9 years of age and seropositive to at least one dengue serotypes at baseline. In certain preferred embodiments, the subject is 4 to 5 years of age, 6 to 11 years of age or 12 to 16 years of age.

[00513] In certain embodiments, the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

5 **[00514]** In certain embodiments, the subject is from a dengue endemic region or from a dengue non-endemic region.

[00515] In certain embodiments, the subject is from Asia Pacific or Latin America.

[00516] In certain embodiments, the composition provides a seropositivity rate when it is administered to a subject population of at least 50 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population are seronegative to all dengue serotypes at baseline, in particular wherein at least one month
10 after administration of the first unit dose, such as at day 30, at least 80% of the subject population are seropositive for all four dengue serotypes, and/or at least 80% of the subject population are seropositive for all four dengue serotypes before or at the time of the administration of the second unit dose, such as at day 90, and/or at least 80%, or at least 85% or at least 90%, or at least 95% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 120, and/or at least 80%, or at least 85%, or at least
15 90% of the subject population are seropositive for all four dengue serotypes after the administration of the second unit dose, such as at day 270.

[00517] In certain embodiments, the composition provides a seropositivity rate, when it is administered to a subject population of at least 100 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population comprises from 20% to 40% subjects who are seronegative to all dengue serotypes and from
20 60% to 80% subjects who are seropositive to at least one dengue serotype at base line, wherein at day 120 and/or day 270 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 10%-points and/or wherein at day 120 the seropositivity rate for all four dengue serotypes in the seronegative
25 part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 5%-points.

[00518] The present invention is in part directed to the unit dose of the invention as described herein for use in a method of preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described
30 herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described
35 herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or
40 not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00519] The present invention is in part directed to the unit dose of the invention as described herein for use in a method of preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00520] The geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with the microneutralization test disclosed herein, for example according to the method described in Example 2.

[00521] In certain embodiments the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein said unit dose is administered by subcutaneous injection. According to some of these embodiments the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00522] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein the subject or subject population is seronegative to all dengue serotypes.

[00523] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein a single unit dose of the invention as described herein is administered.

[00524] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90 or at day 1 and day 90. According to some of these embodiments, a third reconstituted unit dose of the invention as described herein may be administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration. .

[00525] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein the reconstituted unit dose of the invention as described herein is administered at most in two doses or in one dose.

[00526] In certain embodiments of the invention the subject is seronegative with respect to all dengue serotypes. In certain embodiments of the invention the subject is seronegative with respect to all dengue serotypes and the reconstituted unit dose is administered to the seronegative subject by subcutaneous injection.

[00527] In certain other embodiments of the invention the subject is seropositive with respect to at least one dengue serotype.

[00528] In certain embodiments the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the reconstituted unit dose of the invention as described herein is administered to a subject or subject population from a dengue endemic region. In some of these embodiments, the subject or subject population is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the subject or subject population is from a dengue non-endemic region. Such a subject population or such a subject may be vaccinated according to the invention in the context of traveling to a dengue-endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population from a dengue endemic region or from a dengue non-endemic region.

[00529] In some embodiments the invention is directed to the unit dose of the invention as described herein for said uses, wherein the subject or subject population is of 2 to 60 years of age, or more than 17 years, or more than 18 years, or 18 to 60 years of age. In certain embodiments, the subject or subject population is of 1 to 17 years of age, or less than 9 years of age, or less than 4 years of age or less than 2 years of age. In further specific embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. According to some of these embodiments the subject or subject population is seronegative and from a dengue-endemic region.

[00530] In certain embodiments, the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the unit dose of the invention as described herein is administered to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00531] In certain embodiments, the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the reconstituted unit dose is administered subcutaneously to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00532] The unit dose for use in the methods described above may be any unit dose of a dengue vaccine composition as described above under the headings "Unit dose" or "Dengue vaccine composition" and comprise any dengue virus strain as described above under the heading "Dengue virus strain".

[00533] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) in an elderly subject.

[00534] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein the elderly subject is seronegative to all dengue serotypes.

[00535] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein the elderly subject is seronegative to all dengue serotypes.

[00536] In certain embodiments the invention is directed to a reconstituted unit dose of the invention as described herein for said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments, a third reconstituted unit dose of the invention as described herein may be administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00537] In certain embodiments of the invention the elderly subject is seronegative with respect to all dengue serotypes. In certain embodiments of the invention the elderly subject is seronegative with respect to all dengue serotypes and the reconstituted unit dose is administered to the seronegative subject by subcutaneous injection.

[00538] In certain other embodiments of the invention the elderly subject is seropositive with respect to at least one dengue serotype.

[00539] In certain embodiments the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the reconstituted unit dose of the invention as described herein is administered to an elderly subject from a dengue endemic region. In some of these embodiments, the elderly subject is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the elderly subject is from a dengue non-endemic region. Such an elderly subject may be vaccinated according to the invention in the context of traveling to a dengue-endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject from a dengue endemic region or from a dengue non-endemic region.

[00540] In certain embodiments, the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the elderly subject has at least one chronic condition or disease. The at least one chronic condition or disease may be selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

[00541] In certain embodiments, the invention is directed to the reconstituted unit dose of the invention as described herein for said uses, wherein the elderly subject has an impaired immune system.

Use for the manufacture of a medicament for preventing dengue disease

[00542] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject.

[00543] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease (in particular virologically confirmable dengue, VCD) in a subject population.

[00544] The present invention is therefore directed to the use of a tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4 in the manufacture of a medicament for the method of inoculating a subject against virologically confirmable dengue disease, wherein in particular the tetravalent dengue virus composition includes a chimeric dengue serotype 2/1 strain and a

dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain, wherein in particular the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 (SEQ ID NO 11) and differs in at least three nucleotides from the wild type as follows:

d) 5'-noncoding region (NCR)-57 (nt-57 C-to-T): major attenuation locus

5 e) NS1-53 Gly-to-Asp (nt-2579 G-to-A): major attenuation locus

f) NS3-250 Glu-to-Val (nt-5270 A-to-T): major attenuation locus; and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- 10 - a DENV-2/1 chimera,
 - a DENV-2/3 chimera and
 - a DENV-2/4 chimera.

[00545] Further information regarding the serotypes of the tetravalent composition can be derived from section "Dengue virus strains" above.

15 **[00546]** The present invention is in particular directed to such use wherein the tetravalent dengue virus composition is in the form of a unit dose comprising:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
 (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
 (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
 20 (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00547] The present invention is in particular directed to such use wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

- (i) a dengue serotype 1 in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
 25 (ii) a dengue serotype 2, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
 (iii) a dengue serotype 3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
 (iv) a dengue serotype 4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00548] The present invention is also in particular directed to such use wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8%, or at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18%, and wherein the subject is preferably 2 to 17 years of age or 4 to 16 years of age.

[00549] The present invention is also in particular directed to such use wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6% and wherein the subject preferably is 18 to 60 years of age.

[00550] Further information regarding the tetravalent composition or the unit dose can be derived from section "Dengue vaccine composition" and "Unit dose" above.

[00551] According to one embodiment the use is directed to a method comprising a primary vaccination with only two administrations of the unit dose comprising the steps of:

- (A) administering a first unit dose of the tetravalent dengue virus composition to the subject, and
- (B) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

According to this embodiment the administration of only two doses within 3 months is sufficient to provide effective protection against a subsequent dengue infection.

[00552] Such method preferably provides a combined vaccine efficacy against all four serotypes in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 60%, when measured against placebo in a subject population of at least 5,000 healthy subjects irrespective of serostatus at baseline and 14 to 16 years of age, from the first administration of the administration schedule until 18 months after the second administration of the administration schedule.

[00553] Such method also preferably provides a combined vaccine efficacy against all four serotypes, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 45 %, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects seronegative against all serotypes at baseline and 14 to 16 years of age, from 30 days after the second administration of the administration schedule until 18 months after the second administration of the administration schedule.

[00554] According to certain embodiments the use is for a method of inoculation against the virologically confirmable dengue disease is due to a dengue serotype 2, and/or due to a dengue serotype 1. The method has very high efficacy against dengue serotype 2 and dengue serotype 1 and the highest efficacy against dengue serotype 2.

[00555] In certain embodiments, the invention is directed to the use wherein said methods have a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 30%, is more than 35% is more than 40%, is more than 45%, is more than 50%, or is more than 54%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line and the lower bound is more than 35%. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 with a 2-sided 95% confidence interval, wherein the lower bounds are within 10 %-points.

[00556] In certain embodiments, the invention is directed to said use wherein said methods have a vaccine efficacy against serotype 1, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 40%, is more than 50%, is more than 60%, or is more than 65%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 1 which are within 5 %-points.

[00557] In certain embodiments, the invention is directed to said use wherein said methods have a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the lower bound is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 85%. In certain such embodiments the subject population of at least 1,500, is seronegative against all serotypes. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 with a 2-sided 95% confidence interval, wherein the lower bounds are within 5 %-points.

[00558] In certain embodiments, the invention is directed to said use wherein said methods have a vaccine efficacy against serotype 2, in preventing virologically confirmable dengue disease, when measured against placebo in a subject population of at least 1,500, or at least 2,000, or at least 5,000 healthy subjects (or at least 10,000, or at least 15,000 healthy subjects) irrespective of serostatus at baseline and 4 to 16 years of age from 30 days post second administration until 12 to 18 months (e.g. at 12 or at 18 months) after the second administration. In certain such embodiments, the vaccine efficacy is more than 60%, is more than 70%, is more than 80%, or is more than 90%. In certain such embodiments the subject population of at least 1,500 is seronegative against all serotypes at base line. In certain such embodiments the seronegative and seropositive population each provide a vaccine efficacy against serotype 2 which are within 5 %-points.

[00559] The efficacy of the method is further described in more detail in the section "method of preventing, method of inoculating".

[00560] In certain embodiments the unit dose is reconstituted and administered by subcutaneous injection. According to some of these embodiments, the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00561] According to one embodiment such use is directed to a method which does not include a step of determination of a previous dengue infection in the subjects preferably at any time before, during or after the steps of administration or wherein the serostatus of the subject is unknown preferably at any time before, during or after the steps of administration.

[00562] The method according to the invention does not require the testing of the serostatus before vaccination and thus allows immediate treatment and outbreak control. According to certain embodiments the use is for a method wherein the subject is exposed to a dengue outbreak. In certain such embodiments the outbreak is due to a dengue serotype 2, and/or due to a serotype 1.

[00563] According to one embodiment such a method the subject is from a region wherein the seroprevalence rate is unknown and/or wherein the seroprevalence rate is below 80%, or below 70%, or below 60%.

[00564] According to one embodiment of such a method the subject is seronegative at baseline and is from a region or travels to a region wherein the seroprevalence rate is high with respect to serotype 1 and/or serotype 2 i.e. 80%, or 90% or above.

[00565] According this embodiment the vaccine and corresponding method is safe for seronegative and seropositive subjects and thus does not require an analysis of the serostatus or a determination of a previous dengue infection or a high seroprevalence rate in the region. Such a method preferably provides a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 65%, when measured against placebo in a subject population of at least 5,000 healthy 4 to 16 year old subjects irrespective of serostatus at baseline, preferably in at least 1,500 healthy 4 to 16 year old subjects seronegative at baseline, from first administration of the administration schedule until 12 to 18 months after the second administration of the administration schedule. Preferably, the 2-sided 95% confidence interval of the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes when comparing seropositive and seronegative subjects provides for lower bounds of the 2-sided confidence interval which are within 10% points or within 15% points or within 20% points. The method is preferably safe with respect to serotype 1 and serotype 2 which may therefore be used in outbreak situations due to serotype 1 and/or serotype 2 or even for seronegative subjects (e.g. travelers) or subjects with unknown serostatus in regions with very high seroprevalence rates (>80%) due to serotype 1 and/or serotype 2.

[00566] The safety of the method is further described in more detail in the section "method of preventing, method of inoculating".

[00567] According to one embodiment such a method does not include the active surveillance with respect to febrile illness of the subject after the administration of the first- and second-unit dose. During active surveillance any subject with febrile illness (defined as fever $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days) will be asked to return to the site for dengue fever evaluation by the Investigator. Subjects/guardians will be contacted at least weekly to ensure robust identification of febrile illness by reminding subjects/guardians of their obligation to return to the site in case of febrile illness. This contact will be implemented through appropriate methods that may differ in each trial site (eg, phone calls, text messaging, home visits, school-based surveillance).

[00568] According to one embodiment such a method does not include vaccine immunogenicity analysis including GMTs for dengue neutralizing antibodies.

[00569] According to one embodiment such a method does not include a reactogenicity analysis. Such a reactogenicity analysis relates to solicited local AEs (injection site pain, injection site erythema, and injection site swelling) and solicited systemic AEs (child < 6 years: fever, irritability/fussiness, drowsiness and loss of appetite; child ≥ 6 years: asthenia, fever, headache, malaise and myalgia) which will e.g. be assessed for 7 days and 14 days, respectively, following each vaccination (vaccination day included) via collection of diary cards.

[00570] According to one embodiment the method does not include an active surveillance, an immunogenicity analysis and a reactogenicity analysis.

[00571] According to such embodiments the vaccine and the corresponding method of inoculation are safe and therefore do not require further steps of surveillance or analysis.

[00572] In view of the above according to one embodiment the use is directed to a method comprises a primary vaccination consisting of the steps of:

- (A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination of a previous dengue infection, and
- (B) administering a first unit dose of the tetravalent dengue virus composition to the subject, and

(C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose.

Therefore the method of inoculating is finalized without determination of a previous dengue infection. The method however further optionally comprises at least 1 years after the administration of the second unit dose a booster dose of the unit dose.

[00573] Selecting the subject may include all types of considerations but preferably not the determination of a previous dengue infection. The selection may include consideration of the age, health conditions, and threat of infection. The threat of infection includes consideration of the seroprevalence rate in the region in which the subject normally lives or intends to travel, the serotype specific seroprevalence rate and an outbreak situation or serotype specific outbreak situations. The subject may be selected due to its exposure to serotype 1 and/or serotype 2 or due to the fact it requires protection against a specific dengue serotype, i.e. serotype 1 and/or serotype 2.

[00574] According to the invention the method is applicable to subjects of all kinds of ages. According to one embodiment the subject is under 9 years of age, or 4 to 5 years of age, or 6 to 11 years of age or 12 to 16 years, or 6 to 16 years of age or 4 to 16 years of age, or 2 to 17 years of age, or 9 years of age, or over 9 years of age, or 9 to 17 years of age, , or 18 to 45 years of age, or 46 to 60 years of age, or over 60 years of age.

[00575] According to certain such embodiments the unit dose of the tetravalent dengue virus composition comprising (i), (ii), (iii), and (iv) upon reconstitution with a pharmaceutically acceptable diluent provides a total concentration of pfu/0.5 mL of (i), (ii), (iii), and (iv) and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 10%, and the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, and the concentration of (i) in pfu/0.5 mL is preferably at least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 8%, or more preferred at least 10%, or at least 12%, or at least 14%, or at least 16%, or at least 18% and the subject is 2 to 17 years of age or 4 to 16 years of age.

[00576] According to certain such embodiments the unit dose of the tetravalent dengue virus composition comprising (i), (ii), (iii), and (iv) upon reconstitution with a pharmaceutically acceptable diluent provides a total concentration of pfu/0.5 mL of (i), (ii), (iii), and (iv) and based on said total concentration the concentration of (ii) in pfu/0.5 mL is preferably less than 2%, the concentration of (iv) in pfu/0.5 mL is preferably at least 50%, the concentration of (i) in pfu/0.5 mL is at preferably least 1%, and the concentration of (iii) in pfu/0.5 mL is preferably at least 6% and the subject is 18 to 60 years of age.

[00577] Any method described herein above under the heading "Method of preventing" is to be understood to be also disclosed as the use of a unit dose for the manufacture of a medicament for preventing dengue disease in a subject or subject population with such a method irrespective of whether it is expressly stated below.

[00578] Further specific embodiments are described below.

[00579] The present invention is in part directed to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue

serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00580] The present invention is in part directed to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00581] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with the microneutralization test disclosed herein, for example according to the method described in Example 2.

[00582] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection. According to some of these embodiments the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00583] In certain embodiments the invention is directed to said uses, wherein one reconstituted unit dose of the invention as described is administered by subcutaneous injection. According to some of these embodiments, the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

[00584] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In one embodiment, the two unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90 or at day 1/0 and day 90. According to some of these embodiments a third unit dose of the invention as described herein may be administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00585] In certain embodiments of the invention the subject is seronegative with respect to all dengue serotypes.

[00586] In certain other embodiments of the invention the subject is seropositive with respect to at least one dengue serotype.

[00587] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose is administered to the seronegative subject by subcutaneous injection.

5 **[00588]** In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose is administered to a subject of unknown serostatus and/or wherein no test has been carried out to determine whether the subject is seropositive or seronegative before the unit dose is administered.

[00589] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered to a subject or subject population from a dengue endemic region. In
10 some of these embodiments, the subject or subject population is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the subject or subject population is from a dengue non-endemic region. Such a subject population or subject may be vaccinated according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is
15 administered subcutaneously to a subject or subject population from a dengue endemic region or from a dengue non-endemic region.

[00590] In certain embodiments the invention is directed to said uses, wherein the subject is of 2 to 60 years of age or more than 17 years, or more than 18 years, or 18 to 60 years of age. In certain embodiments the subject is 1 to 17 years of age, or less than 9 years of age, or less than 4 years of age or less than 2 years of age. In further embodiments,
20 the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. According to some of these embodiments the subject is seronegative and from a dengue-endemic region.

[00591] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is administered to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to
25 some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00592] In certain embodiments, the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a pediatric subject or pediatric subject population of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1
30 year of age. According to some of these embodiments, the pediatric subject or pediatric subject population is seronegative and from a dengue endemic region.

[00593] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in an elderly subject.

[00594] The present invention is directed in part to the use of a unit dose of the invention as described herein for
35 the manufacture of a medicament for preventing dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) in an elderly subject.

[00595] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection. According to some of these embodiments the subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm.

5 [00596] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In one embodiment, the two unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a third unit dose of the invention as described herein may be administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first
10 administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00597] In certain embodiments of the invention the elderly subject is seronegative with respect to all dengue serotypes.

15 [00598] In certain other embodiments of the invention the elderly subject is seropositive with respect to at least one dengue serotype.

[00599] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose is administered to the seronegative elderly subject by subcutaneous injection.

20 [00600] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered to an elderly subject from a dengue endemic region. In some of these embodiments, the elderly subject is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the elderly subject is from a dengue non-endemic region. Such an elderly subject may be vaccinated according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject from a dengue endemic
25 region or from a dengue non-endemic region.

[00601] In certain embodiments, the invention is directed to said uses, wherein the elderly subject has at least one chronic condition or disease. The at least one chronic condition or disease may be selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

30 [00602] In certain embodiments, the invention is directed to said uses, wherein the elderly subject has an impaired immune system.

Method of preventing dengue disease and yellow fever and uses

Method of prevention

35 [00603] The present invention is directed in part to a method of preventing dengue disease as well as yellow fever in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein

the method further comprises preventing yellow fever in the subject by concomitant administration of a yellow fever vaccine, in particular YF-17D, to the subject.

[00604] The present invention is directed in part to a method of preventing dengue disease as well as yellow fever in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing yellow fever in the subject population by concomitant administration of a yellow fever vaccine, in particular YF-17D, to the subject population.

[00605] The present invention is in part directed to said method for preventing dengue disease and yellow fever in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00606] The present invention is in part directed to said method for preventing dengue disease and yellow fever in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00607] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00608] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the

administration of the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are done sequentially.

[00609] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered and the yellow fever vaccine, in particular YF-17D, are administered by subcutaneous injection. According to some embodiments, the subcutaneous injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injections of the unit dose of the invention as described herein and yellow fever vaccine, in particular YF-17D, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00610] In certain embodiments the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 month or more, or within 6 month, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration .

[00611] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- an administration of said yellow fever vaccine on day 0,
- a first administration of the first reconstituted unit dose after said yellow fever vaccine administration, such as 3 months later and preferably on day 90, and
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

[00612] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- a first administration of the first reconstituted unit dose on day 0,
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 90, and
- an administration of said yellow fever vaccine after said second administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

[00613] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- a simultaneous administration of the first reconstituted unit dose and said yellow fever vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 months later and preferably on day 90.

[00614] In a preferred embodiment, the yellow fever vaccine and unit dose of the invention as described herein are administered simultaneously on day 0 or simultaneously on day 90.

[00615] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population and the yellow fever vaccine, in particular YF-17D vaccine, is administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00616] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or subject population from a dengue endemic region. In other embodiments, the subject or subject population is from a dengue non-endemic region. Such a subject population or such a subject may be vaccinated according to the present invention in the context of traveling to a dengue endemic region and yellow fever endemic region.

[00617] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein and of the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and yellow fever non-endemic region. According to some of these embodiments, the subject or subject population are seronegative for all four dengue serotypes.

Unit dose for use in a method of prevention

[00618] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of yellow fever in the subject with a yellow fever vaccine, in particular YF-17D. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a yellow fever vaccine, in particular YF-17D, for use in a method of preventing dengue disease and yellow fever in a subject, respectively.

[00619] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of yellow fever in the subject population with a yellow fever vaccine, in particular YF-17D. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a yellow fever vaccine, in particular YF-17D, for use in a method of preventing dengue disease and yellow fever in a subject population, respectively.

[00620] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the yellow fever vaccine, in particular YF-17D, for use in a method of preventing dengue disease and yellow fever in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject population. According to some embodiments,

the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00621] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the yellow fever vaccine, in particular YF-17D, for use in a method of preventing dengue disease and yellow fever in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00622] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00623] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein said unit dose and said yellow fever vaccine are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of said unit dose and said yellow fever vaccine, in particular YF-17D, are done sequentially.

[00624] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said yellow fever vaccine is administered by subcutaneous injection. According to some embodiments, the subcutaneous injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of said unit dose and the subcutaneous injection of said yellow fever vaccine are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00625] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein two reconstituted unit doses of the invention as

described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00626] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein two reconstituted unit doses of the invention as described herein and one dose of the yellow fever vaccine are administered, in particular according to the following schedule

- an administration of said yellow fever vaccine on day 0,
- a first administration of the first reconstituted unit dose after said yellow fever vaccine administration, such as 3 months later and preferably on day 90, and
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

[00627] In another embodiment the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein two unit doses of the invention as described herein and one dose of the yellow fever vaccine are administered, in particular according to the following schedule

- a first administration of the first reconstituted unit on day 0,
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 90, and
- an administration of said yellow fever vaccine after said second administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

[00628] In another embodiment the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein two unit doses of the invention as described herein and one dose of the yellow fever vaccine are administered, in particular according to the following schedule

- a simultaneous administration of the first reconstituted unit dose and said yellow fever vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 months later and preferably on day 90.

[00629] In a preferred embodiment, the yellow fever vaccine and unit dose of the invention as described herein are administered simultaneously on day 0 or simultaneously on day 90.

[00630] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein said unit dose is reconstituted and administered subcutaneously to a subject or subject population and said yellow fever vaccine is administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative

with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00631] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein said unit dose and said yellow fever vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or subject population from a dengue endemic region. In other embodiments, the subject or subject population is from a dengue non-endemic region. Such a subject population or such a subject may be vaccinated according to the present invention in the context of traveling to a dengue endemic region and yellow fever endemic region.

[00632] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, for said uses, wherein the reconstituted unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or a subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In some embodiments the subject or subject population is from a dengue endemic region. In another embodiment the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and yellow fever non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Use for the manufacture of a medicament in a method of prevention

[00633] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing yellow fever in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing dengue disease and yellow fever in a subject, respectively.

[00634] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, further comprising the use of a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing yellow fever in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing dengue disease and yellow fever in a subject population, respectively.

[00635] The present invention is in part directed to the use of a unit dose of the invention as described herein and a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing dengue disease and yellow fever in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the

invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00636] The present invention is in part directed to the use of a unit dose of the invention as described herein and a yellow fever vaccine, in particular YF-17D, for the manufacture of a medicament for preventing dengue disease and yellow fever in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a yellow fever vaccine, in particular YF-17D, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00637] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00638] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are done sequentially.

[00639] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the yellow fever vaccine, in particular YF-17D, is administered by subcutaneous injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and of the yellow fever vaccine, in particular YF-17D, are administered to different anatomical sites such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00640] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is

administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

5 **[00641]** In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- an administration of said yellow fever vaccine on day 0,
- a first administration of the first reconstituted unit dose after said yellow fever vaccine administration, such
10 as 3 months later and preferably on day 90, and
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

15 **[00642]** In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- a first administration of the first reconstituted unit dose on day 0,
- a second administration of the second reconstituted unit dose said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 90, and
- an administration of said yellow fever vaccine after said second administration of the reconstituted unit
20 dose, such as 3 months later and preferably on day 180.

[00643] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and one dose of a yellow fever vaccine, in particular YF-17D, are administered, in particular according to the following schedule

- a simultaneous administration of the first reconstituted unit dose and said yellow fever vaccine on day 0,
25 and
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 months later and preferably on day 90.

30 **[00644]** In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the yellow fever vaccine, in particular YF-17D, is administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

35 **[00645]** In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or subject population from a dengue endemic region. In other embodiments, the subject or subject population is from a dengue

non-endemic region. Such a subject population or such a subject may be vaccinated according to the present invention in the context of traveling to a dengue endemic region and yellow fever endemic region.

[00646] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein and the yellow fever vaccine, in particular YF-17D, are administered subcutaneously to a subject or subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and yellow fever non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Method of preventing dengue disease and hepatitis A and uses

Method of prevention

[00647] The present invention is directed in part to a method of preventing dengue disease as well as hepatitis A in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing hepatitis A in the subject by concomitant administration of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject.

[00648] The present invention is directed in part to a method of preventing dengue disease as well as hepatitis A in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing hepatitis A in the subject population by concomitant administration of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject population.

[00649] The present invention is in part directed to said method for preventing dengue disease and hepatitis A in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00650] The present invention is in part directed to said method for preventing dengue disease and hepatitis A in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described

herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00651] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00652] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are done sequentially.

[00653] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection and wherein the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments, the subcutaneous injection of the reconstituted unit dose of the invention as described herein and the intramuscular injection of the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00654] In certain embodiments, the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments, the two unit doses of the invention as described herein are administered within 12 month or more, or within 6 month, or within three months, such as at day 0/1 and day 90. According to some of these embodiments, a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00655] In certain embodiments, the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and one dose of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said hepatitis A vaccine on day 0, and

- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00656] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00657] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00658] According to some embodiments, a second dose of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered. The second dose of the hepatitis A vaccine may be administered after the first administration of the hepatitis A vaccine. Such a second administration may act as a booster and may be administered 9 months after the first administration of the hepatitis A vaccine, such as on day 270.

[00659] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and a hepatitis A non-endemic region. According to certain embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Unit dose for use in a method of prevention

[00660] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of hepatitis A in the subject with a hepatitis A vaccine, such as HAVRIX® or VAQTA®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for use in a method of preventing dengue disease and hepatitis A in a subject, respectively.

[00661] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of hepatitis A in the subject population with a hepatitis A vaccine, such as HAVRIX® or VAQTA®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for use in a method of preventing dengue disease and hepatitis A in a subject population, respectively.

[00662] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for use in a method of preventing dengue disease and hepatitis A in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00663] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for use in a method of preventing dengue disease and hepatitis A in a subject comprising administering to the subject a hepatitis A vaccine, such as HAVRIX® or VAQTA®, and at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20, wherein the method further comprises preventing hepatitis A in the subject by concomitant administration of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00664] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00665] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein said unit dose and said hepatitis A vaccine are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of said unit dose and said hepatitis A vaccine are done sequentially.

[00666] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said hepatitis A vaccine is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments, the subcutaneous injection of said unit dose and the intramuscular injection of said hepatitis A vaccine are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00667] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00668] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein two reconstituted unit doses of the invention as described herein and one dose of the hepatitis A vaccine are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and a dose of said hepatitis A vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00669] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein said unit dose is reconstituted and administered subcutaneously to a subject or subject population and said hepatitis A vaccine is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00670] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein said unit dose and said hepatitis A vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00671] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein a further second dose of a hepatitis A

vaccine, such as HAVRIX® or VAQTA®, is administered. The second dose of the hepatitis A vaccine may be administered after the first administration of the hepatitis A vaccine. Such a second administration may act as a booster and may be administered 9 months after the first administration of the hepatitis A vaccine, such as on day 270.

[00672] In some embodiments, the invention is directed to the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, for said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and a hepatitis A non-endemic region. According to certain embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Use for the manufacture of a medicament in a method of prevention

[00673] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing hepatitis A in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing dengue disease and hepatitis A in a subject, respectively.

[00674] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, further comprising the use of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing hepatitis A in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing dengue disease and hepatitis A in a subject population, respectively.

[00675] The present invention is in part directed to the use of a unit dose of the invention as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing dengue disease and hepatitis A in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00676] The present invention is in part directed to the use of a unit dose of the invention as described herein and a hepatitis A vaccine, such as HAVRIX® or VAQTA®, for the manufacture of a medicament for preventing dengue disease and hepatitis A in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved and concomitantly administering a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00677] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00678] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are done sequentially.

[00679] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some embodiments the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00680] In certain embodiments, the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00681] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and one dose of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said hepatitis A vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00682] In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00683] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00684] In certain embodiments, the invention is directed to said uses, wherein a further second dose of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered. The second dose of the hepatitis A vaccine may be administered after the first administration of the hepatitis A vaccine. Such a second administration may act as a booster and may be administered 9 months after the first administration of the hepatitis A vaccine such as on day 270.

[00685] In certain embodiments, the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and the hepatitis A vaccine, such as HAVRIX® or VAQTA®, is administered intramuscularly to a subject or subject population of more than 17 years, or more than 18 years, or 18 to 60 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region, preferably from a dengue non-endemic and hepatitis A non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Method of preventing dengue disease and HPV associated diseases and uses

Method of prevention

[00686] The present invention is directed in part to a method of preventing dengue disease as well as HPV-associated cancers or genital warts in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing HPV-associated cancers or genital warts in the subject by concomitant administration of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject.

[00687] The present invention is directed in part to a method of preventing dengue disease as well as HPV-associated cancers or genital warts in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing HPV-

associated cancers or genital warts in the subject population by concomitant administration of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject population.

[00688] The present invention is in part directed to said method for preventing dengue disease and HPV-associated cancers or genital warts in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00689] The present invention is in part directed to said method for preventing dengue disease and HPV-associated cancers or genital warts in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00690] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00691] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are done sequentially.

[00692] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection and wherein the HPV vaccine, in particular

a 9vHPV vaccine, such as GARDASIL® 9, is administered by intramuscular injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00693] In certain embodiments the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 month or more, or within 6 month, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00694] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and two doses of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said HPV vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 month later and preferably on day 90, and
- a third administration of the second dose of said HPV vaccine after said second administration of the reconstituted unit dose, such as 3 month later and preferably on day 180.

[00695] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00696] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00697] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population of 9 to 26 years of age, preferably 9 to 15 years of age. In some embodiments the subject or subject population is from a dengue endemic

region. According to some of these embodiments, the subject or subject population is female. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00698] In a preferred embodiment the invention is directed to a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, according to the above described administration schedule, wherein the subject is a female subject of 9 to 15 years of age from a dengue endemic region.

Unit dose for use in a method of prevention

[00699] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of HPV-associated cancers or genital warts in the subject with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for use in a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject, respectively.

[00700] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of HPV-associated cancers or genital warts in the subject population with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for use in a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject population, respectively.

[00701] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for use in a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00702] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for use in a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject comprising administering to the subject at

least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00703] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00704] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein said unit dose and said HPV vaccine are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of said unit dose and said HPV vaccine are done sequentially.

[00705] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said HPV vaccine is administered by intramuscular injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of said unit dose and the intramuscular injection of said HPV vaccine are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00706] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00707] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein two reconstituted unit doses of the invention as described herein and two doses of the HPV vaccine are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said HPV vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 month later and preferably on day 90, and
- a third administration of the second dose of said HPV vaccine after said second administration of the reconstituted unit dose, such as 3 month later and preferably on day 180.

[00708] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein said unit dose is reconstituted and administered subcutaneously to a subject or subject population and said HPV vaccine is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00709] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein said unit dose and said HPV vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00710] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscular to a subject or subject population of 9 to 25 years of age, preferably of 9 to 15 years of age. In some embodiments the subject or subject population is from a dengue endemic region. According to some of these embodiments, the subject or subject population is female. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00711] In a preferred embodiment the invention is directed to the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for use in a method of preventing dengue disease and HPV-associated cancers or genital warts in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, according to the above described administration schedule, wherein the subject is a female subject of 9 to 15 years of age from a dengue endemic region.

Use for the manufacture of a medicament in a method of prevention

[00712] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing HPV-associated cancers or genital warts in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a HPV vaccine, in particular a 9vHPV vaccine,

such as GARDASIL® 9, for the manufacture of a medicament for preventing dengue disease and HPV-associated cancers or genital warts in a subject, respectively.

[00713] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, further comprising the use of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing HPV-associated cancers or genital warts in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing dengue disease and HPV-associated cancers or genital warts in a subject population, respectively.

[00714] The present invention is in part directed to the use of a unit dose of the invention as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing dengue disease and HPV-associated cancers or genital warts in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00715] The present invention is in part directed to the use of a unit dose of the invention as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing dengue disease and HPV-associated cancers or genital warts in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00716] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00717] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are done sequentially.

[00718] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered by intramuscular injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered to different anatomical sites such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00719] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00720] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and two doses of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said HPV vaccine on day 0,
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 month later and preferably on day 90, and
- a third administration of the second dose of said HPV vaccine after said second administration of the reconstituted unit dose, such as 3 month later and preferably on day 180.

[00721] In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00722] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00723] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, is administered intramuscularly to a subject or subject population of 9 years to 25 years of age, preferably of 9 to 15 years of age. In some embodiments the subject or subject population is from a dengue endemic region. According to some of these embodiments, the subject or subject population is female. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00724] In a preferred embodiment the invention is directed to the use of a unit dose of a dengue vaccine composition as described herein and a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, for the manufacture of a medicament for preventing dengue disease and HPV-associated cancers or genital warts in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, according to the above described administration schedule, wherein the subject is a female subject of 9 to 15 years of age from a dengue endemic region.

Method of preventing dengue disease and measles, mumps and rubella and uses

Method of prevention

[00725] The present invention is directed in part to a method of preventing dengue disease as well as measles, mumps and rubella in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing measles, mumps and rubella in the subject by concomitant administration of a MMR vaccine, such as M-M-R® II, to the subject.

[00726] The present invention is directed in part to a method of preventing dengue disease as well as measles, mumps and rubella in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing measles, mumps and rubella in the subject population by concomitant administration of a MMR vaccine, such as M-M-R® II, to the subject population.

[00727] The present invention is in part directed to said method for preventing dengue disease and measles, mumps and rubella in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects

at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00728] The present invention is in part directed to said method for preventing dengue disease and measles, mumps and rubella in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00729] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00730] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are done sequentially.

[00731] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection and wherein the MMR vaccine, such as M-M-R® II, is administered by subcutaneous injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and the subcutaneous injection of the MMR vaccine, such as M-M-R® II, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00732] In certain embodiments the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 month or more, or within 6 month, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first

administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00733] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and two doses of a MMR vaccine, such as M-M-R® II, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said MMR vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90, and
- a third administration of the second dose of said MMR vaccine after said second administration of the second reconstituted unit dose, such as 3 to 6 years after said first simultaneous administration.

[00734] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00735] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population from a dengue endemic region.

[00736] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein and wherein the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population of 1 to 10 years of age, preferably 2 months to 7 years of age. In some embodiments the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Unit dose for use in a method of prevention

[00737] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of measles, mumps and rubella in the subject with a MMR vaccine, such as M-M-R® II. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a MMR vaccine, such as M-M-R® II, for use in a method of preventing dengue disease and measles, mumps and rubella in a subject, respectively.

[00738] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of measles, mumps and rubella in the subject population with a MMR vaccine, such as M-M-R® II. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a MMR

vaccine, such as M-M-R® II, for use in a method of preventing dengue disease and measles, mumps and rubella in a subject population, respectively.

[00739] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the MMR vaccine, such as M-M-R® II, for use in a method of preventing dengue disease and measles, mumps and rubella in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00740] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the MMR vaccine, such as M-M-R® II, for use in a method of preventing dengue disease and measles, mumps and rubella in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00741] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00742] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein said unit dose and said MMR vaccine are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of said unit dose and said MMR vaccine are done sequentially.

[00743] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said MMR vaccine is administered by subcutaneous injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these

5 embodiments the subcutaneous injection of said unit dose and the subcutaneous injection of said MMR vaccine are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00744] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein two reconstituted unit doses of the invention as described

10 herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month

15 after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00745] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein two reconstituted unit doses of the invention as described herein and two doses of the MMR vaccine are administered, in particular according to the following schedule

- 20 - a first simultaneous administration of the first reconstituted unit dose and the first dose of said MMR vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90, and
- 25 - a third administration of the second dose of said MMR vaccine after said second administration of the second reconstituted unit dose, such as 3 to 6 years after said first simultaneous administration.

[00746] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein said unit dose is reconstituted and administered

30 subcutaneously to a subject or subject population and said MMR vaccine is administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00747] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein said unit dose and said MMR vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population from a dengue endemic region.

35

[00748] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, for said uses, wherein the reconstituted unit dose of the invention as described

40

herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population of 1 to 10 years of age, preferably of 2 months to 7 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Use for the manufacture of a medicament in a method of prevention

[00749] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing measles, mumps and rubella in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing dengue disease and measles, mumps and rubella in a subject, respectively.

[00750] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, further comprising the use of a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing measles, mumps and rubella in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing dengue disease and measles, mumps and rubella in a subject population, respectively.

[00751] The present invention is in part directed to the use of a unit dose of the invention as described herein and a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing dengue disease and measles, mumps and rubella in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00752] The present invention is in part directed to the use of a unit dose of the invention as described herein and a MMR vaccine, such as M-M-R® II, for the manufacture of a medicament for preventing dengue disease and measles, mumps and rubella in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a MMR vaccine, such as M-M-R® II, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of

the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00753] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00754] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are done sequentially.

[00755] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the MMR vaccine, such as M-M-R® II, is administered by subcutaneous injection. According to some embodiments the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and the subcutaneous injection of the MMR vaccine, such as M-M-R® II, are administered to different anatomical sites such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00756] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00757] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and two doses of a MMR vaccine, such as M-M-R® II, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said MMR vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90, and
- a third administration of the second dose of said MMR vaccine after said second administration of the second reconstituted unit dose, such as 3 to 6 years after said first simultaneous administration.

[00758] In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the MMR vaccine, such as M-M-R® II, is administered subcutaneously to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00759] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population from a dengue endemic region.

[00760] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein and the MMR vaccine, such as M-M-R® II, are administered subcutaneously to a subject or subject population of 1 to 10 years of age, preferably of 2 months to 7 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. In another embodiment, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

Method of preventing dengue disease and tetanus, diphtheria, and pertussis and uses

Method of prevention

[00761] The present invention is directed in part to a method of preventing dengue disease, as well as tetanus, diphtheria, and pertussis in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing tetanus, diphtheria, and pertussis in the subject by concomitant administration of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject.

[00762] The present invention is directed in part to a method of preventing dengue disease, as well as tetanus, diphtheria, and pertussis in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease, in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing tetanus, diphtheria, and pertussis in the subject population by concomitant administration of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject population.

[00763] The present invention is in part directed to said method for preventing dengue disease and tetanus, diphtheria, and pertussis in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric

mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00764] The present invention is in part directed to said method for preventing dengue disease and tetanus, diphtheria, and pertussis in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00765] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00766] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of the unit dose of the invention as described herein and the Tdap vaccine, in particular combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are done sequentially.

[00767] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection and wherein the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments, the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00768] In certain embodiments, the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments, the two unit doses of the invention as described herein are administered within 12 months or more, or within 6 months, or within 3 months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00769] In certain embodiments, the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and one dose of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered, in particular according to the following schedule:

- a first simultaneous administration of the first reconstituted unit dose and said Tdap vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00770] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00771] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00772] In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population of 10 to 18 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00773] In a preferred embodiment, the invention is directed a method of preventing dengue disease, and tetanus, diphtheria and pertussis in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, according to the above described administration schedule, wherein the subject is between 10 years and 18 years of age and from a dengue endemic region.

Unit dose for use in a method of prevention

[00774] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of tetanus, diphtheria, and pertussis in the subject with a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for use in a method of preventing dengue disease, and tetanus, diphtheria, and pertussis in a subject, respectively.

[00775] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of tetanus, diphtheria, and pertussis in a subject population with a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for use in a method of preventing dengue disease, and tetanus, diphtheria, and pertussis in a subject population, respectively.

[00776] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for use in a method of preventing dengue disease and tetanus, diphtheria, and pertussis in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00777] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for use in a method of preventing dengue disease and tetanus, diphtheria, and pertussis in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing

antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00778] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00779] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein said unit dose and said Tdap vaccine are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of said unit dose and said Tdap vaccine are done sequentially.

[00780] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said Tdap vaccine is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments, the subcutaneous injection of said unit dose and the intramuscular injection of said Tdap vaccine are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00781] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein two reconstituted unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and at day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 months after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00782] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein two reconstituted unit doses of the invention as described herein and one dose of the Tdap vaccine are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said Tdap vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00783] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein said unit dose is reconstituted and administered subcutaneously to a subject or subject population and said Tdap vaccine is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00784] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein said unit dose and said Tdap vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00785] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population of 10 to 18 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00786] In a preferred embodiment, the invention is directed to the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for use in a method of preventing dengue disease and tetanus, diphtheria and pertussis in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, according to the above described administration schedule, wherein the subject is of 10 to 18 years of age and from a dengue endemic region.

Use for the manufacture of a medicament in a method of prevention

[00787] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing tetanus, diphtheria, and pertussis in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing dengue disease and tetanus, diphtheria, and pertussis in a subject, respectively.

[00788] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease, in a subject population, further comprising the use of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing tetanus, diphtheria, and pertussis in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccination composition as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing dengue disease and tetanus, diphtheria, and pertussis in a subject population, respectively.

[00789] The present invention is in part directed to the use of a unit dose of the invention as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing dengue disease and tetanus, diphtheria, and pertussis, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00790] The present invention is in part directed to the use of a unit dose of the invention as described herein and a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing dengue disease and tetanus, diphtheria, and pertussis in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00791] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00792] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered simultaneously. In some of these embodiments, the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments, the administration of the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are done sequentially.

[00793] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered by intramuscular injection. According to some embodiments, the injections are administered to the arm, preferably to the deltoid region of the arm. According to some of these embodiments the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered to different anatomical sites, such as to opposite arms, in particular when the vaccines are administered simultaneously.

[00794] In certain embodiments, the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00795] In certain embodiments, the invention is directed to said uses, wherein two unit doses of the invention as described herein and one dose of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said Tdap vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

[00796] In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00797] In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00798] In certain embodiments, the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, is administered intramuscularly to a subject or subject population of 10 to 18 years of age. In some embodiments, the subject or subject population is from a dengue endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00799] In a preferred embodiment the invention is directed to the use of a unit dose of a dengue vaccine composition as described herein and the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, for the manufacture of a medicament for preventing dengue disease and tetanus, diphtheria and pertussis in a subject comprising administering to the subject a subcutaneous injection of the reconstituted unit dose of the invention as described herein and an intramuscular injection of the Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, according to the above described administration schedule, wherein the subject is of 10 to 18 years of age and from a dengue endemic region.

Method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b and uses

Method of prevention

[00800] The present invention is directed in part to a method of preventing dengue disease as well as diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject by concomitant administration of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject.

[00801] The present invention is directed in part to a method of preventing dengue disease as well as diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population. Thus, in certain embodiments the invention is directed to a method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of the invention as described herein, wherein the method further comprises preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject population by concomitant administration of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject population.

[00802] The present invention is in part directed to said method for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00803] The present invention is in part directed to said method for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00804] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00805] In certain embodiments the invention is directed to said methods, wherein the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are done sequentially.

[00806] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered by subcutaneous injection and wherein the DTaP/IPV/Hib vaccine, in

particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered by intramuscular injection. According to some embodiments, the unit dose of the invention as described herein is administered to the arm, preferably to the deltoid region of the arm. According to some embodiments, the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered to different anatomical sites. According to some of these embodiments, said unit dose is administered subcutaneously to the arm, preferably to the deltoid region, and said DTaP/IPV/Hib vaccine is administered intramuscularly to the thigh, preferably to the anterolateral aspect of the thigh.

[00807] In certain embodiments the invention is directed to said methods, wherein two unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 month or more, or within 6 month, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00808] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first simultaneous administration, such as 2 months later and preferably on day 60,
- a third administration of the second reconstituted unit dose after said second administration, such as 3 months after the first simultaneous administration and preferably on day 90,
- a fourth administration of the third dose of said DTaP/IPV/Hib vaccine after said third administration, such as 4 months after the first simultaneous administration and preferably on day 120, and
- a fifth administration of the fourth dose of said DTaP/IPV/Hib vaccine after said fourth administration, such as 9 to 12 months later and preferably on day 390.

[00809] In certain embodiments the invention is directed to said methods, wherein two reconstituted unit doses of the invention as described herein and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered, in particular according to the following schedule

- a first administration of the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first administration, such as 2 months later and preferably on day 60,
- a third administration of the third dose of said DTaP/IPV/Hib vaccine after said second administration, such as 4 months after the first administration and preferably on day 120,
- a fourth simultaneous administration of the first reconstituted unit dose and the fourth dose of said DTaP/IPV/Hib vaccine after said third administration, such as 9 to 12 months later and preferably on day 390, and
- a fifth administration of the second reconstituted unit dose after said fourth simultaneous administration, such as 3 months later and preferably on day 480.

[00810] According to some embodiments, a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered after the administration of the fourth dose of said DTaP/IPV/Hib vaccine. For this purpose a commercially available combined diphtheria, tetanus, pertussis, and poliomyelitis (DTaP-IPV) vaccine marketed under the tradename Quadracel® from Sanofi Pasteur may be used.

Quadracel® is a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. A single dose of Quadracel® is for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series in children who have received 4 doses of Pentacel®. Accordingly, in some embodiments, a further sixth administration of a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Quadracel®, may be conducted 30 to 57 months after the administration of the fourth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®.

[00811] In certain embodiments, the invention is directed to said methods, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject or subject population and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

[00812] In certain embodiments, the invention is directed to said methods, wherein the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00813] In certain embodiments the invention is directed to said methods, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population of 2 months to 4 years of age. In some embodiments the subject or subject population is from a dengue endemic region. In other embodiments, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

[00814] In a preferred embodiment the invention is directed to a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject comprising administering to the subject subcutaneous injections of the reconstituted unit dose of the invention as described herein and intramuscular injections of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, according to one of the above described administration schedule, wherein the subject is a subject of 2 months to 4 years of age from a dengue endemic region.

Unit dose for use in a method of prevention

[00815] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject, wherein the method also comprises the prevention of diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for use in a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject, respectively.

[00816] The present invention is directed in part to the unit dose of the invention as described herein for use in a method of preventing dengue disease in a subject population, wherein the method also comprises the prevention of diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject population with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®. In particular, the present invention is directed in part to a unit dose of a dengue vaccine composition as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for use in a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population, respectively.

[00817] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for use in a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00818] The present invention is in part directed to the unit dose of a dengue vaccine composition as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for use in a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue

serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00819] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00820] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein said unit dose and said DTaP/IPV/Hib vaccine are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of said unit dose and said DTaP/IPV/Hib vaccine are done sequentially.

[00821] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein said unit dose is administered by subcutaneous injection and wherein said DTaP/IPV/Hib vaccine is administered by intramuscular injection. According to some embodiments, said unit dose is administered to the arm, preferably to the deltoid region of the arm. According to some embodiments, the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered to different anatomical sites. According to some of these embodiments, said unit dose is administered subcutaneously to the arm, preferably to the deltoid region, and said DTaP/IPV/Hib vaccine is administered intramuscularly to the thigh, preferably to the anterolateral aspect of the thigh.

[00822] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third reconstituted unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00823] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein two reconstituted unit doses of the invention as described herein and four doses of the DTaP/IPV/Hib vaccine are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said DTaP/IPV/Hib vaccine on day 0,

- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first simultaneous administration, such as 2 months later and preferably on day 60,
- a third administration of the second reconstituted unit dose after said second administration, such as 3 months after the first simultaneous administration and preferably on day 90,
- a fourth administration of the third dose of said DTaP/IPV/Hib vaccine after said third administration, such as 4 months after the first simultaneous administration and preferably on day 120, and
- a fifth administration of the fourth dose of said DTaP/IPV/Hib vaccine after said fourth administration, such as 9 to 12 months later and preferably on day 390.

[00824] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein two reconstituted unit doses of the invention as described herein and four doses of the DTaP/IPV/Hib vaccine are administered, in particular according to the following schedule

- a first administration of the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first administration, such as 2 months later and preferably on day 60,
- a third administration of the third dose of said DTaP/IPV/Hib vaccine after said second administration, such as 4 months after the first administration and preferably on day 120,
- a fourth simultaneous administration of the first reconstituted unit dose and the fourth dose of said DTaP/IPV/Hib vaccine after said third administration, such as 9 to 12 months later and preferably on day 390, and
- a fifth administration of the second reconstituted unit dose after said fourth simultaneous administration, such as 3 months later and preferably on day 480.

- 5 **[00825]** According to some embodiments, a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered after the administration of the fourth dose of said DTaP/IPV/Hib vaccine. For this purpose a commercially available combined diphtheria, tetanus, pertussis, and poliomyelitis (DTaP-IPV) vaccine marketed under the tradename Quadracel® from Sanofi Pasteur may be used. Quadracel® is a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and
- 10 is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. A single dose of Quadracel® is for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series in children who have received 4 doses of Pentacel®. Accordingly, in some embodiments, a further sixth administration of a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Quadracel®, may be
- 15 conducted 30 to 57 months after the administration of the fourth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®.

- [00826]** In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is
- 20 directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein said unit dose is reconstituted and administered subcutaneously to a subject or subject population and said DTaP/IPV/Hib vaccine is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one
- 25 dengue serotype.

[00827] In certain embodiments, the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein said unit dose and said DTaP/IPV/Hib vaccine are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population from a dengue endemic region.

[00828] In certain embodiments the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and wherein the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscular to a subject or subject population of 2 months to 4 years of age. In some embodiments the subject or subject population is from a dengue endemic region. In other embodiments, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

In a preferred embodiment the invention is directed to the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for use in a method of preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject comprising administering to the subject subcutaneous injections of the reconstituted unit dose of the invention as described herein and intramuscular injections of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, according to one of the above described administration schedule, wherein the subject is a subject of 2 months to 4 years of age from a dengue endemic region.

Use for the manufacture of a medicament in a method of prevention

[00829] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject, further comprising the use of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject, respectively.

[00830] The present invention is directed in part to the use of a unit dose of the invention as described herein for the manufacture of a medicament for preventing dengue disease in a subject population, further comprising the use of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject population. In particular, the present invention is directed in part to a use of a unit dose of a dengue vaccine composition as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population, respectively.

[00831] The present invention is in part directed to the use of a unit dose of the invention as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject population, comprising administering to the subject population at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of geometric mean neutralizing antibody titers (GMTs) at day 180 or 365 after administration of said first unit dose to the subject population are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject population. According to some embodiments, the geometric mean neutralizing antibody titer for dengue serotype 2 (GMT DENV-2) and the geometric mean neutralizing antibody titer for dengue serotype 4 (GMT DENV-4) when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of GMT DENV-2 : GMT DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of GMT DENV-2 : GMT DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of GMT DENV-2 : GMT DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00832] The present invention is in part directed to the use of a unit dose of the invention as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing dengue disease and diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject, comprising administering to the subject at least a first reconstituted unit dose of the invention as described herein, wherein certain ratios of neutralizing antibody titers at day 180 or 365 after administration of said first unit dose to the subject are achieved, and concomitantly administering a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject. According to some embodiments, the neutralizing antibody titer for dengue serotype 2 and the neutralizing antibody titer for dengue serotype 4 at day 180 or day 365 after at least a first administration of the reconstituted unit dose of the invention as described herein, and optionally a second administration of a reconstituted unit dose of the invention as described herein 90 days after said first administration, provide a ratio of neutralizing antibody titer for DENV-2 : neutralizing antibody titer for DENV-4 of not more than 50, or not more than 40, or not more than 30, or not more than 20. In some of these embodiments, the ratio of the neutralizing antibody titers of DENV-2 : DENV-1 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose, and/or the ratio of the neutralizing antibody titers of DENV-2 : DENV-3 is not more than 20, or not more than 18, or not more than 15 at day 180 or 365 after administration of said first reconstituted unit dose.

[00833] In some embodiments, the geometric mean neutralizing antibody titers (GMTs) of a subject population or the neutralizing antibody titers of a subject are determined in accordance with a microneutralization test, for example according to the method described in Example 2.

[00834] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered simultaneously. In some of these embodiments the simultaneous administration is on day 0 or day 90, preferably on day 0. In other embodiments the administration of the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are done sequentially.

[00835] In certain embodiments the invention is directed to said uses, wherein the unit dose of the invention as described herein is reconstituted and administered by subcutaneous injection and wherein the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered by intramuscular injection. According to some embodiments, the unit dose of the invention as described herein is administered to the arm, preferably to the deltoid region of the arm. According to some embodiments, the subcutaneous injection of the unit dose of the invention as described herein and the intramuscular injection of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered to different anatomical sites. According to some of these embodiments, said unit dose is administered subcutaneously to the arm, preferably to the deltoid region, and said DTaP/IPV/Hib vaccine is administered intramuscularly to the thigh, preferably to the anterolateral aspect of the thigh.

[00836] In certain embodiments the invention is directed to said uses, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments the two unit doses of the invention as described herein are administered within 12 months or more, or within six months, or within three months, such as at day 0/1 and day 90. According to some of these embodiments a further third unit dose of the invention as described herein is administered after the second administration. Such a third administration may act as a booster and may be administered between 6 to 12 months after the first administration, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00837] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first simultaneous administration, such as 2 months later and preferably on day 60,
- a third administration of the second reconstituted unit dose after said second administration, such as 3 months after the first simultaneous administration and preferably on day 90,
- a fourth administration of the third dose of said DTaP/IPV/Hib vaccine after said third administration, such as 4 months after the first simultaneous administration and preferably on day 120, and
- a fifth administration of the fourth dose of said DTaP/IPV/Hib vaccine after said fourth administration, such as 9 to 12 months later and preferably on day 390.

[00838] In certain embodiments the invention is directed to said uses, wherein two unit doses of the invention as described herein and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered, in particular according to the following schedule

- a first administration of the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first administration, such as 2 months later and preferably on day 60,
- a third administration of the third dose of said DTaP/IPV/Hib vaccine after said second administration, such as 4 months after the first administration and preferably on day 120,
- a fourth simultaneous administration of the first reconstituted unit dose and the fourth dose of said DTaP/IPV/Hib vaccine after said third administration, such as 9 to 12 months later and preferably on day 390, and

- a fifth administration of the second reconstituted unit dose after said fourth simultaneous administration, such as 3 months later and preferably on day 480.

[00839] According to some embodiments, a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered after the administration of the fourth dose of said DTaP/IPV/Hib vaccine. For this purpose a commercially available combined diphtheria, tetanus, pertussis, and poliomyelitis (DTaP-IPV) vaccine marketed under the tradename Quadracel® from Sanofi Pasteur may be used.

- 5 Quadracel® is a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and is indicated for active immunization against diphtheria, tetanus, pertussis and poliomyelitis. A single dose of Quadracel® is for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series in children who have received 4 doses of Pentacel®. Accordingly, in some embodiments, a further sixth administration of a fifth
- 10 dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Quadracel®, may be conducted 30 to 57 months after the administration of the fourth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®.

[00840] In certain embodiments, the invention is directed to said uses, wherein the subject or subject population is seronegative to all dengue serotypes. In certain embodiments, the invention is directed to said uses, wherein the unit

15 dose of the invention as described herein is reconstituted and administered subcutaneously to a subject or subject population and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population, and wherein the subject or the subject population is seronegative with respect to all dengue serotypes. In other embodiments, the subject or subject population is seropositive with respect to at least one dengue serotype.

- 20 **[00841]** In certain embodiments, the invention is directed to said uses, wherein the unit dose of the invention as described herein and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, are administered to a subject or subject population from a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a
- 25 subject or subject population from a dengue endemic region.

[00842] In certain embodiments the invention is directed to said uses, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously and the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, is administered intramuscularly to a subject or subject population of 2 months to 4 years of age. In some embodiments the subject or subject population is from a dengue endemic region.

30 In other embodiments, the subject or subject population is from a dengue non-endemic region. According to some of these embodiments, the subject or subject population is seronegative for all four dengue serotypes.

- [00843]** In a preferred embodiment the invention is directed to the use of a unit dose of a dengue vaccine composition as described herein and a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, for the manufacture of a medicament for preventing dengue disease and diphtheria, tetanus, pertussis,
- 35 poliomyelitis and diseases caused by *Haemophilus influenzae* type b in a subject comprising administering to the subject subcutaneous injections of the reconstituted unit dose of the invention as described herein and intramuscular injections of the DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, according to one of the above described administration schedule, wherein the subject is a subject of 2 months to 4 years of age from a dengue endemic region.

Method of prevention using multiple co-vaccinations

[00844] In case multiple disease should be prevented the unit dose according to the invention (TDV) can be co-administered in at least any of the following combinations.

Double vaccine combinations:

- 5 TDV + YF, TDV + Hepatitis A, TDV + MMR, TDV + Tdap, TDV + DTap, or TDV + HPV

Triple vaccine combinations:

TDV + YF + Hepatitis A, TDV + YF + MMR, TDV + YF + Tdap, TDV + YF + DTap, TDV + YF + HPV, TDV + Hepatitis A + MMR, TDV + Hepatitis A + Tdap, TDV + Hepatitis A + DTap, TDV + Hepatitis A + HPV, TDV + MMR + Tdap, TDV + MMR + DTap, TDV + MMR + HPV, TDV + Tdap + DTap, TDV + Tdap + HPV, or TDV + DTap + HPV.

- 10 Quadruple vaccine combinations

TDV + YF + Hepatitis A + MMR, TDV + YF + Hepatitis A + Tdap, TDV + YF + Hepatitis A + DTap, TDV + YF + Hepatitis A + HPV, TDV + YF + MMR + Tdap, TDV + YF + MMR + DTap, TDV + YF + MMR + HPV, TDV + YF + Tdap + DTap, TDV + YF + Tdap + HPV, TDV + YF + DTap + HPV, TDV + Hepatitis A + MMR + Tdap, TDV + Hepatitis A + MMR + DTap, TDV + Hepatitis A + MMR + HPV, TDV + Hepatitis A + Tdap + DTap, TDV + Hepatitis A + Tdap + HPV, TDV + Hepatitis A + DTap + HPV, TDV + MMR + Tdap + DTap, TDV + MMR + Tdap + HPV, TDV + MMR + DTap + HPV, or TDV + Tdap + DTap + HPV.

Quintuple vaccine combinations

- 20 TDV + YF + Hepatitis A + MMR + Tdap, TDV + YF + Hepatitis A + MMR + Dtap, TDV + YF + Hepatitis A + MMR + HPV, TDV + YF + Hepatitis A + Tdap + DTap, TDV + YF + Hepatitis A + Tdap + HPV, TDV + YF + Hepatitis A + DTap + HPV, TDV + YF + MMR + Tdap + DTap, TDV + YF + MMR + Tdap + HPV, TDV + YF + MMR + DTap + HPV, TDV + YF + Tdap + DTap + HPV, TDV + Hepatitis A + MMR + Tdap + DTap, TDV + Hepatitis A + MMR + Tdap + HPV, TDV + Hepatitis A + MMR + DTap + HPV, TDV + Hepatitis A + Tdap + Dtap + HPV, or TDV + MMR + Tdap + DTap + HPV.

Sextuple vaccine combinations

- 25 TDV + YF + Hepatitis A + MMR + Tdap + DTap, TDV + YF + Hepatitis A + MMR + Tdap + HPV, TDV + YF + Hepatitis A + MMR + DTap + HPV, TDV + YF + Hepatitis A + Tdap + DTap + HPV, TDV + YF + MMR + Tdap + DTap + HPV, or TDV + Hepatitis A + MMR + Tdap + DTap + HPV.

Septuple vaccine combinations

- 30 TDV + YF + Hepatitis A + MMR + Tdap + DTap + HPV.

[00845] A preferred combination is e.g. TDV, YF and MMR.

Method of co-vaccinations with other dengue vaccines

- 35 In certain embodiments of the invention the method is directed to a co-administration with other dengue vaccines such as Dengvaxia®. Dengvaxia® is a tetravalent dengue vaccine based on a yellow fever backbone, CYD-TDV (Dengvaxia®, Sanofi Pasteur, Lyon, France), and has been licensed in several countries based on the clinical demonstration of an overall vaccine efficacy (VE) against virologically-confirmed dengue (VCD) of 56–61% in children in Asia and Latin America (Capeding MR et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-65; Villar LA et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013, 32:1102-9). The preparation of these particular strains CYD1, CYD2, CYD3 and CYD4 has been described in detail in international patent applications WO 98/37911, WO 03/101397, WO07/021672, WO 08/007021, WO 08/047023 and WO 08/065315, to which reference may be made
- 40

for a precise description of the processes for their preparation. The corresponding nucleotide sequences of the prM-E regions of CYD1, CYD2, CYD3 and CYD4 are provided in WO2016034629 and SEQID NOs are set out in Table 16.

Method of co-vaccinations with other travel vaccines

[00846] In certain embodiments of the invention the method is directed to a co-administration with other travel vaccines such as Cholera, Hepatitis A, Hepatitis E, Japanese encephalitis, Meningococcal disease, Rabies, Tick-borne encephalitis, Typhoid fever, and Yellow fever.

[00847] According to one embodiment the dengue vaccine according to the invention is co-administered with all of the above vaccines.

[00848] According to one embodiment the dengue vaccine according to the invention is co-administered with one or more of the above vaccines.

Method of stimulating an immune response and uses

Method of stimulating an immune response

[00849] In certain embodiments the invention is directed to a method for stimulating an immune response, preferably a balanced immune response, to all four dengue serotypes in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein.

[00850] In certain embodiments, the method includes a reconstituted unit dose/tetravalent dengue virus composition of a dengue vaccine composition administered for stimulating an immune response, preferably a balanced immune response, to all four dengue serotypes in a subject or subject population, the reconstituted unit dose comprising: a tetravalent virus composition including four live attenuated dengue virus strains, wherein the unit dose, described herein, is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent the reconstituted unit dose is obtained, wherein the reconstituted unit dose comprises:

- (i) a dengue serotype 1, such as a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
- (ii) a dengue serotype 2, such as a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
- (iii) a dengue serotype 3, such as a chimeric dengue serotype 2/3 strain, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
- (vi) a dengue serotype 4, such as a chimeric dengue serotype 2/4 strain, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml.

[00851] It is preferred that the reconstituted unit dose/tetravalent dengue virus composition is used in the method of stimulating an immune response of the present invention, wherein upon reconstitution of the unit dose with a pharmaceutically acceptable diluent dengue serotypes (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6% and wherein the subject or subject population is of 18 to 60 years of age.

[00852] In another preferred embodiment, the reconstituted unit dose/tetravalent dengue virus composition is used in the method of stimulating an immune response of the present invention, wherein upon reconstitution with a pharmaceutically acceptable diluent dengue serotypes (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL

and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8% and wherein the subject or subject population is of 2 to 17 years of age.

5 **[00853]** The present invention is in part directed to a method for stimulating an immune response to all four serotypes of dengue virus in a subject, comprising administering to the subject a reconstituted unit dose of the invention as described herein by subcutaneous injection.

[00854] In certain embodiments, the invention is directed to said method, wherein the immune response to all four serotypes of dengue virus is balanced.

10 **[00855]** In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose is administered by subcutaneous injection to the arm, preferably to the deltoid region of the arm.

[00856] In certain embodiments, the invention is directed to said method, wherein the subject is seronegative to all dengue serotypes.

15 **[00857]** In certain embodiments, the invention is directed to said method, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90 or at day 1 and day 90. According to some of these embodiments, a third unit dose of the invention as described herein is administered between 6 and 12 months after the administration of said first unit dose, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months after the second
20 administration.

[00858] In certain embodiments, the invention is directed to said method, wherein the unit dose of the invention as described herein is administered to a subject from a dengue endemic region. In some of these embodiments, the subject is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the subject is from a dengue non-
25 endemic region. Such a subject may be subject to a vaccination according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject that is from a dengue endemic region or a dengue non-endemic region.

[00859] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject that is seronegative with respect to all
30 dengue serotypes. In other embodiments, the subject is seropositive with respect to at least one dengue serotype.

[00860] In certain embodiments, the invention is directed to said method, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype
35 2 to the neutralizing antibody titer of dengue serotype 4. In certain embodiments, said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

[00861] In certain embodiments, the invention is directed to said method, wherein the unit dose of the invention as described herein is administered to a subject of 2 to 60 years of age, or more than 17 years, or more than 18 years, or 18 to 60 years of age. In certain embodiments the subject is 1 to 17 years of age, or less than 9 years of age, or less than 4 years of age or less than 2 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. According to some of these embodiments the subject is seronegative and from a dengue-endemic region.

[00862] In certain embodiments, the invention is directed to said method, wherein the unit dose of the invention as described herein is administered to a pediatric subject of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject is seronegative and from a dengue endemic region.

[00863] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a pediatric subject of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject is seronegative and from a dengue endemic region.

[00864] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a yellow fever vaccine, in particular YF-17D. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a yellow fever vaccine, in particular YF-17D, as described in the previous section.

[00865] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, as described in the previous section.

[00866] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a MMR vaccine, such as M-M-R® II. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a MMR vaccine, such as M-M-R® II, as described in the previous section.

[00867] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, as described in the previous section.

[00868] In certain embodiments the invention is directed to a method for stimulating an immune response, preferably a balanced immune response, to all four dengue serotypes in an elderly subject, comprising administering to the elderly subject a reconstituted unit dose of the invention as described herein.

[00869] The present invention is in part directed to a method for stimulating an immune response to all four serotypes of dengue virus in an elderly subject, comprising administering to the elderly subject a reconstituted unit dose of the invention as described herein by subcutaneous injection.

5 [00870] In certain embodiments, the invention is directed to said method, wherein the immune response to all four serotypes of dengue virus is balanced.

[00871] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose is administered by subcutaneous injection to the arm, preferably to the deltoid region of the arm.

[00872] In certain embodiments, the invention is directed to said method, wherein the elderly subject is seronegative to all dengue serotypes.

10 [00873] In certain embodiments, the invention is directed to said method, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90. According to some of these embodiments, a third unit dose of the invention as described herein is administered between 6 and 12 months after the administration of said first unit dose, such as 12 months after the first administration, or
15 later than 12 month after the first administration, such as 12 months after the second administration.

[00874] In certain embodiments, the invention is directed to said method, wherein the unit dose of the invention as described herein is administered to an elderly subject from a dengue endemic region. In some of these embodiments, the elderly subject is from Singapore, Dominican Republic, Panama, Philippines, Colombia, Puerto Rico or Thailand, in particular from Singapore, Dominican Republic, Panama, or Philippines. In other embodiments, the elderly subject is
20 from a dengue non-endemic region. Such an elderly subject may be subject to a vaccination according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject that is from a dengue endemic region or a dengue non-endemic region.

25 [00875] In certain embodiments, the invention is directed to said method, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject that is seronegative with respect to all dengue serotypes. In other embodiments, the elderly subject is seropositive with respect to at least one dengue serotype.

[00876] In certain embodiments, the invention is directed to said method, wherein the elderly subject has at least one chronic condition or disease. The at least one chronic condition or disease may be selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive
30 pulmonary disease.

[00877] In certain embodiments, the invention is directed to said method, wherein the elderly subject has an impaired immune system.

Use for the manufacture of a medicament for stimulating an immune response

35 [00878] The present invention is in part directed to the use of the reconstituted unit dose of the invention as described herein for the manufacture of a medicament for stimulating an immune response to all four serotypes of

dengue virus in a subject. In one embodiment a reconstituted unit dose of the invention as described herein is administered by subcutaneous injection.

[00879] In certain embodiments, the present invention is directed to a use of the reconstituted unit dose/tetravalent dengue virus composition of a dengue vaccine composition for the manufacture of a medicament for stimulating an immune response to all four serotypes of dengue virus in a subject or in a subject population, wherein the reconstituted unit dose comprises a tetravalent virus composition including four live attenuated dengue virus strains, wherein a unit dose, as described herein, is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent the reconstituted unit dose is obtained, wherein the reconstituted unit dose comprises:

- (i) a dengue serotype 1, such as a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2, such as a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a dengue serotype 3, such as a chimeric dengue serotype 2/3 strain, in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (vi) a dengue serotype 4, such as a chimeric dengue serotype 2/4 strain, in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

[00880] It is preferred that the use of the reconstituted unit dose/tetravalent dengue virus composition for the manufacture of a medicament in a method for stimulating an immune response to all four serotypes of dengue virus in a subject or in a subject population is obtained upon reconstitution of the unit dose with a pharmaceutically acceptable diluent and the dengue serotypes (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 2%, the concentration of (iv) in pfu/0.5 mL is at least 50%, the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 6% and wherein the subject or subject population is of 18 to 60 years of age.

[00881] In another preferred embodiment, the use of reconstituted unit dose/tetravalent dengue virus composition for the manufacture of a medicament for a method for stimulating an immune response to all four serotypes of dengue virus in a subject or in a subject population is obtained upon reconstitution of the unit dose described herein with a pharmaceutically acceptable diluent and the dengue serotypes (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10%, and the concentration of (iv) in pfu/0.5 mL is at least 50%, and the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 8% and wherein the subject or subject population is of 2 to 17 years of age.

[00882] In certain embodiments, the invention is directed to said use, wherein the immune response to all four serotypes of dengue virus is balanced.

[00883] In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose is administered by subcutaneous injection to the arm, preferably to the deltoid region of the arm.

[00884] In certain embodiments, the invention is directed the reconstituted unit dose of the invention as described herein for said use, wherein the subject is seronegative to all dengue serotypes.

[00885] In certain embodiments, the invention is directed to said use, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90 or

at day 1 and day 90. According to some of these embodiments, a third reconstituted unit dose is administered 6 to 12 months after the administration of the first reconstituted unit dose, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

5 **[00886]** In certain embodiments, the invention is directed to said use, wherein the subject is from a dengue endemic region. In other embodiments, the subject is from a dengue non-endemic region. Such a subject may be subject to a vaccination according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject that is from a dengue endemic region or a dengue non-endemic region.

10 **[00887]** In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a subject that is seronegative with respect to all dengue serotypes. In other embodiments, the subject is seropositive with respect to at least one dengue serotype.

15 **[00888]** In certain embodiments, the invention is directed to said use, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4. In certain embodiments, said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

20 **[00889]** In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose of the invention as described herein is administered to a subject of 2 to 60 years of age or more than 17 years, or more than 18 years, or 18 to 60 years of age. In certain embodiments the subject is 1 to 17 years of age, or less than 9 years of age, or less than 4 years of age or less than 2 years of age. In further embodiments, the subjects or subject population are adults of more than 21 years, or 21 to 60 years, or 21 to 45 years of age. According to some of these embodiments the subject is seronegative and from a dengue-endemic region.

25 **[00890]** In certain embodiments, the invention is directed to said use, wherein the unit dose of the invention as described herein is administered to a pediatric subject of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject is seronegative and from a dengue endemic region.

30 **[00891]** In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to a pediatric subject of less than 2 years of age, preferably of 2 months to 2 years of age or 2 months to 1.5 years of age or 2 months to 1 year of age. According to some of these embodiments, the pediatric subject is seronegative and from a dengue endemic region.

35 **[00892]** In certain embodiments, the invention is directed said use, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiments, the reconstituted unit dose of the invention as described herein is administered concomitantly with a yellow fever vaccine, in particular YF-17D. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a yellow fever vaccine, in particular YF-17D, as described in the previous section.

[00893] In certain embodiments, the invention is directed said use, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, as described in the previous section.

[00894] In certain embodiments, the invention is directed said use, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a MMR vaccine, such as M-M-R® II. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a MMR vaccine, such as M-M-R® II, as described in the previous section.

[00895] In certain embodiments, the invention is directed said use, wherein the reconstituted unit dose of the invention as described herein is administered concomitantly with another vaccine. In one embodiment, the reconstituted unit dose of the invention as described herein is administered concomitantly with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®. It is particularly preferred that the reconstituted unit dose of the invention as described herein is administered concomitantly with a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, as described in the previous section.

[00896] The present invention is in part directed to the use of the reconstituted unit dose of the invention as described herein for the manufacture of a medicament for stimulating an immune response to all four serotypes of dengue virus in an elderly subject. In one embodiment a reconstituted unit dose of the invention as described herein is administered by subcutaneous injection.

[00897] In certain embodiments, the invention is directed to said use, wherein the immune response to all four serotypes of dengue virus is balanced.

[00898] In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose is administered by subcutaneous injection to the arm, preferably to the deltoid region of the arm.

[00899] In certain embodiments, the invention is directed the reconstituted unit dose of the invention as described herein for said use, wherein the elderly subject is seronegative to all dengue serotypes.

[00900] In certain embodiments, the invention is directed to said use, wherein two reconstituted unit doses of the invention as described herein are administered. In some embodiments, the two reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90. According to some of these embodiments, a third reconstituted unit dose is administered 6 to 12 months after the administration of the first reconstituted unit dose, such as 12 months after the first administration, or later than 12 month after the first administration, such as 12 months (1 year) after the second administration or even 5 years or longer after the first or second administration.

[00901] In certain embodiments, the invention is directed to said use, wherein the elderly subject is from a dengue endemic region. In other embodiments, the elderly subject is from a dengue non-endemic region. Such an elderly subject may be subject to a vaccination according to the invention in the context of traveling to a dengue endemic region. In certain embodiments, the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject that is from a dengue endemic region or a dengue non-endemic region.

[00902] In certain embodiments, the invention is directed to said use, wherein the reconstituted unit dose of the invention as described herein is administered subcutaneously to an elderly subject that is seronegative with respect to all dengue serotypes. In other embodiments, the elderly subject is seropositive with respect to at least one dengue serotype.

5 **[00903]** In certain embodiments, the invention is directed to said use, wherein the elderly subject has at least one chronic condition or disease. The at least one chronic condition or disease may be selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

10 **[00904]** In certain embodiments, the invention is directed to said use, wherein the elderly subject has an impaired immune system.

Method for determining the titer of neutralizing antibodies

[00905] The present disclosure provides a method for determining the titer of neutralizing antibodies against each of dengue serotypes 1, 2, 3 and 4 in a blood serum sample, the method comprising the steps of:

- 15 (a) seeding cells from a dengue-susceptible cell line on 96-well assay plates and culturing the cells for a culture period;
- (b) preparing serial dilutions of the blood serum sample;
- (c) separately mixing the serially diluted blood serum samples prepared in step (b) with dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4 to obtain separate mixtures for each dengue serotype and incubating the separate mixtures;
- 20 (d) adding the separate mixtures prepared in (c) to the cells seeded and cultured in step (a) and incubating the cells with the separate mixtures;
- (e) providing an overlay for the inoculated cells and incubating the cells for an incubation period of 40 to 75 hours;
- 25 (f) determining the number of plaques in each well and comparing the number of plaques in each well to a control to determine the level of neutralizing antibodies against each of dengue serotypes 1, 2, 3 and 4.

30 **[00906]** Different incubation periods may be used in step (e) for the mixtures of different dengue serotypes. The incubation period for mixtures of dengue serotype 4 may be shorter than the incubation period for mixtures of dengue serotypes 1, 2 and 3, for example the incubation period for mixtures of dengue serotype 4 may be less than 50 hours, preferably 46±2 hours. In some embodiments, the incubation period for mixtures of dengue serotype 2 may be longer than the incubation period for mixtures of dengue serotypes 1, 3 and 4, for example the incubation period for mixtures of dengue serotype 2 may be between 60 and 70 hours, preferably 70±2 hours.

[00907] The dengue-susceptible cell line used in step (a) may be selected from Vero cells, LLC-MK2 cells and BHK-21 cells. The culture period of the cells may be 12 to 36 hours.

35 **[00908]** In step (c) the dengue serotype 1 may be DENV-1 strain 16007, dengue serotype 2 may be DENV-2 strain 16681, dengue serotype 3 may be DENV-3 strain 16562 and dengue serotype 4 may be DENV-4 strain 1036.

[00909] The separate mixtures in step (c) may be incubated overnight at a temperature of 2 to 8°C.

[00910] The overlay in step (e) may be selected from the group consisting of methylcellulose, carboxymethylcellulose and agarose. The cells with the overlay may be incubated at a temperature of 33°C to 35°C.

[00911] The number of plaques in each well may be determined using serotype-specific anti-dengue monoclonal antibodies.

[00912] The disclosure also provides a method for determining the titer of neutralizing antibodies against each of dengue serotypes 1, 2, 3 and 4 in a blood serum sample, the method comprising the steps of:

- 5 (a) seeding Vero cells on 96-well assay plates and culturing the Vero cells for a period of 20 to 30 hours;
- (b) preparing serial dilutions of the serum sample;
- (c) separately mixing the serially diluted serum samples with dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4 to prepare separate mixtures and incubating the separate mixtures overnight at a temperature of 2 to 8°C;
- 10 (d) incubating the cells seeded and cultured in step (a) with the separate mixtures prepared in step (c) in separate wells for 90 to 120 minutes;
- (e) providing a methylcellulose overlay for the inoculated cells and incubating the cells for an incubation period of 40 to 75 hours at 34°C;
- 15 (f) determining the number of plaques in each well using serotype-specific anti-dengue monoclonal antibodies and comparing the number of plaques in each well to a control to determine the level of neutralizing antibodies against each of dengue serotypes 1, 2, 3 and 4.

[00913] The disclosure also provides the use of said method for determining the dengue serostatus of a subject before vaccination with a dengue virus vaccine or for analyzing a subject's immune response after vaccination with a dengue virus vaccine.

20

EXAMPLES

[00914] The following Examples are included to demonstrate certain aspects and embodiments of the invention as described in the claims. It should be appreciated by those of skill in the art, however, that the following description is illustrative only and should not be taken in any way as a restriction of the invention.

Example 1: Preparation of the dengue virus strains.

- 25 **[00915]** The methods used to generate the chimeric dengue strains TDV-1, -3 and -4 were standard molecular cloning and DNA engineering methods and are described in Huang et al. (2003) J. Virology 77(21): 11436-11447. The following well-known methods were used to construct and introduce the prM-E genes of dengue serotypes 1, 3 and 4 into the TDV-2 backbone: Reverse-transcriptase PCR (RT-PCR), PCR, restriction enzyme digestion, DNA fragment ligation, bacterial transformations by electroporation, plasmid DNA preparations, *in vitro* transcription by T7 RNA polymerase, and transfection of Vero cells by electroporation.
- 30

- [00916]** After growing and purifying the different dengue serotypes separately as described in Huang et al. (2013) PLOS Neglected Dis, 7(5):e2243, they are mixed in the concentrations provided in Table 5. The mixture of dengue serotypes is present in a dengue vaccine composition and combined with a composition of pharmaceutically acceptable excipients resulting in a dengue vaccine composition comprising 15% w/v α,α trehalose dihydrate, 1% w/v poloxamer 407, 0.1% w/v human serum albumin and 100 mM sodium chloride. The dengue vaccine composition is lyophilized and represents a lyophilized unit dose of TDV. The lyophilized unit dose is reconstituted with 37 mM aqueous sodium chloride solution and the reconstituted unit dose comprises 15% w/v α,α trehalose dihydrate, 1% w/v poloxamer 407, 0.1% w/v human serum albumin and 137 mM sodium chloride.
- 35

Example 2: Microneutralization test

[00917] Immunogenicity was measured by a microneutralization assay to each one of the four dengue serotypes with titers defined as the dilution resulting in a 50% reduction in plaque values (MNT50). Briefly, on day 1 Vero cells were seeded on 96-well assay plates in DMEM and 10% FBS at a density of 2.5×10^5 cells/ml and incubated at 37°C for 24 hours. On day 2 serial dilutions of the heat-inactivated antibody-containing test and control sera samples (dilutions range 1:10 to 1:20480) were prepared and mixed with a constant concentration of dengue viruses, in particular DENV-1 strain 16007, DENV-2 strain 16681, DENV-3 strain 16562 and DENV-4 strain 1036, (target 60-80 pfu/well) in a 96 well microtiter plate and incubated overnight at 2-8°C to enable the neutralization of the virus by the antibodies present in the sera. After the incubation the mixture of virus and antibodies was transferred onto the 96 well plates with Vero cells and the plates were incubated at 37 °C for 90-120 minutes to infect the Vero cells. A 1% methylcellulose overlay in DMEM was applied to the plate to restrict spread of progeny virus and the plate was incubated for 46-70 hours at 34°C depending on the Dengue serotype:

DENV1 – 66±2 hours

DENV2 - 70±2 hours

DENV3 - 66±2 hours

DENV4 – 46±2 hours

[00918] After the incubation the cells were washed twice with PBS and fixed by adding cold methanol and incubating for 60 minutes at a temperature of $\leq -20^\circ\text{C}$. After fixing the plates were dried and washed three times with washing buffer (1x PBS, pH 7.4 with 0.5% Tween), before 50 µl of serotype-specific anti-dengue monoclonal antibodies in blocking solution (2.5% nonfat dry milk in PBST) per well were added and incubated with the cells for 18±4 hours at 2-8°C.

[00919] The monoclonal antibodies were made as described in Gentry et al. (1982) Am. J. Trop. Med. Hyg. 31, 548–555; Henchal et al. (1985) Am. J. Trop. Med. Hyg. 34, 162–169; and Henchal et al. (1982) Am. J. Trop. Med. Hyg. 31(4):830-6). Briefly, the anti-DENV-1 HBD was made against dengue 1 strain Hawaii, Envelope, the anti-DENV-2 was made against dengue 2 strain New Guinea C, Envelope, isotype 1, the anti-DENV-3 HBD was made against dengue 3 strain H87, Envelope, isotype 2A, and the anti-DENV-4 HBD was made against dengue 4 strain H241, Envelope, isotype 2A.

[00920] After incubation, the plates were washed three times with washing buffer and 50 µl of a secondary peroxidase labelled goat anti-mouse IgG (H + L) (KPL Cat#074-1806) in blocking solution was added and incubated for 90 to 120 minutes at 37°C. Then the plates were washed three times with washing buffer and 50 µl of precipitant substrate (2-amino-9-ethyl carbazole (AEC) tablet in 2.5 ml DMSO, 47.5 ml 50mM acetate buffer and 250 µl hydrogen peroxide) were added and the mixture was incubated for 20 minutes at room temperature. Finally, the substrate was removed, the plates were rinsed with dH_2O and dried.

[00921] Sample titers are calculated using the linear regression method and reported as MNT50 titers for each sample. Clinical data are reported as a geometric mean titer for all the individual MNT50 titers in each treatment group. Briefly, the number of infectious foci in each well was counted and the titer of neutralizing antibodies was determined by comparing the percent reduction of infectious foci centers in wells containing antibody (test samples) in comparison to wells containing virus alone. The MNT50 was calculated using the following linear regression equation:

$$\text{MNT50} = 10^{[(50-c)/m]} \text{ where } c = y \text{ intercept of regression line and } m = \text{slope of regression line}$$

[00922] Each test sample was tested in triplicates and the titer was calculated from the average of the triplicates. A schematic drawing of the steps performed in this test is provided in **Figure 2**.

Example 3: Clinical trial comparing two different unit doses

[00923] A descriptive Phase II, double-blind, randomized, and controlled trial in 351 subjects aged 21 to 45 years living in Singapore was performed comparing two different formulations of a tetravalent dengue vaccine. Subjects were randomized (1:1), stratified by baseline dengue serostatus, into two treatment groups: groups 1 received one subcutaneous (SC) dose of HD-TDV and group 2 received one subcutaneous dose of TDV. The dengue vaccine formulations were prepared as described in Example 1. The concentration of the four dengue serotypes in the HD-TDV vaccine (high dose tetravalent dengue vaccine) and in the TDV vaccine (corresponding to the unit dose of the invention as described herein) is outlined in Table 5.

Table 5. Unit doses used in the trial.

Comparative unit dose (HD-TDV)	0.5 mL comprising TDV-1, TDV-2, TDV-3 and TDV-4 containing 3.2×10^4 PFU, 1.3×10^5 PFU, 2.5×10^5 PFU, and 4×10^5 PFU, respectively. Administered by subcutaneous injection on day 1.
Example 1 unit dose (TDV)	0.5 mL comprising TDV-1, TDV-2, TDV-3 and TDV-4 containing 2.5×10^4 PFU, 6.3×10^3 PFU, 3.2×10^4 PFU, and 4×10^5 PFU, respectively. Administered by subcutaneous injection on day 1.

[00924] Immunogenicity was evaluated at Days 15, 30, 90, 180, and 365 post-vaccination as geometric mean titers (GMTs) and seropositivity rates. Immunogenicity of the vaccines against each of the four dengue serotypes was assessed using a microneutralization assay, with titers corresponding to the dilution resulting in a 50% reduction in plaque reduction (MNT50) as described in Example 2. Primary immunogenicity endpoints were reported in terms of geometric mean titers (GMTs) of neutralizing antibodies, and seropositivity rates (which were defined as percentages of subjects with reciprocal neutralizing titers ≥ 10 for each of the DENV serotypes) in the overall trial population. As a secondary endpoint, GMTs and seropositivity rates were analyzed by dengue baseline seropositivity status. Seropositive at baseline was defined as being seropositive for at least one DENV serotype, whereas seronegative at baseline was defined as being seronegative for all four DENV serotypes.

[00925] Solicited and unsolicited adverse events (AEs) were assessed by severity and causality.

a) Seropositivity

[00926] Dengue seropositivity is based on the result of the microneutralization test (MNT) described in Example 2 and is defined as a reciprocal neutralizing antibody titer ≥ 10 for one or more dengue serotype at baseline. The baseline seropositivity rate for each dengue serotype is defined as the percentage of seropositive subjects for the given dengue serotype and was derived from the neutralizing antibodies titers of the dengue serotypes as measured in the subjects before administration of the first unit dose. The seropositivity rate at day 180 or day 365 is defined as the percentage of seropositive subjects and was derived from the neutralizing antibodies titers of the dengue serotypes as measured in the subjects 180 and 365 days after administration of the first unit dose, respectively.

[00927] In total, 187 subjects (53.6%) were seropositive, based on MNT50, for at least one dengue serotype at baseline: 48.7% were seropositive for DENV-1, 49.0% for DENV-2, 45.2% for DENV-3, and 41.2% for DENV-4. The seropositive status and rate at baseline of the two different vaccination groups is shown in Table 6.

Table 6. Serostatus and seropositivity rate at baseline

	Comparative unit dose	Example 1 unit dose
Baseline seropositivity status (count of participants)		
Seropositive for at least one dengue serotype	92	95
Seronegative for all dengue serotypes	83	80
Baseline seropositivity rate for each serotype (percentage of participants)		
TDV-1	48.6	48.6
TDV-2	47.4	50.3
TDV-3	44.0	46.3
TDV-4	41.7	40.6

[00928] Seropositivity rates increased to Day 30 after administration of the unit doses, and remained high through to Day 365 for each of the four serotypes (**Figure 3**). For the overall trial population, the percentages of subjects who were seropositive for DENV-1 and DENV-3 were similar in the HD-TDV and TDV groups, whereas higher post-baseline seropositivity rates were seen for the HD-TDV group against DENV-2, and for the TDV group against DENV-4 (**Figure 3B**). In general, higher seropositivity rates were seen in subjects already seropositive at baseline than in seronegative subjects. Seropositivity rates rose to nearly 100% against all four dengue serotypes in the seropositive vaccine groups by Day 30, and remained at this level through to Day 365; no difference was seen between HD-TDV and TDV (**Figure 3A**). In the seronegative group, the seropositivity rates increased more gradually to a peak at Day 30, with limited decline until Day 365. The rates were consistently higher for HD-TDV than TDV against DENV-2, but were higher for TDV than HD-TDV against DENV-4, through to Day 365 (**Figure 3A**).

Table 7. Seropositivity rate at day 180

	Comparative unit dose	Example 1 unit dose
Overall number of participants analyzed	166	163
Seropositivity rate at day 180 (95% Confidence Interval)		
Day 180, TDV-1	93.4 (88.5 to 96.6)	89.6 (83.8 to 93.8)
Day 180, TDV-2	98.2 (94.8 to 99.6)	92.6 (87.5 to 96.1)
Day 180, TDV-3	88.0 (82.0 to 92.5)	82.2 (75.5 to 87.7)
Day 180, TDV-4	78.9 (71.9 to 84.9)	84.0 (77.5 to 89.3)

Table 8. Seropositivity rate at day 365

	Comparative unit dose	Example 1 unit dose
Overall number of participants analyzed	160	156
Seropositivity rate at day 365 (95% Confidence Interval)		
Day 365, TDV-1	84.4 (77.8 to 89.6)	89.7 (83.9 to 94.0)
Day 365, TDV-2	98.8 (95.6 to 99.8)	91.0 (85.4 to 95.0)
Day 365, TDV-3	79.4 (72.3 to 85.4)	77.6 (70.2 to 83.8)
Day 365, TDV-4	72.5 (64.9 to 79.3)	81.4 (74.4 to 87.2)

b) Geometric mean neutralizing antibody titers (GMTs)

[00929] Neutralizing antibody titers (GMTs) for each dengue serotype were determined in a serum sample of a subject taken before administration of the first unit dose of the dengue vaccine composition and 180 or 365 days after administration of the first unit dose of the dengue vaccine composition using the microneutralization (MNT) assay as described in Example 2.

[00930] For both HD-TDV and TDV, an increase in GMTs was observed by Day 15, reaching a maximum by Day 30 (**Figure 4**). Antibody titers remained above baseline levels throughout the trial for both unit doses. In the overall trial population, no substantial differences were seen in GMT titers between the two unit dose groups, except against DENV-2, where the response was higher for the HD-TDV group compared with the TDV group (8640.3 versus 1992.7 at Day 30). When assessed by baseline seropositivity status, the GMT profiles were similar as for the entire population, with a rise by Day 15, peak at Day 30, and gradual decline thereafter (**Figure 4B**). In the group who were seropositive at baseline, the difference between the unit dose groups in response to DENV-2 was reduced, with GMTs of 6970.3 and 4193.3 at Day 30 for the HD-TDV and TDV groups, respectively. Responses were higher against DENV-1, DENV-3, and DENV-4 in the baseline seropositive group, compared with the baseline seronegative group, across both unit doses. Against DENV-2, a lower response was seen in baseline seronegative subjects receiving TDV, compared with HD-TDV; Day 30 GMTs were 812.9 in the TDV group, compared with 10965.9 in the HD-TDV group. The response in these subjects also differed against DENV-4, with a higher response being observed in the TDV group (Day 30 GMTs of 57.7, compared with 20.9 in the HD-TDV group); this difference persisted to Day 365 (**Figure 4A**).

Table 9. Geometric mean neutralizing antibody titers (GMTs) at day 180

	Comparative unit dose	Example 1 unit dose
Overall number of participants analyzed	166	163
GMTs (95% Confidence Interval) [units: Titer]		
Day 180, TDV-1	379.4 (252.3 to 570.3)	312.2 (212.2 to 459.2)
Day 180, TDV-2	2585.5 (2088.8 to 3200.3)	1235.0 (890.7 to 1712.5)
Day 180, TDV-3	236.2 (162.2 to 344.0)	161.0 (110.5 to 234.6)
Day 180, TDV-4	91.0 (65.7 to 125.9)	92.9 (68.9 to 125.4)

Table 10. Ratio of geometric mean neutralizing antibody titers (GMTs) at day 180

	Comparative unit dose	Example 1 unit dose
TDV-2 : TDV-1	7	4
TDV-2 : TDV-3	11	8
TDV-2 : TDV-4	28	13

5

Table 11. Geometric mean neutralizing antibody titers (GMTs) at day 365

	Comparative unit dose	Example 1 unit dose
Overall number of participants analyzed	160	156
GMTs (95% Confidence Interval) [units: Titer]		
Day 365, TDV-1	247.3 (160.9 to 380.2)	264.1 (181.1 to 385.1)
Day 365, TDV-2	1726.0 (1392.6 to 2139.3)	809.5 (576.6 to 1136.4)
Day 365, TDV-3	163.2 (110.0 to 242.3)	132.6 (89.9 to 195.5)
Day 365, TDV-4	75.3 (53.8 to 105.4)	77.0 (56.9 to 104.2)

Table 12. Ratio of geometric mean neutralizing antibody titers (GMTs) at day 365

	Comparative unit dose	Example 1 unit dose
TDV-2 : TDV-1	7	3
TDV-2 : TDV-3	11	6
TDV-2 : TDV-4	23	11

10

Table 13. Geometric mean neutralizing antibody titers (GMTs) of all four dengue serotypes assessed by dengue baseline seropositivity status at day 180

	Comparative unit dose	Example 1 unit dose
Seropositive	89 Participants	88 Participants
Day 180, TDV-1 (Seropositive)	2327.2 (1550.4 to 3493.3)	1356.2 (905.5 to 2031.2)
Day 180, TDV-2 (Seropositive)	4412.0 (3586.6 to 5427.4)	2952.0 (2358.2 to 3695.4)
Day 180, TDV-3 (Seropositive)	1248.3 (879.7 to 1771.3)	693.6 (459.6 to 1046.6)
Day 180, TDV-4 (Seropositive)	399.5 (291.3 to 547.9)	268.3 (190.2 to 378.6)
Seronegative	77 Participants	75 Participants
Day 180, TDV-1 (Seronegative)	46.6 (32.0 to 67.9)	55.7 (35.6 to 87.1)
Day 180, TDV-2 (Seronegative)	1394.1 (983.2 to 1976.6)	444.3 (247.2 to 798.5)
Day 180, TDV-3 (Seronegative)	34.5 (23.4 to 50.7)	29.0 (19.4 to 43.3)
Day 180, TDV-4 (Seronegative)	16.4 (12.3 to 22.0)	26.8 (19.0 to 37.7)

Table 14. Ratio of geometric mean neutralizing antibody titers (GMTs) assessed by dengue baseline seropositivity status at day 180 and 365

	Comparative unit dose	Example 1 unit dose
Seropositive 180 Days		
TDV-2 : TDV-1	1.9	2.2
TDV-2 : TDV-3	3.5	4.3
TDV-2 : TDV-4	11.0	11.0
Seronegative 180 Days		
TDV-2 : TDV-1	29.9	8.0
TDV-2 : TDV-3	40.4	15.3
TDV-2 : TDV-4	85.0	16.6

Table 15. Geometric mean neutralizing antibody titers (GMTs) of all four dengue serotypes assessed by dengue baseline seropositivity status at day 365

	Comparative unit dose	Example 1 unit dose
Seropositive	84 Participants	85 Participants
Day 365, TDV-1 (Seropositive)	1633.3 (1055.8 to 2526.7)	1081.5 (724.0 to 1615.6)
Day 365, TDV-2 (Seropositive)	3316.0 (2623.8 to 4190.9)	2177.3 (1613.5 to 2938.1)
Day 365, TDV-3 (Seropositive)	830.6 (551.2 to 1251.5)	600.2 (402.3 to 895.3)
Day 365, TDV-4 (Seropositive)	346.3 (249.2 to 481.1)	212.6 (152.2 to 296.9)
Seronegative	76 Participants	71 Participants
Day 365, TDV-1 (Seronegative)	30.7 (20.4 to 46.2)	48.8 (32.1 to 74.2)
Day 365, TDV-2 (Seronegative)	838.7 (621.9 to 1131.1)	247.6 (143.9 to 426.1)
Day 365, TDV-3 (Seronegative)	27.0 (17.8 to 41.1)	21.7 (14.3 to 33.1)
Day 365, TDV-4 (Seronegative)	13.9 (10.3 to 19.0)	22.9(15.8 to 33.1)

Table 16. Ratio of geometric mean neutralizing antibody titers (GMTs) assessed by dengue baseline seropositivity status at day 365

	Comparative unit dose	Example 1 unit dose
Seropositive 365 Days		
TDV-2 : TDV-1	2.0	2.0
TDV-2 : TDV-3	4.0	3.6
TDV-2 : TDV-4	9.6	10.2
Seronegative 365 Days		
TDV-2 : TDV-1	27.3	5.1
TDV-2 : TDV-3	31.1	11.4
TDV-2 : TDV-4	60.3	10.8

c) Safety

[00931] Overall, rates of solicited local and systemic adverse events (AEs), unsolicited AEs, and serious adverse events (SAEs) were similar across the two unit dose groups. No deaths or AEs leading to discontinuation were recorded in the trial. Three subjects in each unit dose group experienced SAEs, one of these events in the HD-TDV group was considered by the sponsor to be vaccine-related based on temporal association. The SAE was polyarthrititis which began six days following receipt of the vaccine. Rates of solicited reactions were similar across unit dose groups, and seropositivity status at baseline. Overall, 47.4% and 53.7% of subjects reported local reactions, and 52.0% and 50.9% reported solicited systemic AEs, in the HD-TDV and TDV groups, respectively. Most reactions were mild or moderate. The most commonly reported local adverse reaction was injection site pain (46.3% in the HD-TDV group, 52.0% in the TDV group) and the most common systemic AE was headache (28.6% in the HD-TDV group, 34.9% in the TDV group).

d) Conclusion

[00932] Both unit doses showed an acceptable safety profile. The results show a more balanced immune response with the new TDV unit dose compared to the early HD-TDV unit dose, particularly in the subjects who were seronegative prior to vaccination: (i) in baseline seronegative subjects, response to DENV-2 was less dominant with TDV and (ii) DENV-4 seropositivity rates and GMTs were also higher with TDV in these subjects.

Example 4: Cell-mediated immunity stimulated by the dengue vaccine

[00933] A gamma interferon (IFN γ) enzyme-linked immunosorbent spot (ELISPOT) assay was performed using peripheral blood mononuclear cells (PBMCs) from the subjects taking part in the clinical trial of Example 3 and the commercial ELISpot assay kit available from Mabtech according to the manufacturer's instructions. Briefly, cryopreserved PBMCs were thawed and left to rest overnight, then incubated with various peptide pools for 18-22 hours in plates coated with anti-IFN γ antibodies. PBMCs were then removed and spots were developed and then counted. Results were reported as mean spot forming cells (SFC) per 10⁶ PBMCs. Peptide pools matched selected DENV-derived proteins, covering the entire DENV-2 proteome with NS1, NS3, and NS5 proteins from New Guinea C (NGC) and Thailand/16681/84 strains; and C, prM+E, NS2 and NS4 proteins from Thailand/16681/84 only plus TDV-1, TDV-3 and TDV-4 prM+E inserts from DENV-1, -3 and -4 strains Thailand/16007/1964, Philippines/16562/1964 and Indonesia/1036/1976, respectively.

[00934] Response rates to DENV-2 proteome at 6 and 12 months post-single dose of TDV were >90%, and were comparable between subjects seronegative and seropositive at baseline (**Figure 5**).

[00935] The response was primarily directed to the NS proteins, particularly in subjects seronegative at baseline (Figure 6).

[00936] The NS3 and NS5 proteins were the most recognized antigens (by 50 – 75% of subjects). Immunodominance of NS3 and NS5 was independent of baseline serostatus. Durability of the response was maintained equally between NS3 and NS5 throughout the 12-month post-single vaccination follow-up.

Example 5: Antibody responses to non-structural proteins

[00937] The non-structural protein NS-1 from all four dengue serotypes can induce endothelial hyperpermeability of human pulmonary microvascular endothelial cells (HPMEC) as measured by transendothelial electrical resistance (TEER) (Puerta-Guardo et al. (2016) PloS Pathog. 12(7):e1005738). It also interacts with endothelial cells to induce degradation of the glycocalyx via activation of sialidases and the cathepsin L/heparanase pathway (Glasner et al. (2017) PloS Pathog. 13(11): e1006673). In view of these effects, it was investigated whether the comparative unit dose induces antibodies against NS1 and inhibits NS1-mediated physiological effects.

a) Anti-NS1 antibodies

[00938] Serum samples were collected at day 0 before vaccination and day 120 after administration of the first unit dose. Serum was collected from 6 dengue seronegative and 6 dengue seropositive subjects at both day 0 and day 120, and Ab concentrations were determined by ELISA.

[00939] The anti-NS1 antibody concentration in seronegative and seropositive subjects at day 0 and day 120 is shown in Tables 17 and 18:

Table 17. Anti-NS1 antibody concentration in seronegative subjects at day 0 and day 120

Dengue seronegative subjects Anti-NS1 antibody concentration (RU/ml)								
	DENV1		DENV2		DENV3		DENV4	
Subj.	d0	d120	d0	d120	d0	d120	d0	d120
1023014	13.49	602.56	16.22	2570.40	10.00	489.78	28.18	302.00
1025011	66.07	173.78	35.48	794.33	67.61	117.49	42.66	85.11
1025013	5.62	380.19	24.55	2454.71	16.98	316.23	10.00	186.21
1035002	34.67	177.83	31.62	977.24	17.78	114.82	19.05	44.67
1035005	50.12	467.74	20.42	1659.59	104.71	309.03	66.07	288.40
1035001	40.74	186.21	52.48	489.78	44.67	169.82	51.29	177.83

Table 18. Anti-NS1 antibody concentration in seropositive subjects at day 0 and day 120

Dengue seropositive subjects Anti-NS1 antibody concentration (RU/ml)								
	DENV1		DENV2		DENV3		DENV4	
Subj.	d0	d120	d0	d120	d0	d120	d0	d120
1052010	691.83	11481.54	309.03	12022.64	436.52	7585.78	245.47	4677.35
1052014	758.58	1445.44	407.38	891.25	758.58	1122.02	724.44	707.95
1052015	3890.45	3467.37	2570.40	2344.23	3235.94	2818.38	660.69	707.95
1071007	478.63	851.14	239.88	478.63	660.69	1202.26	870.96	1258.93
1071012	691.83	776.25	724.44	676.08	776.25	812.83	346.74	446.68
1082009	5888.44	5370.32	7413.10	6309.57	5248.07	4897.79	891.25	794.33

[00940] These data show that the vaccine induces antibodies against NS1 from all dengue serotypes in both seropositive and seronegative subjects.

b) Transendothelial electrical resistance (TEER)

[00941] The effect of recombinant NS1 proteins from dengue serotypes 1, 2, 3 and 4 and sera from vaccinated seronegative and seropositive subjects on endothelial permeability was evaluated by measuring TEER of HPMEC grown on a 24-well Transwell polycarbonate membrane system (Transwell® permeable support, 0.4 µm, 6.5 mm insert; Corning Inc.) as previously described (Beatty et al. (2015) *Sci. Transl. Med.* 7(304): 304ra141; Puerta-Guardo et al. (2016) *PloS Pathog.* 12(7):e1005738). Briefly, TEER was measured in Ohms (Ω) at sequential 2-hour time-points following the addition of test proteins using an Epithelial Volt Ohm Meter (EVOM) with "chopstick" electrodes (World Precision Instruments). Untreated endothelial cells grown on Transwell inserts were used as negative untreated controls, and inserts with medium alone were used for blank resistance measurements. Relative TEER represents a ratio of resistance values (Ω) as follows: (Ω experimental condition - Ω medium alone) / (Ω non-treated endothelial cells - Ω medium alone). After 24 hours of treatment, 50% of upper and lower chamber media was replaced by fresh endothelial cell medium. For experiments using sera, 30 µl of culture supernatant was removed from the apical chamber and replaced with 30 µl of serum samples immediately before the addition of 5 µg/ml DENV-2 NS1.

[00942] Day 0 serum samples from seronegative subjects did not protect against NS1-mediated barrier dysfunction, but day 120 samples from all seronegative subjects blocked decreases in TEER values induced by NS1 (see **Figure 7A**). Day 0 samples from seropositive subjects produced varying levels of protection, and all day 120 samples from seropositive subjects completely abrogated NS1-induced hyperpermeability (see **Figure 7B**).

c) Degradation of glycocalyx-like layer (EGL)

[00943] Microscopy was performed as previously described (Puerta-Guardo et al. (2016) *PloS Pathog.* 12(7):e1005738). For imaging experiments, HPMEC were grown on coverslips coated with 0.2% gelatin (Sigma) and imaged on a Zeiss LSM 710 Axio Observer inverted fluorescence microscope equipped with a 34-channel spectral detector. Images acquired using the Zen 2010 software (Zeiss) were processed and analyzed with ImageJ software. All RGB images were converted to grayscale, then mean grayscale values and integrated density from selected areas were taken, along with adjacent background readings, and plotted as mean fluorescence intensity (MFI). To assess the effect of sera from vaccinated subjects on DENV2 NS1-induced EGL disruption, the distribution of sialic acid and heparan sulfate was examined on confluent HPMEC monolayers treated with DENV2 NS1 (5 µg/ml) + negative control serum (30 µl), NS1 + positive control serum (30 µl), or NS1 + serum from vaccinated subjects (30 µl) and fixed with 4% paraformaldehyde (PFA) at 6 hours post-treatment. Primary antibodies (Wheat germ agglutinin (WGA) lectin conjugated to Alexa Fluor 647 (WGA-A647, Molecular Probes) to stain N-acetyl neuraminic acid (sialic acid); Ab Heparan Sulfate, purified (clone F58-10E4, Amsbio) were incubated overnight at 4°C, and detection was performed using secondary species-specific anti-IgG or anti-IgM antibodies conjugated to Alexa fluorophores (488 and 647).

[00944] Day 0 sera from seronegative subjects had no substantial protective effect, while day 120 sera from seronegative subjects completely blocked degradation of both sialic acid and heparan sulfate. Similarly, day 0 samples from seropositive subjects exhibited varying levels of protection, and sera from seropositive subjects at day 120 were completely protective (see **Figure 8**). Positive control serum was used as a baseline for protection, and negative control serum represented maximum NS1-mediated disruption. These results show that the anti-NS1 antibody response stimulated by the dengue vaccine can protect against NS1-induced hyperpermeability by preventing the degradation of key EGL components.

[00945] Taken together, these results suggest that the dengue vaccine stimulates robust and protective anti-DENV2 NS1 Ab responses following vaccination.

Example 6: Phase III clinical trial in children

[00946] A Phase III, double-blind, randomized, and placebo-controlled trial in 20100 subjects aged 4 to 16 years living in Thailand, Sri Lanka, Philippines, Panama, Nicaragua, Dominican Republic, Colombia or Brazil was performed evaluating the efficacy, safety and immunogenicity of a tetravalent dengue vaccine referred to hereinafter as TDV. The trial includes 3 parts. Part 1 evaluates vaccine efficacy (VE) and lasts until both of the following 2 criteria are fulfilled: (i) 120 cases of dengue fever are confirmed and (ii) minimum duration of subject follow-up of 12 months post-second vaccination. Part 2 is for an additional 6 months to evaluate VE and for secondary efficacy analyses. Part 3 will evaluate long-term safety by following participants for side effects and will last an additional 3 years.

[00947] Part 1: Active surveillance for the primary assessment of efficacy in all subjects. During this time subjects were contacted at least weekly to ensure identification of febrile illness that could potentially be due to dengue. This part commenced on the day of vaccination and finished once both of the following 2 criteria were fulfilled: (i) 120 cases of dengue fever are confirmed and (ii) minimum duration of subject follow-up of 12 months post-second vaccination. The end of Part 1 was defined for each subject so that the duration of follow up after the second vaccination was approximately the same for all subjects. Virologically-confirmed cases in Part 1 count towards the primary efficacy objective if occurring at least 30 days post-second vaccination. Part 1 was finished 12 months post-second vaccination

[00948] Part 2: Active surveillance for an additional 6 months for each subject following the completion of Part 1, I, i.e. 18 month post second vaccination. During this time subjects were contacted at least weekly to ensure identification of febrile illness that could potentially be due to dengue. Virologically-confirmed cases in Parts 1 and 2 contribute towards the secondary efficacy objectives.

[00949] Part 3: Modified active surveillance for the assessment of safety in all subjects following the completion of Part 2 and lasting 3 years for each subject. The modified surveillance during Part 3 will maintain at least weekly contacts through Part 3 of the trial, but the intensity of investigation will be modified based on the need for hospitalization. Surveillance will identify febrile illness of any severity that could potentially be due to dengue.

[00950] Criteria for Inclusion include:

- The subject was aged 4 to 16 years inclusive, at the time of randomization.
- Individuals who were in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the Investigator.
- The subject and/or the subject's parent/guardian signed and dated an assent/written informed consent form where applicable, and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
- Individuals who can comply with trial procedures and are available for the duration of follow-up.

[00951] Exclusion criteria include:

1. Febrile illness (temperature $\geq 38^{\circ}\text{C}$) or moderate or severe acute illness or infection at the time of randomization.
2. History or any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose an additional risk to the subject due to participation in the trial, including but not limited to:

- a. Known hypersensitivity or allergy to any of the vaccine components.
 - b. Female subjects (post-menarche) who are pregnant or breastfeeding.
 - c. Individuals with any serious chronic or progressive disease according to judgment of the Investigator (e.g., neoplasm, insulin-dependent diabetes, cardiac, renal or hepatic disease, neurologic or seizure disorder or Guillain-Barré syndrome).
 - d. Known or suspected impairment/alteration of immune function, including:
 - i. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥ 12 weeks/ ≥ 2 mg/kg body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed).
 - ii. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥ 12 weeks / ≥ 2 mg/kg body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 1 (Month 0).
 - iii. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial.
 - iv. Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).
 - v. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0).
 - vi. Human Immunodeficiency Virus (HIV) infection or HIV-related disease.
 - vii. Genetic immunodeficiency.
 3. Receipt of any other vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccine within 28 days after Day 1 (Month 0).
 4. Participation in any clinical trial with another investigational product 30 days prior to Day 1 (Month 0) or intent to participate in another clinical trial at any time during the conduct of this trial.
 5. Previous participation in any clinical trial of a dengue candidate vaccine, or previous receipt of a dengue vaccine.
 6. First degree relatives of individuals involved in trial conduct.
 7. Females of childbearing potential who are sexually active, and who have not used any of the acceptable contraceptive method for at least 2 months prior to Day 1 (Month 0).
 8. Females of childbearing potential who are sexually active, and who refuse to use an acceptable contraceptive method up to 6 weeks post-second vaccination.
 9. Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily.
 10. Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures.
 11. Identified as an employee of the Investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that Investigator or trial center.
- [00952]** Eligible subjects were randomized (2:1) into two treatment groups: groups 1 received one subcutaneous (SC) dose of TDV in the upper arm on Day 1 and on Day 90, and group 2 received one subcutaneous dose of placebo in the upper arm on Day 1 and on Day 90. Randomization was stratified by region (Asia Pacific and Latin America) and age range (children aged 4-5 years, 6-11 years, and 12-16 years) to ensure each age range has the appropriate ratio of TDV to placebo in each region. After randomization dropouts were not replaced. Study Day 1 is defined to be the date of the first dose administration of TDV or placebo. The TDV was prepared as described in Example 1. Each subcutaneous dose of TDV was 0.5 mL and the concentration of the four dengue serotypes in the TDV vaccine in each dose was 3.6 log₁₀ PFU/dose, 4.0 log₁₀ PFU/dose, 4.6 log₁₀ PFU/dose and 5.1 log₁₀ PFU/dose of TDV-1, TDV-2, TDV-3 and TDV-4, respectively.

[00953] The „total concentration in pfu/0.5 ml“ which serves as a base value for the calculation of the percentage concentration for each individual component of a tetravalent dengue vaccine is shown for one exemplary tetravalent vaccine composition comprising dengue serotype 1 in a concentration of 3.60 log₁₀pfu/0.5 ml, a dengue serotype 2 concentration of 4.00 log₁₀pfu/0.5 ml, a dengue serotype 3 concentration of 4.60 log₁₀pfu/0.5 ml and a dengue serotype 4 concentration of 5.11 log₁₀pfu/0.5 ml.

Primarily, the logarithmic values of the concentrations are converted into numerical values. The results of this conversion are 4x10³ pfu/0.5 ml for serotype 1, 1x10⁴ pfu/0.5ml for serotype 2, 4x10⁴ pfu/0.5 ml for serotype 3 and 1.3x10⁵ pfu/0.5 ml for serotype 4. The total concentration in pfu/0.5 ml is the sum of the preceding numerical values resulting in 1.84 x10⁵ pfu/0.5 ml.

[00954] The “percentage concentration” for each of the serotypes 1, 2, 3 and 4 is obtained by dividing the numerical concentration value (expressed as pfu/0.5 ml) of an individual serotype by the total concentration (expressed in pfu/0.5 ml) and multiplying the result by 100 i.e.:

Percentage concentration of serotype 1 = (4x10³ pfu/0.5 ml ÷ 1.84 x10⁵ pfu/0.5 ml) x 100 = 2%

Percentage concentration of serotype 2 = (1x10⁴ pfu/0.5ml ÷ 1.84 x10⁵ pfu/0.5 ml) x 100 = 5%

Percentage concentration of serotype 3 = (4x10⁴ pfu/0.5 ml ÷ 1.84 x10⁵ pfu/0.5 ml) x 100 = 22%

Percentage concentration of serotype 4 = (1.3x10⁵ pfu/0.5 ml ÷ 1.84 x10⁵ pfu/0.5 ml) x 100 = 71%.

The percentage concentrations are rounded to whole numbers.

[00955] Primary Outcome Measures included the vaccine efficacy (VE) of two doses of TDV in preventing virologically-confirmed dengue (VCD) fever induced by any dengue serotype [time frame: 30 days post-second vaccination (Day 120) until the end of Part 1]. VE is defined as $1 - (\lambda_v/\lambda_c)$, wherein λ_v and λ_c denote the hazard rates for the TDV and placebo groups, respectively. A virologically-confirmed dengue case is defined as febrile illness (defined as temperature $\geq 38^\circ\text{C}$ on any 2 of 3 consecutive days) or illness clinically suspected to be dengue by the Investigator with a positive serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR). A febrile illness will require an interval of at least 14 days from a previous febrile illness to avoid overlap of acute and convalescent visits from one episode with those from a second episode.

[00956] Secondary Outcome Measures include:

1) VE of two doses of TDV in preventing virologically-confirmed dengue fever induced by each dengue serotype [time frame: from 30 days post-second vaccination (Day 120) until the end of Part 2].

2) VE of two doses of TDV in preventing virologically-confirmed dengue fever induced by any dengue serotype in participants dengue seronegative at baseline [time frame: from 30 days post-second vaccination (Day 120) until the end of Part 2 (up to 21 months)].

3) VE of two doses of TDV in preventing virologically-confirmed dengue fever induced by any dengue serotype in participants dengue seropositive at baseline [time frame: from 30 days post-second vaccination (Day 120) until the end of Part 2].

4) VE of two doses of TDV in preventing hospitalization due to virologically-confirmed dengue fever induced by any dengue serotype [time frame: from 30 days post-second vaccination (Day 120) until the end of Part 2].

5) VE of two doses of TDV in preventing virologically-confirmed severe dengue fever induced by any dengue serotype [time frame: from 30 days post-second vaccination (Day 120) until the end of Part 2].

6) Percentage of participants with solicited local injection site adverse events (AEs) in the safety subset [time frame: Days 1 through 7 after each vaccination] and severity of solicited local injection AEs. Solicited local AEs at injection site are defined as pain, erythema and swelling that occurred within 7 days after each vaccination.

7) Percentage of participants with solicited systemic adverse events (AEs) in the safety subset [time frame: Days 1 through 14 after each vaccination] and severity of solicited systemic AEs. Solicited systemic AEs in children (< 6 years) are defined as fever, irritability/fussiness, drowsiness and loss of appetite that occurred within 14 days after each vaccination. Solicited systemic AEs in children ($\geq$ 6 years) are defined as fever, headache, asthenia, malaise and myalgia that occurred within 14 days after each vaccination.

8) Percentage of participants with any unsolicited adverse events (AEs) in the safety subset [time frame: Days 1 through 28 after each vaccination]. Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined above.

9) Percentage of participants with serious adverse events (SAEs) during Parts 1 and 2 [time frame: from Day 1 until the end of Parts 1 and 2]. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

10) Percentage of participants with fatal SAEs and SAEs related to study drug during the first and second half of Part 3 [time frame: for 3 years (18 month halves) beginning at the end of Part 2 (approximately 21 months after the first vaccination)].

11) Percentage of participants with a seropositive response for each of the four dengue serotypes in the immunogenicity subset [time frame: Day 1 and months 1, 3, 4, 9, 15 and then annually (up to 3 years)]. Seropositive response is defined as a reciprocal neutralizing titer $\geq$ 10. The four DENV serotypes are DEN-1, DEN-2, DEN-3 and DEN-4.

12) Percentage of participants with a seropositive response for multiple dengue serotypes in the immunogenicity subset [time frame: Day 1 and months 1, 3, 4, 9, 15 and then annually (up to 3 years)].

13) Geometric Mean Titers (GMTs) of neutralizing antibodies for each of the four dengue serotypes in the immunogenicity subset [time frame: Day 1 and months 1, 3, 4, 9, 15 and then annually (up to 3 years)]. GMTs of neutralizing antibodies will be measured via microneutralization test (MNT) as described in Example 2.

a) Study population

[00957] After screening, 20,099 participants were randomized, and 20,071 received at least one injection. In total, 97.4% of placebo participants (n/N: 6,521/6,698) and 97.3% of vaccinees (n/N: 13,038/13,401) completed Part 1 of the study (Figure 9). Reasons for study withdrawals included AEs, participants lost to follow-up, pregnancy, protocol violations, and withdrawal by participants (or parents/guardians). Baseline characteristics were similar across both treatment groups (Table 19). Mean age of study participants was 9.6 years, with baseline seronegativity of 27.7%, and enrollment was broadly balanced across regions (46.5% in Asia, 53.5% in Latin America). The highest seronegative rate was in Panama (62.2%), followed by Sri Lanka (38.5%), Thailand (34.4%), Brazil (28.8%), Nicaragua (22.3%), Colombia (15.4%), the Philippines (12.4%), and the Dominican Republic (2.8%).

Table 19: Baseline characteristics of study population (number, %)

	TDV	Placebo	Total
Per Protocol Set			
Number of Participants	12,704	6,317	19,021
Mean Age (Years, SD)	9.6 (3.35)	9.6 (3.34)	9.6 (3.35)
Baseline Seronegative ^a	3,533 (27.8)	1,726 (27.3)	5,259 (27.7)
Female	6,314 (49.7)	3,098 (49.0)	9,412 (49.5)
Male	6,390 (50.3)	3,219 (51.0)	9,609 (50.5)
Asia Pacific	5,896 (46.4)	2,942 (46.6)	8,838 (46.5)
Baseline Seronegative ^a	1,503 (25.5)	773 (26.3)	2,276 (25.8)
Latin America	6,808 (53.6)	3,375 (53.4)	10,183 (53.5)
Baseline Seronegative ^a	2,030 (29.8)	953 (28.2)	2,983 (29.3)
Safety Set^b			
Number of Participants	13,380	6,687	20,071
Mean Age (Years, SD)	9.6 (3.36)	9.6 (3.34)	9.6 (3.35)
Baseline Seronegative ^a	3,714 (27.8)	1,832 (27.4)	5,547 (27.6)
Female	6,651 (49.7)	3,276 (49.0)	9,929 (49.5)
Male	6,729 (50.3)	3,411 (51.0)	10,142 (50.5)
Safety Set of Subset^b			
Number of Participants	2,663	1,329	3,993
Baseline Seronegative ^a	740 (27.8)	369 (27.8)	1,109 (27.8)

^aSeronegative for all serotypes; seropositive defined as reciprocal neutralizing antibody titer ≥ 10 ; SD, standard deviation.

^bnumbers of participants in TVD plus placebo groups are not equal to total numbers shown because misallocated participants (i.e. those who received both TVD and placebo due to an administrative error) are not included in the TDV and placebo group data.

b) Febrile illnesses and VCD

[00958] During Part 1, 5,754 and 4,663 episodes of febrile illness were reported in Asian and Latin American sites, respectively. Acute samples were obtained in 99.5% and 96.6% of these cases, with 98.3% and 85.1% of samples taken within five days, in Asia and Latin America, respectively. There were 278 VCD cases (76 hospitalized) in the safety set during the entire Part 1 period, of which 210 (58 hospitalized) were 30 days post-second vaccination in the PPS (Table 20; Table 22) and were included in primary endpoint analysis.

c) Distribution of VCD included in primary endpoint analysis

[00959] DENV-1 was reported in all countries with VCD and included all the 21 cases in Panama. In Sri Lanka, 54 of 60 VCD were DENV-2, and 87 of 109 VCD in the Philippines were DENV-3. All seven DENV-4 VCD were reported in the Philippines. No VCD were reported in Nicaragua or the Dominican Republic. Of the associated 58 hospitalized VCD, 43 were reported in Sri Lanka. A total of two severe dengue (both DENV-3) and five dengue hemorrhagic fever (DHF; three DENV-2; two DENV-3) cases were reported (Table 21). These seven were also the only such cases in the entire part 1 safety set.

d) Vaccine efficacy

[00960] VE against VCD of any serotype was 80.2% (95% CI: 73.3–85.3; $P < 0.001$). A similar efficacy of 81% (95% CI: 64.1–90.0) between the doses and from first dose onwards in the safety set (Table 20) suggests that the vaccine was efficacious after the first dose. Exploratory analysis of the secondary efficacy endpoints showed a trend of

differential efficacy by serotype, with the highest efficacy against DENV-2 (97.7%), followed by DENV-1 (73.7%), DENV-4 (63.2% with CI containing zero), and DENV-3 (62.6%; Table 3). Overall, efficacy was similar in baseline seronegatives (74.9%) and seropositives (82.2%; Figure 10A); however, this varied by serotype. Efficacy against DENV-2 was not impacted by serostatus; efficacy against DENV-1 was slightly higher in baseline seropositives (79.8%; 95% CI: 51.3–91.6) than baseline seronegatives (67.2%; 95% CI: 23.2–86.0). No efficacy was observed against DENV-3 in baseline seronegatives (–38.7%; 95% CI: –335.7–55.8) compared to baseline seropositives (71.3%; 95% CI: 54.2–82.0). Efficacy by serostatus could not be calculated for DENV-4 because no cases were observed in baseline seronegatives. In the primary endpoint timeframe of the PPS, only five VCD requiring hospitalization were reported in the vaccine group compared with 53 cases in the placebo group, with a VE of 95.4% (95% CI: 88.4–98.2; 97.2% for baseline seronegatives and 94.4% for baseline seropositives; Table 21; Figure 10B), consistent with a VE of 93.3% (95% CI: 86.7–96.7) in the safety set from first dose onwards.

[00961] The primary vaccine efficacy (VE) of two doses of TDV in preventing virologically-confirmed dengue (VCD) fever induced by any dengue serotype is shown in Table 20.

Table 20. Vaccine efficacy of TDV in preventing virologically-confirmed dengue (VCD) fever against any serotype from 30 days post-second vaccination until end of part 1 Per Protocol Set (PPS), i.e. 12 months post-second vaccination. Safety set analysis from first dose to end of Part 1 study period, i.e. 12 months post-second vaccination

	Placebo n= 6317	TDV (PPS) n= 12,704
number of subject evaluated	6,316	12,700
number of subjects with febrile illness	1,712	3,195
number of febrile illness cases	2,591	4,692
virologically confirmed dengue fever (n [%])	149 [2.4]	61 [0.5]
Person-years at risk	5,670.1	11,578.7
incident density	2.6	0.5
relative risk	0.20	
95% CI of relative risk	(0.15, 0.27)	
vaccine efficacy (%)	80.2	
95% CI of vaccine efficacy	(73.3, 85.3)	
p-value for vaccine efficacy	<0.001	
	Placebo	TDV (Safety Set)*
number of subject evaluated	6,687	13,380
virologically confirmed dengue fever (n [%])	199 [3.0]	78 [0.6]
Person-years at risk	8,072.0	16,351.5
incident density	2.5	0.5
vaccine efficacy (%)	80.9	
95% CI of vaccine efficacy	(75.2, 85.3)	

Note 1: Percentage of virologically confirmed dengue (VCD) fever are based on number of subjects evaluated.

Note 2: Person-years at risks is defined as cumulative time in years until start of VCD fever or until end of Part 1

study period or discontinuation date, whichever comes first. Incident density is defined as the number of cases per 100 person-years at risk. Percentages are based on total number (denominator) of analysis set participants evaluated and may not be equal to the total number of participants in the per protocol analysis set.

*One participant had two instances of VCD during Part 1, only the first VCD was included in efficacy calculation

Note 3: Vaccine efficacy (VE) and 2-sided 95% CIs are estimated from a Cox proportional hazard model with TDV as

a factor, adjusted for age and stratified by region.

Note 4: Statistical significance will be concluded if the lower bound of the 95% CI for VE is above 25%. Since the hypotheses will be tested in a confirmatory manner at a 2-sided significance level of 5%, the calculated p-value should be compared with 0.025.

- 5 Note 5: Relative risk is calculated as the number of events divided by the number of subjects evaluated in the TDV group, over the number of events divided by the number of subjects evaluated in the placebo group.

10 **[00962]** For the efficacy evaluation shown in Table 20, a case of VCD was defined as febrile illness (defined as fever $\geq 38^{\circ}\text{C}$ on any 2 of 3 consecutive days) with a positive serotype-specific RT-PCR (i.e., positive dengue detection RT-PCR) and occurring at any time starting from 30 days post-second vaccination (Day 120 [Month 4]) through the end of Part 1. The analysis was performed on the Per-Protocol Set (PPS) and Safety Set.

15 **[00963]** As used herein, the "Per-Protocol Set (PPS)" consist of all subjects in the Full Analysis Set (FAS) consisting of all randomized subjects who received at least one dose of TDV or placebo who had no major protocol violations. Major protocol violations are not receiving both doses of TDV or placebo administration, not receiving both doses in the correct interval, not having the correct administration of TDV or placebo, use of prohibited medications / vaccines by the subject, the subject meets any of the exclusion criteria of 2d, 3, 4 or 5 defined above or product preparation error.

[00964] The p-value is obtained by solving the critical value Z in the following equation:

Upper bound of 1-sided (1-p%) CI of $\text{HR}=0.75$, wherein HR is the hazard ratio and defined as $\text{HR} = \lambda\text{V}/\lambda\text{C}$.

$e^{[\hat{\beta} + Z * SE]} = 0.75$, wherein $\hat{\beta}$ defines the treatment and SE the related standard error.

- 20 The 1-sided p-value is 1-(area to the left of the critical value Z from a standard normal distribution). Since the hypotheses will be tested in a confirmatory manner 2-sided at a significance level of 5%, the calculated 1-sided p-value should be compared with 0.025.

25 **[00965]** In summary in Part 1 of this study, a high vaccine efficacy of 80.2% against virologically-confirmed dengue of any serotype in children 4–16 years of age was found. It included an efficacy of 74.9% in baseline seronegatives and a robust 95.4% reduction in hospitalizations. Onset of protection could be seen after the first dose with 81% efficacy between doses. Overall, these results suggest a potential benefit for each vaccine recipient regardless of prior dengue exposure or age. This finding is significant because vaccine development against dengue has been challenging, especially for dengue naïve individuals, and dengue remains one of the WHO's top ten threats to global health in 2019.19 Furthermore, the onset of protection after the first dose has potential utility in the context of outbreak control or travel vaccination, offering a reduction in the risk of dengue after only one dose.

35 **[00966]** Severe forms of dengue were assessed as follows: Dengue Hemorrhagic Fever (DHF) as defined by the 1997 WHO definition. Severe Dengue through the Dengue Case Adjudication Committee. The Dengue Case Adjudication Committee (DCAC) consisted of four members: a voting chairperson, two voting members, and an independent non-voting statistician. The three DCAC voting members are all physicians and clinical dengue experts. DCAC members are not study investigators and do not have any conflict of interest that would bias their review of the trial data. All non-hospitalized cases were considered non-severe. The DCAC severe dengue case criteria applied in a blinded manner to virologically-confirmed hospitalized dengue cases are as follows: 1) bleeding abnormality, for a case to be considered severe there needs to be a significant intervention required in response to the bleeding episode such as blood transfusion, nasal packing, hormonal therapy, or, bleeding occurred into critical organs such as the brain; 2) plasma leakage, for a case to be considered severe there needs to be evidence of both plasma leakage and functional impairment (plasma leakage includes clinical evidence, radiological evidence, or hematocrit elevated

>20% above normal levels or baseline; functional impairment defined as shock or respiratory distress); 3) liver, for a case to be considered severe there needs to be evidence of both hepatitis and functional impairment (hepatitis defined as an aspartate aminotransferase [AST] or alanine aminotransferase [ALT] >10 upper limit of normal range [ULN]; functional impairment defined as prothrombin [PT] >1.5 ULN or hypoalbuminemia); 4) renal, serum creatinine >2.5 times ULN or requiring dialysis; 5) cardiac, abnormalities intrinsic to the heart (i.e. not resulting from intravascular volume depletion) and with evidence of functional impairment (examples of intrinsic abnormality: myocarditis, pericarditis, and myopericarditis; example of functional impairment: new conduction abnormality resulting in irregular heart rhythm [i.e. not transient first-degree heart block]); 6) central nervous system, any abnormality with the exception of a simple febrile convulsion or a brief delirium; 7) shock, all shock cases considered severe. At least 1 functional impairment (of criterion 3,4,5,6), needs to be present but the totality of data were considered by the members in their assessment.

[00967] Further results of part 1 and part 2 are presented in Tables 21a to c.

Table 21a: Distribution of cases contributing to primary endpoint by per protocol set subgroup (30 days after second vaccination until end of Part 1, i.e. 12 months after second vaccination)

	TDV		TDV	Placebo		Placebo	Vaccine Efficacy
	Dengue Cases		Incidence Density	Dengue Cases		Incidence Density	(95% CI)
VCD cases							
Baseline Seropositive ^a	41/9,165 (0.4%)		0.5	110/4,587 (2.4%)		2.7	82.2% (74.5%–87.6%)
Baseline Seronegative ^a	20/3,531 (0.6%)		0.6	39/1,726 (2.3%)		2.5	74.9% (57.0%–85.4%)
DENV-1	16/12,700 (0.1%)		0.1	30/6,316 (0.5%)		0.5	73.7% (51.7%–85.7%)
DENV-2	3/12,700 (<0.1%)		<0.1	64/6,316 (1.0%)		1.1	97.7% (92.7%–99.3%)
DENV-3	39/12,700 (0.3%)		0.3	51/6,316 (0.8%)		0.9	62.6% (43.3%–75.4%)
DENV-4 ^d	3/12,700 (<0.1%)		<0.1	4/6,316 (<0.1%)		<0.1	63.2% (-64.6%–91.8%)
4–5 Years Old	13/1,619 (0.8%)		0.9	23/801 (2.9%)		3.2	72.8% (46.2%–86.2%)
6–11 Years Old	34/7,009 (0.5%)		0.5	85/3,491 (2.4%)		2.7	80.7% (71.3%–87.0%)
12–16 Years Old	14/4,072 (0.3%)		0.4	41/2,024 (2.0%)		2.2	83.3% (69.3%–90.9%)
Asia	54/5,894 (0.9%)		1.0	127/2,942 (4.3%)		4.9	79.5% (71.8%–85.1%)
Latin America	7/6,806 (0.1%)		0.1	22/3,374 (0.7%)		0.7	84.3% (63.1%–93.3%)
Hospitalized VCD cases							
Baseline Seropositive ^a	4/9,165 (<0.1%)		<0.1	35/4,587 (0.8%)		0.8	94.4% (84.3%–98.0%)
Baseline Seronegative ^a	1/3,531 (<0.1%)		<0.1	18/1,726 (1.0%)		1.2	97.2% (79.1%–99.6%)
Cases of DHF ^b							
All participants	1/12,700 (<0.1%)		<0.1	4/6,316 (<0.1%)		<0.1	87.3% (-13.5%–98.6%)
Severe VCD Cases ^c							
All participants	1/12,700 (<0.1%)		<0.1	1/6,316 (<0.1%)		<0.1	50.8% (-686.9%–96.9%)

VCD, virologically-confirmed dengue; DHF, dengue hemorrhagic fever

^aSeronegative for all serotypes; baseline seropositive defined as reciprocal neutralizing antibody titer ≥10 to one or more serotypes.^bVCD cases meeting WHO 1997 DHF criteria; incidence density defined as the number of cases per 100 person-years at risk; percentages are based on total number (denominator) of per protocol set participants evaluated.^ctwo severe VCD were not classified as DHF.^d The number of cases identified was sufficient to provide reasonably precise estimates of vaccine efficacy against all individual serotypes, except DENV-4.

Table 21b: Distribution of cases contributing to secondary endpoint by per protocol set subgroup (30 days after second vaccination until end of Part 2, i.e. 18 months after second vaccination)

	TDV		TDV		Placebo		Vaccine Efficacy	
	Dengue Cases		Incidence Density		Dengue Cases		Incidence Density	
VCD cases								
Overall								73.3% (66.5%–78.8%)
Baseline Seropositive ^a	75		0.6		150		2.4	76.1% (68.5%–81.9%)
Baseline Seronegative ^a	39		0.8		56		2.4	66.2% (49.1%–77.5%)
DENV-1	38		0.2		62		0.7	69.8% (54.8%–79.9%)
Baseline Seropositive ^a	21		0.2		37		0.6	72.0 (52.2%–83.6%)
Baseline Seronegative ^a	17		0.3		25		1	67.8 (40.3%–82.6%)
DENV-2	8		<0.1		80		0.9	95.1% (89.9%–97.6%)
Baseline Seropositive ^a	7		<0.1		54		0.9	93.7 (86.1%–97.1%)
Baseline Seronegative ^a	1		<0.1		26		1.1	98.1 (85.8%–99.7%)
Hospitalized VCD cases								
Overall	13		<0.1		66		0.8	90.4% (82.6%–94.7%)
Baseline Seropositive ^a	8		<0.1		45		0.7	91.4% (81.7%–95.9%)
Baseline Seronegative ^a	5		0.1		21		0.9	88.1% (68.5%–95.5%)

VCD, virologically-confirmed dengue;

^aSeronegative for all serotypes; baseline seropositive defined as reciprocal neutralizing antibody titer ≥10 to one or more serotypes.

Table 21c: Distribution of cases contributing to secondary endpoint by safety set (first vaccination until end of Part 2, i.e. 21 months after first vaccination)

	TDV Dengue Cases	TDV Incidence Density	Placebo Dengue Cases	Placebo Incidence Density	Vaccine Efficacy (95% CI)
VCD cases					
Overall					75.3 % (69.5%-80.0%)
Overall in between ^a					81.0% (64.1%-90.0%)
Baseline Seropositive ^b	89	0.5	187	2.3	77.2% (70.6%-82.3%)
Baseline Seronegative ^b	42	0.7	70	2.3	70.6% (56.9%-79.9%)
DENV-1	41	0.2	78	0.7	73.9% (61.9%-82.1%)
DENV-2	14	<0.1	109	1.0	93.7% (89.0%-96.4%)
Hospitalized VCD cases					
Overall	17	<0.1	81	0.7	89.7% (82.6%-93.9%)

VCD, virologically-confirmed dengue;

^aIn between: VCD after first vaccination and before second vaccination.

^bSeronegative for all serotypes; baseline seropositive defined as reciprocal neutralizing antibody titer ≥10 to one or more serotypes.

Table 21d: Dengvaxia® VCD (first vaccination until 25 months after first vaccination (i.e.13 month after third vaccination), ITT from CYD15, 9 to 16 years of age)^a

Vaccine Efficacy (95% CI)	
Overall VCD	64.7 % (58.7%-69.8%)
Baseline Seropositive ^b	83.7% (62.2%-93.7%)
Baseline Seronegative ^b	43.2% (-61.5%-80.0%)
DENV-1	54.8% (40.2%-65.9%)
DENV-2	50.2%(31.8%-63.6%)
Overall Hospitalized VCD	80.3% (64.7%-89.5%)

^aLuis Villar et al. Efficacy of a tetravalent dengue vaccine in Children in Latin America. N Engl J of Med 2015 Vol. 372 No2, 113-123

[00968] Clinical signs and symptoms of virologically-confirmed dengue cases during Part 1 study period in safety set data are shown in **Table 22**.

Table 22: Clinical signs and symptoms of virologically-confirmed dengue cases during Part 1 study period (safety set data)

	TDV (N=13,380)	Placebo (N=6,687)	Relative Risk
Number of VCD Cases	78	200	—
Median Duration of Febrile Illness (days; 95% CI) ^a	6.0 (5.7–7.4)	6.0 (5.9–6.8)	—
Median Duration of Fever (days; 95% CI)	4.0 (3.9–4.6)	5.0 (4.5–5.0)	—
Number of Hospitalized VCD Cases	9	67	—
Median Duration of Hospitalization (days; 95% CI)	5.0 (2.8–5.4)	5.0 (4.6–5.4)	—
Evidence of Bleeding (%; n/N)	3.8% (3/78)	3.5% (7/200)	1.10
Plasma Leakage (%; n/N)	2.6% (2/78)	6.5% (13/200)	0.39
Plasma Leakage - Pleural Effusion (%; n/N)	1.3% (1/78)	1.5% (3/200)	—
Plasma Leakage - Ascites (%; n/N)	1.3% (1/78)	3.0% (6/200)	—
Plasma Leakage - Radiological Signs (%; n/N)	40.0% (2/5)	19.6% (10/51)	—
Plasma Leakage - Hematocrit Increase ≥20% (%; n/N) ^b	3.8% (2/53)	9.5% (13/137)	—
Platelet Count ≤100x10 ⁹ (%; n/N) ^c	6.4% (5/78)	22.0% (44/200)	0.29
Platelet Count ≤50x10 ⁹ (%; n/N) ^c	3.8% (3/78)	11.0% (22/200)	0.35
ALT or AST ≥1000 U/L (%; n/N) ^c	0% (0/78)	0% (0/200)	—

VCD, virologically-confirmed dengue; ALT, alanine aminotransferase; AST, aspartate aminotransferase

^aDuration of febrile illness defined as start date of earliest symptom to end date of latest symptom plus one day (symptoms considered include fever and any general symptoms).

^bHematocrit increase defined as maximum hematocrit between Day 3 and Day 7 inclusive, from onset of fever ≥20% increase over minimum hematocrit before Day 3 or after Day 7 from onset of fever.

^cFor platelet, ALT, and AST data, assessments within 14 days of onset of febrile illness have been considered.

N refers to number of VCD cases with available data for the specific parameter

e) Immunogenicity

[00969] The highest geometric mean titers (GMTs) were observed against DENV-2 regardless of baseline serostatus (Table 24). A very high tetravalent seropositivity rate (99.5%) in baseline seronegatives one month after the second dose (Tables 23 and 24) was observed.

[00970] Seropositivity rate (% of seropositive subjects) for each of the four dengue serotypes is determined at prevaccination on Day 1 (Month 0), post-first vaccination on Day 30 (Month 1), prevaccination on Day 90 (Month 3), post-second vaccination on Day 120 (Month 4), Day 270 (Month 9), Day 450 (Month 15), and then annually. Seropositivity rates (% participants, 95% CI) by dengue serotype per protocol set for immunogenicity data for Day 0, Day 30, Day 90, Day 120, and Day 270 are shown in Table 23.

[00971] Seropositivity rates (% participants, 95% CI) by dengue serotype against three or more serotypes (trivalent) and against all four serotypes (tetravalent) per protocol set for immunogenicity data for Day 0, Day 30, Day 90, Day 120, and Day 270 are shown in Table 23. The tetravalent seropositivity rates were high (>91%) in baseline seronegatives six months after second dose.

Table 23: Seropositivity rates (% participants, 95% CI) by dengue serotype (per protocol set for immunogenicity data)

BASELINE SEROPOSITIVE		BASELINE SERONEGATIVE	
TDV N=1,816	Placebo N=902	TDV N=702	Placebo N=345
DENV-1			
89.1 (87.6–90.5)	90.6 (88.5–92.4)	0 (0–0.5)	0 (0–1.1)
99.5 (99.1–99.8)	88.6 (86.3–90.7)	94.1 (92.0–95.8)	4.9 (2.8–7.8)
99.3 (98.8–99.6)	90.2 (88.1–92.1)	91.6 (89.3–93.5)	6.1 (3.8–9.2)
>99.9 (99.7–100)	90.3 (88.1–92.3)	99.5 (98.6–99.9)	8.3 (5.5–11.9)
99.6 (99.1–99.8)	89.8 (87.5–91.8)	95.1 (93.0–96.6)	9.0 (6.0–12.8)
DENV-2			
96.5 (95.6–97.3)	97.2 (95.9–98.2)	0 (0–0.5)	0 (0–1.1)
99.9 (99.6–100)	93.3 (91.4–94.9)	98.6 (97.4–99.4)	10.7 (7.5–14.5)
>99.9 (99.7–100)	94.0 (92.2–95.5)	99.0 (98.0–99.6)	12.2 (8.9–16.1)
99.9 (99.6–100)	93.6 (91.7–95.2)	100 (99.4–100)	14.7 (11.0–19.1)
100 (99.8–100)	94.6 (92.8–96.1)	100 (99.4–100)	18.3 (14.1–23.2)
DENV-3			
88.1 (86.5–89.6)	88.0 (85.7–90.1)	0 (0–0.5)	0 (0–1.1)
99.8 (99.4–99.9)	87.6 (85.1–89.7)	96.1 (94.3–97.4)	4.0 (2.1–6.7)
99.5 (99.1–99.8)	87.3 (84.9–89.4)	94.4 (92.5–96.0)	2.0 (0.8–4.1)
99.8 (99.5–100)	87.9 (85.5–90.1)	100 (99.4–100)	5.1 (2.9–8.2)
99.7 (99.4–99.9)	87.1 (84.6–89.4)	96.4 (94.6–97.7)	7.7 (4.9–11.3)
DENV-4			
88.1 (86.5–89.6)	87.4 (85.0–89.5)	0 (0–0.5)	0 (0–1.1)
99.6 (99.2–99.9)	86.6 (84.1–88.8)	90.5 (88.0–92.6)	1.8 (0.7–3.9)
99.3 (98.8–99.7)	86.9 (84.5–89.0)	92.0 (89.8–93.9)	2.9 (1.4–5.3)
>99.9 (99.7–100)	88.3 (85.9–90.4)	99.8 (99.1–100)	4.8 (2.7–7.8)
99.7 (99.3–99.9)	87.6 (85.1–89.9)	97.0 (95.4–98.2)	6.3 (3.9–9.7)
Three or More Serotypes			
87.5 (85.9–89.0)	87.3 (84.9–89.4)	0 (0–0.5)	0 (0–1.1)
99.8 (99.5–100)	87.2 (84.7–89.4)	96.5 (94.8–97.8)	1.2 (0.3–3.1)
99.7 (99.3–99.9)	87.7 (85.3–89.7)	94.9 (93.0–96.4)	1.7 (0.6–3.7)
99.9 (99.6–100)	88.4 (86.0–90.5)	99.8 (99.1–100)	4.2 (2.2–7.0)
99.7 (99.4–99.9)	87.3 (84.7–89.5)	97.5 (96.0–98.6)	5.7 (3.3–8.9)
All Four Serotypes			
83.5 (81.7–85.2)	83.5 (80.9–85.8)	0 (0–0.5)	0 (0–1.1)
99.1 (98.5–99.5)	82.9 (80.2–85.4)	85.3 (82.4–87.9)	0.9 (0.2–2.6)
98.6 (97.9–99.1)	83.6 (81.0–86.0)	84.3 (81.4–86.9)	1.4 (0.5–3.3)
99.8 (99.5–100)	85.2 (82.6–87.6)	99.5 (98.6–99.9)	3.5 (1.8–6.2)
99.2 (98.7–99.6)	84.6 (81.9–87.0)	91.3 (88.7–93.4)	5.3 (3.1–8.5)

Seropositivity rates (% participants, 95% CI) by dengue serotype (per protocol set for immunogenicity data; seropositive defined as a reciprocal neutralizing antibody titer ≥ 10 ; baseline seronegative defined as seronegative to all serotype; baseline seropositive defined as seropositive to one or more serotypes; N refers to number of participants in the analysis set; number of participants evaluated at each timepoint may vary)

[00972] Geometric mean titers (GMTs) of neutralizing antibodies (microneutralization test [MNT]) for each dengue

serotype are determined at pre-vaccination on Day 1 (Month 0), post-first vaccination on Day 30 (Month 1), pre-vaccination on Day 90 (Month 3), post-second vaccination on Day 120 (Month 4), Day 270 (Month 9), Day 450 (Month 15), and then annually. Geometric mean titers (95% CI) by dengue serotype per protocol set for immunogenicity data for Day 0, Day 30, Day 90, Day 120, and Day 270 are shown in Table 24.

Table 24: Geometric mean titers (95% CI) by dengue serotype (per protocol set for immunogenicity data)

	BASELINE SEROPOSITIVE		BASELINE SERONEGATIVE	
	TDV N=1,816	Placebo N=902	TDV N=702	Placebo N=345
DENV-1				
Day 1	410 (365–461)	445 (377–524)	5.0 (5.0–5.0)	5.0 (5.0–5.0)
Day 30	2,404 (2,204–2,622)	430 (361–512)	118 (106–131)	5.8 (5.3–6.3)
Day 90	1,945 (1,791–2,112)	410 (349–481)	91 (82–102)	5.9 (5.4–6.3)
Day 120	2,115 (1,957–2,286)	451 (381–534)	184 (169–201)	6.3 (5.7–7.0)
Day 270	1,447 (1,329–1,574)	415 (350–492)	87 (79–97)	6.3 (5.7–6.9)
DENV-2				
Day 1	745 (674–825)	802 (697–924)	5.0 (5.0–5.0)	5.0 (5.0–5.0)
Day 30	6,697 (6,301–7,117)	744 (635–870)	6,277 (5,648–6,977)	6.6 (6.0–7.3)
Day 90	4,826 (4,571–5,096)	729 (629–845)	1,682 (1,544–1,834)	7.0 (6.3–7.9)
Day 120	4,897 (4,646–5,163)	766 (655–896)	1,730 (1,614–1,855)	7.7 (6.7–8.8)
Day 270	3,692 (3,496–3,898)	776 (665–906)	929 (856–1,010)	8.7 (7.4–10.2)
DENV-3				
Day 1	357 (321–398)	356 (305–415)	5.0 (5.0–5.0)	5.0 (5.0–5.0)
Day 30	2,255 (2,094–2,428)	349 (298–409)	194 (173–218)	5.5 (5.2–5.9)
Day 90	1,563 (1,453–1,682)	321 (277–374)	94 (85–104)	5.5 (5.1–5.9)
Day 120	1,761 (1,646–1,885)	353 (301–414)	228 (212–246)	6.0 (5.4–6.6)
Day 270	1,089 (1,009–1,175)	307 (261–360)	72 (66–78)	6.3 (5.7–7.0)
DENV-4				
Day 1	218 (198–241)	234 (203–270)	5.0 (5.0–5.0)	5.0 (5.0–5.0)
Day 30	1,303 (1,221–1,391)	222 (191–258)	111 (98–125)	5.4 (5.0–5.7)
Day 90	1,002 (940–1,069)	215 (187–248)	63 (57–70)	5.5 (5.1–5.9)
Day 120	1,129 (1,066–1,196)	241 (208–280)	144 (134–155)	5.8 (5.3–6.4)
Day 270	778 (730–830)	229 (197–266)	64 (59–70)	6.2 (5.6–6.9)

[00973] Vaccine viremia is assessed by three PCRs: dengue detection RT-PCR, vaccine screening PCR and TDV sequencing in subjects with febrile illness within 30 days after each vaccination.

f) Safety

[00974] Rates of serious adverse events (SAEs) were similar in the vaccine and placebo groups (3.1% and 3.8% of participants, respectively; Table 25). One vaccinee and four placebo recipients experienced SAEs considered to be related to receiving blinded investigational product by the investigator (two experienced hypersensitivity, two were diagnosed with dengue, and one with DHF). There were five deaths during Part 1, and all were considered unrelated to the investigational product or study procedures. Total rates of unsolicited AEs were similar between the vaccine and placebo groups. The most commonly ($\geq 1\%$ of vaccine-recipients) reported unsolicited AEs within four weeks of any dose by preferred term were pyrexia (vaccine group 1.5%; placebo 1.4%), nasopharyngitis (vaccine 2.7%; placebo 3.0%), upper respiratory tract infection (vaccine 2.6%; placebo 2.9%), and viral infection (vaccine 1.1%; placebo 0.9%). Solicited local reactions were reported more frequently in the vaccine group.

Table 25a: Overview of safety data. Subjects with at least one adverse event after any vaccine dose. Data presented as number of events (percentage of subjects; number [n] of subjects/total [N] subjects) unless otherwise stated (safety set data)

	TDV	Placebo
Safety Set	N=13,380	N=6,687
SAEs	3.1% (409/13,380)	3.8% (255/6,687)
Non-IP-Related ^a SAEs	3.0% (408/13,380)	3.8% (251/6,687)
IP-Related ^a SAEs	<0.1% (1/13,380)	<0.1% (4/6,687)
SAEs Leading to IP Withdrawal and / or Trial Discontinuation	0.1% (18/13,380)	0.1% (8/6,687)
Deaths	<0.1% (4/13,380)	<0.1% (1/6,687)
IP-Related Deaths	0% (0/13,380)	0% (0/6,687)
Safety Subset	N=2,663	N=1,329
Unsolicited AEs Occurring Within 4 Weeks of Any Dose	18.4% (490/2,663)	18.8% (250/1,329)
IP-Related ^a Unsolicited AEs Occurring Within 4 Weeks of Any Dose	1.0% (27/2,663)	1.6% (21/1,329)
Solicited Systemic AEs Occurring Within 2 Weeks of Any Dose ^b	42.0% (1,107/2,635)	38.0% (501/1,317)
IP-Related ^a Solicited Systemic AEs Occurring Within 2 Weeks of Any Dose	31.2% (821/2,635)	28.2% (371/1,317)
Solicited Local Reactions Occurring Within 1 Week of Any Dose ^c	36.7% (967/2,633)	25.7% (338/1,317)

AE, adverse event; SAE, serious adverse event; IP, investigational product/TDV

^aIP-related, defined as related to the investigational product as assessed by investigator

^bonly participants with diary data available were evaluated

^call injection site (solicited local) reactions considered to be IP-related

Table 25b: Number of participants (%) with serious adverse events after any vaccination during Part 1 by MedDRA (Medical Dictionary for Regulatory Activities)System Organ Class in the order of decreasing frequency (safety set data presented by TDV and placebo group for events that occurred in > 3 participants due to risk of unblinding).

MedDRA System Organ Class	TDV N=13,380	Placebo N=6,687	Total* N=20,071
Any Serious Adverse Events	409 (3.1)	255 (3.8)	664 (3.3)
Infections and infestations	235 (1.8)	179 (2.7)	414 (2.1)
Injury, poisoning and procedural complications	87 (0.7)	37 (0.6)	124 (0.6)
Gastrointestinal disorders	23 (0.2)	9 (0.1)	32 (0.2)
Nervous system disorders	14 (0.1)	6 (<0.1)	20 (<0.1)
Respiratory, thoracic and mediastinal disorders	14 (0.1)	6 (<0.1)	20 (<0.1)
Renal and urinary disorders	15 (0.1)	3 (<0.1)	18 (<0.1)
Blood and lymphatic system disorders	8 (<0.1)	2 (<0.1)	10 (<0.1)
Pregnancy, puerperium and perinatal conditions	8 (<0.1)	2 (<0.1)	10 (<0.1)
Skin and subcutaneous tissue disorders	7 (<0.1)	3 (<0.1)	10 (<0.1)
Psychiatric disorders	7 (<0.1)	2 (<0.1)	9 (<0.1)
General disorders and administration site conditions	5 (<0.1)	3 (<0.1)	8 (<0.1)
Immune system disorders	3 (<0.1)	4 (<0.1)	7 (<0.1)
Metabolism and nutrition disorders	6 (<0.1)	1 (<0.1)	7 (<0.1)
Musculoskeletal and connective tissue	1 (<0.1)	5 (<0.1)	6 (<0.1)
Social circumstances	2 (<0.1)	4 (<0.1)	6 (<0.1)
Congenital, familial and genetic disorders	3 (<0.1)	2 (<0.1)	5 (<0.1)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	3 (<0.1)	1 (<0.1)	4 (<0.1)
Endocrine disorders	–	–	3 (<0.1)
Hepatobiliary disorders	–	–	3 (<0.1)
Reproductive system and breast disorders	–	–	3 (<0.1)
Vascular disorders	–	–	3 (<0.1)
Cardiac disorders	–	–	2 (<0.1)
Eye disorders	–	–	2 (<0.1)
Investigations	–	–	1 (<0.1)
Product issues	–	–	1 (<0.1)
Surgical and medical procedures	–	–	1 (<0.1)

*Total column includes participants who received both TAK-003 and placebo due to administration error and are excluded from the TAK-003 and placebo groups. N in column header refers to number of participants in the safety set

Table 25c: Number of participants (%) with unsolicited adverse events of any severity up to 28-days after any vaccination by MedDRA System Organ Class in the order of decreasing frequency (Subset of safety set data presented by TDV and placebo group for events that occurred in > 6 participants due to risk of unblinding).

MedDRA System Organ Class	TDV N=2,663	Placebo N=1,329	Total N=3,993
Any Unsolicited Adverse Events	487 (18.3)	249 (18.7)	736 (18.4)
Infections and infestations	368 (13.8)	190 (14.3)	558 (14.0)
Injury, poisoning and procedural complications	21 (0.8)	22 (1.7)	43 (1.1)
Gastrointestinal disorders	33 (1.2)	9 (0.7)	42 (1.1)
General disorders and administration site conditions	30 (1.1)	11 (0.8)	41 (1.0)
Skin and subcutaneous tissue disorders	27 (1.0)	7 (0.5)	34 (0.9)
Nervous system disorders	18 (0.7)	13 (1.0)	31 (0.8)
Respiratory, thoracic and mediastinal disorders	18 (0.7)	10 (0.8)	28 (0.7)
Blood and lymphatic system disorders	6 (0.2)	5 (0.4)	11 (0.3)
Musculoskeletal and connective tissue disorders	6 (0.2)	5 (0.4)	11 (0.3)
Immune system disorders	–	–	6 (0.2)
Psychiatric disorders	–	–	3 (<0.1)
Reproductive system and breast disorders	–	–	3 (<0.1)
Ear and labyrinth disorders	–	–	2 (<0.1)
Cardiac disorders	–	–	1 (<0.1)
Congenital, familial and genetic disorders	–	–	1 (<0.1)
Eye disorders	–	–	1 (<0.1)
Renal and urinary disorders	–	–	1 (<0.1)
Social circumstances	–	–	1 (<0.1)

*Total column includes participants who received both TAK-003 and placebo due to administration error and are excluded from the TAK-003 and placebo groups. N in column header refers to number of participants in the subset of safety set.

Table 25d: Summary of diary reported injection site reactions up to 7 days and systemic adverse events up to 14 days after any vaccination (Subset of safety set data). Data presented as number of participants with events / number of evaluated participants in the analysis set (% of evaluated participants with events).

5

Solicited Events	TDV	Placebo
Injection site reactions (Age < 6 years)		
Any	106/331 (32.0)	43/169 (25.4)
Pain	104/331 (31.4)	43/169 (25.4)
Erythema	5/331 (1.5)	1/169 (0.6)
Swelling	11/331 (3.3)	2/169 (1.2)
Injection site reactions (Age ≥ 6 years)		
Any	861/2302 (37.4)	295/1148 (25.7)
Pain	853/2302 (37.1)	293/1148 (25.5)
Erythema	33/2301 (1.4)	1/1147 (<0.1)
Swelling	33/2300 (1.4)	6/1147 (0.5)
Systemic adverse events (Age < 6 years)		
Any	88/331 (26.6)	35/169 (20.7)
Irritability/Fussiness	41/331 (12.4)	16/169 (9.5)
Drowsiness	45/331 (13.6)	21/169 (12.4)
Loss of Appetite	57/331 (17.2)	22/169 (13.0)
Fever (Body temperature ≥ 38°C or 100.4°F)	45/327 (13.8)	23/169 (13.6)
Systemic adverse events (Age ≥ 6 years)		
Any	941/2302 (40.9)	422/1147 (36.8)
Headache	715/2302 (31.1)	326/1147 (28.4)
Asthenia	404/2302 (17.5)	187/1147 (16.3)
Malaise	510/2301 (22.2)	226/1147 (19.7)
Myalgia	554/2302 (24.1)	216/1147 (18.8)
Fever (Body temperature ≥ 38°C or 100.4°F)	221/2279 (9.7)	124/1134 (10.9)

Example 7: Concomitant administration of a yellow fever vaccine and a dengue vaccine

[00975] A phase 3, observer-blind, randomized, multi-center trial will be conducted in about 900 healthy adults aged 18 to 60 years in non-endemic areas for dengue disease and yellow fever to investigate the immunogenicity and safety of the concomitant and sequential administration of the unit dose as described herein (TDV) and YF-17D vaccine.

5 Subjects will be randomized equally (1:1:1 ratio) to one of the following 3 trial groups (300 subjects per trial group):

- Group 1: YF-17D vaccine and placebo concomitantly administered on day 0 (month 0), first dose of TDV administered on day 90 (month 3), and second dose of TDV administered on day 180 (month 6).
- Group 2: first dose of TDV and placebo concomitantly administered on day 0 (month 0), second dose of TDV administered on day 90 (month 3), and YF-17D vaccine administered on day 180 (month 6).
- 10 – Group 3: first dose of TDV and YF-17D vaccine concomitantly administered on day 0 (month 0), second dose of TDV administered on day 90 (month 3), and placebo administered on day 180 (month 6).

[00976] Concomitantly administered vaccines will be injected to opposite arms. All subjects will be followed-up for 6 months after the third vaccination (administered approximately 6 months after the first vaccination), so the trial duration will be approximately 360 days (12 months) for each subject.

15 **[00977]** For evaluation of the immune response to TDV and YF-17D blood samples will be collected and analyzed. Blood samples for the measurement of dengue neutralizing antibodies (microneutralization test 50% (MNT50)) will be collected at pre-first vaccination (Day 0 (month 0)), 1 month post first vaccination (Day 30 (month 1)), pre-second vaccination (Day 90 (month 3)), 1 month post second vaccination (Day 120 (month 4)), pre-third vaccination (Day 180 (month 6)), and 1 month post third vaccination (Day 210 (month 7)). Blood samples for the measurement of YF

20 neutralizing antibodies (plaque reduction neutralization test (PRNT)) will be collected at pre-first vaccination (Day 0 (month 0)), 1 month post first vaccination (Day 30 (month 1)), pre-third vaccination (Day 180 (month 6)), and 1 month post third vaccination (Day 210 (month 7)).

Example 8: Concomitant administration of a hepatitis A vaccine and a dengue vaccine

[00978] A randomized, observer blind, phase 3 trial will be conducted in about 900 healthy adult subjects aged 18 to 60 years (distributed across the entire age range) in non-endemic countries for dengue and hepatitis A virus (HAV) to investigate the immunogenicity and safety of 2 doses of tetravalent dengue vaccine TDV (subcutaneous (SC) injection), and of the co-administration of a single dose of HAV vaccine (intramuscular (IM) injection) and TDV (SC injection). Subjects will be randomized equally (1:1:1 ratio) to one of the following 3 trial groups (300 subjects per group):

- 30 - Group 1: HAV vaccine (IM) and placebo (SC), co-administered at day 0 (month 0); placebo (SC) administered at day 90 (month 3).
- Group 2: TDV (SC) and placebo (IM), co-administered at day 0 (month 0); TDV (SC) administered at day 90 (month 3).
- Group 3: TDV (SC) and HAV vaccine (IM), co-administered at day 0 (month 0); TDV (SC) administered at day 90
- 35 (month 3).

[00979] Co-administered trial vaccines will be injected to opposite arms. Normal saline solution for injection (0.9% NaCl) will be used as placebo. A blood sample for an anti-HAV antibody test will be collected at screening from all subjects to exclude subjects who are positive for anti-HAV antibodies. All subjects will be followed-up for 6 months after the second vaccination at day 90 (month 3), so the trial duration will be 270 days or 9 months for each subject

40 (not including the screening period). Outside the context of this trial, subjects in Groups 1 and 3 will be offered a HAV

vaccine booster dose after the completion of trial procedures at day 270 (month 9).

[00980] Dengue neutralizing antibodies (microneutralization test (MNT50)) will be measured using blood samples collected at pre-first trial vaccination (day 0 (month 0)), 1 month post first trial vaccination (day 30 (month 1)), and 1 month post second trial vaccination (day 120 (month 4)). Blood samples for the measurement of anti-HAV antibodies (enzyme-linked immunosorbent assay (ELISA)) will be collected at pre-first trial vaccination (day 0 (month 0)) and 1 month post first trial vaccination (day 30 (month 1)).

[00981] The primary endpoint includes the proportion of HAV/DENV-naïve subjects at baseline who are seroprotected against HAV at day 30 (month 1) as measured by enzyme-linked immunosorbent assay (ELISA) (seroprotection rate) in a subset of 120 subjects in each group (immunogenicity subset) will be determined. Seroprotection is defined as serum anti-HAV antibody levels ≥ 10 mIU/mL. Immunological naivety to HAV/DENV is defined as anti-HAV antibody levels < 10 mIU/mL and reciprocal neutralizing titers for all 4 dengue serotypes < 10 .

[00982] The secondary endpoints include the geometric mean titers of neutralizing antibodies (GMTs) (microneutralization test (MNT50)) for each of the 4 dengue serotypes at day 30 (month 1) and day 120 (month 4) will be determined in HAV/DENV-naïve subjects at baseline, the proportion of HAV/DENV-naïve subjects at baseline who are seropositive for each of the 4 dengue serotypes at day 30 (month 1) and day 120 (month 4) (seropositivity rate), and Geometric mean concentrations (GMC) of anti-HAV antibodies at day 30 (month 1) in subjects HAV/DENV-naïve at baseline.

[00983] Seropositivity for dengue virus is defined as a reciprocal neutralizing titer ≥ 10 for any of the four dengue serotypes.

Example 9: Concomitant administration of a HPV vaccine and a dengue vaccine

[00984] A phase 3, open-label, randomized, multicenter trial will be conducted in about 430 healthy females aged ≥ 9 to < 15 years in dengue endemic regions to investigate the immunogenicity and safety of the co-administration of TDV and 9vHPV vaccine vs 9vHPV vaccine alone. Subjects will be randomized equally to 1 of 2 groups (about 215 subjects per trial group):

- Group 1: first doses of 9vHPV vaccine + TDV co-administered on day 0 (month 0), second dose of TDV administered on Day 90 (month 3), second dose of 9vHPV vaccine administered on Day 180 (month 6).
- Group 2: first dose of 9vHPV vaccine administered on day 0 (month 0), second dose of 9vHPV vaccine administered on Day 180 (month 6).

[00985] Concomitantly administered vaccines will be injected to opposite arms. All subjects will be followed-up for 6 months after the last trial vaccination, so the trial duration will be approximately 360 days (or 12 months) for each subject.

[00986] Blood samples for the measurement of HPV neutralizing antibodies (Merck assay) for both Groups 1 and 2 will be collected at pre-first vaccination (day 0 (Month 0)) and at 1 month post-second 9vHPV vaccination (day 210 (month 7)). Blood samples for the measurement of dengue neutralizing antibodies (by microneutralization test 50% (MNT50)) will be collected for Group 1 only at pre-first vaccination (day 0 (month 0)) and at 1 month post-second TDV vaccination (day 120 (month 4)).

[00987] The primary endpoints includes the geometric mean titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, 58 on day 210 (month 7).

[00988] The secondary endpoints includes seropositivity rates (% of subjects seropositive) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 on day 210 (month 7) as measured by competitive Luminex immunoassay (cLIA) or equivalent assay, GMTs of neutralizing antibodies (by MNT50) for each of the 4 dengue serotypes on day 120 (month 4), and seropositivity rates (% of subjects seropositive) for each of the 4 dengue serotypes and for multiple (2, 3 or 4) dengue serotypes on day 120 (month 4).

[00989] Seropositivity for dengue virus is defined as a reciprocal neutralizing antibody titer ≥ 10 for any of the 4 dengue serotypes.

[00990] Seropositivity for HPV is defined as an anti-HPV titer greater than or equal to the pre-specified serostatus cut-off for a given HPV type. Seronegativity is defined as an anti-HPV titer less than the pre-specified serostatus cut-off for a given HPV type. The serostatus cut-off is the antibody titer level above the assay's lower limit of quantification that reliably distinguishes sera samples classified by clinical likelihood of HPV infection and positive or negative status by previous versions of cLIA or equivalent assay. The lower limits of quantification and serostatus cut-offs for each of the 9 vaccine HPV types are shown below.

Table 26. Competitive Luminex Immunoassay Limits of Quantification and Serostatus Cutoffs for 9vHPV types

HPV type	cLIA Lower Limit of Quantification (mMU ^(a) /mL)	cLIA Serostatus Cutoff (mMU ^(a) /mL)
HPV 6	16	30
HPV 11	6	16
HPV 16	12	20
HPV 18	8	24
HPV 31	4	10
HPV 33	4	8
HPV 45	3	8
HPV 52	3	8
HPV 58	4	8

^(a) mMU = milli-Merck Units

[00991] Serum antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 will be measured with a competitive Luminex immunoassay or equivalent assay. Titers will be reported in milli Merck Units/mL with the use of the Luminex immunoassay.

Example 10: Concomitant administration of a Tdap vaccine and a dengue vaccine

[00992] A phase 3, open-label, randomized trial will be conducted in about 840 healthy subjects aged of ≥ 10 to < 18 years in dengue endemic areas, where the Tdap vaccine is licensed for children and adolescents from 10 up to 18 years of age to investigate the immunogenicity and safety of the co-administration of TDV and the Tdap vaccine BOOSTRIX® vs BOOSTRIX® alone.

[00993] TDV will be administered subcutaneously and BOOSTRIX® will be administered intramuscularly. Subjects will be randomized equally (1:1 ratio) to each one of the following 2 trial groups (about 420 subjects per trial group):

- Group 1: first dose of TDV + Tdap vaccine co-administered on day 0 (month 0); and second dose of TDV administered on day 90 (month 3).
- Group 2: Tdap vaccine administered on day 0 (month 0).

[00994] Concomitantly administered vaccines will be injected to opposite arms. All subjects will be followed up for 9 months (270 days) after the first vaccination, so the trial duration will be approximately 270 days for each subject.

[00995] For each subject there will be 5 scheduled clinic visits: day 0 (month 0), day 30 (month 1), day 90 (month 3), day 120 (month 4), and day 270 (month 9). Blood samples for the measurement of antibody response to the Tdap vaccine will be collected on day 0 (month 0) and on day 30 (month 1) from all subjects in Group 1 and 2. Antibodies against the following antigens will be measured:

- pertussis antigens (inactivated pertussis toxin (iPT), formaldehyde-treated filamentous hemagglutinin (FHA)), and pertactin (PRN)),
- tetanus toxoid antigen, and
- diphtheria toxoid antigen.

[00996] Blood samples for the measurement of dengue neutralizing antibodies (by microneutralization test 50% (MNT50)) will be collected from Group 1 on day 0 (month 0), day 30 (month 1), and day 120 (month 4). Blood samples will also be collected prior to vaccination.

[00997] The primary endpoints include:

- (i) the proportion of subjects seroprotected for diphtheria as measured by Neutralizing Toxin Assay (NTA) or equivalent assay on day 30 (month 1), wherein seroprotection is defined as anti-diphtheria antibody levels (NTA or equivalent assay) ≥ 0.1 IU/mL in serum
- (ii) The proportion of subjects seroprotected for tetanus as measured by Enzyme Linked Immunosorbent Assay (ELISA) or equivalent assay on day 30 (month 1), wherein seroprotection is defined as anti-tetanus antibody levels (ELISA or equivalent assay) ≥ 0.1 IU/mL in the serum.
- (iii) Geometric mean concentration (GMC) of acellular pertussis antibodies (anti-iPT antibodies, anti-FHA antibodies, anti-PRN antibodies,) as measured by ELISA or equivalent assay on day 30 (month 1).

[00998] The secondary endpoints include evaluations include geometric mean neutralizing antibody titers (GMTs) of antibodies (by MNT50) for each of the four dengue serotypes on day 30 (month 1) following a first dose with TDV and on day 120 (month 4) following a second dose of TDV, seropositivity rates (% of subjects seropositive) for each of the four dengue serotypes and for multiple (2, 3 or 4) dengue serotypes on day 30 (month 1) following a first dose with TDV and on day 120 (month 4) following a second dose of TDV, wherein seropositive for each dengue serotype is defined as the percentage of subjects with a reciprocal neutralizing antibody titer of ≥ 10 .

FIRST LIST OF ITEMS OF THE PRESENT INVENTION

1. A unit dose of a dengue vaccine composition comprising:
a tetravalent dengue virus composition including four live, attenuated dengue virus strains wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
2. The unit dose of item 1, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent
 - (v) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
 - (vi) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
 - (vii) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
 - (viii) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL.
3. The unit dose of item 1 or 2, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent
 - (i) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 3.6 log₁₀ pfu/0.5 mL,
 - (ii) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.0 log₁₀ pfu/0.5 mL,
 - (iii) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 4.6 log₁₀ pfu/0.5 mL, and
 - (iv) has a concentration of 4.5 log₁₀ pfu/0.5 mL or 4.6 log₁₀ pfu/0.5 mL to 5.1 log₁₀ pfu/0.5 mL.
4. The unit dose of any one of items 1 to 3, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10% or less than 8%, and the concentration of (iv) in pfu/0.5 mL is at least 50%.
5. The unit dose of item 4, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 7% or at least 8%.
6. The unit dose of any one of items 1 to 5, wherein reconstitution with a pharmaceutically acceptable diluent is made with 0.5 ml of the pharmaceutically acceptable diluent.
7. The unit dose of any one of items 1 to 6, wherein the lyophilized unit dose is prepared from a solution further comprising a non-reducing sugar, a surfactant, a protein and an inorganic salt.
8. The unit dose of item 7, wherein the non-reducing sugar is trehalose, the surfactant is poloxamer 407, the protein is human serum albumin and the inorganic salt is sodium chloride.
9. The unit dose of item 7 or 8, wherein the solution comprises:
 - from about 10 % (w/v) to about 20 % (w/v) α,α-trehalose dihydrate or an equimolar amount of other forms of α,α-trehalose,
 - from about 0.5 % (w/v) to about 1.5 % (w/v) poloxamer 407,

- from about 0.05 % (w/v) to about 2 % (w/v) human serum albumin, and
- from about 70 mM to about 140 mM sodium chloride.

10. The unit dose of any one of items 1 to 9, wherein the lyophilized unit dose is prepared from a solution comprising:

- about 15 % (w/v) α,α -trehalose dihydrate,
- about 1 % (w/v) poloxamer 407,
- about 0.1 % (w/v) human serum albumin, and
- and about 100 mM sodium chloride.

11. The unit dose of any one of items 1 to 10, wherein each one of the four live attenuated dengue virus strains has attenuating mutations in the 5'-noncoding region (NCR) at nucleotide 57 from cytosine to thymine, in the NS1 gene at nucleotide 2579 from guanine to adenine resulting in an amino acid change at position 828 from glycine to asparagine, and in the NS3 gene at nucleotide 5270 from adenine to thymine resulting in an amino acid change at position 1725 from glutamine to valine, preferably further comprising one or more of the mutations selected from the list comprising:

- a) a mutation in the NS2A gene at nucleotide 4018 from cytosine to thymine resulting in an amino acid at position 1308 from leucine to phenylalanine,
- b) a silent mutation in the NS3 gene at nucleotide 5547 from thymine to cytosine, and
- c) a mutation in the NS4A gene at nucleotide 6599 from guanine to cytosine resulting in an amino acid change at position 2168 from glycine to alanine.

12. The unit dose of item 11, wherein (i) further comprises one or more of the mutations selected from the list comprising:

- a mutation in the NS2A gene at nucleotide 3823 from adenine to cytosine resulting in an amino acid change at position 1243 from isoleucine to leucine,
- a mutation in the NS2B gene at nucleotide 4407 from adenine to thymine resulting in an amino acid change at position 1437 from glutamine to asparagine, and
- a silent mutation in the NS4B gene at nucleotide 7311 from adenine to guanine.

13. The unit dose of item 11 or 12, wherein (ii) further comprises one or more of the mutations selected from the list comprising:

- a mutation in the prM gene at nucleotide 592 from adenine to guanine resulting in an amino acid change at position 166 from lysine to glutamine, and
- a mutation in the NS5 gene at nucleotide 8803 from adenine to guanine resulting in an amino acid change at position 2903 from isoleucine to valine.

14. The unit dose of any one of items 11 to 13, wherein (iii) further comprises one or more of the mutations selected from the list comprising:

- a mutation in the E gene at nucleotide 1603 from adenine to thymine resulting in an amino acid change at position 503 from threonine to serine, and
- a silent mutation in the NS5 gene at nucleotide 7620 from adenine to guanine.

15. The unit dose of any one of items 11 to 14, wherein (iv) further comprises one or more of the mutations selected from the list comprising

- a silent mutation in the C gene at nucleotide 225 from adenine to thymine,
- a mutation in the NS2A gene at nucleotide 3674 from adenine to guanine resulting in an amino acid change at position 1193 from asparagine to glycine,
- a mutation in the NS2A gene at nucleotide 3773 from adenine to an adenine/guanine mix resulting in an amino acid change at position 1226 from lysine to a lysine/asparagine mix,
- a silent mutation in the NS3 gene at nucleotide 5391 from cytosine to thymine,
- a mutation in the NS4A gene at nucleotide 6437 from cytosine to thymine resulting in an amino acid change at position 2114 from alanine to valine,
- a silent mutation in the NS4B gene at nucleotide 7026 from thymine to a thymine/cytosine mix, and
- a silent mutation in the NS5 gene at nucleotide 9750 from adenine to cytosine.

16. The unit dose of any one of items 1 to 15, wherein

- (i) has the amino acid sequence of SEQ ID NO. 2,
- (ii) has the amino acid sequence of SEQ ID NO. 4,
- (iii) has the amino acid sequence of SEQ ID NO. 6, and
- (iv) has the amino acid sequence of SEQ ID NO. 8.

17. The unit dose of any one of items 1 to 16 reconstituted with 0.3 to 0.8 mL of liquid for reconstitution.

18. The unit dose of item 17 reconstituted with 0.5 mL of liquid for reconstitution.

19. The unit dose of item 17 or 18, wherein the liquid for reconstitution is 37 mM aqueous sodium chloride solution.

20. A kit for preparing a reconstituted unit dose comprising the following components:

- a) a unit dose of any one of items 1 to 16, and
- b) a pharmaceutically acceptable diluent for reconstitution.

21. The kit of item 20, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

22. Container, such as a vial, comprising one to ten unit doses of any one of items 1 to 19.

23. A method of preventing dengue disease in a subject population comprising administering to the subject population a reconstituted unit dose of any one of items 17 to 19.

24. The method of item 23, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

25. The method of item 24, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

5 26. A method of preventing dengue disease in a subject comprising administering to the subject a reconstituted unit dose of any one of items 17 to 19.

10 27. The method of item 26, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

15 28. The method of item 27, wherein said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

20 29. The method of any one of items 23 to 28, wherein the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

30. The method of any one of items 23 to 29, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.

25 31. The method of any one of items 23 to 30, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more.

30 32. The method of any one of items 23 to 30, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within six months, preferably within three months.

33. The method of item 32, wherein the two reconstituted unit doses are administered at day 0 and day 90.

35 34. The method of any one of items 31 to 33, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the first unit dose.

35 35. The method of any one of items 31 to 33, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the second unit dose.

40 36. The method of any one of items 23 to 35, wherein the subject or subject population is seronegative with respect to all dengue serotypes.

37. The method of any one of items 23 to 35, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

38. The method of any one of items 23 to 37, wherein the subject or subject population is of 2 to 60 years of age.
39. The method of any one of items 23 to 37, wherein the subject or subject population is under 9 years of age,
5 under 4 years of age, or under 2 years of age.
40. The method of any one of items 23 to 39, wherein the subject or subject population is from a dengue endemic region.
- 10 41. The method of any one of items 23 to 39, wherein the subject or subject population is from a dengue non-endemic region.
42. A method for stimulating an immune response to all four serotypes of dengue virus in a subject, comprising administering to the subject a reconstituted unit dose of items 17 to 19.
- 15 43. The method of item 42, wherein the immune response to all four serotypes of dengue virus is balanced.
44. The method of item 42 or 43, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.
- 20 45. The method of any one of items 42 to 44, wherein two unit doses of any one of items 17 to 19 are administered within 12 months or more.
46. The method of any one of items 42 to 45, wherein two reconstituted unit doses of any one of items 17 to 19
25 are administered within six months, preferably within three months.
47. The method of item 46, wherein the two reconstituted unit doses are administered at day 0 and day 90.
48. The method of any one of items 45 to 47, wherein a third unit dose is administered after the administration
30 of the second unit dose, preferably within 12 month of administration of the first unit dose.
49. The method of any one of items 45 to 47, wherein a third unit dose is administered after the administration of the second unit dose, preferably within 12 month of administration of the second unit dose.
- 35 50. The method of any one of items 42 to 49, wherein the subject is from a dengue endemic region.
51. The method of any one of items 42 to 49, wherein the subject is from a dengue non-endemic region.
52. The method of any one of items 42 to 51, wherein the subject is seronegative with respect to all dengue
40 serotypes.
53. The method of any one of items 42 to 51, wherein the subject is seropositive with respect to at least one dengue serotype.

54. The method of any one of items 42 to 53, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said reconstituted unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

55. The method of item 54, wherein said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

56. The method of any one of items 42 to 55, wherein the subject is of 2 and 60 years of age.

57. The method of any one of items 42 to 55, wherein the subject is under 9 years of age, under 4 years of age, or under 2 years of age.

58. The method of any one of items 23 to 57, wherein the reconstituted unit dose is obtained from the kit according to item 20 or 21.

59. The reconstituted unit dose of any one of items 17 to 19 for use in a method of items 23 to 58.

60. Use of a reconstituted unit dose of any one of items 17 to 19 for the manufacture of a medicament for a method according to items 23 to 58.

SECOND LIST OF ITEMS OF THE INVENTION

1. A unit dose of a dengue vaccine composition comprising:
a tetravalent dengue virus composition including four live, attenuated dengue virus strains wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:
 - 5 (v) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (vi) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (vii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (viii) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
- 10 2. The unit dose of item 1, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent
 - (i) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
 - (ii) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
 - (iii) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
 - (iv) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL.
- 15 3. The unit dose of item 1, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent:
 - (i) has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/0.5 mL,
 - (ii) has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/0.5 mL,
 - (iii) has a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/0.5 mL, and
 - 20 (iv) has a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/0.5 mL.
4. The unit dose of any one of items 1 to 3, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent
 - (v) has a concentration of 3.3 log₁₀ pfu/0.5 mL to 3.6 log₁₀ pfu/0.5 mL,
 - 25 (vi) has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.0 log₁₀ pfu/0.5 mL,
 - (vii) has a concentration of 4.0 log₁₀ pfu/0.5 mL to 4.6 log₁₀ pfu/0.5 mL, and
 - (viii) has a concentration of 4.5 log₁₀ pfu/0.5 mL to 5.1 log₁₀ pfu/0.5 mL.
- 30 5. The unit dose of any one of items 1 to 4, wherein upon reconstitution with a pharmaceutically acceptable diluent
 - (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (ii) in pfu/0.5 mL is less than 10% or less than 8%, and the concentration of (iv) in pfu/0.5 mL is at least 50%.
- 35 6. The unit dose of item 5, wherein upon reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (i) in pfu/0.5 mL is at least 1%, and the concentration of (iii) in pfu/0.5 mL is at least 7% or at least 8%.
- 40 7. The unit dose of any one of items 1 to 6, wherein upon reconstitution with a pharmaceutically acceptable diluent
 - (i), (ii), (iii), and (iv) provide a total concentration of pfu/0.5 mL and based on said total concentration the concentration of (i) in pfu/0.5 mL is 1% to 7% of the total concentration, (ii) in pfu/0.5 mL is less than 8% of the total concentration, such as in the range of 1% to 8% of the total concentration, (iii) in pfu/0.5 mL is at least 10% of the total concentration, and (iv) in pfu/0.5 mL is at least 65% of the total concentration, such as in the range of 65% to 80%.

8. The unit dose of any one of items 1 to 7, wherein the arithmetic sum of all four serotypes is in the range of 4.6 log₁₀ pfu/0.5 mL to 6.7 log₁₀ pfu/0.5 mL, preferably in the range of 4.6 log₁₀ pfu/0.5 mL to 5.5 log₁₀ pfu/0.5 mL.
- 5 9. The unit dose of any one of items 1 to 8, wherein reconstitution with a pharmaceutically acceptable diluent is made with 0.5 ml of the pharmaceutically acceptable diluent.
10. The unit dose of any one of items 1 to 9, wherein the lyophilized unit dose is prepared from a solution further comprising a non-reducing sugar, a surfactant, a protein and an inorganic salt.
- 10 11. The unit dose of item 10, wherein the non-reducing sugar is trehalose, the surfactant is poloxamer 407, the protein is human serum albumin and the inorganic salt is sodium chloride.
12. The unit dose of item 10 or 11, wherein the solution comprises:
- 15 - from about 10 % (w/v) to about 20 % (w/v) α,α-trehalose dihydrate or an equimolar amount of other forms of α,α-trehalose,
- from about 0.5 % (w/v) to about 1.5 % (w/v) poloxamer 407,
- from about 0.05 % (w/v) to about 2 % (w/v) human serum albumin, and
- from about 70 mM to about 140 mM sodium chloride.
- 20 13. The unit dose of any one of items 1 to 12, wherein the lyophilized unit dose is prepared from a solution comprising:
- about 15 % (w/v) α,α-trehalose dihydrate,
- about 1 % (w/v) poloxamer 407,
- 25 - about 0.1 % (w/v) human serum albumin, and
- and about 100 mM sodium chloride.
14. The unit dose of any one of items 1 to 13, wherein each one of the four live attenuated dengue virus strains has attenuating mutations in the 5'-noncoding region (NCR) at nucleotide 57 from cytosine to thymidine, in the NS1 gene at nucleotide 2579 from guanine to adenine resulting in an amino acid change at position 828 from glycine to asparagine, and in the NS3 gene at nucleotide 5270 from adenine to thymine resulting in an amino acid change at position 1725 from glutamine to valine, preferably further comprising one or more of the mutations selected from the list comprising:
- 30 a) a mutation in the NS2A gene at nucleotide 4018 from cytosine to thymidine resulting in an amino acid at position 1308 from leucine to phenylalanine,
- 35 b) a silent mutation in the NS3 gene at nucleotide 5547 from thymidine to cytosine, and
- c) a mutation in the NS4A gene at nucleotide 6599 from guanine to cytosine resulting in an amino acid change at position 2168 from glycine to alanine.
- 40 15. The unit dose of item 14, wherein (i) further comprises one or more of the mutations selected from the list comprising:
- a mutation in the NS2A gene at nucleotide 3823 from adenine to cytosine resulting in an amino acid change at position 1243 from isoleucine to leucine,
- a mutation in the NS2B gene at nucleotide 4407 from adenine to thymidine resulting in an amino acid change at position 1437 from glutamine to asparagine, and
- 45

- a silent mutation in the NS4B gene at nucleotide 7311 from adenine to guanine.

16. The unit dose of item 14 or 15, wherein (ii) further comprises one or more of the mutations selected from the list comprising:

- a mutation in the prM gene at nucleotide 592 from adenine to guanine resulting in an amino acid change at position 166 from lysine to glutamine, and
- a mutation in the NS5 gene at nucleotide 8803 from adenine to guanine resulting in an amino acid change at position 2903 from isoleucine to valine.

17. The unit dose of any one of items 14 to 16, wherein (iii) further comprises one or more of the mutations selected from the list comprising:

- a mutation in the E gene at nucleotide 1603 from adenine to thymidine resulting in an amino acid change at position 503 from threonine to serine, and
- a silent mutation in the NS5 gene at nucleotide 7620 from adenine to guanine.

18. The unit dose of any one of items 14 to 17, wherein (iv) further comprises one or more of the mutations selected from the list comprising

- a silent mutation in the C gene at nucleotide 225 from adenine to thymidine,
- a mutation in the NS2A gene at nucleotide 3674 from adenine to guanine resulting in an amino acid change at position 1193 from asparagine to glycine,
- a mutation in the NS2A gene at nucleotide 3773 from adenine to an adenine/guanine mix resulting in an amino acid change at position 1226 from lysine to a lysine/asparagine mix,
- a silent mutation in the NS3 gene at nucleotide 5391 from cytosine to thymidine,
- a mutation in the NS4A gene at nucleotide 6437 from cytosine to thymidine resulting in an amino acid change at position 2114 from alanine to valine,
- a silent mutation in the NS4B gene at nucleotide 7026 from thymidine to a thymidine/cytosine mix, and
- a silent mutation in the NS5 gene at nucleotide 9750 from adenine to cytosine.

19. The unit dose of any one of items 1 to 18, wherein

- (v) has the amino acid sequence of SEQ ID NO. 2,
- (vi) has the amino acid sequence of SEQ ID NO. 4,
- (vii) has the amino acid sequence of SEQ ID NO. 6, and
- (viii) has the amino acid sequence of SEQ ID NO. 8.

20. The unit dose of any one of items 1 to 19 reconstituted with 0.3 to 0.8 mL of liquid for reconstitution.

21. The unit dose of item 20 reconstituted with 0.5 mL of liquid for reconstitution.

22. The unit dose of item 20 or 21, wherein the liquid for reconstitution is 37 mM aqueous sodium chloride solution.

23. A kit for preparing a reconstituted unit dose comprising the following components:

- a) a unit dose of any one of items 1 to 19, and
- b) a pharmaceutically acceptable diluent for reconstitution.

24. The kit of item 23, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.
- 5 25. Container, such as a vial, comprising one to ten unit doses of any one of items 1 to 22.
26. A method of preventing dengue disease in a subject population comprising administering to the subject population a reconstituted unit dose of any one of items 20 to 22.
- 10 27. A method of preventing virologically confirmable dengue disease in a subject population comprising administering to the subject population a reconstituted unit dose of a tetravalent dengue virus composition including four live, attenuated dengue virus strains.
- 15 28. A method of preventing virologically confirmable dengue disease with hospitalization in a subject population comprising administering to the subject population a reconstituted unit dose of a tetravalent dengue virus composition including four live, attenuated dengue virus strains.
- 20 29. The method of items 26 to 28, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.
- 25 30. The method of item 29, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.
- 30 31. A method of preventing dengue disease in a subject comprising administering to the subject a reconstituted unit dose of any one of items 20 to 22.
32. A method of preventing virologically confirmable dengue disease in a subject comprising administering to the subject a reconstituted unit dose of a tetravalent dengue virus composition including four live, attenuated dengue virus strains.
- 35 33. A method of preventing virologically confirmable dengue disease with hospitalization in a subject comprising administering to the subject a reconstituted unit dose of a tetravalent dengue virus composition including four live, attenuated dengue virus strains.
- 40 34. The method of items 31 to 33, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

35. The method of item 34, wherein said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

5

36. The method of any one of items 26 to 35, wherein the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

37. The method of any one of items 26 to 36, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.

10

38. The method of any one of items 26 to 37, wherein two reconstituted unit doses of any one of items 20 to 22 are administered within 12 months or more.

15

39. The method of any one of items 26 to 37, wherein two reconstituted unit doses of any one of items 20 to 22 are administered within six months, preferably within three months.

40. The method of item 39, wherein the two reconstituted unit doses are administered at day 0 and day 90 or at day 1 and day 90.

20

41. The method of item 38 to 40, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the first unit dose.

42. The method of item 38 to 40, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the second unit dose.

25

43. The method of any one of items 26 to 42, wherein the subject or subject population is seronegative with respect to all dengue serotypes.

44. The method of any one of items 26 to 42, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

30

45. The method of any one of items 26 to 44, wherein the subject or subject population is of 2 to 60 years of age.

35

46. The method of any one of items 26 to 44, wherein the subject or subject population is of 2 to 17 years of age.

47. The method of any one of items 26 to 44, wherein the subject or subject population is under 9 years of age, under 4 years of age, or under 2 years of age or from 2 to 9 years of age, or from 2 to 5 years of age, or from 4 to 9 years of age or from 6 to 9 years of age, and optionally wherein the subject is seronegative with respect to all dengue serotypes.

40

48. The method of any one of items 26 to 44, wherein the subject or subject population is of 4 to 16 years of age.

45

49. The method of item 48, wherein the subject or subject population is of 4 to 5 years of age
50. The method of item 48, wherein the subject or subject population is of 6 to 11 years of age.
51. The method of item 48, wherein the subject or subject population is of 12 to 16 years of age.
52. The method of any one of items 26 to 51, wherein the subject or subject population is from a dengue endemic region.
53. The method of any one of items 26 to 51, wherein the subject or subject population is from a dengue non-endemic region.
54. The method of any one of items 52 or 53, wherein the subject or subject population is from Asia Pacific or Latin America.
55. The method of any one of items 26 to 54, wherein the subject or subject population has been subject to prior vaccination against Yellow Fever, wherein prior vaccination against Yellow Fever refers to a vaccination prior to the second administration or prior to the first administration.
56. The method of any one of items 26 to 54, wherein the subject or subject population is has been subject to prior vaccination against Japanese Encephalitis, wherein prior vaccination against Japanese Encephalitis refers to a vaccination prior to the second administration or prior to the first administration.
57. The method of any one of items 26 to 54, wherein the subject or subject population is has not been subject to prior vaccination against Yellow Fever.
58. The method of any one of items 26 to 54, wherein the subject or subject population is has not been subject to prior vaccination against Japanese Encephalitis.
59. The method of any one of items 26 to 58 having a combined vaccine efficacy against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.
60. The method of item 59, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 70% or is more than 72%.
61. The method of any one of items 26 to 60 having a combined vaccine efficacy against all four serotypes of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

62. The method of item 61, wherein the combined vaccine efficacy against all four serotypes is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 70%, is more than 75% is more than 78%, is more than 79% or is about 80%.

63. The method of any one of items 26 to 62 having a combined relative risk against all four serotypes with a 2-sided 95% confidence interval, wherein the upper bound is less than 0.75, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

64. The method of item 63, wherein the upper bound is less than 0.70, is less than 0.65, is less than 0.60, is less than 0.55, is less than 0.50, is less than 0.45, is less than 0.40, is less than 0.35, is less than 0.30 or is less than 0.28.

65. The method of any one of items 26 to 64, wherein the combined relative risk against all four serotypes is less than 0.70, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

66. The method of item 65, wherein the combined relative risk against all four serotypes is less than 0.65, is less than 0.60, is less than 0.55, is less than 0.50, is less than 0.45, is less than 0.40, is less than 0.35, is less than 0.30, is less than 0.25 or is less than 0.23.

67. The method of any one of items 26 to 58 having a combined vaccine efficacy against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 61.0%, or more than 65.0% or more than 70.0% or more than 72.0% when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects from endemic irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 or 13 months after the last administration of the administration schedule.

68. The method of any one of items 26 to 58 having a combined vaccine efficacy against all four serotypes of more than 66 %, or of more than 70%, or of more than 75%, or of more than 77%, or of more than 80%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects from endemic areas irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 months or 13 month after the last administration of the administration schedule.

69. The method of item 67 or 68, wherein the combined vaccine efficacy against all four serotypes is measured about 30 days after the last administration of the administration schedule until 12 or 13 months after the last administration of the administration schedule.

70. The method of item 67 or 68, wherein said unit dose or said placebo is administered twice within three months, in particular at about day 1 and about day 90, and wherein the combined vaccine efficacy against all four serotypes is measured 30 days after the second administration until 12 or 13 months after the second administration of the administration schedule.

5

71. The method of any one of items 26 to 70 being effective and safe.

72. The method of any one of items 26 to 71 having a relative risk for virologically confirmed dengue with hospitalization which is 1 or less, or 0.8 or less, or 0.6 or less, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects.

10

73. The method of any one of items 59 to 72, wherein the healthy subjects of the subject population are of 4 to 16 years of age at the time of randomization.

15

74. The method of any one of items 59 to 72, wherein the healthy subjects of the subject population are of 4 to 5 years of age at the time of randomization

75. The method of any one of items 59 to 72, wherein the healthy subjects of the subject population are of 6 to 11 years of age at the time of randomization.

20

76. The method of any one of items 59 to 72, wherein the healthy subjects of the subject population are of 12 to 16 years of age at the time of randomization.

77. The method of any one of items 59 to 72, wherein the healthy subjects of the subject population are from Asia Pacific or Latin America.

25

78. The method of any one of items 59 to 77, wherein the healthy subjects of the subject population are seropositive with respect to at least one serotype at baseline.

30

79. The method of any one of items 59 to 77, wherein the healthy subjects of the subject population are seronegative with respect to all serotypes at baseline.

80. The method of any one of items 59 to 79, wherein the healthy subjects of the subject population have been subject to prior vaccination against Yellow Fever.

35

81. The method of any one of items 59 to 79, wherein the healthy subjects of the subject population have been subject to prior vaccination against Japanese Encephalitis.

82. The method of any one of items 59 to 79, wherein the healthy subjects of the subject population have not been subject to prior vaccination against Yellow Fever.

40

83. The method of any one of items 59 to 79, wherein the healthy subjects of the subject population have not been subject to prior vaccination against Japanese Encephalitis.

45

84. A method for stimulating an immune response to all four serotypes of dengue virus in a subject, comprising administering to the subject a reconstituted unit dose of items 20 to 22.

85. The method of item 84, wherein the immune response to all four serotypes of dengue virus is balanced.

86. The method of item 84 or 85, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.

5 87. The method of any one of items 84 to 86, wherein two unit doses of any one of items 20 to 22 are administered within 12 months or more.

88. The method of any one of items 84 to 87, wherein two reconstituted unit doses of any one of items 20 to 22 are administered within six months, preferably within three months.

10

89. The method of item 88, wherein the two reconstituted unit doses are administered at day 0 and day 90 or at day 1 and day 90.

15

90. The method of item 87 to 89, wherein a third unit dose is administered after the administration of the second unit dose, preferably within 12 month of administration of the first unit dose.

91. The method of item 87 to 89, wherein a third unit dose is administered after the administration of the second unit dose, preferably within 12 month of administration of the second unit dose.

20

92. The method of any one of items 84 to 91, wherein the subject is from a dengue endemic region.

93. The method of any one of items 84 to 91, wherein the subject is from a dengue non-endemic region.

25

94. The method of any one of items 84 to 93, wherein the subject is seronegative with respect to all dengue serotypes.

95. The method of any one of items 84 to 93, wherein the subject is seropositive with respect to at least one dengue serotype.

30

96. The method of any one of items 84 to 95, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said reconstituted unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

35

97. The method of item 96, wherein said neutralizing antibody titers of the subject further provide a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

40

98. The method of any one of items 84 to 97, wherein the subject is of 2 and 60 years of age.

99. The method of any one of items 84 to 97, wherein the subject is under 9 years of age, under 4 years of age, or under 2 years of age.

100. The method of any one of items 26 to 99, wherein the reconstituted unit dose is obtained from the kit according to item 23 or 24.

5 101. The reconstituted unit dose of any one of item 20 to 22 for use in a method of items 26 to 100.

102. Use of a reconstituted unit dose of any one of items 20 to 22 for the manufacture of a medicament for a method according to items 26 to 100.

THIRD LIST OF ITEMS OF THE INVENTION

1. A dengue vaccine composition for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, and wherein the dengue vaccine composition is a tetravalent dengue virus composition including four live, attenuated dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, wherein the attenuated dengue virus strains comprise chimeric dengue viruses and at least one non-chimeric dengue virus, and wherein the dengue serotype 1 and the dengue serotype 2 are present each in a concentration based on the total concentration in pfu/0.5 mL which is within 5%-points of each other and/or are together less than about 10% of the total concentration in pfu/0.5 mL.

2. The composition for use of item 1, wherein the method does not comprise a determination of a previous dengue infection in the subject before the administration of the first unit dose of the tetravalent dengue virus composition and wherein the method is safe and effective.

3. The composition for use of item 1 or 2, wherein the dengue serotype 3 is at least about 10% of the total concentration in pfu/0.5 mL and/or wherein the dengue serotype 4 is at least about 70% of the total concentration in pfu/0.5 mL.

4. The composition for use of any one of items 1 to 3, wherein the dengue serotype 4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 and dengue serotype 2 each represent lower concentrations than the concentration of serotype 3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

5. The composition for use of any one of items 1 to 4, wherein the dengue serotype 1 is a chimeric dengue serotype 2/1 strain, the dengue serotype 2 is a non-chimeric dengue serotype 2 strain, the dengue serotype 3 is a chimeric dengue serotype 2/3 strain and the dengue serotype 4 is a chimeric dengue serotype 2/4 strain.

6. The composition for use of any one of items 1 to 5, wherein the dengue serotype 1 has the amino acid sequence of SEQ ID NO. 2, the dengue serotype 2 has the amino acid sequence of SEQ ID NO. 4, the dengue serotype 3 has the amino acid sequence of SEQ ID NO. 6, and the dengue serotype 4 has the amino acid sequence of SEQ ID NO. 8.

7. The composition for use of any one of items 1 to 6, wherein the unit dose upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

- (i) dengue serotype 1 has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
- (iii) dengue serotype 3 has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
- (iv) dengue serotype 4 has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL.

8. The composition for use of any one of items 1 to 7, wherein the composition further comprises about 15 % (w/v) α,α-trehalose dihydrate, about 1 % (w/v) poloxamer 407, about 0.1 % (w/v) human serum albumin, and about 100 mM sodium chloride when measured in 0.5mL.

9. The composition for use of any one of items 1 to 8, wherein the unit doses are administered to the deltoid region of the arm.

5 10. The composition for use of any one of items 1 to 9, wherein the subject is seronegative to all dengue serotypes at baseline and/or is under 9 years of age.

11. The composition for use of any one of items 1 to 10, wherein the subject is 4 to 5 years of age or 6 to 11 years of age or 12 to 16 years of age.

10

12. The composition for use of any one of items 1 to 11, wherein the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

13. The composition for use of any one of items 1 to 12, wherein the subject is from a dengue endemic region.

15

14. The composition for use of any one of items 1 to 12, wherein the subject is from a dengue non-endemic region.

15. The composition for use of any one of items 1 or 14, wherein the subject is from Asia Pacific or Latin America.

20

16. The composition for use of any one items of 1 to 15, wherein the composition provides a seropositivity rate when it is administered to a subject population of at least 50 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population are seronegative to all dengue serotypes at baseline.

25

17. The composition for use of item 16, wherein at least one month after administration of the first unit dose, such as at day 30, at least 80% of the subject population are seropositive for all four dengue serotypes.

18. The composition for use of item 16 or 17, wherein before or at the time of the administration of the second unit dose, such as at day 90, at least 80% of the subject population are seropositive for all four dengue serotypes.

30

19. The composition for use of any one of items 16 to 18, wherein after the administration of the second unit dose, such as at day 120, at least 80%, or at least 85%, or at least 90% or at least 95% of the subject population are seropositive for all four dengue serotypes.

35

20. The composition for use of any one of items 11 to 14, wherein after the administration of the second unit dose, such as at day 270, at least 80%, or at least 85%, or at least 90% of the subject population are seropositive for all four dengue serotypes.

40

21. The composition for use of any one of items 16 to 20, wherein the composition provides a seropositivity rate, when it is administered to a subject population of at least 100 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population comprises from 20% to 40% subjects who are seronegative to all dengue serotypes and from 60% to 80% subjects who are seropositive to at least one dengue serotype at baseline, wherein at day 120 and/or day 270 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 10%-points and/or wherein at day 120 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 5%-points.

45

22. A method of inoculating a subject against virologically confirmable dengue disease in a subject comprising administering to the subject a tetravalent dengue virus composition including four dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4.

5

23. A method of inoculating a subject against virologically confirmable dengue disease consisting of administering to the subject a tetravalent dengue virus composition including four dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4.

10

24. The method of item 22 or 23, wherein the method does not comprise a determination of a previous dengue infection in the subject before the administration of the tetravalent dengue virus composition.

15

25. The method of any one of items 22 to 24, wherein the inoculation is safe irrespective of whether there is a determination that the subject had a previous dengue infection before the administration of the tetravalent dengue virus composition.

26. The method of any one of items 22 to 25 which is safe.

20

27. The method of any one of items 22 to 26 which is effective.

28. The method of any one of items 22 to 27, wherein the virus strains are live, attenuated dengue virus strains.

25

29. The method of any one of items 22 to 28, wherein the composition includes at least one chimeric dengue virus and optionally at least one non-chimeric dengue virus.

30. The method of any one of items 22 to 29, wherein the composition includes a chimeric dengue serotype 2/1 strain and a dengue serotype 2 strain and a chimeric dengue serotype 2/3 strain and a chimeric dengue serotype 2/4 strain.

30

31. The method of any one of items 22 to 30, wherein the subject is seronegative to all dengue serotypes at base line and/or under 9 years of age, 4 to 5 years of age, 6 to 11 years of age or 12 to 16 years of age.

32. The method of any one of items 22 to 31, wherein the composition is administered by subcutaneous injection.

35

33. The method of any one of items 22 to 32 including consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least four 4 apart, optionally at about day 1 and at about day 90.

40

34. The method of any one of items 22 to 33, wherein the dengue serotypes 1 and 2 are present in similar amounts and/or make up less than about 10% of the total viral concentration.

35. The method of any one of items 22 to 34, wherein the dengue serotype 3 makes up at least about 10% of the total viral concentration.

45

36. The method of any one of items 22 to 35, wherein the dengue serotype 4 makes up at least about 70% of the total viral concentration.

37. The method of any one of items 22 to 36 wherein the dengue serotype 4 represents the highest concentration in the composition of all four serotypes, preferably with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 represents the second highest concentration in the composition of all four serotypes, preferably with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 and dengue serotype 2 each represent lower concentrations than the concentration of serotype 3, and optionally together represent less than about 10% of the total concentration in pfu/0.5 mL.

38. The method of any one of items 22 to 37, wherein the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

39. The method of any one of items 22 to 38 wherein the subject or subject population is from a dengue endemic region.

40. The method of any one of items 22 to 38, wherein the subject or subject population is from a dengue non-endemic region.

41. The method of any one of items 22 to 40, wherein the subject or subject population is from Asia Pacific or Latin America.

42. The method of any one of items 22 to 41 having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, and optionally at least 4 weeks apart, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

43. The method of item 42, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 70% or is more than 72%.

44. The method of any one of items 22 to 43 having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, and optionally at least 4 weeks apart, 30 days after the second administration until at least 12 months after the second administration.

45. The method of item 44, wherein the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 55%, is more than 60%, is more than 65%, is more than 70%, is more than 75% is more than 78%, is more than 79% or is about 80%.

46. The method of any one of items 22 to 45 having a combined vaccine efficacy against all four dengue serotypes in seronegative subjects with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose or said placebo is administered at least twice within less than

6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

47. The method of item 46, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, or is more than 55%.

48. The method of any one of items 22 to 47 having a combined vaccine efficacy against all four dengue serotypes in seronegative subjects of more than 30%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

49. The method of item 48, wherein the combined vaccine efficacy against all four dengue serotypes in seronegative subjects is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

50. The method of any one of items 22 to 49 having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 4 to 5 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

51. The method of item 50, wherein the lower bound is more than 30%, is more than 40%, is more than 45%.

52. The method of any one of items 22 to 51 having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 4 to 5 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

53. The method of item 52, wherein the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

54. The method of any one of items 22 to 53 having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 6 to 11 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

55. The method of item 54, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, or is more than 70%.

56. The method of any one of items 22 to 55 having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 6 to 11 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

57. The method of item 56, wherein the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 75%, or is more than 80%.

58. The method of any one of items 26 to 57 having a combined vaccine efficacy against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,000 healthy subjects 12 to 16 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

59. The method of item 58, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 68%.

60. The method of any one of items 26 to 59 having a combined vaccine efficacy against all four dengue serotypes of more than 30%, when measured against placebo in a subject population of at least 1,000 healthy subjects 12 to 16 years of age at the time of randomization and irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

61. The method of item 60, wherein the combined vaccine efficacy against all four dengue serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 75%, or is more than 80%.

62. The method of any one of items 22 to 61 having a vaccine efficacy against dengue serotype 1 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

63. The method of item 62, wherein the lower bound is more than 30%, is more than 40%, or is more than 50%.

64. The method of any one of items 22 to 63 having a vaccine efficacy against dengue serotype 1 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

65. The method of item 64, wherein the vaccine efficacy against dengue serotype 1 is more than 40%, is more than 50%, is more than 60%, is more than 65%, or is more than 70%.

66. The method of any one of items 22 to 65 having a vaccine efficacy against dengue serotype 2 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

67. The method of item 66, wherein the lower bound is more than 30%, is more than 40%, is more than 50, is more than 60, is more than 70, is more than 80, or is more than 90%.

68. The method of any one of items 22 to 67 having a vaccine efficacy against dengue serotype 2 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

69. The method of item 68, wherein the vaccine efficacy against dengue serotype 2 is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80, or is more than 90%.

70. The method of any one of items 22 to 69 having a vaccine efficacy against dengue serotype 3 with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

71. The method of item 70, wherein the lower bound is more than 30%, is more than 40%.

72. The method of any one of items 22 to 71 having a vaccine efficacy against dengue serotype 3 of more than 30%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

73. The method of item 72, wherein the vaccine efficacy against dengue serotype 3 is more than 40%, is more than 50%, is more than 55%, or is more than 60%.

74. The method of any one of items 22 to 73 having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

75. The method of item 74, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 70%, or is more than 75%.

76. The method of any one of items 22 to 75 having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes of more than 30%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects, healthy subjects being seronegative against all serotypes at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

77. The method of item 76, wherein the combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 90%.

78. The method of any one of items 21 to 77 having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 25%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects being seropositive at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, about 30 days after the second administration of the administration schedule until at least 12 months after the second administration of the administration schedule.

79. The method of item 78, wherein the lower bound is more than 30%, is more than 40%, is more than 50%, is more than 60%, is more than 70%, or is more than 80%.

80. The method of any one of items 22 to 79 having a combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes of more than 30%, when measured against placebo in a subject population of at least 1,500 or at least 2,000 healthy subjects, healthy subjects being seropositive at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

81. The method of item 80, combined vaccine efficacy against virologically-confirmed dengue with hospitalization against all four serotypes is more than 40%, is more than 50%, is more than 60%, is more than 70%, is more than 80%, or is more than 90%.

82. The method of any one of items 22 to 81 having a combined relative risk against all four dengue serotypes with a 2-sided 95% confidence interval, wherein the upper bound is less than 0.75, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

83. The method of item 82, wherein the upper bound is less than 0.70, is less than 0.65, is less than 0.60, is less than 0.55, is less than 0.50, is less than 0.45, is less than 0.40, is less than 0.35, is less than 0.30 or is less than 0.28.

84. The method of any one of items 22 to 83, wherein the combined relative risk against all four dengue serotypes is less than 0.70, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects irrespective of serostatus at baseline, wherein said unit dose or said placebo is administered at least twice within less than 6 months, such as within 3 months, 30 days after the second administration until at least 12 months after the second administration.

85. The method of item 84, wherein the combined relative risk against all four serotypes is less than 0.65, is less than 0.60, is less than 0.55, is less than 0.50, is less than 0.45, is less than 0.40, is less than 0.35, is less than 0.30, is less than 0.25 or is less than 0.23.

86. The method of any one of items 22 to 85 having a combined vaccine efficacy against all four serotypes with a 2-sided 95% confidence interval, wherein the lower bound is more than 61.0%, or more than 65.0 or more than 70.0% or more than 72.0% when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects from endemic regions irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 or 13 months after the last administration of the administration schedule.

87. The method of any one of items 22 to 86 having a combined vaccine efficacy against all four serotypes of more than 66 %, or of more than 70%, or of more than 75%, or of more than 77%, or of more than 80.0%, when measured against placebo in a subject population of at least 5,000 healthy subjects, or at least 10,000 healthy subjects, or at least 15,000 healthy subjects from endemic regions irrespective of serostatus at baseline and being selected from the group consisting of 4 to 16 year old subjects at the time of randomization, wherein said unit dose or said placebo is administered at least twice within 6 months or less, about 30 days after the last administration of the administration schedule until at least 12 months or 13 month after the last administration of the administration schedule.

88. The method of any one of items 22 to 87, wherein said unit dose or said placebo is administered at day 1 and day 90.

89. The method of any one of items 22 to 88 having a relative risk for virologically confirmed dengue with hospitalization which is 1 or less, or 0.8 or less, or 0.6 or less, when measured against placebo in a subject population of at least 1,000 healthy subjects, or at least 5,000 healthy subjects, or at least 10,000 healthy subjects irrespective of serostatus at baseline and in age groups from 4 to 16 years, in particular in subjects 4 to 5 years of age at the time of randomization.

90. The method of any one of items 22 to 89, wherein the occurrence of vaccine related serious adverse events is less than 0.1%.

91. The method of any one of items 22 to 90, wherein the occurrence of vaccine related unsolicited adverse events occurring within 4 weeks of administration is less than 2%.

92. The method of any one of items 22 to 91, wherein the occurrence of vaccine related solicited adverse events occurring within 2 weeks of administration is less than 35%.

93. The method of any one of items 22 to 92, wherein the occurrence of solicited local reactions occurring within 1 weeks of administration is less than 40%.

94. The method of any one of items 22 to 93, wherein the unit dose upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

- (i) dengue serotype 1 has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,

- (iii) dengue serotype 3 has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
- (iv) dengue serotype 4 has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL, and optionally comprises about 15 % (w/v) α,α-trehalose dihydrate, about 1 % (w/v) poloxamer 407, about 0.1 % (w/v) human serum albumin, and about 100 mM sodium chloride when measured in 0.5 mL.

5

95. A reconstituted unit dose of a dengue vaccine composition for use in a method of preventing virologically confirmable dengue disease in a subject comprising consecutively administering at least a first and a second unit dose of the dengue vaccine composition to the subject, wherein said first and second unit dose are administered subcutaneously within 3 months and at least 4 weeks apart, optionally at about day 1 and at about day 90, wherein the dengue vaccine composition is a tetravalent dengue virus composition including four dengue virus strains representing dengue serotype 1, dengue serotype 2, dengue serotype 3 and dengue serotype 4, optionally wherein the dengue virus strains are live, attenuated, and wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

10

- (i) dengue serotype 1 has a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) dengue serotype 3 has a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) dengue serotype 4 has a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

15

96. The unit dose for use of item 95, wherein the subject is under 9 years of age and/or when the serostatus of the subject is unknown or seronegative.

20

97. The unit dose for use of item 95 or 96, which is effective.

98. The unit dose for use of any one of items 95 to 97, which is effective against all four dengue serotypes.

25

99. The unit dose for use of any one of items 95 to 98, which is safe.

100. The unit dose for use of any one of items 95 to 99, wherein the unit dose includes at least one chimeric dengue virus.

30

101. The unit dose for use of any one of items 95 to 100, wherein the unit dose includes at least one non-chimeric dengue virus and at least one chimeric dengue virus.

102. The unit dose for use of any one of items 95 to 101, wherein the subject is seronegative to all dengue serotypes at baseline and/or is under 9 years of age.

35

103. The unit dose for use of any one of items 95 to 102, wherein the subject is 4 to 5 years of age or 6 to 11 years of age or 12 to 16 years of age.

104. The unit dose for use of any one of items 95 to 103, wherein the method does not comprise a determination of a previous dengue infection in the subject before the administration of the first unit dose of the tetravalent dengue virus composition.

40

105. The unit dose for use of any one of items 95 to 104, wherein the dengue serotype 4 represents the highest concentration in the composition of all four serotypes, optionally with at least about 70% of the total concentration in pfu/0.5 mL, dengue serotype 3 represents the second highest concentration in the composition of all four serotypes

45

with at least about 10% of the total concentration in pfu/0.5 mL, and dengue serotype 1 and dengue serotype 2 each represent lower concentrations than the concentration of serotype 3 and together represent less than about 10% of the total concentration in pfu/0.5 mL and/or which are within 5%-points of each other.

5 106. The unit dose for use of any one of items 95 to 105, wherein the dengue serotype 1 is a chimeric dengue serotype 2/1 strain, the dengue serotype 2 is a non-chimeric dengue serotype 2 strain, the dengue serotype 3 is a chimeric dengue serotype 2/3 strain and the dengue serotype 4 is a chimeric dengue serotype 2/4 strain.

10 107. The unit dose for use of any one of items 95 to 106, wherein the dengue serotype 1 has the amino acid sequence of SEQ ID NO. 2, the dengue serotype 2 has the amino acid sequence of SEQ ID NO. 4, the dengue serotype 3 has the amino acid sequence of SEQ ID NO. 6, and the dengue serotype 4 has the amino acid sequence of SEQ ID NO. 8.

15 108. The unit dose for use of any one of items 95 to 107, wherein the unit dose further comprises from about 10 % w/v to about 20 % w/v α,α -trehalose dihydrate or an equimolar amount of other forms of α,α -trehalose, from about 0.5 % w/v to about 1.5 % w/v poloxamer 407, from about 0.05 % w/v to about 2 % w/v human serum albumin, and from about 70 mM to 140 mM sodium chloride when measured in 0.5 mL.

20 109. The unit dose for use of any one of items 95 to 108, wherein the unit dose further comprises about 15 % (w/v) α,α -trehalose dihydrate, about 1 % (w/v) poloxamer 407, about 0.1 % (w/v) human serum albumin, and about 100 mM sodium chloride when measured in 0.5 mL.

25 110. The unit dose for use of any one of items 95 to 109, wherein the method is for preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).

111. The unit dose for use of any one of items 95 to 110, wherein the subject is from a dengue endemic region.

30 112. The unit dose for use of any one of items 95 to 111, wherein the subject is from a dengue non-endemic region.

113. The unit dose for use of any one of items 95 to 112, wherein the subject is from Asia Pacific or Latin America.

35 114. The unit dose for use of any one items of 95 to 113, wherein the unit dose provides a seropositivity rate when it is administered to a subject population of at least 50 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population are seronegative to all dengue serotypes at baseline.

115. The unit dose for use of item 114, wherein at least one month after administration of the first unit dose, such as at day 30, at least 80% of the subject population are seropositive for all four dengue serotypes.

40 116. The unit dose for use of item 114 or 115, wherein before or at the time of the administration of the second unit dose, such as at day 90, at least 80% of the subject population are seropositive for all four dengue serotypes.

45 117. The unit dose for use of any one of items 114 to 116, wherein after the administration of the second unit dose, such as at day 120, at least 80%, or at least 85%, or at least 90% or at least 95% of the subject population are seropositive for all four dengue serotypes.

118. The unit dose for use of any one of items 114 to 117, wherein after the administration of the second unit dose, such as at day 270, at least 80%, or at least 85%, or at least 90% of the subject population are seropositive for all four dengue serotypes.

5 119. The unit dose for use of any one of items 114 to 118, wherein the unit dose provides a seropositivity rate, when it is administered to a subject population of at least 100 subjects in two unit doses subcutaneously at day 1 and at day 90, wherein the subjects of the subject population comprises from 20% to 40% subjects who are seronegative to all dengue serotypes and from 60% to 80% subjects who are seropositive to at least one dengue serotype at base line, wherein at day 120 and/or day 270 the seropositivity rate for all four dengue serotypes in the seronegative part
10 of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 10%-points and/or wherein at day 120 the seropositivity rate for all four dengue serotypes in the seronegative part of the subject population and the seropositivity rate for all four dengue serotypes in the seropositive part of the subject population do not deviate more than 5%-points.

15 120. The unit dose for use of any one of items 95 to 119, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent

- (i) dengue serotype 1 has a concentration of 3.3 log₁₀ pfu/0.5 mL to 5.0 log₁₀ pfu/0.5 mL,
- (ii) dengue serotype 2 has a concentration of 2.7 log₁₀ pfu/0.5 mL to 4.9 log₁₀ pfu/0.5 mL,
- (iii) dengue serotype 3 has a concentration of 4.0 log₁₀ pfu/0.5 mL to 5.7 log₁₀ pfu/0.5 mL, and
20 (iv) dengue serotype 4 has a concentration of 4.5 log₁₀ pfu/0.5 mL to 6.2 log₁₀ pfu/0.5 mL.

121. The unit dose for use of any one of items 95 to 120, wherein upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent:

- (i) dengue serotype 1 has a concentration of 3.3 log₁₀ pfu/dose to 5.0 log₁₀ pfu/0.5 mL,
- 25 (ii) dengue serotype 2 has a concentration of 2.7 log₁₀ pfu/dose to 4.9 log₁₀ pfu/0.5 mL,
- (iii) dengue serotype 3 has a concentration of 4.0 log₁₀ pfu/dose to 5.7 log₁₀ pfu/0.5 mL, and
- (iv) dengue serotype 4 has a concentration of 4.5 log₁₀ pfu/dose to 5.5 log₁₀ pfu/0.5 mL.

FOURTH LIST OF ITEMS OF THE INVENTION

1. A yellow fever vaccine, in particular YF-17D, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing yellow fever and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises

- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

2. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

3. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

4. A yellow fever vaccine, in particular YF-17D, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing yellow fever and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises

- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

5. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

6. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said yellow fever vaccine is simultaneous or sequential.

9. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said yellow fever vaccine is administered by subcutaneous injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said yellow fever vaccine are administered to different anatomical sites, such as to opposite arms.

11. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

12. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and one dose of said yellow fever vaccine, in particular according to the following schedule

- an administration of said yellow fever vaccine on day 0,
- a first administration of the first reconstituted unit dose after said yellow fever vaccine administration, such as 3 months later and preferably on day 90, and
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

13. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and one dose of said yellow fever vaccine, in particular according to the following schedule

- a first administration of the first reconstituted unit dose on day 0,
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 90, and
- an administration of said yellow fever vaccine after said second administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

14. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and one dose of said yellow fever vaccine, in particular according to the following schedule

- a simultaneous administration of the first reconstituted unit dose and said yellow fever vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 months later and preferably on day 90.

15. The yellow fever vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 14, wherein the subject population or subject is from a dengue endemic region.
- 5 16. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing yellow fever in the subject by concomitant administration of a yellow fever vaccine, in particular YF-17D, to the subject.
- 10 17. The method of item 16, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.
- 15 18. The method of item 17, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.
- 20 19. The method of any one of items 16 to 18, wherein the subject population or subject is seronegative with respect to all dengue serotypes.
20. The method of any one of items 16 to 19, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.
- 25 21. The method of any one of items 16 to 20, wherein the administration of said reconstituted unit dose and said yellow fever vaccine is simultaneous or sequential.
- 30 22. The method of any one of items 16 to 22, wherein said reconstituted unit dose is administered by subcutaneous injection and said yellow fever vaccine is administered by subcutaneous injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.
- 35 23. The method of item 22, wherein said reconstituted unit dose and said yellow fever vaccine are administered to different anatomical sites, such as to opposite arms.
- 40 24. The method of any one of items 16 to 23, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.
25. The method of any one of items 16 to 24, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and one dose of a yellow fever vaccine, in particular YF-17D, in particular according to the following schedule
- an administration of said yellow fever vaccine on day 0,
 - a first administration of the first reconstituted unit dose after said yellow fever vaccine administration, such as 3

months later and preferably on day 90, and

- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

5 26. The method of any one of items 16 to 25, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and one dose of a yellow fever vaccine, in particular YF-17D, in particular according to the following schedule

- a first administration of the first reconstituted unit dose on day 0,
- a second administration of the second reconstituted unit dose after said first administration of the reconstituted unit dose, such as 3 months later and preferably on day 90, and
- an administration of said yellow fever vaccine after said second administration of the reconstituted unit dose, such as 3 months later and preferably on day 180.

10 27. The method of any one of items 16 to 27, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and one dose of a yellow fever vaccine, in particular YF-17D, in particular according to the following schedule

- a simultaneous administration of the first reconstituted unit dose and said yellow fever vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said simultaneous administration, such as 3 months later and preferably on day 90.

20 28. The method of any one of items 16 to 27, wherein the subject population or subject is of 2 to 60 years of age.

25 29. The method of any one of items 16 to 28, wherein the subject population or subject is from a dengue endemic region.

30 30. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue non-endemic region, preferably from a dengue non-endemic region and a yellow fever non-endemic region.

31. A kit for comprising the following components:

- a) a reconstituted unit dose of any one of items 1 to 15,
- b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and
- c) a yellow fever vaccine.

35 32. The kit of item 31, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

FIFTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A hepatitis A vaccine, such as HAVRIX® or VAQTA®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing hepatitis A and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
2. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.
3. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.
4. A hepatitis A vaccine, such as HAVRIX® or VAQTA®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing hepatitis A and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
5. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.
6. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said hepatitis A vaccine is simultaneous.

9. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said hepatitis A vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said hepatitis A vaccine are administered to different anatomical sites, such as to opposite arms.

11. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

12. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and one dose of said hepatitis A vaccine, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said hepatitis A vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

13. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the subject population or subject is of 2 to 60 years of age.

14. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 13, wherein the subject population or subject is from a dengue endemic region.

15. The hepatitis A vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 13, wherein the subject population or subject is from a dengue non-endemic region, preferably from a dengue non-endemic and hepatitis-A non-endemic region.

16. A method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing hepatitis A in the subject population by concomitant administration of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject population.

17. The method of item 16, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a

first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

5 18. The method of item 17, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

10 19. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 16 to 18, wherein the method further comprises preventing hepatitis A in the subject by concomitant administration of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, to the subject.

15 20. The method of item 19, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

20 21. The method of item 20, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

25 22. The method of any one of items 16 to 21, wherein the subject population or subject is seronegative with respect to all dengue serotypes.

23. The method of any one of items 16 to 22, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

30 24. The method of any one of items 16 to 23, wherein the administration of said reconstituted unit dose and said hepatitis A vaccine is simultaneous or sequential.

35 25. The method of any one of items 16 to 24, wherein said reconstituted unit dose is administered by subcutaneous injection and said hepatitis A vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

26. The method of item 25, wherein said reconstituted unit dose and said hepatitis A vaccine are administered to different anatomical sites, such as to opposite arms.

40 27. The method of any one of items 16 to 26, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

28. The method of any one of items 16 to 27, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and one dose of a hepatitis A vaccine, such as HAVRIX® or VAQTA®, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said hepatitis A vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

29. The method of any one of items 16 to 28, wherein the subject population or subject is of 2 to 60 years of age.

30. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue endemic region.

31. The method of any one of items 16 to 30, wherein the subject population or subject is from a dengue non-endemic region, preferably from a dengue non-endemic region and a hepatitis A non-endemic region.

32. A kit for comprising the following components:

- a) a unit dose of any one of items 1 to 16,
- b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and
- c) a hepatitis A vaccine.

33. The kit of item 32, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

SIXTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing HPV-associated cancers or genital warts and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
2. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.
3. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.
4. A HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing HPV-associated cancers or genital warts and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
5. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.
6. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more

than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said HPV vaccine is simultaneous.

9. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said HPV vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said HPV vaccine are administered to different anatomical sites, such as to opposite arms.

11. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

12. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and two doses of said HPV vaccine in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said HPV vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 month later and preferably on day 90, and
- a third administration of the second dose of said HPV vaccine after said second administration of the reconstituted unit dose, such as 3 month later and preferably on day 180.

13. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the subject population or subject is of 9 to 25 years of age.

14. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 13, wherein the subject population or subject is from a dengue endemic region.

15. The HPV vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 14, wherein the subject population or subject is female.

16. A method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing HPV-associated cancers or genital warts in the subject population by concomitant administration of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject population.

17. The method of item 16, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

18. The method of item 17, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

19. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing HPV-associated cancers or genital warts in the subject by concomitant administration of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, to the subject.

20. The method of item 19, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

21. The method of item 20, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

22. The method of any one of items 16 to 21, wherein the subject population or subject is seronegative with respect to all dengue serotypes.

23. The method of any one of items 16 to 22, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

24. The method of any one of items 16 to 23, wherein the administration of said reconstituted unit dose and said HPV vaccine is simultaneous or sequential.

25. The method of any one of items 16 to 24, wherein said reconstituted unit dose is administered by subcutaneous injection and said HPV vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

26. The method of item 25, wherein said reconstituted unit dose and said HPV vaccine are administered to different anatomical sites, such as to opposite arms.

27. The method of any one of items 16 to 26, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

5 28. The method of any one of items 16 to 27, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 16 and two doses of a HPV vaccine, in particular a 9vHPV vaccine, such as GARDASIL® 9, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said HPV vaccine on day 0,

10 - a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 month later and preferably on day 90, and

- a third administration of the second dose of said HPV vaccine after said second administration of the reconstituted unit dose, such as 3 month later and preferably on day 180.

15 29. The method of any one of items 16 to 28, wherein the subject population or subject is of 9 to 25 years of age.

30. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue endemic region.

20

31. The method of any one of items 16 to 30, wherein the subject population or subject is from a dengue non-endemic region.

32. The method of any one of items 16 to 31, wherein the subject population or subject is female.

25

33. A kit for comprising the following components:

a) a unit dose of any one of items 1 to 16,

b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and

c) a HPV vaccine.

30

34. The kit of item 33, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

SEVENTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A MMR vaccine, such as M-M-R® II, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing measles, mumps and rubella and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

2. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

3. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

4. A MMR vaccine, such as M-M-R® II, and a reconstituted unit dose of a dengue vaccine composition and a MMR vaccine, such as M-M-R® II, for use in a method of preventing measles, mumps and rubella and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

5. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to claim 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

6. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to claim 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said MMR vaccine is simultaneous or sequential.

9. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said MMR vaccine is administered by subcutaneous injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said MMR vaccine are administered to different anatomical sites, such as to opposite arms.

11. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of item 1 to 10, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

12. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of item 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and two doses of said MMR vaccine in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said MMR vaccine on day 0,
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90, and
- a third administration of the second dose of said MMR vaccine after said second administration of the second reconstituted unit dose, such as 3 to 6 years after said first simultaneous administration.

13. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the subject population or subject is of 1 to 10 years of age.

14. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the subject population or subject is of 2 months to 7 years of age.

15. The MMR vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 14, wherein the subject population or subject is from a dengue endemic region or from a dengue non-endemic region.

16. A method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing measles, mumps and rubella in the subject population by concomitant administration of a MMR vaccine, such as M-M-R® II, to the subject population.

17. The method of item 16, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

18. The method of item 17, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

19. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing measles, mumps and rubella in the subject by concomitant administration of a MMR vaccine, such as M-M-R® II, to the subject.

20. The method of item 19, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

21. The method of item 20, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

22. The method of any one of items 16 to 21, wherein the subject population or subject is seronegative with respect to all dengue serotypes.

23. The method of any one of items 16 to 22, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

24. The method of any one of items 16 to 23, wherein the administration of said reconstituted unit dose and said MMR vaccine is simultaneous or sequential.

25. The method of any one of items 16 to 23, wherein said reconstituted unit dose is administered by subcutaneous injection and said MMR vaccine is administered by subcutaneous injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

26. The method of item 25, wherein said reconstituted unit dose and said MMR vaccine are administered to different anatomical sites, such as to opposite arms.

27. The method of any one of items 16 to 26, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

28. The method of any one of items 16 to 27, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and two doses of a MMR vaccine, such as M-M-R® II, in particular according to the following schedule

- 5 - a first simultaneous administration of the first reconstituted unit dose and the first dose of said MMR vaccine on day 0,
 - a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90, and
10 - a third administration of the second dose of said MMR vaccine after said second administration of the second reconstituted unit dose, such as 3 to 6 years after said first simultaneous administration.

29. The method of any one of items 16 to 28, wherein the subject population or subject is of 1 to 10 years of age, preferably of 2 months to 7 years of age.

- 15 30. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue endemic region.

31. The method of any one of items 16 to 30, wherein the subject population or subject is from a dengue non-endemic region.

20

32. A kit for comprising the following components:

- a) a unit dose of any one of items 1 to 15,
b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and
c) a MMR vaccine.

25

33. The kit of item 32, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

EIGHTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A tetanus, diphtheria, and pertussis (Tdap) vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing tetanus, diphtheria, and pertussis and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
2. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.
3. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.
4. A tetanus, diphtheria, and pertussis (Tdap) vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing tetanus, diphtheria, and pertussis and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
5. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.
6. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more

than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said Tdap vaccine is simultaneous.

9. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said Tdap vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said Tdap vaccine are administered to different anatomical sites, such as to opposite arms.

11. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

12. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein the method comprises the administration of two of said reconstituted unit doses and one dose of said Tdap vaccine in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said Tdap vaccine on day 0, and
- a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

13. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the subject population or subject is of 10 to 18 years of age.

14. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 13, wherein the subject population or subject is from a dengue endemic region.

15. The Tdap vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 13, wherein the subject population or subject is from a dengue non-endemic region.

16. A method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing tetanus, diphtheria, and pertussis in the subject population by concomitant administration of a tetanus, diphtheria, and pertussis (Tdap) vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject population.

17. The method of item 16, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

18. The method of item 17, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

19. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing tetanus, diphtheria, and pertussis in the subject by concomitant administration of a tetanus, diphtheria, and pertussis (Tdap) vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, to the subject.

20. The method of item 19, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 1 to 15 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

21. The method of item 20, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

22. The method of any one of items 16 to 21, wherein the subject population or subject is seronegative with respect to all dengue serotypes.

23. The method of any one of items 16 to 22, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.

24. The method of any one of items 16 to 23, wherein the administration of said reconstituted unit dose and said Tdap vaccine is simultaneous or sequential.

25. The method of any one of items 16 to 24, wherein said reconstituted unit dose is administered by subcutaneous injection and said Tdap vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

26. The method of item 25, wherein said reconstituted unit dose and said Tdap vaccine are administered to different anatomical sites, such as to opposite arms.

27. The method of any one of items 16 to 26, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

5 28. The method of any one of items 16 to 27, wherein the method comprises the administration of two reconstituted unit doses of items 1 to 15 and one dose of a Tdap vaccine, in particular a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (adsorbed) vaccine, such as BOOSTRIX®, in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and said Tdap vaccine on day 0, and
- 10 - a second administration of the second reconstituted unit dose after said first simultaneous administration, such as 3 months later and preferably on day 90.

29. The method of any one of items 16 to 28, wherein the subject population or subject is of 10 to 18 years of age.

15 30. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue endemic region.

31. The method of any one of items 16 to 29, wherein the subject population or subject is from a dengue non-endemic region.

32. A kit for comprising the following components:

- a) a unit dose of any one of items 1 to 15,
- b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and
- 25 c) a Tdap vaccine.

33. The kit of item 32, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

NINTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b and dengue disease in a subject population, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises

- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

2. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said reconstituted unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

3. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 2, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

4. A DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, and a reconstituted unit dose of a dengue vaccine composition for use in a method of preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b and dengue disease in a subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises

- (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
- (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
- (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
- (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.

5. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of said unit dose 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.

6. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 5, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio

of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.

7. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 6, wherein the subject population or subject is seronegative to all dengue serotypes.

8. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 7, wherein the administration of said reconstituted unit dose and said DTaP/IPV/Hib vaccine is simultaneous or sequential.

9. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein said reconstituted unit dose is administered by subcutaneous injection and said DTaP/IPV/Hib vaccine is administered by intramuscular injection, wherein said injections are preferably administered to the arm, more preferably to the deltoid region of the arm.

10. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9, wherein said reconstituted unit dose and said DTaP/IPV/Hib vaccine are administered to different anatomical sites, such as to arm and thigh.

11. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 9 or 10, wherein said subcutaneous injection of said unit dose is administered to the arm, preferably to the deltoid region of the arm, and said intramuscular injection of said DTaP/IPV/Hib vaccine is administered to the thigh, preferably to the anterolateral aspect of the thigh.

12. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 11, wherein two of said reconstituted unit doses are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.

13. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the method comprises the administration of two of said reconstituted unit doses and four doses of said DTaP/IPV/Hib vaccine in particular according to the following schedule

- a first simultaneous administration of the first reconstituted unit dose and the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first simultaneous administration, such as 2 months later and preferably on day 60,
- a third administration of the second reconstituted unit dose after said second administration, such as 3 months after the first simultaneous administration and preferably on day 90,
- a fourth administration of the third dose of said DTaP/IPV/Hib vaccine after said third administration, such as 4 months after the first simultaneous administration and preferably on day 120, and
- a fifth administration of the fourth dose of said DTaP/IPV/Hib vaccine after said fourth administration, such as 9 to 12 months later and preferably on day 390.

14. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the method comprises the administration of two of said reconstituted unit doses and four doses of said DTaP/IPV/Hib vaccine in particular according to the following schedule

- a first administration of the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first administration, such as 2 months later and preferably on day 60,
- a third administration of the third dose of said DTaP/IPV/Hib vaccine after said second administration, such as 4 months after the first administration and preferably on day 120,
- a fourth simultaneous administration of the first reconstituted unit dose and the fourth dose of said DTaP/IPV/Hib vaccine after said third administration, such as 9 to 12 months later and preferably on day 390, and
- a fifth administration of the second reconstituted unit dose after said fourth simultaneous administration, such as 3 months later and preferably on day 480.

5 15. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to item 13 or 14, wherein a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Quadracel®, is administered after the administration of the fourth dose of said DTaP/IPV/Hib vaccine, such as 30 to 57 months after the administration of the fourth dose of a DTaP/IPV/Hib vaccine, such as Pentacel®.

10 16. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 15, wherein the subject population or subject is of 2 months to 4 years of age.

15 17. The DTaP/IPV/Hib vaccine and the reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 16, wherein the subject population or subject is from a dengue endemic region or from a dengue non-endemic region.

20 18. A method of preventing dengue disease in a subject population, comprising administering to the subject population a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing diphtheria, tetanus, pertussis, poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject population by concomitant administration of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject population.

25 19. The method of item 18, wherein the geometric mean neutralizing antibody titers (GMTs) of the subject population when tested in at least 40, or at least 50, or at least 60 subjects at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 17 to 19 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 4.

30 20. The method of item 19, wherein said GMTs of the subject population further provide a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 1, and/or a ratio of not more than 20 for the GMT of dengue serotype 2 to the GMT of dengue serotype 3.

35 21. A method of preventing dengue disease in a subject, comprising administering to the subject a reconstituted unit dose of any one of items 1 to 15, wherein the method further comprises preventing diphtheria, tetanus, pertussis,

poliomyelitis and diseases caused by *Haemophilus influenzae* type b in the subject by concomitant administration of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, to the subject.

22. The method of item 21, wherein the neutralizing antibody titers of the subject when tested at day 180 or day 365 after at least a first administration of said unit dose, and optionally a second administration of a reconstituted unit dose of any one of items 1 to 15 90 days after said first administration, provide a ratio of not more than 50, or not more than 40, or not more than 30, or not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 4.
23. The method of item 22, wherein said neutralizing antibody titers of the subject further provide a ratio not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 1, and/or a ratio of not more than 20 for the neutralizing antibody titer of dengue serotype 2 to the neutralizing antibody titer of dengue serotype 3.
24. The method of any one of items 18 to 23, wherein the subject population or subject is seronegative with respect to all dengue serotypes.
25. The method of any one of items 18 to 24, wherein the subject population or subject is seropositive with respect to at least one dengue serotype.
26. The method of any one of items 18 to 25, wherein the administration of said reconstituted unit dose and said DTaP/IPV/Hib vaccine is simultaneous or sequential.
27. The method of any one of items 18 to 26, wherein said reconstituted unit dose is administered by subcutaneous injection and said DTaP/IPV/Hib vaccine is administered by intramuscular injection.
28. The method of item 27, wherein said reconstituted unit dose and said DTaP/IPV/Hib vaccine are administered to different anatomical sites, such as to arm and thigh.
29. The method of item 27 or 28, wherein said subcutaneous injection is administered to the arm, preferably to the deltoid region of the arm, and said intramuscular injection is administered to the thigh, preferably to the anterolateral aspect of the thigh.
30. The method of any one of items 18 to 29, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more, or within six months, or within three months, such as at day 0 and day 90.
31. The method of any one of items 18 to 30, wherein the method comprises the administration of two reconstituted unit doses of items 17 to 19 and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, in particular according to the following schedule
 - a first simultaneous administration of the first reconstituted unit dose and the first dose of said DTaP/IPV/Hib vaccine on day 0,
 - a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first simultaneous administration, such as 2 months later and preferably on day 60,

- a third administration of the second reconstituted unit dose after said second administration, such as 3 months after the first simultaneous administration and preferably on day 90,
- a fourth administration of the third dose of said DTaP/IPV/Hib vaccine after said third administration, such as 4 months after the first simultaneous administration and preferably on day 120, and
- 5 – a fifth administration of the fourth dose of said DTaP/IPV/Hib vaccine after said fourth administration, such as 9 to 12 months later and preferably on day 390.

32. The method of any one of items 18 to 31, wherein the method comprises the administration of two reconstituted unit doses of items 17 to 19 and four doses of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Pentacel®, in particular according to the following schedule

- a first administration of the first dose of said DTaP/IPV/Hib vaccine on day 0,
- a second administration of the second dose of said DTaP/IPV/Hib vaccine after said first administration, such as 2 months later and preferably on day 60,
- a third administration of the third dose of said DTaP/IPV/Hib vaccine after said second administration, such as 4 months after the first administration and preferably on day 120,
- a fourth simultaneous administration of the first reconstituted unit dose and the fourth dose of said DTaP/IPV/Hib vaccine after said third administration, such as 9 to 12 months later and preferably on day 390, and
- a fifth administration of the second reconstituted unit dose after said fourth simultaneous administration, such as 3 months later and preferably on day 480.

33. The method of item 18 to 32, wherein a fifth dose of a DTaP/IPV/Hib vaccine, in particular a combined DTaP/IPV/Hib vaccine, such as Quadracel®, is administered after the administration of the fourth dose of said DTaP/IPV/Hib vaccine, such as 30 to 57 months after the administration of the fourth dose of a DTaP/IPV/Hib vaccine, in particular after the fourth dose of a combined DTaP/IPV/Hib vaccine, such as Pentacel®.

34. The method of any one of items 18 to 33, wherein the subject population or subject is of 2 months to 4 years of age.

35. The method of any one of items 18 to 34, wherein the subject population or subject is from a dengue endemic region.

36. The method of any one of items 18 to 35, wherein the subject population or subject is from a dengue non-endemic region.

37. A kit for comprising the following components: a) a unit dose of any one of items 1 to 15, b) a pharmaceutically acceptable diluent for reconstitution of said unit dose, and c) a DTaP/IPV/Hib vaccine.

38. The kit of 37, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

TENTH LIST OF ITEMS OF THE PRESENT INVENTION

1. A reconstituted unit dose of a dengue vaccine composition for use in a method of preventing dengue disease in an elderly subject, wherein said reconstituted unit dose comprises a tetravalent dengue virus composition including four live, attenuated dengue virus strains and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises
 - (i) a chimeric dengue serotype 2/1 strain in a concentration of at least 3.3 log₁₀ pfu/0.5 mL,
 - (ii) a dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 mL,
 - (iii) a chimeric dengue serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 mL, and
 - (iv) a chimeric dengue serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 mL.
2. The reconstituted unit dose of a dengue vaccine composition for use according to item 1, wherein dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are prevented in the elderly subject.
3. The reconstituted unit dose of a dengue vaccine composition for use according to item 1 or 2, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.
4. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 3, wherein two of said reconstituted unit doses are administered.
5. The reconstituted unit dose of a dengue vaccine composition for use according to item 4, wherein said two unit doses are administered within 12 months, preferably within 3 months, such as at about day 0 and about day 90.
6. The reconstituted unit dose of a dengue vaccine composition for use according to item 4 or 5, wherein a third unit dose is administered after administration of said second unit dose.
7. The reconstituted unit dose of a dengue vaccine composition for use according to item 6, wherein said third unit dose is administered between 6 to 12 months after the first administration, such as 12 month after the first administration.
8. The reconstituted unit dose of a dengue vaccine composition for use according to claim 6, wherein said third unit dose is administered later than 12 months after the first administration, such as 12 months after the second administration.
9. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein the elderly subject is from a dengue endemic region.
10. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 8, wherein the elderly subject is from a dengue non-endemic region.
11. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein the elderly subject is seronegative with respect to all dengue serotypes.

12. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 10, wherein the elderly subject is seropositive with respect to at least one dengue serotype.

13. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 12, wherein the elderly subject has at least one chronic condition or disease.

14. The reconstituted unit dose of a dengue vaccine composition for use according to item 13, wherein the at least one chronic condition or disease is selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

15. The reconstituted unit dose of a dengue vaccine composition for use according to any one of items 1 to 14, wherein the elderly subject has an impaired immune system.

16. A method of preventing dengue disease in an elderly subject comprising administering to the elderly subject a reconstituted unit dose of any one of items 1 to 15.

17. A method of preventing dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) in an elderly subject comprising administering to the elderly subject a reconstituted unit dose of any one of items 1 to 15.

18. The method of items 16 or 17, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.

19. The method of any one of items 16 to 18, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within 12 months or more.

20. The method of any one of items 16 to 19, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within six months, preferably within three months.

21. The method of item 20, wherein the two reconstituted unit doses are administered at day 0 and day 90.

22. The method of any one of items 16 to 21, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the first unit dose.

23. The method of any one of items 16 to 21, wherein a third unit dose is administered after administration of the second unit dose, preferably within 12 months after administration of the second unit dose.

24. The method of any one of items 16 to 24, wherein the elderly subject is seronegative with respect to all dengue serotypes.

25. The method of any one of items 16 to 24, wherein the elderly subject is seropositive with respect to at least one dengue serotypes.

26. The method of any one of items 16 to 25, wherein the elderly subject is of more than 60 years of age.

27. The method of any one of items 16 to 26, wherein the elderly subject is from a dengue endemic region.

28. The method of any one of items 16 to 27, wherein the elderly subject is from a dengue non-endemic region.
29. The method of any one of items 16 to 28, wherein the elderly subject has at least one chronic condition or disease.
- 5 30. The method of item 29, wherein the at least one chronic condition or disease is selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.
- 10 31. The method of any one of items 16 to 30, wherein the elderly subject has an impaired immune system.
32. A method for stimulating an immune response to all four serotypes of dengue virus in an elderly subject, comprising administering to the elderly subject a reconstituted unit dose of items 1 to 15.
- 15 33. The method of item 32, wherein the immune response to all four serotypes of dengue virus is balanced.
34. The method of items 32 or 33, wherein the reconstituted unit dose is administered by subcutaneous injection, preferably to the deltoid region of the arm.
- 20 35. The method of any one of items 32 to 34, wherein two unit doses of any one of items 17 to 19 are administered within 12 months or more.
36. The method of any one of items 32 to 35, wherein two reconstituted unit doses of any one of items 17 to 19 are administered within six months, preferably within three months.
- 25 37. The method of item 36, wherein the two reconstituted unit doses are administered at day 0 and day 90.
38. The method of any one of items 32 to 37, wherein a third unit dose is administered after the administration of the second unit dose, preferably within 12 month of administration of the first unit dose.
- 30 39. The method of any one of items 32 to 38, wherein a third unit dose is administered after the administration of the second unit dose, preferably within 12 month of administration of the second unit dose.
40. The method of any one of items 32 to 39, wherein the elderly subject is from a dengue endemic region.
- 35 41. The method of any one of items 32 to 40, wherein the elderly subject is from a dengue non-endemic region.
42. The method of any one of items 32 to 41, wherein the elderly subject is seronegative with respect to all dengue serotypes.
- 40 43. The method of any one of items 32 to 42, wherein the elderly subject is seropositive with respect to at least one dengue serotype.

44. The method of any one of items 32 to 43, wherein the elderly subject has at least one chronic condition or disease.

5 45. The method of item 44, wherein the at least one chronic condition or disease is selected from diabetes, hypertension, allergies, previous strokes, ischemic heart disease, chronic renal impairment and chronic obstructive pulmonary disease.

46. The method of any one of items 32 to 45, wherein the elderly subject has an impaired immune system.

10 47. The method of any one of items 17 to 47, wherein the reconstituted unit dose is obtained from the kit according to item 50 or 51.

48. The reconstituted unit dose of any one of items 1 to 16 for use in a method of items 17 to 54.

15 49. Use of a reconstituted unit dose of any one of items 1 to 16 for the manufacture of a medicament for a method according to items 17 to 48.

50. A kit for preparing a reconstituted unit dose comprising the following components:

- 20 a) a unit dose of any one of items 1 to 16, and
b) a pharmaceutically acceptable diluent for reconstitution.

51. The kit of item 50, wherein the pharmaceutically acceptable diluent for reconstitution is 37 mM sodium chloride.

25

CLAIMS

1. A unit dose of a dengue vaccine composition comprising:

a tetravalent virus composition including four live attenuated dengue virus serotypes wherein the unit dose is lyophilized and upon reconstitution with 0.5 mL of a pharmaceutically acceptable diluent comprises:

 - (i) a chimeric dengue serotype 2/1 strain, in a concentration of at least 3.3 log₁₀ pfu/0.5 ml,
 - (ii) a dengue serotype 2 strain, in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
 - (iii) a chimeric dengue serotype 2/3, in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
 - (iv) a chimeric dengue serotype 2/4, in a concentration of at least 4.5 log₁₀ pfu/0.5 ml, wherein

upon said reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii) and (iv) provide a total concentration of pfu/0.5 ml and based on said total concentration of pfu/0.5 ml

 - the concentration of (i) in pfu/0.5 ml is at least 1%,
 - the concentration of (ii) in pfu/0.5 ml is less than 10%,
 - the concentration of (iii) in pfu/0.5 ml is at least 10%, and
 - the concentration of (iv) in pfu/0.5 ml is at least 50%,

wherein the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 and differs in at least three nucleotides from the wild type as follows:

 - a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
 - b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
 - c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

 - a DENV-2/1 chimera,
 - a DENV-2/3 chimera and
 - a DENV-2/4 chimera.
2. The unit dose according to claim 1, wherein based on said total concentration of pfu/0.5 ml the concentration of (iii) in pfu/0.5 mL is at least 12%, or at least 14%, or at least 16%, or at least 18%.
3. The unit dose according to claim 1 or 2, wherein the unit dose comprises:
 - (i) the chimeric serotype 2/1 strain in a concentration of 3.3 to 3.6 log₁₀ pfu/0.5 ml to 3.8 log₁₀pfu/0.5ml,
 - (ii) the dengue serotype 2 strain in a concentration of at least 2.7 log₁₀ pfu/0.5 ml,
 - (iii) the chimeric serotype 2/3 strain in a concentration of at least 4.0 log₁₀ pfu/0.5 ml, and
 - (iv) the chimeric serotype 2/4 strain in a concentration of at least 4.5 log₁₀ pfu/0.5 ml or at least 4.6 log₁₀ pfu/0.5 ml to optionally 6.2 log₁₀ pfu/0.5 ml.
4. A tetravalent dengue virus composition including four live attenuated dengue virus strains representing serotype 1, serotype 2, serotype 3 and serotype 4 when used in a method of preventing dengue disease in a subject 4 to 16 years of age wherein the method comprises a primary vaccination with only two administrations of a unit dose comprising the steps of:
 - administering a first unit dose of the tetravalent dengue virus composition to the subject, and

administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administration of the first unit dose, wherein

the tetravalent dengue virus composition is in the form of a lyophilised unit dose which upon reconstitution with 0.5 ml of a pharmaceutically acceptable diluent comprises:

- (i) a chimeric dengue serotype 2/1 strain, in a concentration of at least $3.3 \log_{10}$ pfu/0.5 ml,
- (ii) a dengue serotype 2 strain, in a concentration of at least $2.7 \log_{10}$ pfu/0.5 ml,
- (iii) a chimeric dengue serotype 2/3 strain, in a concentration of at least $4.0 \log_{10}$ pfu/0.5 ml, and
- (iv) a chimeric dengue serotype 2.4 strain, in a concentration of at least $4.5 \log_{10}$ pfu/0.5 ml, wherein

upon said reconstitution with a pharmaceutically acceptable diluent (i), (ii), (iii) and (iv) provide a total concentration of pfu/0.5 ml and based on said total concentration of pfu/0.5 ml

- the concentration of (i) in pfu/0.5 ml is at least 1%,
- the concentration of (ii) in pfu/0.5 ml is less than 10%,
- the concentration of (iii) in pfu/0.5 ml is at least 10%, and
- the concentration of (iv) in pfu/0.5 ml is at least 50%,

and

wherein the dengue serotype 2 strain is derived from the wild type virus strain DEN-2 16681 and differs in at least three nucleotides from the wild type as follows:

- a) 5'-noncoding region (NCR)-57 (nt-57 C-to-T)
- b) NS1-53 Gly-to-Asp (nt-2579 G-to-A)
- c) NS3-250 Glu-to-Val (nt-5270 A-to-T); and

wherein the three chimeric dengue strains are derived from the serotype 2 strain by replacing the structural proteins prM and E from serotype 2 strain with the corresponding structural proteins from the other dengue serotypes, resulting in the following chimeric dengue strains:

- a DENV-2/1 chimera,
- a DENV-2/3 chimera and
- a DENV-2/4 chimera.

5. The tetravalent dengue virus composition when used according to claim 4, wherein the method does not include a step of determination whether there was a previous dengue infection in the subject before administration of the unit dose or wherein the serostatus of the subject is unknown before administration of the unit dose.

6. The tetravalent dengue virus composition when used according to claim 4 or claim 5, wherein the method does not include a step of determination whether there was a previous dengue infection in the subjects at any time before, during or after the steps of administration, or wherein the serostatus of the subject is unknown at any time before, during or after the steps of administration.

7. The tetravalent dengue virus composition when used according to claim 4 or claim 6, wherein the method does not include the active surveillance of the subject after the administration of the first- and second- unit dose with respect to febrile illness, preferable fever $\geq 38^{\circ}\text{C}$ on any 2 or 3 consecutive days.

8. The tetravalent dengue virus composition when used according to claim 4 or claim 6, wherein the method does not include after the administration of the first- and second- unit dose a vaccine immunogenicity analysis including GMTs for dengue neutralizing antibodies.

9. The tetravalent dengue virus composition when used according to claim 4 or claim 6, wherein the method does not include a reactogenicity analysis related to solicited local and/or systemic adverse events.

10. The tetravalent dengue virus composition when used according to claim 4, wherein the method comprises a primary vaccination consisting of the steps of:


- (A) selecting a subject for administration of the unit doses of the tetravalent dengue virus composition in need for protection against dengue infection without determination whether there was a previous dengue infection, and
- (B) administering a first unit dose of the tetravalent dengue virus composition to the subject; and
- (C) administering a second unit dose of the tetravalent dengue virus composition to the subject within 3 months of administering the first unit dose.

11. The tetravalent dengue virus composition when used according to any one of claims 4 to 10, wherein the dengue disease is due to a dengue serotype 2, and/or due to a dengue serotype 1.

12. The tetravalent dengue virus composition when used according to any one of claims 4 to 11, wherein the subject is 4 to 5 years of age, 6 to 11 years of age, or 12 to 16 years of age, or 6 to 16 years of age, or 9 years of age.

13. The tetravalent dengue virus composition when used according to any one of claims 4 to 12, wherein based on said total concentration of pfu/0.5 ml the concentration of (iii) is a least 12%, or at least 14%, or at least 16%, or at least 18%.

1/13

Figure 1

2/13


**Figure 2**

Figure 3 A




Figure 3 B





Figure 4 A

Figure 4 B




Figure 5





Figure 6







Figure 8



11/13






Figure 9



	Month 0	Month 3.0	Month 14.5	Month 14.5	Month 18.0
Placebo-Seronegative	n = 1,832	n = 1,817	n = 1,744	n = 94	n = 7
Placebo-Seropositive	n = 4,852	n = 4,805	n = 4,607	n = 218	n = 6
TDV -Seronegative	n = 3,714	n = 3,690	n = 4,615	n = 157	n = 10
TDV -Seropositive	n = 9,661	n = 9,591	n = 9,391	n = 417	n = 10

Figure 10A

	Month 0	Month 3.0	Month 14.5	Month 15.9	Month 18.0
Placebo-Seronegative	n = 1,832	n = 1,827	n = 1,776	n = 94	n = 7
Placebo-Seropositive	n = 4,852	n = 4,823	n = 4,700	n = 220	n = 6
TDV -Seronegative	n = 3,714	n = 3,693	n = 3,635	n = 157	n = 6
TDV -Seropositive	n = 9,661	n = 9,599	n = 9,435	n = 417	n = 10

Figure 10B

Study Design




Figure 11

SEQUENCE LISTING

<110> Takeda Vaccines, Inc.

<120> DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF

<130> T08269W01/MH

<140>

<141>

<150> EP18 192 701.3

<151> 2018-09-05

<150> EP18 192 776.5

<151> 2018-09-05

<150> EP18 192 793.0

<151> 2018-09-05

<150> EP18 192 800.3

<151> 2018-09-05

<150> EP18 192 711.2

<151> 2018-09-05

<150> EP18 192 717.9

<151> 2018-09-05

<150> EP18 192 814.4

<151> 2018-09-05

<150> EP19 154 334.7

<151> 2019-01-29

<150> EP19 161 184.7

<151> 2019-03-07

<150> EP18 192 787.2

<151> 2018-09-05

<150> US16/295,611

<151> 2019-03-07

<160> 16

<170> PatentIn version 3.5

<210> 1

<211> 10723

<212> DNA

<213> chimeric dengue seroytpe 2/1 (MVS)

<400> 1

agttgttagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaatgta	60
gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg	120
aaaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtgcaacag	180
ctgacaaaga gattctcact tggaatgctg cagggacgag gaccattaaa actgttcatg	240
gccctggtgg cgttccttcg tttcctaaca atcccaccaa cagcagggat attgaagaga	300
tggggaacaa ttaaaaaatc aaaagctatt aatgttttga gagggttcag gaaagagatt	360
ggaaggatgc tgaacatctt gaataggaga cgcagatctg caggcatgat cattatgctg	420
attccaacag tgatggcggt ccatttaacc acgcgtgggg gagagccgca tatgatagtt	480
agcaagcagg aaagaggaaa gtcacttttg ttcaagacct ctgcagggtg caacatgtgc	540
accctcattg cgatggattt gggagagttg tgtgaggaca cgatgaccta caaatgcccc	600
cggatcactg aggcggaacc agatgacgtt gactgttggt gcaatgccac ggacacatgg	660
gtgacctatg gaacgtgctc tcaaactggc gaacaccgac gagacaaacg ttccgtcgca	720
ttggccccac acgtggggct tggcctagaa acaagagccg aaacgtggat gtcctctgaa	780
ggtgcttggg aacagataca aaaagtagag acttgggctc tgagacatcc aggattcacg	840
gtgatagccc tttttctagc acatgccata ggaacatcca tcaccagaa agggatcatt	900
ttcatthttgc tgatgctggt aacaccatct atggccatgc gatgcgtggg aataggcaac	960
agagacttcg tggaaggact gtcaggagca acatgggtgg atgtggtact ggagcatgga	1020
agttgcgtca ccaccatggc aaaaaacaaa ccaacactgg acattgaact cttgaagacg	1080
gaggtcacia accctgcagt tctgcgtaaa ttgtgcattg aagctaaaat atcaaacacc	1140
accaccgatt cgagatgtcc aacacaagga gaagccacac tgggtggaaga acaagacgcg	1200
aactttgtgt gccgacgaac gttcgtggac agaggctggg gcaatggctg tgggctattc	1260
ggaaaaggta gtctaataac gtgtgccaag ttttaagtgtg tgacaaaact agaaggaaag	1320
atagttcaat atgaaaacct aaaatattca gtgatagtca cagtccacac tggagatcag	1380
caccaggtgg gaaatgagac tacagaacat ggaacaactg caaccataac acctcaagct	1440
cctacgtcgg aaatacagct gaccgactac ggaaccctta cattagattg ttcacctagg	1500
acagggctag attttaacga gatggtgttg ctgacaatga aagaaagatc atggcttgtc	1560
cacaaacaat ggttcctaga cttaccactg ctttggaacct ctggggcttc aacatcccaa	1620

gagacttgga acagacaaga tttactggtc acattttaaga cagctcatgc aaagaagcag	1680
gaagtagtcg tactaggatc acaagaagga gcaatgcaca ctgcgctgac tggagcgaca	1740
gaaatccaaa cgtcaggaac gacaacaatt ttcgcaggac acctaaaatg cagactaaaa	1800
atggacaaac taactttaaa agggatgtca tatgtgatgt gcacaggctc attcaagtta	1860
gagaaagaag tggctgagac ccagcatgga actgttctgg tgcagggtta atataagga	1920
acagacgcac catgcaagat tcccttttcg acccaagatg agaaaggagc aaccagaat	1980
gggagattaa taacagccaa ccccatagtc actgacaaag aaaaaccagt caatattgag	2040
gcagaaccac cttttggtga gagctacatc gtggtaggag cagggtgaaa agctttgaaa	2100
ctaagctggt tcaagaaagg aagcagcata gggaaaatgt ttgaagcaac tgcccgagga	2160
gcacgaagga tggccattct gggagacacc gcatgggact tcggttctat aggaggagt	2220
ttcacgtcta tgggaaaact ggtacaccag gtttttgga ctgcatatgg agttttgttt	2280
agcggagttt cttggaccat gaaaatagga atagggattc tgctgacatg gctaggatta	2340
aattcaagga acacgtccct ttcgatgatg tgcacgcag ccggcattgt gacactgtat	2400
ttgggagtca tgggtgcaggc cgatagtggg tgcgttgtga gctggaaaaa caaagaactg	2460
aaatgtggca gtgggatttt catcacagac aacgtgcaca catggacaga acaatacaag	2520
ttccaaccag aatccccttc aaaactagct tcagctatcc agaaagcca tgaagaggac	2580
atattgtgga tccgctcagt aacaagactg gagaatctga tgtggaaaca aataacacca	2640
gaattgaatc acattctatc agaaaatgag gtgaagttaa ctattatgac aggagacatc	2700
aaaggaatca tgcaggcagg aaaacgatct ctgcggcctc agcccactga gctgaagtat	2760
tcattggaaa catggggcaa agcaaaaatg ctctctacag agtctcataa ccagaccttt	2820
ctcattgatg gccccgaaac agcagaatgc cccaacacaa atagagcttg gaattcggtg	2880
gaagttgaag actatggctt tggagtattc accaccaata tatggctaaa attgaaagaa	2940
aaacaggatg tattctgcga ctcaaaactc atgtcagcgg ccataaaaga caacagagcc	3000
gtccatgccg atatgggtta ttggatagaa agtgcactca atgacacatg gaagatagag	3060
aaagcctctt tcattgaagt taaaaactgc cactggccaa aatcacacac cctctggagc	3120
aatggagtgc tagaaagtga gatgataatt ccaaagaatc tcgctggacc agtgtctcaa	3180
cacaactata gaccaggcta ccatacacia ataacaggac catggcatct aggttaagctt	3240

gagatggact ttgatttctg tgatggaaca acagtggtag tgactgagga ctgcggaaat	3300
agaggaccct ctttgagaac aaccactgcc tctggaaaac tcataacaga atggtgctgc	3360
cgatcttgca cattaccacc gctaagatac agaggtgagg atgggtgctg gtacgggatg	3420
gaaatcagac cattgaagga gaaagaagag aatttggtca actccttggt cacagctgga	3480
catgggcagg tcgacaactt ttcactagga gtcttgggaa tggcattgtt cctggaggaa	3540
atgcttagga cccgagtagg aacgaaacat gcaatactac tagttgcagt ttcttttgtg	3600
acattgatca cagggaacat gtcctttaga gacctgggaa gagtgatggt tatggtaggc	3660
gccactatga cggatgacat aggtatgggc gtgacttatac ttgccctact agcagccttc	3720
aaagtcagac caacttttgc agctggacta ctcttgagaa agctgacctc caaggaattg	3780
atgatgacta ctataggaat tgtactcctc tcccagagca ccctaccaga gaccattctt	3840
gagttgactg atgcgttagc cttaggcatg atggctctca aaatgggtgag aaatatggaa	3900
aagtatcaat tggcagtgac tatcatggct atcttgtgcg tcccaaacgc agtgatatta	3960
caaaacgcat ggaaagtgag ttgcacaata ttggcagtggt tgtccgtttc cccactgttc	4020
ttaacatcct cacagcaaaa aacagattgg ataccattag cattgacgat caaaggtctc	4080
aatccaacag ctattttttct aacaaccctc tcaagaacca gcaagaaaag gagctggcca	4140
ttaaatgagg ctatcatggc agtcgggatg gtgagcattt tagccagttc tctcctaaaa	4200
aatgatattc ccatgacagg accattagtg gctggagggc tcctcactgt gtgctacgtg	4260
ctcactggac gatcggccga tttggaactg gagagagcag ccgatgtcaa atgggaagac	4320
caggcagaga tatcaggaag cagtccaatc ctgtcaataa caatatcaga agatggtagc	4380
atgtcgataa aaaatgaaga ggaagatcaa aactgacca tactcattag aacaggattg	4440
ctggtgatct caggactttt tcctgtatca ataccaatca cggcagcagc atggtacctg	4500
tgggaagtga agaaacaacg ggccggagta ttgtgggatg ttccttcacc cccacccatg	4560
ggaaaggctg aactggaaga tggagcctat agaattaagc aaaaagggat tcttgatat	4620
tcccagatcg gagccggagt ttacaaagaa ggaacattcc atacaatgtg gcatgtcaca	4680
cgtggcgctg ttctaattga taaaggaaag aggattgaac catcatgggc ggacgtcaag	4740
aaagacctaa tatcatatgg aggaggctgg aagttagaag gagaatggaa ggaaggagaa	4800
gaagtccagg tattggcact ggagcctgga aaaaatccaa gagccgtcca aacgaaacct	4860

ggtcttttca aaaccaacgc cggaacaata ggtgctgtat ctctggactt ttctcctgga	4920
acgtcaggat ctccaattat cgacaaaaaa ggaaaagttg tgggtcttta tggtaatggt	4980
gttgttacaa ggagtggagc atatgtgagt gctatagccc agactgaaaa aagcattgaa	5040
gacaaccag agatcgaaga tgacattttc cgaaagagaa gactgaccat catggacctc	5100
caccagagg cgggaaagac gaagagatac cttccggcca tagtcagaga agctataaaa	5160
cggggtttga gaacattaat cttggccccc actagagttg tggcagctga aatggaggaa	5220
gcccttagag gacttccaat aagataccag accccagcca tcagagctgt gcacaccggg	5280
cgggagattg tggacctaat gtgtcatgcc acatttacca tgaggctgct atcaccagtt	5340
agagtgccaa actacaacct gattatcatg gacgaagccc atttcacaga cccagcaagt	5400
atagcagcta gaggatacat ctcaactcga gtggagatgg gtgaggcagc tgggattttt	5460
atgacagcca ctccccggg aagcagagac ccatttcctc agagcaatgc accaatcata	5520
gatgaagaaa gagaaatccc tgaacgctcg tggaattccg gacatgaatg ggtcacggat	5580
tttaaagga agactgtttg gttcgtttca agtataaaag caggaaatga tatagcagct	5640
tgcctgagga aaaatggaaa gaaagtgata caactcagta ggaagacctt tgattctgag	5700
tatgtcaaga ctagaaccaa tgattgggac ttcgtggtta caactgacat ttcagaaatg	5760
ggtgccatt tcaaggctga gagggttata gacccagac gctgcatgaa accagtcata	5820
ctaacagatg gtgaagagcg ggtgattctg gcaggaccta tgccagtga cactctagt	5880
gcagcacaaa gaagaggagg aataggaaga aatccaaaa atgagaatga ccagtacata	5940
tacatggggg aacctctgga aaatgatgaa gactgtgcac actggaaaga agctaaaatg	6000
ctcctagata acatcaacac gccagaagga atcattccta gcatgttcga accagagcgt	6060
gaaaaggtgg atgccattga tggcgaatac cgcttgagag gagaagcaag gaaaacctt	6120
gtagacttaa tgagaagagg agacctacca gtctggttgg cctacagagt ggcagctgaa	6180
ggcatcaact acgcagacag aaggtggtgt tttgatggag tcaagaacaa ccaaacccta	6240
gaagaaaacg tggaagttga aatctggaca aaagaagggg aaaggaagaa attgaaaccc	6300
agatggttgg atgctaggat ctattctgac cactggcgc taaaagaatt taaggaattt	6360
gcagccggaa gaaagtctct gaccctgaac ctaatcacag aaatgggtag gctccaacc	6420
ttcatgactc agaaggcaag agacgcactg gacaacttag cagtgtgca cacggctgag	6480

gcaggtggaa	gggcgtacaa	ccatgctctc	agtgaactgc	cggagaccct	ggagacattg	6540
cttttactga	cacttctggc	tacagtcacg	ggagggatct	ttttattctt	gatgagcgca	6600
aggggcatag	ggaagatgac	cctgggaatg	tgctgcataa	tcacggctag	catcctccta	6660
tggtagcac	aaatacagcc	acactggata	gcagcttcaa	taatactgga	gttttttctc	6720
atagttttgc	ttattccaga	acctgaaaaa	cagagaacac	cccaagacaa	ccaactgacc	6780
tacgttgtca	tagccatcct	cacagtgggtg	gccgcaacca	tggcaaacga	gatgggtttc	6840
ctagaaaaaa	cgaagaaaga	tctcggattg	ggaagcattg	caaccagca	acccgagagc	6900
aacatcctgg	acatagatct	acgtcctgca	tcagcatgga	cgctgtatgc	cgtggccaca	6960
acatttgta	caccaatgtt	gagacatagc	attgaaaatt	cctcagtga	tgtgtcccta	7020
acagctatag	ccaaccaagc	cacagtgtta	atgggtctcg	ggaaaggatg	gccattgtca	7080
aagatggaca	tcggagttcc	ccttctcgcc	attggatgct	actcacaagt	caaccata	7140
actctcacag	cagctctttt	cttattggta	gcacattatg	ccatcatagg	gccaggactc	7200
caagcaaaag	caaccagaga	agctcagaaa	agagcagcgg	cgggcatcat	gaaaaacca	7260
actgtcgatg	gaataacagt	gattgaccta	gatccaatac	cttatgatcc	gaagtttgaa	7320
aagcagttgg	gacaagtaat	gctcctagtc	ctctgcgtga	ctcaagtatt	gatgatgagg	7380
actacatggg	ctctgtgtga	ggctttaacc	ttagctaccg	ggcccatctc	cacattgtgg	7440
gaaggaaatc	cagggagggtt	ttggaacact	accattgcgg	tgtcaatggc	taacattttt	7500
agagggagtt	acttggccgg	agctggactt	ctcttttcta	ttatgaagaa	cacaaccaac	7560
acaagaaggg	gaactggcaa	cataggagag	acgcttggag	agaaatggaa	aagccgattg	7620
aacgcattgg	gaaaaagtga	attccagatc	tacaagaaaa	gtggaatcca	ggaagtggat	7680
agaaccttag	caaaagaagg	cattaaaaga	ggagaaacgg	accatcacgc	tgtgtcgcga	7740
ggctcagcaa	aactgagatg	gttcgttgag	agaaacatgg	tcacaccaga	agggaaagta	7800
gtggacctcg	gttgtggcag	aggaggctgg	tcatactatt	gtggaggact	aaagaatgta	7860
agagaagtca	aaggcctaac	aaaaggagga	ccaggacacg	aagaacccat	ccccatgtca	7920
acatatgggt	ggaatctagt	gcgtcttcaa	agtggagttg	acgttttctt	catcccgcca	7980
gaaaagtgtg	acacattatt	gtgtgacata	ggggagtcac	caccaaattc	cacagtggaa	8040
gcaggacgaa	cactcagagt	ccttaactta	gtagaaaatt	ggttgaacaa	caacactcaa	8100

ttttgcataa aggttctcaa cccatatatg ccctcagtca tagaaaaaat ggaagcacta	8160
caaaggaaat atggaggagc cttagtgagg aatccactct cacgaaactc cacacatgag	8220
atgtactggg tatccaatgc ttccgggaac atagtgtcat cagtgaacat gatttcaagg	8280
atgttgatca acagatttac aatgagatac aagaaagcca cttacgagcc ggatgttgac	8340
ctcggaagcg gaacccgtaa catcgggatt gaaagtgaga taccaaacct agatataatt	8400
gggaaaagaa tagaaaaaat aaagcaagag catgaaacat catggcacta tgaccaagac	8460
caccataca aaacgtgggc ataccatggt agctatgaaa caaaacagac tggatcagca	8520
tcatccatgg tcaacggagt ggtcaggctg ctgacaaaac cttgggacgt cgtcccatg	8580
gtgacacaga tggcaatgac agacacgact ccatttggac aacagcgcgt ttttaaagag	8640
aaagtggaca cgagaaccca agaaccgaaa gaaggcacga agaaactaat gaaaataaca	8700
gcagagtggc tttggaaaga attaggggaag aaaaagacac ccaggatgtg caccagagaa	8760
gaattcacia gaaaggtgag aagcaatgca gccttggggg ccatattcac tgatgagaac	8820
aagtggaagt cggcacgtga ggctgttgaa gatagtaggt tttgggagct ggttgacaag	8880
gaaaggaatc tccatcttga aggaaagtgt gaaacatgtg tgtacaacat gatgggaaaa	8940
agagagaaga agctagggga attcggcaag gcaaaaggca gcagagccat atggtacatg	9000
tggcttggag cacgcttctt agagtttgaa gccctaggat tcttaaataga agatcactgg	9060
ttctccagag agaactccct gagtggagtg gaaggagaag ggctgcacia gctaggttac	9120
attctaagag acgtgagcaa gaaagaggga ggagcaatgt atgccgatga caccgcagga	9180
tgggatacaa gaatcacact agaagaccta aaaaatgaag aaatggtaac aaaccacatg	9240
gaaggagaac acaagaaact agccgaggcc attttcaaac taacgtacca aaacaaggtg	9300
gtgcgtgtgc aaagaccaac accaagaggc acagtaatgg acatcatatc gagaagagac	9360
caaagaggta gtggacaagt tggcacctat ggactcaata ctttcaccaa tatggaagcc	9420
caactaatca gacagatgga gggagaagga gtcttttaaaa gcattcagca cctaacaatc	9480
acagaagaaa tcgctgtgca aaactggtta gcaagagtgg ggcgcgaaag gttatcaaga	9540
atggccatca gtggagatga ttgtgttgtg aaacctttag atgacagggt cgcaagcgct	9600
ttaacagctc taaatgacat gggaaagatt aggaaagaca tacaacaatg ggaaccttca	9660
agaggatgga atgattggac acaagtgcc ttctgttcac accatttcca tgagttaatc	9720

atgaaagacg gtcgcgtact cgttgttcca ttagaaaacc aagatgaact gattggcaga	9780
gcccgaatct cccaaggagc aggggtggtct ttgcgggaga cggcctgttt ggggaagtct	9840
tacgccccaa tgtggagctt gatgtacttc cacagacgcg acctcaggct ggcggcaa	9900
gctatttgct cggcagtacc atcacattgg gttccaacaa gtcgaacaac ctggtccata	9960
catgctaaac atgaatggat gacaacggaa gacatgctga cagtctggaa caggggtgtg	10020
attcaagaaa acccatggat ggaagacaaa actccagtgg aatcatggga ggaaatccca	10080
tacttgggga aaagagaaga ccaatggtgc ggctcattga ttgggttaac aagcagggcc	10140
acctgggcaa agaacaatcca agcagcaata aatcaagtta gatcccttat aggcaatgaa	10200
gaatacacag attacatgcc atccatgaaa agattcagaa gagaagagga agaagcagga	10260
gttctgtggt agaaagcaaa actaacatga aacaaggcta gaagtcaggt cggattaagc	10320
catagtacgg aaaaaactat gctacctgtg agccccgtcc aaggacgtta aaagaagtca	10380
ggccatcata aatgccatag cttgagtaaa ctatgcagcc thtagctcca cctgagaagg	10440
tgtaaaaaat ccgggaggcc acaaaccatg gaagctgtac gcatggcgta gtggactagc	10500
ggtagagga gaccctccc ttacaaatcg cagcaacaat gggggcccaa ggcgagatga	10560
agctgtagtc tcgctggaag gactagaggt tagaggagac ccccccgaac caaaaaacag	10620
catattgacg ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca	10680
gaacgccaga aaatggaatg gtgctgttga atcaacaggt tct	10723

<210> 2
 <211> 3391
 <212> PRT
 <213> chimeric dengue serotype 2/1 (MVS)

<400> 2

Met	Asn	Asn	Gln	Arg	Lys	Lys	Ala	Lys	Asn	Thr	Pro	Phe	Asn	Met	Leu
1				5				10						15	

Lys	Arg	Glu	Arg	Asn	Arg	Val	Ser	Thr	Val	Gln	Gln	Leu	Thr	Lys	Arg
			20					25					30		

Phe	Ser	Leu	Gly	Met	Leu	Gln	Gly	Arg	Gly	Pro	Leu	Lys	Leu	Phe	Met
		35					40					45			

Ala Leu Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala Gly
50 55 60

Ile Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala Ile Asn Val
65 70 75 80

Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn
85 90 95

Arg Arg Arg Arg Ser Ala Gly Met Ile Ile Met Leu Ile Pro Thr Val
100 105 110

Met Ala Phe His Leu Thr Thr Arg Gly Gly Glu Pro His Met Ile Val
115 120 125

Ser Lys Gln Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr Ser Ala Gly
130 135 140

Val Asn Met Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Leu Cys Glu
145 150 155 160

Asp Thr Met Thr Tyr Lys Cys Pro Arg Ile Thr Glu Ala Glu Pro Asp
165 170 175

Asp Val Asp Cys Trp Cys Asn Ala Thr Asp Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Ser Gln Thr Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala
195 200 205

Leu Ala Pro His Val Gly Leu Gly Leu Glu Thr Arg Ala Glu Thr Trp
210 215 220

Met Ser Ser Glu Gly Ala Trp Lys Gln Ile Gln Lys Val Glu Thr Trp
225 230 235 240

Ala Leu Arg His Pro Gly Phe Thr Val Ile Ala Leu Phe Leu Ala His
245 250 255

Ala Ile Gly Thr Ser Ile Thr Gln Lys Gly Ile Ile Phe Ile Leu Leu
260 265 270

Met Leu Val Thr Pro Ser Met Ala Met Arg Cys Val Gly Ile Gly Asn
275 280 285

Arg Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val
290 295 300

Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Ile Glu Leu Leu Lys Thr Glu Val Thr Asn Pro Ala Val Leu
325 330 335

Arg Lys Leu Cys Ile Glu Ala Lys Ile Ser Asn Thr Thr Thr Asp Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Ala Thr Leu Val Glu Glu Gln Asp Ala
355 360 365

Asn Phe Val Cys Arg Arg Thr Phe Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Ser Leu Ile Thr Cys Ala Lys Phe Lys
385 390 395 400

Cys Val Thr Lys Leu Glu Gly Lys Ile Val Gln Tyr Glu Asn Leu Lys
405 410 415

Tyr Ser Val Ile Val Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430

Asn Glu Thr Thr Glu His Gly Thr Thr Ala Thr Ile Thr Pro Gln Ala
435 440 445

Pro Thr Ser Glu Ile Gln Leu Thr Asp Tyr Gly Thr Leu Thr Leu Asp
450 455 460

Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Thr
465 470 475 480

Met Lys Glu Arg Ser Trp Leu Val His Lys Gln Trp Phe Leu Asp Leu
485 490 495

Pro Leu Pro Trp Thr Ser Gly Ala Ser Thr Ser Gln Glu Thr Trp Asn
500 505 510

Arg Gln Asp Leu Leu Val Thr Phe Lys Thr Ala His Ala Lys Lys Gln
515 520 525

Glu Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu
530 535 540

Thr Gly Ala Thr Glu Ile Gln Thr Ser Gly Thr Thr Thr Ile Phe Ala
545 550 555 560

Gly His Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Thr Leu Lys Gly
565 570 575

Met Ser Tyr Val Met Cys Thr Gly Ser Phe Lys Leu Glu Lys Glu Val
580 585 590

Ala Glu Thr Gln His Gly Thr Val Leu Val Gln Val Lys Tyr Glu Gly
595 600 605

Thr Asp Ala Pro Cys Lys Ile Pro Phe Ser Thr Gln Asp Glu Lys Gly
610 615 620

Ala Thr Gln Asn Gly Arg Leu Ile Thr Ala Asn Pro Ile Val Thr Asp
625 630 635 640

Lys Glu Lys Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser
645 650 655

Tyr Ile Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe
660 665 670

Lys Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly
675 680 685

Ala Arg Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser
690 695 700

Ile Gly Gly Val Phe Thr Ser Met Gly Lys Leu Val His Gln Val Phe
705 710 715 720

Gly Thr Ala Tyr Gly Val Leu Phe Ser Gly Val Ser Trp Thr Met Lys
725 730 735

Ile Gly Ile Gly Ile Leu Leu Thr Trp Leu Gly Leu Asn Ser Arg Asn
740 745 750

Thr Ser Leu Ser Met Met Cys Ile Ala Ala Gly Ile Val Thr Leu Tyr
755 760 765

Leu Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys
770 775 780

Asn Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Ile Thr Asp Asn Val
785 790 795 800

His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys
805 810 815

Leu Ala Ser Ala Ile Gln Lys Ala His Glu Glu Asp Ile Cys Gly Ile
820 825 830

Arg Ser Val Thr Arg Leu Glu Asn Leu Met Trp Lys Gln Ile Thr Pro
835 840 845

Glu Leu Asn His Ile Leu Ser Glu Asn Glu Val Lys Leu Thr Ile Met
850 855 860

Thr Gly Asp Ile Lys Gly Ile Met Gln Ala Gly Lys Arg Ser Leu Arg
865 870 875 880

Pro Gln Pro Thr Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala
885 890 895

Lys Met Leu Ser Thr Glu Ser His Asn Gln Thr Phe Leu Ile Asp Gly
900 905 910

Pro Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu
915 920 925

Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu
930 935 940

Lys Leu Lys Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu Met Ser
945 950 955 960

Ala Ala Ile Lys Asp Asn Arg Ala Val His Ala Asp Met Gly Tyr Trp
965 970 975

Ile Glu Ser Ala Leu Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe
980 985 990

Ile Glu Val Lys Asn Cys His Trp Pro Lys Ser His Thr Leu Trp Ser
995 1000 1005

Asn Gly Val Leu Glu Ser Glu Met Ile Ile Pro Lys Asn Leu Ala
1010 1015 1020

Gly Pro Val Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln
1025 1030 1035

Ile Thr Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp
1040 1045 1050

Phe Cys Asp Gly Thr Thr Val Val Val Thr Glu Asp Cys Gly Asn
1055 1060 1065

Arg Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly Lys Leu Ile
1070 1075 1080

Thr Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Tyr
1085 1090 1095

Arg Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Leu
1100 1105 1110

Lys Glu Lys Glu Glu Asn Leu Val Asn Ser Leu Val Thr Ala Gly
1115 1120 1125

His Gly Gln Val Asp Asn Phe Ser Leu Gly Val Leu Gly Met Ala
1130 1135 1140

Leu Phe Leu Glu Glu Met Leu Arg Thr Arg Val Gly Thr Lys His
1145 1150 1155

Ala Ile Leu Leu Val Ala Val Ser Phe Val Thr Leu Ile Thr Gly
1160 1165 1170

Asn Met Ser Phe Arg Asp Leu Gly Arg Val Met Val Met Val Gly
1175 1180 1185

Ala Thr Met Thr Asp Asp Ile Gly Met Gly Val Thr Tyr Leu Ala
1190 1195 1200

Leu Leu Ala Ala Phe Lys Val Arg Pro Thr Phe Ala Ala Gly Leu
1205 1210 1215

Leu Leu Arg Lys Leu Thr Ser Lys Glu Leu Met Met Thr Thr Ile
1220 1225 1230

Gly Ile Val Leu Leu Ser Gln Ser Thr Leu Pro Glu Thr Ile Leu
1235 1240 1245

Glu Leu Thr Asp Ala Leu Ala Leu Gly Met Met Val Leu Lys Met
1250 1255 1260

Val Arg Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala
1265 1270 1275

Ile Leu Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys
1280 1285 1290

Val Ser Cys Thr Ile Leu Ala Val Val Ser Val Ser Pro Leu Phe
1295 1300 1305

Leu Thr Ser Ser Gln Gln Lys Thr Asp Trp Ile Pro Leu Ala Leu
1310 1315 1320

Thr Ile Lys Gly Leu Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu
1325 1330 1335

Ser Arg Thr Ser Lys Lys Arg Ser Trp Pro Leu Asn Glu Ala Ile
1340 1345 1350

Met Ala Val Gly Met Val Ser Ile Leu Ala Ser Ser Leu Leu Lys
1355 1360 1365

Asn Asp Ile Pro Met Thr Gly Pro Leu Val Ala Gly Gly Leu Leu
1370 1375 1380

Thr Val Cys Tyr Val Leu Thr Gly Arg Ser Ala Asp Leu Glu Leu
1385 1390 1395

Glu Arg Ala Ala Asp Val Lys Trp Glu Asp Gln Ala Glu Ile Ser
1400 1405 1410

Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser Glu Asp Gly Ser
1415 1420 1425

Met Ser Ile Lys Asn Glu Glu Glu Asp Gln Thr Leu Thr Ile Leu
1430 1435 1440

Ile Arg Thr Gly Leu Leu Val Ile Ser Gly Leu Phe Pro Val Ser
1445 1450 1455

Ile Pro Ile Thr Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys Lys
1460 1465 1470

Gln Arg Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Met
1475 1480 1485

Gly Lys Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys
1490 1495 1500

Gly Ile Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu
1505 1510 1515

Gly Thr Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
1520 1525 1530

Met His Lys Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys
1535 1540 1545

Lys Asp Leu Ile Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu
1550 1555 1560

Trp Lys Glu Gly Glu Glu Val Gln Val Leu Ala Leu Glu Pro Gly
1565 1570 1575

Lys Asn Pro Arg Ala Val Gln Thr Lys Pro Gly Leu Phe Lys Thr
1580 1585 1590

Asn Ala Gly Thr Ile Gly Ala Val Ser Leu Asp Phe Ser Pro Gly
1595 1600 1605

Thr Ser Gly Ser Pro Ile Ile Asp Lys Lys Gly Lys Val Val Gly
1610 1615 1620

Leu Tyr Gly Asn Gly Val Val Thr Arg Ser Gly Ala Tyr Val Ser
1625 1630 1635

Ala Ile Ala Gln Thr Glu Lys Ser Ile Glu Asp Asn Pro Glu Ile
1640 1645 1650

Glu Asp Asp Ile Phe Arg Lys Arg Arg Leu Thr Ile Met Asp Leu
1655 1660 1665

His Pro Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro Ala Ile Val
1670 1675 1680

Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu Ala Pro
1685 1690 1695

Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu
1700 1705 1710

Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala Val His Thr Gly
1715 1720 1725

Arg	Glu	Ile	Val	Asp	Leu	Met	Cys	His	Ala	Thr	Phe	Thr	Met	Arg
1730						1735					1740			
Leu	Leu	Ser	Pro	Val	Arg	Val	Pro	Asn	Tyr	Asn	Leu	Ile	Ile	Met
1745						1750					1755			
Asp	Glu	Ala	His	Phe	Thr	Asp	Pro	Ala	Ser	Ile	Ala	Ala	Arg	Gly
1760						1765					1770			
Tyr	Ile	Ser	Thr	Arg	Val	Glu	Met	Gly	Glu	Ala	Ala	Gly	Ile	Phe
1775						1780					1785			
Met	Thr	Ala	Thr	Pro	Pro	Gly	Ser	Arg	Asp	Pro	Phe	Pro	Gln	Ser
1790						1795					1800			
Asn	Ala	Pro	Ile	Ile	Asp	Glu	Glu	Arg	Glu	Ile	Pro	Glu	Arg	Ser
1805						1810					1815			
Trp	Asn	Ser	Gly	His	Glu	Trp	Val	Thr	Asp	Phe	Lys	Gly	Lys	Thr
1820						1825					1830			
Val	Trp	Phe	Val	Pro	Ser	Ile	Lys	Ala	Gly	Asn	Asp	Ile	Ala	Ala
1835						1840					1845			
Cys	Leu	Arg	Lys	Asn	Gly	Lys	Lys	Val	Ile	Gln	Leu	Ser	Arg	Lys
1850						1855					1860			
Thr	Phe	Asp	Ser	Glu	Tyr	Val	Lys	Thr	Arg	Thr	Asn	Asp	Trp	Asp
1865						1870					1875			
Phe	Val	Val	Thr	Thr	Asp	Ile	Ser	Glu	Met	Gly	Ala	Asn	Phe	Lys
1880						1885					1890			
Ala	Glu	Arg	Val	Ile	Asp	Pro	Arg	Arg	Cys	Met	Lys	Pro	Val	Ile
1895						1900					1905			
Leu	Thr	Asp	Gly	Glu	Glu	Arg	Val	Ile	Leu	Ala	Gly	Pro	Met	Pro
1910						1915					1920			
Val	Thr	His	Ser	Ser	Ala	Ala	Gln	Arg	Arg	Gly	Arg	Ile	Gly	Arg
1925						1930					1935			

Asn Pro Lys Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu Pro
1940 1945 1950

Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys Glu Ala Lys Met
1955 1960 1965

Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ser Met
1970 1975 1980

Phe Glu Pro Glu Arg Glu Lys Val Asp Ala Ile Asp Gly Glu Tyr
1985 1990 1995

Arg Leu Arg Gly Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg
2000 2005 2010

Arg Gly Asp Leu Pro Val Trp Leu Ala Tyr Arg Val Ala Ala Glu
2015 2020 2025

Gly Ile Asn Tyr Ala Asp Arg Arg Trp Cys Phe Asp Gly Val Lys
2030 2035 2040

Asn Asn Gln Ile Leu Glu Glu Asn Val Glu Val Glu Ile Trp Thr
2045 2050 2055

Lys Glu Gly Glu Arg Lys Lys Leu Lys Pro Arg Trp Leu Asp Ala
2060 2065 2070

Arg Ile Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Glu Phe
2075 2080 2085

Ala Ala Gly Arg Lys Ser Leu Thr Leu Asn Leu Ile Thr Glu Met
2090 2095 2100

Gly Arg Leu Pro Thr Phe Met Thr Gln Lys Ala Arg Asp Ala Leu
2105 2110 2115

Asp Asn Leu Ala Val Leu His Thr Ala Glu Ala Gly Gly Arg Ala
2120 2125 2130

Tyr	Asn	His	Ala	Leu	Ser	Glu	Leu	Pro	Glu	Thr	Leu	Glu	Thr	Leu
	2135					2140					2145			
Leu	Leu	Leu	Thr	Leu	Leu	Ala	Thr	Val	Thr	Gly	Gly	Ile	Phe	Leu
	2150					2155					2160			
Phe	Leu	Met	Ser	Ala	Arg	Gly	Ile	Gly	Lys	Met	Thr	Leu	Gly	Met
	2165					2170					2175			
Cys	Cys	Ile	Ile	Thr	Ala	Ser	Ile	Leu	Leu	Trp	Tyr	Ala	Gln	Ile
	2180					2185					2190			
Gln	Pro	His	Trp	Ile	Ala	Ala	Ser	Ile	Ile	Leu	Glu	Phe	Phe	Leu
	2195					2200					2205			
Ile	Val	Leu	Leu	Ile	Pro	Glu	Pro	Glu	Lys	Gln	Arg	Thr	Pro	Gln
	2210					2215					2220			
Asp	Asn	Gln	Leu	Thr	Tyr	Val	Val	Ile	Ala	Ile	Leu	Thr	Val	Val
	2225					2230					2235			
Ala	Ala	Thr	Met	Ala	Asn	Glu	Met	Gly	Phe	Leu	Glu	Lys	Thr	Lys
	2240					2245					2250			
Lys	Asp	Leu	Gly	Leu	Gly	Ser	Ile	Ala	Thr	Gln	Gln	Pro	Glu	Ser
	2255					2260					2265			
Asn	Ile	Leu	Asp	Ile	Asp	Leu	Arg	Pro	Ala	Ser	Ala	Trp	Thr	Leu
	2270					2275					2280			
Tyr	Ala	Val	Ala	Thr	Thr	Phe	Val	Thr	Pro	Met	Leu	Arg	His	Ser
	2285					2290					2295			
Ile	Glu	Asn	Ser	Ser	Val	Asn	Val	Ser	Leu	Thr	Ala	Ile	Ala	Asn
	2300					2305					2310			
Gln	Ala	Thr	Val	Leu	Met	Gly	Leu	Gly	Lys	Gly	Trp	Pro	Leu	Ser
	2315					2320					2325			
Lys	Met	Asp	Ile	Gly	Val	Pro	Leu	Leu	Ala	Ile	Gly	Cys	Tyr	Ser
	2330					2335					2340			

Gln Val Asn Pro Ile Thr Leu Thr Ala Ala Leu Phe Leu Leu Val
2345 2350 2355

Ala His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr
2360 2365 2370

Arg Glu Ala Gln Lys Arg Ala Ala Ala Gly Ile Met Lys Asn Pro
2375 2380 2385

Thr Val Asp Gly Ile Thr Val Ile Asp Leu Asp Pro Ile Pro Tyr
2390 2395 2400

Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val
2405 2410 2415

Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala Leu
2420 2425 2430

Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Ile Ser Thr Leu Trp
2435 2440 2445

Glu Gly Asn Pro Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser
2450 2455 2460

Met Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu
2465 2470 2475

Leu Phe Ser Ile Met Lys Asn Thr Thr Asn Thr Arg Arg Gly Thr
2480 2485 2490

Gly Asn Ile Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu
2495 2500 2505

Asn Ala Leu Gly Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly
2510 2515 2520

Ile Gln Glu Val Asp Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg
2525 2530 2535

Gly Glu Thr Asp His His Ala Val Ser Arg Gly Ser Ala Lys Leu
2540 2545 2550

Arg Trp Phe Val Glu Arg Asn Met Val Thr Pro Glu Gly Lys Val
2555 2560 2565

Val Asp Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Cys Gly
2570 2575 2580

Gly Leu Lys Asn Val Arg Glu Val Lys Gly Leu Thr Lys Gly Gly
2585 2590 2595

Pro Gly His Glu Glu Pro Ile Pro Met Ser Thr Tyr Gly Trp Asn
2600 2605 2610

Leu Val Arg Leu Gln Ser Gly Val Asp Val Phe Phe Ile Pro Pro
2615 2620 2625

Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Pro
2630 2635 2640

Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu Asn Leu
2645 2650 2655

Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Ile Lys Val
2660 2665 2670

Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Lys Met Glu Ala Leu
2675 2680 2685

Gln Arg Lys Tyr Gly Gly Ala Leu Val Arg Asn Pro Leu Ser Arg
2690 2695 2700

Asn Ser Thr His Glu Met Tyr Trp Val Ser Asn Ala Ser Gly Asn
2705 2710 2715

Ile Val Ser Ser Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg
2720 2725 2730

Phe Thr Met Arg Tyr Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp
2735 2740 2745

Leu Gly Ser Gly Thr Arg Asn Ile Gly Ile Glu Ser Glu Ile Pro
2750 2755 2760

Asn Leu Asp Ile Ile Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu
2765 2770 2775

His Glu Thr Ser Trp His Tyr Asp Gln Asp His Pro Tyr Lys Thr
2780 2785 2790

Trp Ala Tyr His Gly Ser Tyr Glu Thr Lys Gln Thr Gly Ser Ala
2795 2800 2805

Ser Ser Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro Trp
2810 2815 2820

Asp Val Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr
2825 2830 2835

Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg
2840 2845 2850

Thr Gln Glu Pro Lys Glu Gly Thr Lys Lys Leu Met Lys Ile Thr
2855 2860 2865

Ala Glu Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys Thr Pro Arg
2870 2875 2880

Met Cys Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn Ala
2885 2890 2895

Ala Leu Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys Ser Ala
2900 2905 2910

Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu Leu Val Asp Lys
2915 2920 2925

Glu Arg Asn Leu His Leu Glu Gly Lys Cys Glu Thr Cys Val Tyr
2930 2935 2940

Asn Met Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys
2945 2950 2955

Ala Lys Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg
2960 2965 2970

Phe Leu Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp
2975 2980 2985

Phe Ser Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu
2990 2995 3000

His Lys Leu Gly Tyr Ile Leu Arg Asp Val Ser Lys Lys Glu Gly
3005 3010 3015

Gly Ala Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile
3020 3025 3030

Thr Leu Glu Asp Leu Lys Asn Glu Glu Met Val Thr Asn His Met
3035 3040 3045

Glu Gly Glu His Lys Lys Leu Ala Glu Ala Ile Phe Lys Leu Thr
3050 3055 3060

Tyr Gln Asn Lys Val Val Arg Val Gln Arg Pro Thr Pro Arg Gly
3065 3070 3075

Thr Val Met Asp Ile Ile Ser Arg Arg Asp Gln Arg Gly Ser Gly
3080 3085 3090

Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala
3095 3100 3105

Gln Leu Ile Arg Gln Met Glu Gly Glu Gly Val Phe Lys Ser Ile
3110 3115 3120

Gln His Leu Thr Ile Thr Glu Glu Ile Ala Val Gln Asn Trp Leu
3125 3130 3135

Ala Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser Gly
3140 3145 3150

Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg Phe Ala Ser Ala
3155 3160 3165

Leu Thr Ala Leu Asn Asp Met Gly Lys Ile Arg Lys Asp Ile Gln
3170 3175 3180

Gln Trp Glu Pro Ser Arg Gly Trp Asn Asp Trp Thr Gln Val Pro
3185 3190 3195

Phe Cys Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg
3200 3205 3210

Val Leu Val Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg
3215 3220 3225

Ala Arg Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala
3230 3235 3240

Cys Leu Gly Lys Ser Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe
3245 3250 3255

His Arg Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser Ala
3260 3265 3270

Val Pro Ser His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile
3275 3280 3285

His Ala Lys His Glu Trp Met Thr Thr Glu Asp Met Leu Thr Val
3290 3295 3300

Trp Asn Arg Val Trp Ile Gln Glu Asn Pro Trp Met Glu Asp Lys
3305 3310 3315

Thr Pro Val Glu Ser Trp Glu Glu Ile Pro Tyr Leu Gly Lys Arg
3320 3325 3330

Glu Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala
3335 3340 3345

Thr Trp Ala Lys Asn Ile Gln Ala Ala Ile Asn Gln Val Arg Ser
 3350 3355 3360

Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser Met Lys
 3365 3370 3375

Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
 3380 3385 3390

<210> 3
 <211> 10723
 <212> DNA
 <213> dengue serotype 2 (MVS)

<400> 3
 agttgttagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaatgta 60
 gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg 120
 aaaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtgcaacag 180
 ctgacaaaga gattctcact tggaatgctg caggagcag gaccattaaa actgttcatg 240
 gccctggtgg cgttccttcg tttcctaaca atcccaccaa cagcagggat attgaagaga 300
 tggggaacaa ttaaaaaatc aaaagctatt aatgttttga gagggttcag gaaagagatt 360
 ggaaggatgc tgaacatctt gaataggaga cgcagatctg caggcatgat cattatgctg 420
 attccaacag tgatggcggt ccatttaacc acacgtaacg gagaaccaca catgatcgtc 480
 agcagacaag agaaagggaa aagtcttctg tttaaaacag aggttggcgt gaacatgtgt 540
 accctcatgg ccatggacct tggatgaattg tgtgaagaca caatcacgta cgagtgtccc 600
 cttctcaggc agaatgagcc agaagacata gactgttggg gcaactctac gtccacgtgg 660
 gtaacttatg ggacgtgtac caccatggga gaacatagaa gagaaaaaag atcagtggca 720
 ctcgttcac atgtgggaat gggactggag acacgaactg aaacatggat gtcacagaa 780
 ggggcctgga aacatgtcca gagaattgaa acttgatctt tgagacatcc aggcttcacc 840
 atgatggcag caatcctggc atacaccata ggaacgacac atttccaaag agccctgatc 900
 ttcattctac tgacagctgt cactccttca atgacaatgc gttgcatagg aatgtcaaatt 960
 agagactttg tggaaggggt ttcaggagga agctgggttg acatagtctt agaacatgga 1020
 agctgtgtga cgacgatggc aaaaaacaaa ccaacattgg attttgaact gataaaaaa 1080

gaagccaaac agcctgccac cctaaggaag tactgtatag aggcaaagct aaccaacaca	1140
acaacagaat ctcgctgccc aacacaaggg gaaccagacc taaatgaaga gcaggacaaa	1200
aggttcgtct gcaaacactc catggttagac agaggatggg gaaatggatg tggactat	1260
ggaaagggag gcattgtgac ctgtgctatg ttcagatgca aaaagaacat ggaaggaaaa	1320
gttgtgcaac cagaaaactt ggaatacacc atttgtataa cacctcactc aggggaagag	1380
catgcagtcg gaaatgacac aggaaaacat ggcaaggaaa tcaaaataac accacagagt	1440
tccatcacag aagcagaatt gacaggttat ggcaactgtc caatggagtg ctctccaaga	1500
acgggcctcg acttcaatga gatgggtgtg ctgcagatgg aaaataaagc ttggctgggtg	1560
cacaggcaat ggttcctaga cctgccgtta ccatggttgc ccggagcgga cacacaaggg	1620
tcaaattgga tacagaaaga gacattggtc actttcaaaa atccccatgc gaagaaacag	1680
gatgttgttg ttttaggatc ccaagaaggg gccatgcaca cagcacttac aggggccaca	1740
gaaatccaaa tgtcatcagg aaacttactc ttcacaggac atctcaagt caggctgaga	1800
atggacaagc tacagctcaa aggaatgtca tactctatgt gcacaggaaa gtttaaagtt	1860
gtgaaggaaa tagcagaaac acaacatgga acaatagtta tcagagtgc atatgaaggg	1920
gacggctctc catgcaagat cctttttgag ataatggatt tggaaaaaag acatgtctta	1980
ggtcgcctga ttacagtcaa cccaattgtg acagaaaaag atagcccagt caacatagaa	2040
gcagaacctc catttgagga cagctacatc atcataggag tagagccggg acaactgaag	2100
ctcaactggg ttaagaaagg aagttctatc ggccaaatgt ttgagacaac aatgaggggg	2160
gcgaagagaa tggccatttt aggtgacaca gcctgggatt ttggatcctt gggaggagt	2220
ttacatcta taggaaaggc tctccaccaa gtctttggag caatctatgg agctgccttc	2280
agtgggggtt catggactat gaaaatcctc ataggagtca ttatcacatg gataggaatg	2340
aattcacgca gcacctcact gtctgtgaca ctagtattgg tgggaattgt gacactgtat	2400
ttgggagtca tgggtgcaggc cgatagtggg tgcgttgtga gctggaaaaa caaagaactg	2460
aaatgtggca gtgggatttt catcacagac aacgtgcaca catggacaga acaatacaag	2520
ttccaaccag aatccccttc aaaactagct tcagctatcc agaaagccca tgaagaggac	2580
atttgtggaa tccgctcagt aacaagactg gagaatctga tgtggaaaca aataacacca	2640
gaattgaatc acattctatc agaaaatgag gtgaagttaa ctattatgac aggagacatc	2700

aaaggaatca tgcaggcagg aaaacgatct ctgcggcctc agcccactga gctgaagtat	2760
tcatggaaaa catggggcaa agcaaaaatg ctctctacag agtctcataa ccagaccttt	2820
ctcattgatg gccccgaaac agcagaatgc cccaacacaa atagagcttg gaattcgttg	2880
gaagttgaag actatggctt tggagtattc accaccaata tatggctaaa attgaaagaa	2940
aaacaggatg tattctgcga ctcaaaactc atgtcagcgg ccataaaaga caacagagcc	3000
gtccatgccg atatgggtta ttggatagaa agtgcactca atgacacatg gaagatagag	3060
aaagcctctt tcattgaagt taaaaactgc cactggccaa aatcacacac cctctggagc	3120
aatggagtgc tagaaagtga gatgataatt ccaaagaatc tcgctggacc agtgtctcaa	3180
cacaactata gaccaggcta ccatacacia ataacaggac catggcatct aggtaagctt	3240
gagatggact ttgatttctg tgatggaaca acagtggtag tgactgagga ctgcggaaat	3300
agaggaccct ctttgagaac aaccactgcc tctggaaaac tcataacaga atgggtgctgc	3360
cgatcttgca cattaccacc gctaagatac agaggtgagg atgggtgctg gtacgggatg	3420
gaaatcagac cattgaagga gaaagaagag aatttgggtca actccttgggt cacagctgga	3480
catgggcagg tcgacaactt ttcactagga gtcttgggaa tggcattgtt cctggaggaa	3540
atgcttagga cccgagtagg aacgaaacat gcaatactac tagttgcagt ttcttttgtg	3600
acattgatca cagggaacat gtcctttaga gacctgggaa gagtgatggt tatggtaggc	3660
gccactatga cggatgacat aggtatgggc gtgacttatc ttgccctact agcagccttc	3720
aaagtcagac caacttttgc agctggacta ctcttgagaa agctgacctc caaggaattg	3780
atgatgacta ctataggaat tgtactctc tcccagagca ccataccaga gaccattctt	3840
gagttgactg atgcgttagc cttaggcatg atggctctca aaatgggtgag aaatatggaa	3900
aagtatcaat tggcagtgac tatcatggct atcttgtgcg tcccaaacgc agtgatatta	3960
caaaacgcat ggaaagtgag ttgcacaata ttggcagtggt tgtccgtttc cccactgttc	4020
ttaacatcct cacagcaaaa aacagattgg ataccattag cattgacgat caaaggtctc	4080
aatccaacag ctatttttct aacaaccctc tcaagaacca gcaagaaaag gagctggcca	4140
ttaaattgagg ctatcatggc agtcgggatg gtgagcattt tagccagttc tctcctaaaa	4200
aatgatattc ccatgacagg accattagtg gctggagggc tcctcactgt gtgctacgtg	4260
ctcactggac gatcggccga tttggaactg gagagagcag ccgatgtcaa atgggaagac	4320

caggcagaga	tatcaggaag	cagtccaatc	ctgtcaataa	caatatcaga	agatggtagc	4380
atgtcgataa	aaaatgaaga	ggaagaacaa	acactgacca	tactcattag	aacaggattg	4440
ctggatgatct	caggactttt	tcctgtatca	ataccaatca	cggcagcagc	atggtacctg	4500
tgggaagtga	agaaacaacg	ggccggagta	ttgtgggatg	ttccttcacc	cccacccatg	4560
ggaaaggctg	aactggaaga	tggagcctat	agaattaagc	aaaaagggat	tcttggatat	4620
tcccagatcg	gagccggagt	ttacaaagaa	ggaacattcc	atacaatgtg	gcatgtcaca	4680
cgtggcgctg	ttctaattga	taaaggaaag	aggattgaac	catcatgggc	ggacgtcaag	4740
aaagacctaa	tatcatatgg	aggaggctgg	aagttagaag	gagaatggaa	ggaaggagaa	4800
gaagtccagg	tattggcact	ggagcctgga	aaaaatccaa	gagccgtcca	aacgaaacct	4860
ggtcttttca	aaaccaacgc	cggacaataa	ggtgctgtat	ctctggactt	ttctcctgga	4920
acgtcaggat	ctccaattat	cgacaaaaaa	ggaaaagttg	tgggtcttta	tggtaatggt	4980
gttgttacaa	ggagtggagc	atatgtgagt	gctatagccc	agactgaaaa	aagcattgaa	5040
gacaaccag	agatcgaaga	tgacattttc	cgaaagagaa	gactgaccat	catggacctc	5100
caccaggag	cgggaaagac	gaagagatac	cttccggcca	tagtcagaga	agctataaaa	5160
cggggtttga	gaacattaat	cttggcccc	actagagttg	tggcagctga	aatggaggaa	5220
gcccttagag	gacttccaat	aagataccag	accccagcca	tcagagctgt	gcacaccggg	5280
cgggagattg	tggacctaat	gtgtcatgcc	acatttacca	tgaggctgct	atcaccagtt	5340
agagtgccaa	actacaacct	gattatcatg	gacgaagccc	atttcacaga	cccagcaagt	5400
atagcagcta	gaggatacat	ctcaactcga	gtggagatgg	gtgaggcagc	tgggattttt	5460
atgacagcca	ctccccggg	aagcagagac	ccatttcctc	agagcaatgc	accaatcata	5520
gatgaagaaa	gagaaatccc	tgaacgctcg	tggaattccg	gacatgaatg	ggtcacggat	5580
tttaaaggga	agactgtttg	gttcgttcca	agtataaaaag	caggaaatga	tatagcagct	5640
tgctgagga	aaaatggaaa	gaaagtgata	caactcagta	ggaagacctt	tgattctgag	5700
tatgtcaaga	ctagaaccaa	tgattgggac	ttcgtggtta	caactgacat	ttcagaaatg	5760
ggtgccaat	tcaaggctga	gagggttata	gaccccagac	gctgcatgaa	accagtcata	5820
ctaacagatg	gtgaagagcg	ggtgattctg	gcaggaccta	tgccagtgac	ccactctagt	5880
gcagcacaaa	gaagagggag	aataggaaga	aatccaaaaa	atgagaatga	ccagtacata	5940

tacatggggg aacctctgga aaatgatgaa gactgtgcac actggaaaga agctaaaatg	6000
ctcctagata acatcaacac gccagaagga atcattccta gcatgttcga accagagcgt	6060
gaaaaggtgg atgccattga tggcgaatac cgcttgagag gagaagcaag gaaaaccttt	6120
gtagacttaa tgagaagagg agacctacca gtctggttgg cctacagagt ggagctgaa	6180
ggcatcaact acgcagacag aaggtggtgt tttgatggag tcaagaacaa ccaaattccta	6240
gaagaaaacg tggaagttga aatctggaca aaagaagggg aaaggaagaa attgaaaccc	6300
agatggttgg atgctaggat ctattctgac ccactggcgc taaaagaatt taaggaattt	6360
gcagccggaa gaaagtctct gaccctgaac ctaatcacag aaatgggtag gctcccaacc	6420
ttcatgactc agaaggcaag agacgcactg gacaacttag cagtgtgca cacggctgag	6480
gcaggtggaa gggcgtacaa ccatgctctc agtgaactgc cggagaccct ggagacattg	6540
cttttactga cacttctggc tacagtcacg ggagggatct ttttattctt gatgagcgca	6600
aggggcatag ggaagatgac cctgggaatg tgctgcataa tcacggctag catcctccta	6660
tggtacgcac aaatacagcc acactggata gcagcttcaa taatactgga gttttttctc	6720
atagttttgc ttattccaga acctgaaaaa cagagaacac cccaagacaa ccaactgacc	6780
tacgttgtca tagccatcct cacagtgggtg gccgcaacca tggcaaacga gatgggtttc	6840
ctagaaaaaa cgaagaaaga tctcggattg ggaagcattg caaccagca acccgagagc	6900
aacatcctgg acatagatct acgtcctgca tcagcatgga cgctgtatgc cgtggccaca	6960
acatttgta caccaatgtt gagacatagc attgaaaatt cctcagtga tgtgtcccta	7020
acagctatag ccaaccaagc cacagtgtta atgggtctcg ggaaaggatg gccattgtca	7080
aagatggaca tcggagttcc ctttctcgcc attggatgct actcacaagt caaccccata	7140
actctcacag cagctctttt cttattggta gcacattatg ccatcatagg gccaggactc	7200
caagcaaaag caaccagaga agctcagaaa agagcagcgg cgggcatcat gaaaaacca	7260
actgtcgatg gaataacagt gattgacctt gatccaatac cttatgatcc aaagtttgaa	7320
aagcagttgg gacaagtaat gctcctagtc ctctgcgtga ctcaagtatt gatgatgagg	7380
actacatggg ctctgtgtga ggctttaacc ttagctaccg ggcccatctc cacattgtgg	7440
gaaggaaatc caggaggtt ttggaacact accattgcgg tgtcaatggc taacattttt	7500
agagggagtt acttgccgg agctggactt ctcttttcta ttatgaagaa cacaaccaac	7560

acaagaaggg gaactggcaa cataggagag acgcttggag agaaatggaa aagccgattg	7620
aacgcattgg gaaaaagtga attccagatc tacaagaaaa gtggaatcca ggaagtggat	7680
agaaccttag caaaagaagg cattaaaaga ggagaaacgg accatcacgc tgtgtcgcga	7740
ggctcagcaa aactgagatg gttcgttgag agaaacatgg tcacaccaga agggaaagta	7800
gtggacctcg gttgtggcag aggaggctgg tcatactatt gtggaggact aaagaatgta	7860
agagaagtca aaggcctaac aaaaggagga ccaggacacg aagaacccat ccccatgtca	7920
acatatgggt ggaatctagt gcgtcttcaa agtggagttg acgttttctt catcccgcca	7980
gaaaagtgtg acacattatt gtgtgacata ggggagtcac caccaaacc cacagtggaa	8040
gcaggacgaa cactcagagt ccttaactta gtagaaaatt ggttgaacaa caaactcaa	8100
ttttgcataa aggttctcaa cccatatatg ccctcagtca tagaaaaaat ggaagcacta	8160
caaaggaaat atggaggagc cttagtgagg aatccactct cacgaaactc cacacatgag	8220
atgtactggg tatccaatgc ttccgggaac atagtgtcat cagtgaacat gatttcaagg	8280
atgttgatca acagatttac aatgagatac aagaaagcca cttacgagcc ggatgttgac	8340
ctcgggaagcg gaacccgtaa catcgggatt gaaagtgaga taccaaacct agatataatt	8400
gggaaaagaa tagaaaaaat aaagcaagag catgaaacat catggcacta tgaccaagac	8460
cacccatata aaacgtgggc ataccatggt agctatgaaa caaaacagac tggatcagca	8520
tcatccatgg tcaacggagt ggtcaggctg ctgacaaaac cttgggacgt cgtcccatg	8580
gtgacacaga tggcaatgac agacacgact ccatttggac aacagcgcgt ttttaaagag	8640
aaagtggaca cgagaacca agaaccgaaa gaaggcacga agaaactaat gaaaataaca	8700
gcagagtggc tttggaaaga attagggaag aaaaagacac ccaggatgtg caccagagaa	8760
gaattcacia gaaaggtgag aagcaatgca gccttggggg ccgtattcac tgatgagaac	8820
aagtggaagt cggcacgtga ggctgttgaa gatagtaggt tttgggagct ggttgacaag	8880
gaaaggaatc tccatcttga aggaaagtgt gaaacatgtg tgtacaacat gatgggaaaa	8940
agagagaaga agctagggga attcggcaag gcaaaaggca gcagagccat atggtacatg	9000
tggcttggag cacgcttctt agagtttgaa gccctaggat tcttaaatga agatcactgg	9060
ttctccagag agaactccct gagtggagtg gaaggagaag ggctgcacia gctaggttac	9120
attctaagag acgtgagcaa gaaagaggga ggagcaatgt atgccgatga caccgcagga	9180

tgggatacaa gaatcacact agaagaccta aaaaatgaag aaatggtaac aaaccacatg	9240
gaaggagaac acaagaaact agccgaggcc attttcaaac taacgtacca aaacaagggtg	9300
gtgcgtgtgc aaagaccaac accaagaggc acagtaatgg acatcatatc gagaagagac	9360
caaagaggta gtggacaagt tggcacctat ggactcaata ctttcaccaa tatggaagcc	9420
caactaatca gacagatgga gggagaagga gtcttttaaaa gcattcagca cctaacaatc	9480
acagaagaaa tcgctgtgca aaactggtta gcaagagtgg ggcgcgaaaag gttatcaaga	9540
atggccatca gtggagatga ttgtgtttgtg aaaccttttag atgacagggtt cgcaagcgct	9600
ttaacagctc taaatgacat gggaaagatt aggaaagaca tacaacaatg ggaaccttca	9660
agaggatgga atgattggac acaagtgtccc ttctgttcac accattttcca tgagttaatc	9720
atgaaagacg gtcgctgact cgttggttcca tgtagaaacc aagatgaact gattggcaga	9780
gcccgaatct cccaaggagc aggggtggtct ttgcgggaga cggcctgttt ggggaagtct	9840
tacgccccaa tgtggagctt gatgtacttc cacagacgcg acctcaggct ggcggaat	9900
gctatttgct cggcagtacc atcacattgg gttccaacaa gtcgaacaac ctggtccata	9960
catgctaaac atgaatggat gacaacggaa gacatgctga cagtctggaa cagggtgtgg	10020
attcaagaaa acccatggat ggaagacaaa actccagtgg aatcatggga ggaaatccca	10080
tacttgggga aaagagaaga ccaatggtgc ggctcattga ttgggttaac aagcagggcc	10140
acctgggcaa agaacatcca agcagcaata aatcaagtta gatcccttat aggcaatgaa	10200
gaatacacag attacatgcc atccatgaaa agattcagaa gagaagagga agaagcagga	10260
gttctgtggt agaaagcaaa actaacatga aacaaggcta gaagtcagggt cggattaagc	10320
catagtacgg aaaaaactat gctacctgtg agccccgtcc aaggacgtta aaagaagtca	10380
ggccatcata aatgccatag cttgagtaaa ctatgcagcc tgtagctcca cctgagaagg	10440
tgtaaaaaat ccgggaggcc acaaaccatg gaagctgtac gcatggcgta gtggactagc	10500
ggttagagga gaccctccc ttacaaatcg cagcaacaat gggggcccaa ggcgagatga	10560
agctgtagtc tcgctggaag gactagaggt tagaggagac ccccccgaac caaaaaacag	10620
catattgacg ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca	10680
gaacgccaga aaatggaatg gtgctgttga atcaacaggt tct	10723

<211> 3391
<212> PRT
<213> dengue seroytpe 2 (MVS)

<400> 4

Met Asn Asn Gln Arg Lys Lys Ala Lys Asn Thr Pro Phe Asn Met Leu
1 5 10 15

Lys Arg Glu Arg Asn Arg Val Ser Thr Val Gln Gln Leu Thr Lys Arg
20 25 30

Phe Ser Leu Gly Met Leu Gln Gly Arg Gly Pro Leu Lys Leu Phe Met
35 40 45

Ala Leu Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala Gly
50 55 60

Ile Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala Ile Asn Val
65 70 75 80

Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn
85 90 95

Arg Arg Arg Arg Ser Ala Gly Met Ile Ile Met Leu Ile Pro Thr Val
100 105 110

Met Ala Phe His Leu Thr Thr Arg Asn Gly Glu Pro His Met Ile Val
115 120 125

Ser Arg Gln Glu Lys Gly Lys Ser Leu Leu Phe Lys Thr Glu Val Gly
130 135 140

Val Asn Met Cys Thr Leu Met Ala Met Asp Leu Gly Glu Leu Cys Glu
145 150 155 160

Asp Thr Ile Thr Tyr Glu Cys Pro Leu Leu Arg Gln Asn Glu Pro Glu
165 170 175

Asp Ile Asp Cys Trp Cys Asn Ser Thr Ser Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Thr Thr Met Gly Glu His Arg Arg Glu Lys Arg Ser Val Ala
195 200 205

Leu Val Pro His Val Gly Met Gly Leu Glu Thr Arg Thr Glu Thr Trp
210 215 220

Met Ser Ser Glu Gly Ala Trp Lys His Val Gln Arg Ile Glu Thr Trp
225 230 235 240

Ile Leu Arg His Pro Gly Phe Thr Met Met Ala Ala Ile Leu Ala Tyr
245 250 255

Thr Ile Gly Thr Thr His Phe Gln Arg Ala Leu Ile Phe Ile Leu Leu
260 265 270

Thr Ala Val Thr Pro Ser Met Thr Met Arg Cys Ile Gly Met Ser Asn
275 280 285

Arg Asp Phe Val Glu Gly Val Ser Gly Gly Ser Trp Val Asp Ile Val
290 295 300

Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Phe Glu Leu Ile Lys Thr Glu Ala Lys Gln Pro Ala Thr Leu
325 330 335

Arg Lys Tyr Cys Ile Glu Ala Lys Leu Thr Asn Thr Thr Thr Glu Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Pro Ser Leu Asn Glu Glu Gln Asp Lys
355 360 365

Arg Phe Val Cys Lys His Ser Met Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Gly Ile Val Thr Cys Ala Met Phe Arg
385 390 395 400

Cys Lys Lys Asn Met Glu Gly Lys Val Val Gln Pro Glu Asn Leu Glu
405 410 415

Tyr Thr Ile Val Ile Thr Pro His Ser Gly Glu Glu His Ala Val Gly
420 425 430

Asn Asp Thr Gly Lys His Gly Lys Glu Ile Lys Ile Thr Pro Gln Ser
435 440 445

Ser Ile Thr Glu Ala Glu Leu Thr Gly Tyr Gly Thr Val Thr Met Glu
450 455 460

Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Gln
465 470 475 480

Met Glu Asn Lys Ala Trp Leu Val His Arg Gln Trp Phe Leu Asp Leu
485 490 495

Pro Leu Pro Trp Leu Pro Gly Ala Asp Thr Gln Gly Ser Asn Trp Ile
500 505 510

Gln Lys Glu Thr Leu Val Thr Phe Lys Asn Pro His Ala Lys Lys Gln
515 520 525

Asp Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu
530 535 540

Thr Gly Ala Thr Glu Ile Gln Met Ser Ser Gly Asn Leu Leu Phe Thr
545 550 555 560

Gly His Leu Lys Cys Arg Leu Arg Met Asp Lys Leu Gln Leu Lys Gly
565 570 575

Met Ser Tyr Ser Met Cys Thr Gly Lys Phe Lys Val Val Lys Glu Ile
580 585 590

Ala Glu Thr Gln His Gly Thr Ile Val Ile Arg Val Gln Tyr Glu Gly
595 600 605

Asp Gly Ser Pro Cys Lys Ile Pro Phe Glu Ile Met Asp Leu Glu Lys
610 615 620

Arg His Val Leu Gly Arg Leu Ile Thr Val Asn Pro Ile Val Thr Glu
625 630 635 640

Lys Asp Ser Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Asp Ser
645 650 655

Tyr Ile Ile Ile Gly Val Glu Pro Gly Gln Leu Lys Leu Asn Trp Phe
660 665 670

Lys Lys Gly Ser Ser Ile Gly Gln Met Phe Glu Thr Thr Met Arg Gly
675 680 685

Ala Lys Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser
690 695 700

Leu Gly Gly Val Phe Thr Ser Ile Gly Lys Ala Leu His Gln Val Phe
705 710 715 720

Gly Ala Ile Tyr Gly Ala Ala Phe Ser Gly Val Ser Trp Thr Met Lys
725 730 735

Ile Leu Ile Gly Val Ile Ile Thr Trp Ile Gly Met Asn Ser Arg Ser
740 745 750

Thr Ser Leu Ser Val Thr Leu Val Leu Val Gly Ile Val Thr Leu Tyr
755 760 765

Leu Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys
770 775 780

Asn Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Ile Thr Asp Asn Val
785 790 795 800

His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys
805 810 815

Leu Ala Ser Ala Ile Gln Lys Ala His Glu Glu Asp Ile Cys Gly Ile
820 825 830

Arg Ser Val Thr Arg Leu Glu Asn Leu Met Trp Lys Gln Ile Thr Pro
835 840 845

Glu Leu Asn His Ile Leu Ser Glu Asn Glu Val Lys Leu Thr Ile Met
850 855 860

Thr Gly Asp Ile Lys Gly Ile Met Gln Ala Gly Lys Arg Ser Leu Arg
865 870 875 880

Pro Gln Pro Thr Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala
885 890 895

Lys Met Leu Ser Thr Glu Ser His Asn Gln Thr Phe Leu Ile Asp Gly
900 905 910

Pro Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu
915 920 925

Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu
930 935 940

Lys Leu Lys Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu Met Ser
945 950 955 960

Ala Ala Ile Lys Asp Asn Arg Ala Val His Ala Asp Met Gly Tyr Trp
965 970 975

Ile Glu Ser Ala Leu Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe
980 985 990

Ile Glu Val Lys Asn Cys His Trp Pro Lys Ser His Thr Leu Trp Ser
995 1000 1005

Asn Gly Val Leu Glu Ser Glu Met Ile Ile Pro Lys Asn Leu Ala
1010 1015 1020

Gly Pro Val Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln
1025 1030 1035

Ile Thr Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp
1040 1045 1050

Phe	Cys	Asp	Gly	Thr	Thr	Val	Val	Val	Thr	Glu	Asp	Cys	Gly	Asn
	1055					1060					1065			
Arg	Gly	Pro	Ser	Leu	Arg	Thr	Thr	Thr	Ala	Ser	Gly	Lys	Leu	Ile
	1070					1075					1080			
Thr	Glu	Trp	Cys	Cys	Arg	Ser	Cys	Thr	Leu	Pro	Pro	Leu	Arg	Tyr
	1085					1090					1095			
Arg	Gly	Glu	Asp	Gly	Cys	Trp	Tyr	Gly	Met	Glu	Ile	Arg	Pro	Leu
	1100					1105					1110			
Lys	Glu	Lys	Glu	Glu	Asn	Leu	Val	Asn	Ser	Leu	Val	Thr	Ala	Gly
	1115					1120					1125			
His	Gly	Gln	Val	Asp	Asn	Phe	Ser	Leu	Gly	Val	Leu	Gly	Met	Ala
	1130					1135					1140			
Leu	Phe	Leu	Glu	Glu	Met	Leu	Arg	Thr	Arg	Val	Gly	Thr	Lys	His
	1145					1150					1155			
Ala	Ile	Leu	Leu	Val	Ala	Val	Ser	Phe	Val	Thr	Leu	Ile	Thr	Gly
	1160					1165					1170			
Asn	Met	Ser	Phe	Arg	Asp	Leu	Gly	Arg	Val	Met	Val	Met	Val	Gly
	1175					1180					1185			
Ala	Thr	Met	Thr	Asp	Asp	Ile	Gly	Met	Gly	Val	Thr	Tyr	Leu	Ala
	1190					1195					1200			
Leu	Leu	Ala	Ala	Phe	Lys	Val	Arg	Pro	Thr	Phe	Ala	Ala	Gly	Leu
	1205					1210					1215			
Leu	Leu	Arg	Lys	Leu	Thr	Ser	Lys	Glu	Leu	Met	Met	Thr	Thr	Ile
	1220					1225					1230			
Gly	Ile	Val	Leu	Leu	Ser	Gln	Ser	Thr	Ile	Pro	Glu	Thr	Ile	Leu
	1235					1240					1245			
Glu	Leu	Thr	Asp	Ala	Leu	Ala	Leu	Gly	Met	Met	Val	Leu	Lys	Met
	1250					1255					1260			

Val Arg Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala
1265 1270 1275

Ile Leu Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys
1280 1285 1290

Val Ser Cys Thr Ile Leu Ala Val Val Ser Val Ser Pro Leu Phe
1295 1300 1305

Leu Thr Ser Ser Gln Gln Lys Thr Asp Trp Ile Pro Leu Ala Leu
1310 1315 1320

Thr Ile Lys Gly Leu Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu
1325 1330 1335

Ser Arg Thr Ser Lys Lys Arg Ser Trp Pro Leu Asn Glu Ala Ile
1340 1345 1350

Met Ala Val Gly Met Val Ser Ile Leu Ala Ser Ser Leu Leu Lys
1355 1360 1365

Asn Asp Ile Pro Met Thr Gly Pro Leu Val Ala Gly Gly Leu Leu
1370 1375 1380

Thr Val Cys Tyr Val Leu Thr Gly Arg Ser Ala Asp Leu Glu Leu
1385 1390 1395

Glu Arg Ala Ala Asp Val Lys Trp Glu Asp Gln Ala Glu Ile Ser
1400 1405 1410

Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser Glu Asp Gly Ser
1415 1420 1425

Met Ser Ile Lys Asn Glu Glu Glu Glu Gln Thr Leu Thr Ile Leu
1430 1435 1440

Ile Arg Thr Gly Leu Leu Val Ile Ser Gly Leu Phe Pro Val Ser
1445 1450 1455

Ile Pro Ile Thr Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys Lys
1460 1465 1470

Gln Arg Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Met
1475 1480 1485

Gly Lys Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys
1490 1495 1500

Gly Ile Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu
1505 1510 1515

Gly Thr Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
1520 1525 1530

Met His Lys Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys
1535 1540 1545

Lys Asp Leu Ile Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu
1550 1555 1560

Trp Lys Glu Gly Glu Glu Val Gln Val Leu Ala Leu Glu Pro Gly
1565 1570 1575

Lys Asn Pro Arg Ala Val Gln Thr Lys Pro Gly Leu Phe Lys Thr
1580 1585 1590

Asn Ala Gly Thr Ile Gly Ala Val Ser Leu Asp Phe Ser Pro Gly
1595 1600 1605

Thr Ser Gly Ser Pro Ile Ile Asp Lys Lys Gly Lys Val Val Gly
1610 1615 1620

Leu Tyr Gly Asn Gly Val Val Thr Arg Ser Gly Ala Tyr Val Ser
1625 1630 1635

Ala Ile Ala Gln Thr Glu Lys Ser Ile Glu Asp Asn Pro Glu Ile
1640 1645 1650

Glu Asp Asp Ile Phe Arg Lys Arg Arg Leu Thr Ile Met Asp Leu
1655 1660 1665

His Pro Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro Ala Ile Val
1670 1675 1680

Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu Ala Pro
1685 1690 1695

Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu
1700 1705 1710

Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala Val His Thr Gly
1715 1720 1725

Arg Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg
1730 1735 1740

Leu Leu Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met
1745 1750 1755

Asp Glu Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly
1760 1765 1770

Tyr Ile Ser Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe
1775 1780 1785

Met Thr Ala Thr Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser
1790 1795 1800

Asn Ala Pro Ile Ile Asp Glu Glu Arg Glu Ile Pro Glu Arg Ser
1805 1810 1815

Trp Asn Ser Gly His Glu Trp Val Thr Asp Phe Lys Gly Lys Thr
1820 1825 1830

Val Trp Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Ala
1835 1840 1845

Cys Leu Arg Lys Asn Gly Lys Lys Val Ile Gln Leu Ser Arg Lys
1850 1855 1860

Thr Phe Asp Ser Glu Tyr Val Lys Thr Arg Thr Asn Asp Trp Asp
1865 1870 1875

Phe Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Lys
1880 1885 1890

Ala Glu Arg Val Ile Asp Pro Arg Arg Cys Met Lys Pro Val Ile
1895 1900 1905

Leu Thr Asp Gly Glu Glu Arg Val Ile Leu Ala Gly Pro Met Pro
1910 1915 1920

Val Thr His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly Arg
1925 1930 1935

Asn Pro Lys Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu Pro
1940 1945 1950

Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys Glu Ala Lys Met
1955 1960 1965

Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ser Met
1970 1975 1980

Phe Glu Pro Glu Arg Glu Lys Val Asp Ala Ile Asp Gly Glu Tyr
1985 1990 1995

Arg Leu Arg Gly Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg
2000 2005 2010

Arg Gly Asp Leu Pro Val Trp Leu Ala Tyr Arg Val Ala Ala Glu
2015 2020 2025

Gly Ile Asn Tyr Ala Asp Arg Arg Trp Cys Phe Asp Gly Val Lys
2030 2035 2040

Asn Asn Gln Ile Leu Glu Glu Asn Val Glu Val Glu Ile Trp Thr
2045 2050 2055

Lys Glu Gly Glu Arg Lys Lys Leu Lys Pro Arg Trp Leu Asp Ala
2060 2065 2070

Arg Ile Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Glu Phe
2075 2080 2085

Ala Ala Gly Arg Lys Ser Leu Thr Leu Asn Leu Ile Thr Glu Met
2090 2095 2100

Gly Arg Leu Pro Thr Phe Met Thr Gln Lys Ala Arg Asp Ala Leu
2105 2110 2115

Asp Asn Leu Ala Val Leu His Thr Ala Glu Ala Gly Gly Arg Ala
2120 2125 2130

Tyr Asn His Ala Leu Ser Glu Leu Pro Glu Thr Leu Glu Thr Leu
2135 2140 2145

Leu Leu Leu Thr Leu Leu Ala Thr Val Thr Gly Gly Ile Phe Leu
2150 2155 2160

Phe Leu Met Ser Ala Arg Gly Ile Gly Lys Met Thr Leu Gly Met
2165 2170 2175

Cys Cys Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala Gln Ile
2180 2185 2190

Gln Pro His Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe Leu
2195 2200 2205

Ile Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln
2210 2215 2220

Asp Asn Gln Leu Thr Tyr Val Val Ile Ala Ile Leu Thr Val Val
2225 2230 2235

Ala Ala Thr Met Ala Asn Glu Met Gly Phe Leu Glu Lys Thr Lys
2240 2245 2250

Lys Asp Leu Gly Leu Gly Ser Ile Ala Thr Gln Gln Pro Glu Ser
2255 2260 2265

Asn Ile Leu Asp Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu
2270 2275 2280

Tyr Ala Val Ala Thr Thr Phe Val Thr Pro Met Leu Arg His Ser
2285 2290 2295

Ile Glu Asn Ser Ser Val Asn Val Ser Leu Thr Ala Ile Ala Asn
2300 2305 2310

Gln Ala Thr Val Leu Met Gly Leu Gly Lys Gly Trp Pro Leu Ser
2315 2320 2325

Lys Met Asp Ile Gly Val Pro Leu Leu Ala Ile Gly Cys Tyr Ser
2330 2335 2340

Gln Val Asn Pro Ile Thr Leu Thr Ala Ala Leu Phe Leu Leu Val
2345 2350 2355

Ala His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr
2360 2365 2370

Arg Glu Ala Gln Lys Arg Ala Ala Ala Gly Ile Met Lys Asn Pro
2375 2380 2385

Thr Val Asp Gly Ile Thr Val Ile Asp Leu Asp Pro Ile Pro Tyr
2390 2395 2400

Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val
2405 2410 2415

Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala Leu
2420 2425 2430

Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Ile Ser Thr Leu Trp
2435 2440 2445

Glu Gly Asn Pro Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser
2450 2455 2460

Met Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu
2465 2470 2475

Leu Phe Ser Ile Met Lys Asn Thr Thr Asn Thr Arg Arg Gly Thr
2480 2485 2490

Gly Asn Ile Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu
2495 2500 2505

Asn Ala Leu Gly Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly
2510 2515 2520

Ile Gln Glu Val Asp Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg
2525 2530 2535

Gly Glu Thr Asp His His Ala Val Ser Arg Gly Ser Ala Lys Leu
2540 2545 2550

Arg Trp Phe Val Glu Arg Asn Met Val Thr Pro Glu Gly Lys Val
2555 2560 2565

Val Asp Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Cys Gly
2570 2575 2580

Gly Leu Lys Asn Val Arg Glu Val Lys Gly Leu Thr Lys Gly Gly
2585 2590 2595

Pro Gly His Glu Glu Pro Ile Pro Met Ser Thr Tyr Gly Trp Asn
2600 2605 2610

Leu Val Arg Leu Gln Ser Gly Val Asp Val Phe Phe Ile Pro Pro
2615 2620 2625

Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Pro
2630 2635 2640

Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu Asn Leu
2645 2650 2655

Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Ile Lys Val
2660 2665 2670

Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Lys Met Glu Ala Leu
2675 2680 2685

Gln Arg Lys Tyr Gly Gly Ala Leu Val Arg Asn Pro Leu Ser Arg
2690 2695 2700

Asn Ser Thr His Glu Met Tyr Trp Val Ser Asn Ala Ser Gly Asn
2705 2710 2715

Ile Val Ser Ser Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg
2720 2725 2730

Phe Thr Met Arg Tyr Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp
2735 2740 2745

Leu Gly Ser Gly Thr Arg Asn Ile Gly Ile Glu Ser Glu Ile Pro
2750 2755 2760

Asn Leu Asp Ile Ile Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu
2765 2770 2775

His Glu Thr Ser Trp His Tyr Asp Gln Asp His Pro Tyr Lys Thr
2780 2785 2790

Trp Ala Tyr His Gly Ser Tyr Glu Thr Lys Gln Thr Gly Ser Ala
2795 2800 2805

Ser Ser Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro Trp
2810 2815 2820

Asp Val Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr
2825 2830 2835

Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg
2840 2845 2850

Thr Gln Glu Pro Lys Glu Gly Thr Lys Lys Leu Met Lys Ile Thr
2855 2860 2865

Ala Glu Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys Thr Pro Arg
2870 2875 2880

Met Cys Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn Ala
2885 2890 2895

Ala Leu Gly Ala Val Phe Thr Asp Glu Asn Lys Trp Lys Ser Ala
2900 2905 2910

Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu Leu Val Asp Lys
2915 2920 2925

Glu Arg Asn Leu His Leu Glu Gly Lys Cys Glu Thr Cys Val Tyr
2930 2935 2940

Asn Met Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys
2945 2950 2955

Ala Lys Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg
2960 2965 2970

Phe Leu Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp
2975 2980 2985

Phe Ser Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu
2990 2995 3000

His Lys Leu Gly Tyr Ile Leu Arg Asp Val Ser Lys Lys Glu Gly
3005 3010 3015

Gly Ala Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile
3020 3025 3030

Thr Leu Glu Asp Leu Lys Asn Glu Glu Met Val Thr Asn His Met
3035 3040 3045

Glu Gly Glu His Lys Lys Leu Ala Glu Ala Ile Phe Lys Leu Thr
3050 3055 3060

Tyr Gln Asn Lys Val Val Arg Val Gln Arg Pro Thr Pro Arg Gly
3065 3070 3075

Thr Val Met Asp Ile Ile Ser Arg Arg Asp Gln Arg Gly Ser Gly
3080 3085 3090

Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala
3095 3100 3105

Gln Leu Ile Arg Gln Met Glu Gly Glu Gly Val Phe Lys Ser Ile
3110 3115 3120

Gln His Leu Thr Ile Thr Glu Glu Ile Ala Val Gln Asn Trp Leu
3125 3130 3135

Ala Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser Gly
3140 3145 3150

Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg Phe Ala Ser Ala
3155 3160 3165

Leu Thr Ala Leu Asn Asp Met Gly Lys Ile Arg Lys Asp Ile Gln
3170 3175 3180

Gln Trp Glu Pro Ser Arg Gly Trp Asn Asp Trp Thr Gln Val Pro
3185 3190 3195

Phe Cys Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg
3200 3205 3210

Val Leu Val Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg
3215 3220 3225

Ala Arg Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala
3230 3235 3240

Cys Leu Gly Lys Ser Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe
3245 3250 3255

His Arg Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser Ala
3260 3265 3270

Val Pro Ser His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile
3275 3280 3285

His Ala Lys His Glu Trp Met Thr Thr Glu Asp Met Leu Thr Val
 3290 3295 3300

Trp Asn Arg Val Trp Ile Gln Glu Asn Pro Trp Met Glu Asp Lys
 3305 3310 3315

Thr Pro Val Glu Ser Trp Glu Glu Ile Pro Tyr Leu Gly Lys Arg
 3320 3325 3330

Glu Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala
 3335 3340 3345

Thr Trp Ala Lys Asn Ile Gln Ala Ala Ile Asn Gln Val Arg Ser
 3350 3355 3360

Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser Met Lys
 3365 3370 3375

Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
 3380 3385 3390

<210> 5
 <211> 10717
 <212> DNA
 <213> chimeric dengue serotype 2/3 (MVS)

<400> 5
 agttgtagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaatgta 60
 gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg 120
 aaaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtgcaacag 180
 ctgacaaaga gattctcact tggaatgctg cagggacgag gaccattaaa actgttcatg 240
 gccctggtgg cgttccttcg tttcctaaca atcccaccaa cagcagggat attgaagaga 300
 tggggaacaa ttaaaaaatc aaaagctatt aatgttttga gagggttcag gaaagagatt 360
 ggaaggatgc tgaacatctt gaataggaga cgcagatctg caggcatgat cattatgctg 420
 attccaacag tgatggcggtt ccatttaacc acgcgtgatg gagagccgcg catgattgtg 480
 gggaagaatg aaagaggaaa atccctactt ttcaagacag cctctggaat caacatgtgc 540

acactcatag ctatggatct gggagagatg tgtgatgaca cggtcactta caaatgcccc	600
cacattaccg aagtggagcc tgaagacatt gactgctggg gcaaccttac atcgacatgg	660
gtgacttatg gaacatgcaa tcaagctgga gagcatagac gcgataagag atcagtggcg	720
ttagctcccc atgttggcat gggactggac acacgcactc aaacctggat gtcggctgaa	780
ggagcttgga gacaagtcga gaaggtagag acatgggccc ttaggcaccc agggtttacc	840
atactagccc tatttcttgc ccattacata ggcacttcct tgacccagaa agtggttatt	900
tttatactat taatgctggg taccatcc atgacaatga gatgtgtagg agtaggaaac	960
agagattttg tggaaggcct atcgggagct acgtgggttg acgtgggtgct cgagcacggg	1020
gggtgtgtga ctaccatggc taagaacaag cccacgctgg acatagagct tcagaagacc	1080
gaggccaccc aactggcgac cctaaggaag ctatgcattg agggaaaaat taccaacata	1140
acaaccgact caagatgtcc caccgaagg gaagcgattt tacctgagga gcaggaccag	1200
aactacgtgt gtaagcatac atacgtggac agaggctggg gaaacgggtg tggtttgttt	1260
ggcaagggaa gcttggtgac atgcgcgaaa tttcaatgtt tagaatcaat agagggaaaa	1320
gtggtgcaac atgagaacct caaatacacc gtcacatca cagtgcacac aggagaccaa	1380
caccaggtgg gaaatgaaac gcaggagtc acggctgaga taacacccca ggcatcaacc	1440
gctgaagcca ttttacctga atatggaacc ctcgggctag aatgctcacc acggacaggt	1500
ttggatttca atgaaatgat ctcatgaca atgaagaaca aagcatggat ggtacataga	1560
caatggttct ttgacttacc cctaccatgg acatcaggag cttcagcaga aacaccaact	1620
tggaacagga aagagcttct tgtgacattt aaaaatgcac atgcaaaaaa gcaagaagta	1680
gttgttcttg gatcacaaga gggagcaatg catacagcac tgacaggagc tacagagatc	1740
caaacctcag gaggcacaag tatctttgcg gggcacttaa aatgtagact caagatggac	1800
aaattggaac tcaaggggat gagctatgca atgtgcttga gtagctttgt gttgaagaaa	1860
gaagtctccg aaacgcagca tgggacaata ctcatgaagg ttgagtacaa aggggaagat	1920
gcaccctgca agattccttt ctccacggag gatggacaag gaaaagctct caatggcaga	1980
ctgatcacag ccaatccagt ggtgaccaag aaggaggagc ctgtcaacat tgaggctgaa	2040
cctccttttg gagaaagtaa catagtaatt ggaattggag acaaagccct gaaaatcaac	2100
tggatcaaga aggaagctc gattgggaag atgttcgagg ccactgccag aggtgcaagg	2160

cgcatggcca tcttgggaga cacagcctgg gactttggat cagtgggtgg tgttttgaat	2220
tcattaggga aaatggtcca ccaaataattt gggagtgcctt acacagccct atttggtgga	2280
gtctcctgga tgatgaaaat tggaataggt gtcctcttaa cctggatagg gttgaactca	2340
aaaaatactt ctatgtcatt ttcatgcata gcggccggca ttgtgacact gtatttggga	2400
gtcatggtgc aggccgatag tggttgcgtt gtgagctgga aaaacaaaga actgaaatgt	2460
ggcagtggga ttttcatcac agacaacgtg cacacatgga cagaacaata caagttccaa	2520
ccagaatccc cttcaaaact agcttcagct atccagaaag cccatgaaga ggacatttgt	2580
ggaatccgct cagtaacaag actggagaat ctgatgtgga aacaaataac accagaattg	2640
aatcacattc tatcagaaaa tgaggtgaag ttaactatta tgacaggaga catcaaagga	2700
atcatgcagg caggaaaacg atctctgcgg cctcagccca ctgagctgaa gtattcatgg	2760
aaaacatggg gcaaagcaaa aatgctctct acagagtctc ataaccagac ctttctcatt	2820
gatggccccg aaacagcaga atgccccaac acaaatagag cttggaattc gttggaagtt	2880
gaagactatg gctttggagt attcaccacc aatatatggc taaaattgaa agaaaaacag	2940
gatgtattct gcgactcaaa actcatgtca gcggccataa aagacaacag agccgtccat	3000
gccgatatgg gttattggat agaaagtgca ctcaatgaca catggaagat agagaaagcc	3060
tctttcattg aagttaaaaa ctgccactgg ccaaatacac acaccctctg gagcaatgga	3120
gtgctagaaa gtgagatgat aattccaaag aatctcgctg gaccagtgtc tcaacacaac	3180
tatagaccag gctaccatac acaaataaca ggaccatggc atctaggtaa gcttgagatg	3240
gactttgatt tctgtgatgg aacaacagtg gtagtgactg aggactgcgg aaatagagga	3300
ccctctttga gaacaaccac tgcctctgga aaactcataa cagaatgggtg ctgccgatct	3360
tgcacattac caccgctaag atacagaggt gaggatgggt gctggtacgg gatggaaatc	3420
agaccattga aggagaaaga agagaatttg gtcaactcct tggtcacagc tggacatggg	3480
caggtcgaca acttttctact aggagtcttg ggaatggcat tgttcctgga ggaaatgctt	3540
aggacccgag taggaacgaa acatgcaata ctactagtgt cagtttcttt tgtgacattg	3600
atcacaggga acatgtcctt tagagacctg ggaagagtga tggttatggt aggcgccact	3660
atgacggatg acataggtat gggcgtgact tatcttgccc tactagcagc cttcaaagtc	3720
agaccaactt ttgcagctgg actactcttg agaaagctga cctccaagga attgatgatg	3780

actactatag gaattgtact cctctcccag agcaccatac cagagaccat tcttgagttg	3840
actgatgcgt tagccttagg catgatggtc ctcaaaatgg tgagaaatat ggaaaagtat	3900
caattggcag tgactatcat ggctatcttg tgcgtcccaa acgcagtgat attacaaaac	3960
gcatggaaag tgagttgcac aatattggca gtggtgtccg tttccccact gttcttaaca	4020
tcctcacagc aaaaaacaga ttggatacca ttagcattga cgatcaaagg tctcaatcca	4080
acagctatth ttctaacaac cctctcaaga accagcaaga aaaggagctg gccattaaat	4140
gaggctatca tggcagtcgg gatggtgagc attttagcca gttctctcct aaaaaatgat	4200
attcccatga caggaccatt agtggctgga gggctcctca ctgtgtgcta cgtgctcact	4260
ggacgatcgg ccgatttgga actggagaga gcagccgatg tcaaatggga agaccaggca	4320
gagatatcag gaagcagtc aatcctgtca ataacaatat cagaagatgg tagcatgtcg	4380
ataaaaaatg aagaggaaga acaaacactg accatactca ttagaacagg attgctgggtg	4440
atctcaggac tttttcctgt atcaatacca atcacggcag cagcatggta cctgtgggaa	4500
gtgaagaaac aacgggccgg agtattgtgg gatgttcctt cacccccacc catgggaaag	4560
gctgaactgg aagatggagc ctatagaatt aagcaaaaag ggattcttgg atattcccag	4620
atcggagccg gagtttacia agaaggaaca ttccatacaa tgtggcatgt cacacgtggc	4680
gctgttctaa tgcataaagg aaagaggatt gaaccatcat gggcggacgt caagaaagac	4740
ctaatatcat atggaggagg ctggaagtta gaaggagaat ggaaggaagg agaagaagtc	4800
caggatattg cactggagcc tggaaaaaat ccaagagccg tccaaacgaa acctggtctt	4860
ttcaaaacca acgccgaac aataggtgct gtatctctgg acttttctcc tggaacgtca	4920
ggatctccaa ttatcgacia aaaaggaaaa gttgtgggtc tttatggtaa tgggtgttgtt	4980
acaaggagtg gagcatatgt gagtgctata gcccagactg aaaaaagcat tgaagacaac	5040
ccagagatcg aagatgacat tttccgaaag agaagactga ccatcatgga cctccacca	5100
ggagcgggaa agacgaagag ataccttccg gccatagtca gagaagctat aaaacggggt	5160
ttgagaacat taatcttggc cccactaga gttgtggcag ctgaaatgga ggaagccctt	5220
agaggacttc caataagata ccagaccca gccatcagag ctgtgcacac cgggcgggag	5280
attgtggacc taatgtgtca tgccacattt accatgaggc tgctatcacc agttagagtg	5340
ccaaactaca acctgattat catggacgaa gccatttca cagaccagc aagtatagca	5400

gctagaggat	acatctcaac	tcgagtggag	atgggtgagg	cagctgggat	ttttatgaca	5460
gccactcccc	cgggaagcag	agaccatttt	cctcagagca	atgcaccaat	catagatgaa	5520
gaaagagaaa	tccctgaacg	ctcgtggaat	tccggacatg	aatgggtcac	ggattttaaa	5580
gggaagactg	tttggttcgt	tccaagtata	aaagcaggaa	atgatatagc	agcttgccctg	5640
aggaaaaatg	gaaagaaagt	gatacaactc	agtaggaaga	cctttgattc	tgagtatgtc	5700
aagactagaa	ccaatgattg	ggacttcgtg	gttacaactg	acatttcaga	aatgggtgcc	5760
aatttcaagg	ctgagagggt	tatagacccc	agacgctgca	tgaaaccagt	catactaaca	5820
gatggtgaag	agcgggtgat	tctggcagga	cctatgccag	tgaccactc	tagtgcagca	5880
caaagaagag	ggagaatagg	aagaaatcca	aaaaatgaga	atgaccagta	catatacatg	5940
ggggaacctc	tggaaaatga	tgaagactgt	gcacactgga	aagaagctaa	aatgctccta	6000
gataacatca	acacgccaga	aggaatcatt	cctagcatgt	tcgaaccaga	gcgtgaaaag	6060
gtggatgcca	ttgatggcga	ataccgcttg	agaggagaag	caaggaaaac	ctttgtagac	6120
ttaatgagaa	gaggagacct	accagtctgg	ttggcctaca	gagtggcagc	tgaaggcatc	6180
aactacgcag	acagaagggt	gtgttttgat	ggagtcaaga	acaaccaa	cctagaagaa	6240
aacgtggaag	ttgaaatctg	gacaaaagaa	ggggaaagga	agaaattgaa	accagatgg	6300
ttggatgcta	ggatctattc	tgaccactg	gcgctaaaag	aatttaagga	atttgcagcc	6360
ggaagaaagt	ctctgaccct	gaacctaatc	acagaaatgg	gtaggctccc	aaccttcatg	6420
actcagaagg	caagagacgc	actggacaac	ttagcagtgc	tgcacacggc	tgaggcaggt	6480
ggaagggcgt	acaaccatgc	tctcagtga	ctgccggaga	ccctggagac	attgctttta	6540
ctgacacttc	tggctacagt	cacgggaggg	atctttttat	tcttgatgag	cgcaaggggc	6600
atagggaaga	tgaccctggg	aatgtgctgc	ataatcacgg	ctagcatcct	cctatggtac	6660
gcacaaatac	agccacactg	gatagcagct	tcaataatac	tggagttttt	tctcatagtt	6720
ttgcttattc	cagaacctga	aaaacagaga	acacccaag	acaaccaact	gacctacgtt	6780
gtcatagcca	tcctcacagt	ggtggccgca	accatggcaa	acgagatggg	tttcctagaa	6840
aaaacgaaga	aagatctcgg	attgggaagc	attgcaaccc	agcaaccgga	gagcaacatc	6900
ctggacatag	atctacgtcc	tgcatcagca	tggacgtgt	atgccgtggc	cacaacattt	6960
gttacaccaa	tgttgagaca	tagcattgaa	aattcctcag	tgaatgtgtc	cctaacagct	7020

atagccaacc aagccacagt gttaatgggt ctctgggaaag gatggccatt gtcaaagatg	7080
gacatcggag ttccccttct cgccattgga tgctactcac aagtcaaccc cataactctc	7140
acagcagctc ttttcttatt ggtagcacat tatgccatca tagggccagg actccaagca	7200
aaagcaacca gagaagctca gaaaagagca gcggcgggca tcatgaaaaa cccaactgtc	7260
gatggaataa cagtgattga cctagatcca ataccttatg atccaaagtt tgaaaagcag	7320
ttgggacaag taatgctcct agtcctctgc gtgactcaag tattgatgat gaggactaca	7380
tgggctctgt gtgaggcttt aaccttagct accgggcccc tctccacatt gtgggaagga	7440
aatccaggga ggttttggaa cactaccatt gcggtgtcaa tggctaacat ttttagaggg	7500
agttacttgg ccggagctgg acttctcttt tctattatga agaacacaac caacacaaga	7560
aggggaactg gcaacatagg agagacgctt ggagagaaat ggaaaagccg attgaacgcg	7620
ttgggaaaaa gtgaattcca gatctacaag aaaagtggaa tccaggaagt ggatagaacc	7680
ttagcaaaaag aaggcattaa aagaggagaa acggaccatc acgctgtgtc gcgaggctca	7740
gcaaaactga gatggttcgt tgagagaaac atggtcacac cagaagggaag agtagtggac	7800
ctcggttggtg gcagaggagg ctggtcatac tattgtggag gactaaagaa tgtaagagaa	7860
gtcaaaggcc taacaaaagg aggaccagga cacgaagaac ccatccccat gtcaacatat	7920
gggtggaatc tagtgcgtct tcaaagtgga gttgacgttt tcttcatccc gccagaaaag	7980
tgtgacacat tattgtgtga cataggggag tcatcaccaa atcccacagt ggaagcagga	8040
cgaacactca gagtccctaa cttagtagaa aattggttga acaacaacac tcaattttgc	8100
ataaagggtt tcaaccata tatgccctca gtcatagaaa aaatggaagc actacaaagg	8160
aaatatggag gagccttagt gaggaatcca ctctcacgaa actccacaca tgagatgtac	8220
tgggtatcca atgcttccgg gaacatagtg tcatcagtga acatgatttc aaggatgttg	8280
atcaacagat ttacaatgag atacaagaaa gccacttacg agccggatgt tgacctcgga	8340
agcggaaccc gtaacatcgg gattgaaagt gagataccaa acctagatat aattgggaaa	8400
agaatagaaa aaataaagca agagcatgaa acatcatggc actatgacca agaccacca	8460
tacaaaacgt gggcatacca tggtagctat gaaacaaaac agactggatc agcatcatcc	8520
atggtcaacg gagtggtcag gctgctgaca aaaccttggg acgtcgtccc catggtgaca	8580
cagatggcaa tgacagacac gactccattt ggacaacagc gcgtttttta agagaaaagt	8640

gacacgagaa cccaagaacc gaaagaaggc acgaagaaac taatgaaaat aacagcagag	8700
tggcttttga aagaattagg gaagaaaaag acaccagga tgtgcaccag agaagaattc	8760
acaagaaagg tgagaagcaa tgcagccttg ggggccatat tcactgatga gaacaagtgg	8820
aagtcggcac gtgaggctgt tgaagatagt aggttttggg agctggttga caaggaaagg	8880
aatctccatc ttgaaggaaa gtgtgaaaca tgttgtgtaca acatgatggg aaaaagagag	8940
aagaagctag gggaattcgg caaggcaaaa ggcagcagag ccatatggta catgtggctt	9000
ggagcacgct tcttagagtt tgaagcccta ggattcttaa atgaagatca ctggttctcc	9060
agagagaact ccctgagtgg agtggaagga gaagggtgc acaagctagg ttacattcta	9120
agagacgtga gcaagaaaga gggaggagca atgtatgccg atgacaccgc aggatgggat	9180
acaagaatca cactagaaga cctaaaaaat gaagaaatgg taacaaacca catggaagga	9240
gaacacaaga aactagccga ggccattttc aaactaacgt accaaaacaa ggtggtgcgt	9300
gtgcaaagac caacaccaag aggcacagta atggacatca tatcgagaag agaccaaaga	9360
ggtagtggac aagttggcac ctatggactc aatactttca ccaatatgga agcccaacta	9420
atcagacaga tggagggaga aggagtcttt aaaagcattc agcacctaac aatcacagaa	9480
gaaatcgctg tgcaaaactg gttagcaaga gtggggcgcg aaaggttatc aagaatggcc	9540
atcagtggag atgatttgtt tgtgaaacct ttagatgaca ggttcgcaag cgctttaaca	9600
gctctaaatg acatgggaaa gattaggaaa gacatacaac aatgggaacc ttcaagagga	9660
tggaatgatt ggacacaagt gcccttctgt tcacaccatt tccatgagtt aatcatgaaa	9720
gacggtcgcg tactcgttgt tccatgtaga aaccaagatg aactgattgg cagagcccga	9780
atctcccaag gagcagggtg gtcttttcgg gagacggcct gtttggggaa gtcttacgcc	9840
caaatgtgga gcttgatgta cttccacaga cgcgacctca ggctggcggc aaatgctatt	9900
tgctcggcag taccatcaca ttgggttcca acaagtcgaa caacctggtc catacatgct	9960
aaacatgaat ggatgacaac ggaagacatg ctgacagtct ggaacagggt gtggattcaa	10020
gaaaacccat ggatggaaga caaaactcca gtggaatcat gggaggaaat cccatacttg	10080
gggaaaagag aagaccaatg gtgcggctca ttgattgggt taacaagcag ggccacctgg	10140
gcaaagaaca tccaagcagc aataaatcaa gttagatccc ttataggcaa tgaagaatac	10200
acagattaca tgccatccat gaaaagattc agaagagaag aggaagaagc aggagtctctg	10260

tggtagaaag caaaactaac atgaaacaag gctagaagtc aggtcggatt aagccatagt	10320
acggaaaaaa ctatgctacc tgtgagcccc gtccaaggac gttaaaagaa gtcaggccat	10380
cataaatgcc atagcttgag taaactatgc agcctgtagc tccacctgag aaggtgtaaa	10440
aaatccggga ggccacaaac catggaagct gtacgcatgg cgtagtggac tagcggttag	10500
aggagacccc tcccttacia atcgcagcaa caatgggggc ccaaggcgag atgaagctgt	10560
agtctcgctg gaaggactag aggttagagg agaccccccc gaaacaaaaa acagcatatt	10620
gacgctggga aagaccagag atcctgctgt ctcctcagca tcattccagg cacagaacgc	10680
cagaaaatgg aatggtgctg ttgaatcaac aggttct	10717

<210> 6
 <211> 3389
 <212> PRT
 <213> chimeric dengue serotype 2/3 (MVS)

<400> 6

Met	Asn	Asn	Gln	Arg	Lys	Lys	Ala	Lys	Asn	Thr	Pro	Phe	Asn	Met	Leu
1				5				10						15	

Lys	Arg	Glu	Arg	Asn	Arg	Val	Ser	Thr	Val	Gln	Gln	Leu	Thr	Lys	Arg
		20						25					30		

Phe	Ser	Leu	Gly	Met	Leu	Gln	Gly	Arg	Gly	Pro	Leu	Lys	Leu	Phe	Met
		35					40					45			

Ala	Leu	Val	Ala	Phe	Leu	Arg	Phe	Leu	Thr	Ile	Pro	Pro	Thr	Ala	Gly
	50					55					60				

Ile	Leu	Lys	Arg	Trp	Gly	Thr	Ile	Lys	Lys	Ser	Lys	Ala	Ile	Asn	Val
65					70					75				80	

Leu	Arg	Gly	Phe	Arg	Lys	Glu	Ile	Gly	Arg	Met	Leu	Asn	Ile	Leu	Asn
			85					90						95	

Arg	Arg	Arg	Arg	Ser	Ala	Gly	Met	Ile	Ile	Met	Leu	Ile	Pro	Thr	Val
			100					105					110		

Met	Ala	Phe	His	Leu	Thr	Thr	Arg	Asp	Gly	Glu	Pro	Arg	Met	Ile	Val
		115					120					125			

Gly Lys Asn Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr Ala Ser Gly
130 135 140

Ile Asn Met Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Met Cys Asp
145 150 155 160

Asp Thr Val Thr Tyr Lys Cys Pro His Ile Thr Glu Val Glu Pro Glu
165 170 175

Asp Ile Asp Cys Trp Cys Asn Leu Thr Ser Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Asn Gln Ala Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala
195 200 205

Leu Ala Pro His Val Gly Met Gly Leu Asp Thr Arg Thr Gln Thr Trp
210 215 220

Met Ser Ala Glu Gly Ala Trp Arg Gln Val Glu Lys Val Glu Thr Trp
225 230 235 240

Ala Leu Arg His Pro Gly Phe Thr Ile Leu Ala Leu Phe Leu Ala His
245 250 255

Tyr Ile Gly Thr Ser Leu Thr Gln Lys Val Val Ile Phe Ile Leu Leu
260 265 270

Met Leu Val Thr Pro Ser Met Thr Met Arg Cys Val Gly Val Gly Asn
275 280 285

Arg Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val
290 295 300

Leu Glu His Gly Gly Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Ile Glu Leu Gln Lys Thr Glu Ala Thr Gln Leu Ala Thr Leu
325 330 335

Arg Lys Leu Cys Ile Glu Gly Lys Ile Thr Asn Ile Thr Thr Asp Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Ala Ile Leu Pro Glu Glu Gln Asp Gln
355 360 365

Asn Tyr Val Cys Lys His Thr Tyr Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Ser Leu Val Thr Cys Ala Lys Phe Gln
385 390 395 400

Cys Leu Glu Ser Ile Glu Gly Lys Val Val Gln His Glu Asn Leu Lys
405 410 415

Tyr Thr Val Ile Ile Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430

Asn Glu Thr Gln Gly Val Thr Ala Glu Ile Thr Pro Gln Ala Ser Thr
435 440 445

Ala Glu Ala Ile Leu Pro Glu Tyr Gly Thr Leu Gly Leu Glu Cys Ser
450 455 460

Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Ile Ser Leu Thr Met Lys
465 470 475 480

Asn Lys Ala Trp Met Val His Arg Gln Trp Phe Phe Asp Leu Pro Leu
485 490 495

Pro Trp Thr Ser Gly Ala Ser Ala Glu Thr Pro Thr Trp Asn Arg Lys
500 505 510

Glu Leu Leu Val Thr Phe Lys Asn Ala His Ala Lys Lys Gln Glu Val
515 520 525

Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu Thr Gly
530 535 540

Ala Thr Glu Ile Gln Thr Ser Gly Gly Thr Ser Ile Phe Ala Gly His
545 550 555 560

Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Glu Leu Lys Gly Met Ser
565 570 575

Tyr Ala Met Cys Leu Ser Ser Phe Val Leu Lys Lys Glu Val Ser Glu
580 585 590

Thr Gln His Gly Thr Ile Leu Ile Lys Val Glu Tyr Lys Gly Glu Asp
595 600 605

Ala Pro Cys Lys Ile Pro Phe Ser Thr Glu Asp Gly Gln Gly Lys Ala
610 615 620

Leu Asn Gly Arg Leu Ile Thr Ala Asn Pro Val Val Thr Lys Lys Glu
625 630 635 640

Glu Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser Asn Ile
645 650 655

Val Ile Gly Ile Gly Asp Lys Ala Leu Lys Ile Asn Trp Tyr Lys Lys
660 665 670

Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly Ala Arg
675 680 685

Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Val Gly
690 695 700

Gly Val Leu Asn Ser Leu Gly Lys Met Val His Gln Ile Phe Gly Ser
705 710 715 720

Ala Tyr Thr Ala Leu Phe Gly Gly Val Ser Trp Met Met Lys Ile Gly
725 730 735

Ile Gly Val Leu Leu Thr Trp Ile Gly Leu Asn Ser Lys Asn Thr Ser
740 745 750

Met Ser Phe Ser Cys Ile Ala Ala Gly Ile Val Thr Leu Tyr Leu Gly
755 760 765

Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys Asn Lys
770 775 780

Glu Leu Lys Cys Gly Ser Gly Ile Phe Ile Thr Asp Asn Val His Thr
785 790 795 800

Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys Leu Ala
805 810 815

Ser Ala Ile Gln Lys Ala His Glu Glu Asp Ile Cys Gly Ile Arg Ser
820 825 830

Val Thr Arg Leu Glu Asn Leu Met Trp Lys Gln Ile Thr Pro Glu Leu
835 840 845

Asn His Ile Leu Ser Glu Asn Glu Val Lys Leu Thr Ile Met Thr Gly
850 855 860

Asp Ile Lys Gly Ile Met Gln Ala Gly Lys Arg Ser Leu Arg Pro Gln
865 870 875 880

Pro Thr Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala Lys Met
885 890 895

Leu Ser Thr Glu Ser His Asn Gln Thr Phe Leu Ile Asp Gly Pro Glu
900 905 910

Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu Glu Val
915 920 925

Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu Lys Leu
930 935 940

Lys Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu Met Ser Ala Ala
945 950 955 960

Ile Lys Asp Asn Arg Ala Val His Ala Asp Met Gly Tyr Trp Ile Glu
965 970 975

Ser Ala Leu Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe Ile Glu
980 985 990

Val Lys Asn Cys His Trp Pro Lys Ser His Thr Leu Trp Ser Asn Gly
995 1000 1005

Val Leu Glu Ser Glu Met Ile Ile Pro Lys Asn Leu Ala Gly Pro
1010 1015 1020

Val Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln Ile Thr
1025 1030 1035

Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp Phe Cys
1040 1045 1050

Asp Gly Thr Thr Val Val Val Thr Glu Asp Cys Gly Asn Arg Gly
1055 1060 1065

Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly Lys Leu Ile Thr Glu
1070 1075 1080

Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Tyr Arg Gly
1085 1090 1095

Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Leu Lys Glu
1100 1105 1110

Lys Glu Glu Asn Leu Val Asn Ser Leu Val Thr Ala Gly His Gly
1115 1120 1125

Gln Val Asp Asn Phe Ser Leu Gly Val Leu Gly Met Ala Leu Phe
1130 1135 1140

Leu Glu Glu Met Leu Arg Thr Arg Val Gly Thr Lys His Ala Ile
1145 1150 1155

Leu Leu Val Ala Val Ser Phe Val Thr Leu Ile Thr Gly Asn Met
1160 1165 1170

Ser Phe Arg Asp Leu Gly Arg Val Met Val Met Val Gly Ala Thr
1175 1180 1185

Met Thr Asp Asp Ile Gly Met Gly Val Thr Tyr Leu Ala Leu Leu
1190 1195 1200

Ala Ala Phe Lys Val Arg Pro Thr Phe Ala Ala Gly Leu Leu Leu
1205 1210 1215

Arg Lys Leu Thr Ser Lys Glu Leu Met Met Thr Thr Ile Gly Ile
1220 1225 1230

Val Leu Leu Ser Gln Ser Thr Ile Pro Glu Thr Ile Leu Glu Leu
1235 1240 1245

Thr Asp Ala Leu Ala Leu Gly Met Met Val Leu Lys Met Val Arg
1250 1255 1260

Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala Ile Leu
1265 1270 1275

Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys Val Ser
1280 1285 1290

Cys Thr Ile Leu Ala Val Val Ser Val Ser Pro Leu Phe Leu Thr
1295 1300 1305

Ser Ser Gln Gln Lys Thr Asp Trp Ile Pro Leu Ala Leu Thr Ile
1310 1315 1320

Lys Gly Leu Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu Ser Arg
1325 1330 1335

Thr Ser Lys Lys Arg Ser Trp Pro Leu Asn Glu Ala Ile Met Ala
1340 1345 1350

Val Gly Met Val Ser Ile Leu Ala Ser Ser Leu Leu Lys Asn Asp
1355 1360 1365

Ile Pro Met Thr Gly Pro Leu Val Ala Gly Gly Leu Leu Thr Val
1370 1375 1380

Cys Tyr Val Leu Thr Gly Arg Ser Ala Asp Leu Glu Leu Glu Arg
1385 1390 1395

Ala Ala Asp Val Lys Trp Glu Asp Gln Ala Glu Ile Ser Gly Ser
1400 1405 1410

Ser Pro Ile Leu Ser Ile Thr Ile Ser Glu Asp Gly Ser Met Ser
1415 1420 1425

Ile Lys Asn Glu Glu Glu Glu Gln Thr Leu Thr Ile Leu Ile Arg
1430 1435 1440

Thr Gly Leu Leu Val Ile Ser Gly Leu Phe Pro Val Ser Ile Pro
1445 1450 1455

Ile Thr Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys Lys Gln Arg
1460 1465 1470

Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Met Gly Lys
1475 1480 1485

Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys Gly Ile
1490 1495 1500

Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu Gly Thr
1505 1510 1515

Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu Met His
1520 1525 1530

Lys Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys Lys Asp
1535 1540 1545

Leu Ile Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu Trp Lys
1550 1555 1560

Glu Gly Glu Glu Val Gln Val Leu Ala Leu Glu Pro Gly Lys Asn
1565 1570 1575

Pro Arg Ala Val Gln Thr Lys Pro Gly Leu Phe Lys Thr Asn Ala
1580 1585 1590

Gly Thr Ile Gly Ala Val Ser Leu Asp Phe Ser Pro Gly Thr Ser
1595 1600 1605

Gly Ser Pro Ile Ile Asp Lys Lys Gly Lys Val Val Gly Leu Tyr
1610 1615 1620

Gly Asn Gly Val Val Thr Arg Ser Gly Ala Tyr Val Ser Ala Ile
1625 1630 1635

Ala Gln Thr Glu Lys Ser Ile Glu Asp Asn Pro Glu Ile Glu Asp
1640 1645 1650

Asp Ile Phe Arg Lys Arg Arg Leu Thr Ile Met Asp Leu His Pro
1655 1660 1665

Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro Ala Ile Val Arg Glu
1670 1675 1680

Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu Ala Pro Thr Arg
1685 1690 1695

Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu Pro Ile
1700 1705 1710

Arg Tyr Gln Thr Pro Ala Ile Arg Ala Val His Thr Gly Arg Glu
1715 1720 1725

Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg Leu Leu
1730 1735 1740

Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met Asp Glu
1745 1750 1755

Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly Tyr Ile
1760 1765 1770

Ser Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe Met Thr
1775 1780 1785

Ala Thr Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser Asn Ala
1790 1795 1800

Pro Ile Ile Asp Glu Glu Arg Glu Ile Pro Glu Arg Ser Trp Asn
1805 1810 1815

Ser Gly His Glu Trp Val Thr Asp Phe Lys Gly Lys Thr Val Trp
1820 1825 1830

Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Ala Cys Leu
1835 1840 1845

Arg Lys Asn Gly Lys Lys Val Ile Gln Leu Ser Arg Lys Thr Phe
1850 1855 1860

Asp Ser Glu Tyr Val Lys Thr Arg Thr Asn Asp Trp Asp Phe Val
1865 1870 1875

Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Lys Ala Glu
1880 1885 1890

Arg Val Ile Asp Pro Arg Arg Cys Met Lys Pro Val Ile Leu Thr
1895 1900 1905

Asp Gly Glu Glu Arg Val Ile Leu Ala Gly Pro Met Pro Val Thr
1910 1915 1920

His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly Arg Asn Pro
1925 1930 1935

Lys Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu Pro Leu Glu
1940 1945 1950

Asn Asp Glu Asp Cys Ala His Trp Lys Glu Ala Lys Met Leu Leu
1955 1960 1965

Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ser Met Phe Glu
1970 1975 1980

Pro Glu Arg Glu Lys Val Asp Ala Ile Asp Gly Glu Tyr Arg Leu
1985 1990 1995

Arg Gly Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg Arg Gly
2000 2005 2010

Asp Leu Pro Val Trp Leu Ala Tyr Arg Val Ala Ala Glu Gly Ile
2015 2020 2025

Asn Tyr Ala Asp Arg Arg Trp Cys Phe Asp Gly Val Lys Asn Asn
2030 2035 2040

Gln Ile Leu Glu Glu Asn Val Glu Val Glu Ile Trp Thr Lys Glu
2045 2050 2055

Gly Glu Arg Lys Lys Leu Lys Pro Arg Trp Leu Asp Ala Arg Ile
2060 2065 2070

Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Glu Phe Ala Ala
2075 2080 2085

Gly Arg Lys Ser Leu Thr Leu Asn Leu Ile Thr Glu Met Gly Arg
2090 2095 2100

Leu Pro Thr Phe Met Thr Gln Lys Ala Arg Asp Ala Leu Asp Asn
2105 2110 2115

Leu Ala Val Leu His Thr Ala Glu Ala Gly Gly Arg Ala Tyr Asn
2120 2125 2130

His Ala Leu Ser Glu Leu Pro Glu Thr Leu Glu Thr Leu Leu Leu
2135 2140 2145

Leu Thr Leu Leu Ala Thr Val Thr Gly Gly Ile Phe Leu Phe Leu
2150 2155 2160

Met Ser Ala Arg Gly Ile Gly Lys Met Thr Leu Gly Met Cys Cys
2165 2170 2175

Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala Gln Ile Gln Pro
2180 2185 2190

His Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe Leu Ile Val
2195 2200 2205

Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln Asp Asn
2210 2215 2220

Gln Leu Thr Tyr Val Val Ile Ala Ile Leu Thr Val Val Ala Ala
2225 2230 2235

Thr Met Ala Asn Glu Met Gly Phe Leu Glu Lys Thr Lys Lys Asp
2240 2245 2250

Leu Gly Leu Gly Ser Ile Ala Thr Gln Gln Pro Glu Ser Asn Ile
2255 2260 2265

Leu Asp Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu Tyr Ala
2270 2275 2280

Val Ala Thr Thr Phe Val Thr Pro Met Leu Arg His Ser Ile Glu
2285 2290 2295

Asn Ser Ser Val Asn Val Ser Leu Thr Ala Ile Ala Asn Gln Ala
2300 2305 2310

Thr Val Leu Met Gly Leu Gly Lys Gly Trp Pro Leu Ser Lys Met
2315 2320 2325

Asp Ile Gly Val Pro Leu Leu Ala Ile Gly Cys Tyr Ser Gln Val
2330 2335 2340

Asn Pro Ile Thr Leu Thr Ala Ala Leu Phe Leu Leu Val Ala His
2345 2350 2355

Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr Arg Glu
2360 2365 2370

Ala Gln Lys Arg Ala Ala Ala Gly Ile Met Lys Asn Pro Thr Val
2375 2380 2385

Asp Gly Ile Thr Val Ile Asp Leu Asp Pro Ile Pro Tyr Asp Pro
2390 2395 2400

Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val Leu Cys
2405 2410 2415

Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala Leu Cys Glu
2420 2425 2430

Ala Leu Thr Leu Ala Thr Gly Pro Ile Ser Thr Leu Trp Glu Gly
2435 2440 2445

Asn Pro Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser Met Ala
2450 2455 2460

Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu Leu Phe
2465 2470 2475

Ser Ile Met Lys Asn Thr Thr Asn Thr Arg Arg Gly Thr Gly Asn
2480 2485 2490

Ile Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu Asn Ala
2495 2500 2505

Leu Gly Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly Ile Gln
2510 2515 2520

Glu Val Asp Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg Gly Glu
2525 2530 2535

Thr Asp His His Ala Val Ser Arg Gly Ser Ala Lys Leu Arg Trp
2540 2545 2550

Phe Val Glu Arg Asn Met Val Thr Pro Glu Gly Lys Val Val Asp
2555 2560 2565

Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Cys Gly Gly Leu
2570 2575 2580

Lys Asn Val Arg Glu Val Lys Gly Leu Thr Lys Gly Gly Pro Gly
2585 2590 2595

His Glu Glu Pro Ile Pro Met Ser Thr Tyr Gly Trp Asn Leu Val
2600 2605 2610

Arg Leu Gln Ser Gly Val Asp Val Phe Phe Ile Pro Pro Glu Lys
2615 2620 2625

Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Pro Asn Pro
2630 2635 2640

Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu Asn Leu Val Glu
2645 2650 2655

Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Ile Lys Val Leu Asn
2660 2665 2670

Pro Tyr Met Pro Ser Val Ile Glu Lys Met Glu Ala Leu Gln Arg
2675 2680 2685

Lys Tyr Gly Gly Ala Leu Val Arg Asn Pro Leu Ser Arg Asn Ser
2690 2695 2700

Thr His Glu Met Tyr Trp Val Ser Asn Ala Ser Gly Asn Ile Val
2705 2710 2715

Ser Ser Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg Phe Thr
2720 2725 2730

Met Arg Tyr Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp Leu Gly
2735 2740 2745

Ser Gly Thr Arg Asn Ile Gly Ile Glu Ser Glu Ile Pro Asn Leu
2750 2755 2760

Asp Ile Ile Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu His Glu
2765 2770 2775

Thr Ser Trp His Tyr Asp Gln Asp His Pro Tyr Lys Thr Trp Ala
2780 2785 2790

Tyr His Gly Ser Tyr Glu Thr Lys Gln Thr Gly Ser Ala Ser Ser
2795 2800 2805

Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro Trp Asp Val
2810 2815 2820

Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr Pro Phe
2825 2830 2835

Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg Thr Gln
2840 2845 2850

Glu Pro Lys Glu Gly Thr Lys Lys Leu Met Lys Ile Thr Ala Glu
2855 2860 2865

Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys Thr Pro Arg Met Cys
2870 2875 2880

Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn Ala Ala Leu
2885 2890 2895

Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys Ser Ala Arg Glu
2900 2905 2910

Ala Val Glu Asp Ser Arg Phe Trp Glu Leu Val Asp Lys Glu Arg
2915 2920 2925

Asn Leu His Leu Glu Gly Lys Cys Glu Thr Cys Val Tyr Asn Met
2930 2935 2940

Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys Ala Lys
2945 2950 2955

Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Phe Leu
2960 2965 2970

Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe Ser
2975 2980 2985

Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu His Lys
2990 2995 3000

Leu Gly Tyr Ile Leu Arg Asp Val Ser Lys Lys Glu Gly Gly Ala
3005 3010 3015

Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile Thr Leu
3020 3025 3030

Glu Asp Leu Lys Asn Glu Glu Met Val Thr Asn His Met Glu Gly
3035 3040 3045

Glu His Lys Lys Leu Ala Glu Ala Ile Phe Lys Leu Thr Tyr Gln
3050 3055 3060

Asn Lys Val Val Arg Val Gln Arg Pro Thr Pro Arg Gly Thr Val
3065 3070 3075

Met Asp Ile Ile Ser Arg Arg Asp Gln Arg Gly Ser Gly Gln Val
3080 3085 3090

Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala Gln Leu
3095 3100 3105

Ile Arg Gln Met Glu Gly Glu Gly Val Phe Lys Ser Ile Gln His
3110 3115 3120

Leu Thr Ile Thr Glu Glu Ile Ala Val Gln Asn Trp Leu Ala Arg
3125 3130 3135

Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser Gly Asp Asp
3140 3145 3150

Cys Val Val Lys Pro Leu Asp Asp Arg Phe Ala Ser Ala Leu Thr
3155 3160 3165

Ala Leu Asn Asp Met Gly Lys Ile Arg Lys Asp Ile Gln Gln Trp
3170 3175 3180

Glu Pro Ser Arg Gly Trp Asn Asp Trp Thr Gln Val Pro Phe Cys
3185 3190 3195

Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg Val Leu
3200 3205 3210

Val Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg Ala Arg
3215 3220 3225

Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys Leu
3230 3235 3240

Gly Lys Ser Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe His Arg
3245 3250 3255

Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser Ala Val Pro
3260 3265 3270

Ser His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile His Ala
3275 3280 3285

Lys His Glu Trp Met Thr Thr Glu Asp Met Leu Thr Val Trp Asn
3290 3295 3300

Arg Val Trp Ile Gln Glu Asn Pro Trp Met Glu Asp Lys Thr Pro
3305 3310 3315

Val Glu Ser Trp Glu Glu Ile Pro Tyr Leu Gly Lys Arg Glu Asp
3320 3325 3330

Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala Thr Trp
3335 3340 3345

Ala Lys Asn Ile Gln Ala Ala Ile Asn Gln Val Arg Ser Leu Ile
3350 3355 3360

Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser Met Lys Arg Phe
3365 3370 3375

Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
3380 3385

<210> 7

<211> 10723

<212> DNA

<213> chimeric dengue seroytpe 2/4 (MVS)

<220>
<221> r
<222> (3773)..(3773)
<223> a or g

<400> 7
agttgttagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaatgta 60
gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg 120
aaaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtgcaacag 180
ctgacaaaga gattctcact tggaatgctg cagggacgag gacctttaaa actgttcatg 240
gccctgggtg cgttccttcg tttcctaaca atcccaccaa cagcagggat attgaagaga 300
tggggaacaa ttaaaaaatc aaaagctatt aatgttttga gagggttcag gaaagagatt 360
ggaaggatgc tgaacatctt gaataggaga cgcagctctg caggcatgat cattatgctg 420
attccaacag tgatggcggt ccatttaacc acgcgtgatg gcgaaccctt catgatagtg 480
gcaaaacatg aaagggggag acctctcttg ttttaagacaa cagaggggat caacaaatgc 540
actctcattg ccatggactt ggggtgaaatg tgtgaggaca ctgtcacgta taaatgcccc 600
ttactgggtca ataccgaacc tgaagacatt gattgctggg gcaatctcac gtctacctgg 660
gtcatgtatg ggacatgcac ccagagcgga gaacggagac gagagaagcg ctcatgtagct 720
ttaacaccac attcaggaat gggatttgaa acaagagctg agacatggat gtcacggaa 780
ggggcttgga agcatgctca gagagtagag agctggatac tcagaaaccc aggattcgcg 840
ctcttggcag gatttatggc ttatatgatt gggcaaacag gaatccagcg aactgtcttc 900
ttgtcctaa tgatgctggg cgccccatcc tacggaatgc gatgcgtagg agtaggaaac 960
agagactttg tggaaggagt ctcaggtgga gcatgggtcg atctgggtgct agaacatgga 1020
ggatgcgtca caaccatggc ccagggaata ccaaccttgg attttgaact gactaagaca 1080
acagccaagg aagtggctct gttaagaacc tattgcattg aagcctcaat atcaaacata 1140
accacggcaa caagatgtcc aacgcaagga gagccttatc taaaagagga acaagaccaa 1200
cagtacattt gccggagaga tgtggtagac agagggtggg gcaatggctg tggcttgttt 1260
ggaaaaggag gagttgtgac atgtgcgaag ttttcatgtt cggggaagat aacaggcaat 1320
ttggtccaaa ttgagaacct tgaatacaca gtggttgtaa cagtccacaa tggagacacc 1380
catgcagtag gaaatgacac gtccaatcat ggagttacag ccacgataac tcccagggtca 1440

ccatcggtgg aagtcaaatt gccggactat ggagaactaa cactcgattg tgaacccagg	1500
tctggaattg actttaatga gatgattctg atgaaaatga aaaagaaaac atggcttgtg	1560
cataagcaat ggTTTTTgga tctacctcta ccatggacag caggagcaga cacatcagag	1620
gttacttgga attacaaaga gagaatggtg acatttaagg ttctcatgc caagagacag	1680
gatgtgacag tgctgggatc tcaggaagga gccatgcatt ctgccctcgc tggagccaca	1740
gaagtggact ccggtgatgg aaatcacatg tttgcaggac atctcaagtg caaagtccgt	1800
atggagaaat tgagaatcaa gggaatgtca tacacgatgt gttcaggaaa gttctcaatt	1860
gacaaagaga tggcagaaac acagcatggg acaacagtgg tgaaagtcaa gtatgaaggt	1920
gctggagctc cgtgtaaagt ccccatagag ataagagatg tgaacaagga aaaagtgggt	1980
gggcgtatca tctcatccac ccctttggct gagaatacca acagtgtaac caacatagag	2040
ttagaacccc cctttgggga cagctacata gtgatagggt ttggaaacag tgcattaaca	2100
ctccattgggt tcaggaaagg gagttccatt ggcaagatgt ttgagtccac atacagaggt	2160
gcaaaacgaa tggccattct aggtgaaaca gcttgggatt ttggttccgt tgggtggactg	2220
ttcacatcat tgggaaaggc tgtgcaccag gtttttggaa gtgtgtatac aaccctgttt	2280
ggaggagtct catggatgat tagaatccta attgggttcc tagtgttgtg gattggcacg	2340
aactcaagga acatttcaat ggctatgacg tgcatagctg ccggcattgt gacactgtat	2400
ttgggggtca tgggtgcaggc cgatagtgggt tgcgttgtga gctggaaaaa caaagaactg	2460
aaatgtggca gtgggatttt catcacagac aacgtgcaca catggacaga acaatacaag	2520
ttccaaccag aatccccctt aaaactagct tcagctatcc agaaagccca tgaagaggac	2580
atttgtggaa tccgctcagt aacaagactg gagaatctga tgtggaaaca aataacacca	2640
gaattgaatc acattctatc agaaaatgag gtgaagttaa ctattatgac aggagacatc	2700
aaaggaatca tgcaggcagg aaaacgatct ctgcggcctc agcccactga gctgaagtat	2760
tcatggaaaa catggggcaa agcaaaaatg ctctctacag agtctcataa ccagaccttt	2820
ctcattgatg gccccgaaac agcagaatgc cccaacacaa atagagcttg gaattcgttg	2880
gaagttgaag actatggctt tggagtattc accaccaata tatggctaaa attgaaagaa	2940
aaacaggatg tattctgcga ctcaaaactc atgtcagcgg ccataaaaga caacagagcc	3000
gtccatgccg atatgggtta ttggatagaa agtgcactca atgacacatg gaagatagag	3060

aaagcctctt tcattgaagt taaaaactgc cactggccaa aatcacacac cctctggagc	3120
aatggagtgc tagaaagtga gatgataatt ccaaagaatc tcgctggacc agtgtctcaa	3180
cacaactata gaccaggcta ccatacacia ataacaggac catggcatct aggtaagctt	3240
gagatggact ttgatttctg tgatggaaca acagtggtag tgactgagga ctgcggaaat	3300
agaggaccct ctttgagaac aaccactgcc tctggaaaac tcataacaga atgggtgctgc	3360
cgatcttgca cattaccacc gctaagatac agaggtagg atgggtgctg gtacgggatg	3420
gaaatcagac cattgaagga gaaagaagag aatttgggtca actccttgggt cacagctgga	3480
catgggcagg tcgacaactt ttcactagga gtcttgggaa tggcattgtt cctggaggaa	3540
atgcttagga cccgagtagg aacgaaacat gcaatactac tagttgcagt ttcttttctg	3600
acattgatca cagggaacat gtcctttaga gacctgggaa gagtgatggt tatggtaggc	3660
gccactatga cgggtgacat aggtatgggc gtgacttatt ttgccctact agcagccttc	3720
aaagtcagac caacttttgc agctggacta ctcttgagaa agctgacctc carggaattg	3780
atgatgacta ctataggaat tgtactcttc tcccagagca ccataccaga gaccattctt	3840
gagttgactg atgcgttagc cttaggcatt atggctctca aaatgggtgag aaatatggaa	3900
aagtatcaat tggcagtgac tatcatggct atcttgtgcg tcccaaacgc agtgatatta	3960
caaaacgcat ggaaagtgag ttgcacaata ttggcagtggt tgtccgtttc cccactgttc	4020
ttaacatcct cacagcaaaa aacagattgg ataccattag cattgacgat caaaggcttc	4080
aatccaacag ctatttttct aacaaccctc tcaagaacca gcaagaaaag gagctggcca	4140
ttaaattgagg ctatcatggc agtcgggatg gtgagcattt tagccagttc tctcctaaaa	4200
aatgatattc ccatgacagg accattagtg gctggagggc tcctcactgt gtgctacgtg	4260
ctcactggac gatcggccga tttggaactg gagagagcag ccgatgtcaa atgggaagac	4320
caggcagaga tatcaggaag cagtccaatc ctgtcaataa caatatcaga agatggtagc	4380
atgtcgataa aaaatgaaga ggaagaacaa aactgacca tactcattag aacaggattg	4440
ctggtgatct caggactttt tcctgtatca ataccaatca cggcagcagc atgggtacgtg	4500
tgggaagtga agaaacaacg ggccggagta ttgtgggatg ttccttcacc cccacccatg	4560
ggaaaggctg aactggaaga tggagcctat agaattaagc aaaaagggat tcttgatat	4620
tcccagatcg gagccggagt ttacaaagaa ggaacattcc atacaatgtg gcatgtcaca	4680

cgtggcgctg ttctaattgca taaaggaaag aggattgaac catcatgggc ggacgtcaag	4740
aaagacctaa tatcatatgg aggaggctgg aagttagaag gagaatggaa ggaaggagaa	4800
gaagtccagg tattggcact ggagcctgga aaaaatccaa gagccgtcca aacgaaacct	4860
ggtcttttca aaaccaacgc cggaacaata ggtgctgtat ctctggactt ttctcctgga	4920
acgtcaggat ctccaattat cgacaaaaaa ggaaaagttg tgggtcttta tggtaatggt	4980
gttgttacaa ggagtggagc atatgtgagt gctatagccc agactgaaaa aagcattgaa	5040
gacaaccag agatcgaaga tgacattttc cgaaagagaa gactgaccat catggacctc	5100
caccagagg cgaggaaagac gaagagatac cttccggcca tagtcagaga agctataaaa	5160
cggggtttga gaacattaat cttggcccc actagagttg tggcagctga aatggaggaa	5220
gcccttagag gacttccaat aagataccag accccagcca tcagagctgt gcacaccggg	5280
cgggagattg tggacctaat gtgtcatgcc acatttacca tgaggctgct atcaccagtt	5340
agagtgccaa actacaacct gattatcatg gacgaagccc atttcacaga tccagcaagt	5400
atagcagcta gaggatacat ctcaactcga gtggagatgg gtgaggcagc tgggattttt	5460
atgacagcca ctccccggg aagcagagac ccatttcctc agagcaatgc accaatcata	5520
gatgaagaaa gagaaatccc tgaacgctcg tggaattccg gacatgaatg ggtcacggat	5580
tttaaaggga agactgtttg gttcgtttca agtataaaaag caggaaatga tatagcagct	5640
tgcctgagga aaaatggaaa gaaagtgata caactcagta ggaagacctt tgattctgag	5700
tatgtcaaga ctagaaccaa tgattgggac ttcgtgggta caactgacat ttcagaaatg	5760
ggtgccatt tcaaggctga gaggggtata gaccccagac gctgcatgaa accagtcata	5820
ctaacagatg gtgaagagcg ggtgattctg gcaggaccta tgccagtgaac ccactctagt	5880
gcagcacaaa gaagaggagg aataggaaga aatccaaaaa atgagaatga ccagtacata	5940
tacatggggg aacctctgga aaatgatgaa gactgtgcac actggaaaga agctaaaatg	6000
ctcctagata acatcaacac gccagaagga atcattccta gcatgttcga accagagcgt	6060
gaaaaggtgg atgccattga tggcgaatac cgcttgagag gagaagcaag gaaaaccttt	6120
gtagacttaa tgagaaggagg agacctacca gtctgggttg cctacagagt ggcagctgaa	6180
ggcatcaact acgcagacag aaggtggtgt tttgatggag tcaagaacaa ccaaattccta	6240
gaagaaaacg tggaagttga aatctggaca aaagaagggg aaaggaagaa attgaaacct	6300

agatggttgg atgctaggat ctattctgac ccactggcgc taaaagaatt taaggaattt	6360
gcagccggaa gaaagtctct gaccctgaac ctaatcacag aaatgggtag gctcccaacc	6420
ttcatgactc agaaggtaag agacgcactg gacaacttag cagtgtgca cacggctgag	6480
gcaggtggaa gggcgtacaa ccatgctctc agtgaactgc cggagaccct ggagacattg	6540
cttttactga cacttctggc tacagtcacg ggagggatct ttttattctt gatgagcgca	6600
aggggcatag ggaagatgac cctgggaatg tgctgcataa tcacggctag catcctccta	6660
tggtacgcac aaatacagcc aactggata gcagcttcaa taatactgga gttttttctc	6720
atagttttgc ttattccaga acctgaaaaa cagagaacac cccaagacaa ccaactgacc	6780
tacgttgtca tagccatcct cacagtgggtg gccgcaacca tggcaaacga gatgggtttc	6840
ctagaaaaaa cgaagaaaga tctcggattg ggaagcattg caaccagca acccgagagc	6900
aacatcctgg acatagatct acgtcctgca tcagcatgga cgctgtatgc cgtggccaca	6960
acatttgta caccaatgtt gagacatagc attgaaaatt cctcagtga tgtgtcccta	7020
acagccatag ccaaccaagc cacagtgtta atgggtctcg ggaaaggatg gccattgtca	7080
aagatggaca tcggagttcc ctttctcgcc attggatgct actcacaagt caacccata	7140
actctcacag cagctctttt cttattggta gcacattatg ccatcatagg gccaggactc	7200
caagcaaaag caaccagaga agctcagaaa agagcagcgg cgggcatcat gaaaaacca	7260
actgtcgatg gaataacagt gattgaccta gatccaatac cttatgatcc aaagtttgaa	7320
aagcagttgg gacaagtaat gtcctagtc ctctgcgtga ctcaagtatt gatgatgagg	7380
actacatggg ctctgtgtga ggctttaacc ttagctaccg ggcccatctc cacattgtgg	7440
gaaggaaatc caggaggtt ttggaacact accattgcgg tgtcaatggc taacattttt	7500
agagggagtt acttggccgg agctggactt ctcttttcta ttatgaagaa cacaaccaac	7560
acaagaaggg gaactggcaa cataggagag acgcttggag agaaatggaa aagccgattg	7620
aacgcattgg gaaaaagtga attccagatc tacaagaaaa gtggaatcca ggaagtggat	7680
agaaccttag caaaagaagg cattaaaaga ggagaaacgg accatcacgc tgtgtcgcga	7740
ggctcagcaa aactgagatg gttcgttgag agaaacatgg tcacaccaga agggaaagta	7800
gtggacctcg gttgtggcag aggaggctgg tcatactatt gtggaggact aaagaatgta	7860
agagaagtca aaggcctaac aaaaggagga ccaggacacg aagaacccat ccccatgtca	7920

acatatgggt	ggaatctagt	gcgtcttcaa	agtggagttg	acgttttctt	catcccgcca	7980
gaaaagtgtg	acacattatt	gtgtgacata	ggggagtcac	caccaaacc	cacagtggaa	8040
gcaggacgaa	cactcagagt	ccttaactta	gtagaaaatt	ggttgaacaa	caacactcaa	8100
ttttgcataa	aggttctcaa	cccatatatg	ccctcagtca	tagaaaaaat	ggaagcacta	8160
caaaggaaat	atggaggagc	cttagtgagg	aatccactct	cacgaaactc	cacacatgag	8220
atgtactggg	tatccaatgc	ttccgggaac	atagtgtcat	cagtgaacat	gatttcaagg	8280
atgttgatca	acagatttac	aatgagatac	aagaaagcca	cttacgagcc	ggatgttgac	8340
ctcggaagcg	gaacccgtaa	catcgggatt	gaaagtgaga	taccaaacct	agatataatt	8400
gggaaaagaa	tagaaaaaat	aaagcaagag	catgaaacat	catggcacta	tgaccaagac	8460
cacccataca	aaacgtgggc	ataccatggg	agctatgaaa	caaaacagac	tggatcagca	8520
tcatccatgg	tcaacggagt	ggtcaggctg	ctgacaaaac	cttgggacgt	cgtcccatg	8580
gtgacacaga	tggcaatgac	agacacgact	ccatttggac	aacagcgcgt	ttttaagag	8640
aaagtggaca	cgagaaccca	agaaccgaaa	gaaggcacga	agaaactaat	gaaaataaca	8700
gcagagtggc	tttggaaaga	attaggggaag	aaaaagacac	ccaggatgtg	caccagagaa	8760
gaattcacia	gaaaggtgag	aagcaatgca	gccttggggg	ccatattcac	tgatgagaac	8820
aagtggaggt	cggcacgtga	ggctgttgaa	gatagtaggt	tttgggagct	ggttgacaag	8880
gaaaggaatc	tccatcttga	aggaaagtgt	gaaacatgtg	tgtacaacat	gatgggaaaa	8940
agagagaaga	agctagggga	attcggcaag	gcaaaaggca	gcagagccat	atggtacatg	9000
tggcttggag	cacgcttctt	agagtttgaa	gccctaggat	tcttaaatga	agatcactgg	9060
ttctccagag	agaactccct	gagtggagtg	gaaggagaag	ggctgcacaa	gctaggttac	9120
attctaagag	acgtgagcaa	gaaagaggga	ggagcaatgt	atgccgatga	caccgcagga	9180
tgggatacaa	gaatcacact	agaagacctt	aaaaatgaag	aaatggtaac	aaaccacatg	9240
gaaggagaac	acaagaaact	agccgaggcc	attttcaaac	taacgtacca	aaacaaggtg	9300
gtgcgtgtgc	aaagaccaac	accaagaggc	acagtaatgg	acatcatatc	gagaagagac	9360
caaagaggta	gtggacaagt	tggcacctat	ggactcaata	ctttcaccaa	tatggaagcc	9420
caactaatca	gacagatgga	gggagaagga	gtcttttaaaa	gcattcagca	cctaacaatc	9480
acagaagaaa	tcgctgtgca	aaactgggtt	gcaagagtgg	ggcgcgaaag	gttatcaaga	9540

atggccatca gtggagatga ttgtgtttgtg aaaccttttag atgacagggtt cgcaagcgct	9600
ttaacagctc taaatgacat gggaaagatt aggaaagaca tacaacaatg ggaaccttca	9660
agaggatgga atgattggac acaagtgtccc ttctgtttcac accattttcca tgagttaatc	9720
atgaaagacg gtcgcgtact cgttggtttccc tgtagaaacc aagatgaact gattggcaga	9780
gcccgaatct cccaaggagc aggggtggtct ttgcggggaga cggcctgttt ggggaagtct	9840
tacgccccaaa tgtggagctt gatgtacttc cacagacgcg acctcaggct ggcggcaaat	9900
gctattttgct cggcagtacc atcacattgg gttccaacaa gtcgaacaac ctggtccata	9960
catgctaaac atgaatggat gacaacggaa gacatgctga cagtctggaa cagggtgtgg	10020
attcaagaaa acccatggat ggaagacaaa actccagtgg aatcatggga ggaaatccca	10080
tacttggggga aaagagaaga ccaatggtgc ggctcattga ttgggttaac aagcagggcc	10140
acctgggcaa agaacatcca agcagcaata aatcaagtta gatcccttat aggcaatgaa	10200
gaatacacag attacatgcc atccatgaaa agattcagaa gagaagagga agaagcagga	10260
gttctgtggt agaaagcaaa actaacatga aacaaggcta gaagtcagggt cggattaagc	10320
catagtacgg aaaaaactat gctacctgtg agccccgtcc aaggacgtta aaagaagtca	10380
ggccatcata aatgccatag cttgagtaaa ctatgcagcc tgtagctcca cctgagaagg	10440
tgtaaaaaat ccgggaggcc acaaaccatg gaagctgtac gcatggcgta gtggactagc	10500
ggttagagga gaccctccc ttacaaatcg cagcaacaat gggggcccaa ggcgagatga	10560
agctgtagtc tcgctggaag gactagaggt tagaggagac ccccccgaag caaaaaacag	10620
catattgacg ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca	10680
gaacgccaga aaatggaatg gtgctgttga atcaacaggt tct	10723

<210> 8
 <211> 3391
 <212> PRT
 <213> chimeric dengue serotype 2/4 (MVS)

<220>
 <221> Xaa
 <222> (1226)..(1226)
 <223> Arg or Lys

<400> 8

Met Asn Asn Gln Arg Lys Lys Ala Lys Asn Thr Pro Phe Asn Met Leu
1 5 10 15

Lys Arg Glu Arg Asn Arg Val Ser Thr Val Gln Gln Leu Thr Lys Arg
20 25 30

Phe Ser Leu Gly Met Leu Gln Gly Arg Gly Pro Leu Lys Leu Phe Met
35 40 45

Ala Leu Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala Gly
50 55 60

Ile Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala Ile Asn Val
65 70 75 80

Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn
85 90 95

Arg Arg Arg Ser Ser Ala Gly Met Ile Ile Met Leu Ile Pro Thr Val
100 105 110

Met Ala Phe His Leu Thr Thr Arg Asp Gly Glu Pro Leu Met Ile Val
115 120 125

Ala Lys His Glu Arg Gly Arg Pro Leu Leu Phe Lys Thr Thr Glu Gly
130 135 140

Ile Asn Lys Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Met Cys Glu
145 150 155 160

Asp Thr Val Thr Tyr Lys Cys Pro Leu Leu Val Asn Thr Glu Pro Glu
165 170 175

Asp Ile Asp Cys Trp Cys Asn Leu Thr Ser Thr Trp Val Met Tyr Gly
180 185 190

Thr Cys Thr Gln Ser Gly Glu Arg Arg Arg Glu Lys Arg Ser Val Ala
195 200 205

Leu Thr Pro His Ser Gly Met Gly Leu Glu Thr Arg Ala Glu Thr Trp
210 215 220

Met Ser Ser Glu Gly Ala Trp Lys His Ala Gln Arg Val Glu Ser Trp
225 230 235 240

Ile Leu Arg Asn Pro Gly Phe Ala Leu Leu Ala Gly Phe Met Ala Tyr
245 250 255

Met Ile Gly Gln Thr Gly Ile Gln Arg Thr Val Phe Phe Val Leu Met
260 265 270

Met Leu Val Ala Pro Ser Tyr Gly Met Arg Cys Val Gly Val Gly Asn
275 280 285

Arg Asp Phe Val Glu Gly Val Ser Gly Gly Ala Trp Val Asp Leu Val
290 295 300

Leu Glu His Gly Gly Cys Val Thr Thr Met Ala Gln Gly Lys Pro Thr
305 310 315 320

Leu Asp Phe Glu Leu Thr Lys Thr Thr Ala Lys Glu Val Ala Leu Leu
325 330 335

Arg Thr Tyr Cys Ile Glu Ala Ser Ile Ser Asn Ile Thr Thr Ala Thr
340 345 350

Arg Cys Pro Thr Gln Gly Glu Pro Tyr Leu Lys Glu Glu Gln Asp Gln
355 360 365

Gln Tyr Ile Cys Arg Arg Asp Val Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Gly Val Val Thr Cys Ala Lys Phe Ser
385 390 395 400

Cys Ser Gly Lys Ile Thr Gly Asn Leu Val Gln Ile Glu Asn Leu Glu
405 410 415

Tyr Thr Val Val Val Thr Val His Asn Gly Asp Thr His Ala Val Gly
420 425 430

Asn Asp Thr Ser Asn His Gly Val Thr Ala Thr Ile Thr Pro Arg Ser
435 440 445

Pro Ser Val Glu Val Lys Leu Pro Asp Tyr Gly Glu Leu Thr Leu Asp
450 455 460

Cys Glu Pro Arg Ser Gly Ile Asp Phe Asn Glu Met Ile Leu Met Lys
465 470 475 480

Met Lys Lys Lys Thr Trp Leu Val His Lys Gln Trp Phe Leu Asp Leu
485 490 495

Pro Leu Pro Trp Thr Ala Gly Ala Asp Thr Ser Glu Val His Trp Asn
500 505 510

Tyr Lys Glu Arg Met Val Thr Phe Lys Val Pro His Ala Lys Arg Gln
515 520 525

Asp Val Thr Val Leu Gly Ser Gln Glu Gly Ala Met His Ser Ala Leu
530 535 540

Ala Gly Ala Thr Glu Val Asp Ser Gly Asp Gly Asn His Met Phe Ala
545 550 555 560

Gly His Leu Lys Cys Lys Val Arg Met Glu Lys Leu Arg Ile Lys Gly
565 570 575

Met Ser Tyr Thr Met Cys Ser Gly Lys Phe Ser Ile Asp Lys Glu Met
580 585 590

Ala Glu Thr Gln His Gly Thr Thr Val Val Lys Val Lys Tyr Glu Gly
595 600 605

Ala Gly Ala Pro Cys Lys Val Pro Ile Glu Ile Arg Asp Val Asn Lys
610 615 620

Glu Lys Val Val Gly Arg Ile Ile Ser Ser Thr Pro Leu Ala Glu Asn
625 630 635 640

Thr Asn Ser Val Thr Asn Ile Glu Leu Glu Pro Pro Phe Gly Asp Ser
645 650 655

Tyr Ile Val Ile Gly Val Gly Asn Ser Ala Leu Thr Leu His Trp Phe
660 665 670

Arg Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ser Thr Tyr Arg Gly
675 680 685

Ala Lys Arg Met Ala Ile Leu Gly Glu Thr Ala Trp Asp Phe Gly Ser
690 695 700

Val Gly Gly Leu Phe Thr Ser Leu Gly Lys Ala Val His Gln Val Phe
705 710 715 720

Gly Ser Val Tyr Thr Thr Leu Phe Gly Gly Val Ser Trp Met Ile Arg
725 730 735

Ile Leu Ile Gly Phe Leu Val Leu Trp Ile Gly Thr Asn Ser Arg Asn
740 745 750

Thr Ser Met Ala Met Thr Cys Ile Ala Ala Gly Ile Val Thr Leu Tyr
755 760 765

Leu Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys
770 775 780

Asn Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Ile Thr Asp Asn Val
785 790 795 800

His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys
805 810 815

Leu Ala Ser Ala Ile Gln Lys Ala His Glu Glu Asp Ile Cys Gly Ile
820 825 830

Arg Ser Val Thr Arg Leu Glu Asn Leu Met Trp Lys Gln Ile Thr Pro
835 840 845

Glu Leu Asn His Ile Leu Ser Glu Asn Glu Val Lys Leu Thr Ile Met
850 855 860

Thr Gly Asp Ile Lys Gly Ile Met Gln Ala Gly Lys Arg Ser Leu Arg
865 870 875 880

Pro Gln Pro Thr Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala
885 890 895

Lys Met Leu Ser Thr Glu Ser His Asn Gln Thr Phe Leu Ile Asp Gly
900 905 910

Pro Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu
915 920 925

Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu
930 935 940

Lys Leu Lys Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu Met Ser
945 950 955 960

Ala Ala Ile Lys Asp Asn Arg Ala Val His Ala Asp Met Gly Tyr Trp
965 970 975

Ile Glu Ser Ala Leu Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe
980 985 990

Ile Glu Val Lys Asn Cys His Trp Pro Lys Ser His Thr Leu Trp Ser
995 1000 1005

Asn Gly Val Leu Glu Ser Glu Met Ile Ile Pro Lys Asn Leu Ala
1010 1015 1020

Gly Pro Val Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln
1025 1030 1035

Ile Thr Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp
1040 1045 1050

Phe Cys Asp Gly Thr Thr Val Val Val Thr Glu Asp Cys Gly Asn
1055 1060 1065

Arg Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly Lys Leu Ile
1070 1075 1080

Thr Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Tyr
1085 1090 1095

Arg Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Leu
1100 1105 1110

Lys Glu Lys Glu Glu Asn Leu Val Asn Ser Leu Val Thr Ala Gly
1115 1120 1125

His Gly Gln Val Asp Asn Phe Ser Leu Gly Val Leu Gly Met Ala
1130 1135 1140

Leu Phe Leu Glu Glu Met Leu Arg Thr Arg Val Gly Thr Lys His
1145 1150 1155

Ala Ile Leu Leu Val Ala Val Ser Phe Val Thr Leu Ile Thr Gly
1160 1165 1170

Asn Met Ser Phe Arg Asp Leu Gly Arg Val Met Val Met Val Gly
1175 1180 1185

Ala Thr Met Thr Gly Asp Ile Gly Met Gly Val Thr Tyr Leu Ala
1190 1195 1200

Leu Leu Ala Ala Phe Lys Val Arg Pro Thr Phe Ala Ala Gly Leu
1205 1210 1215

Leu Leu Arg Lys Leu Thr Ser Xaa Glu Leu Met Met Thr Thr Ile
1220 1225 1230

Gly Ile Val Leu Leu Ser Gln Ser Thr Ile Pro Glu Thr Ile Leu
1235 1240 1245

Glu Leu Thr Asp Ala Leu Ala Leu Gly Met Met Val Leu Lys Met
1250 1255 1260

Val Arg Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala
1265 1270 1275

Ile Leu Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys
1280 1285 1290

Val Ser Cys Thr Ile Leu Ala Val Val Ser Val Ser Pro Leu Phe
1295 1300 1305

Leu Thr Ser Ser Gln Gln Lys Thr Asp Trp Ile Pro Leu Ala Leu
1310 1315 1320

Thr Ile Lys Gly Leu Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu
1325 1330 1335

Ser Arg Thr Ser Lys Lys Arg Ser Trp Pro Leu Asn Glu Ala Ile
1340 1345 1350

Met Ala Val Gly Met Val Ser Ile Leu Ala Ser Ser Leu Leu Lys
1355 1360 1365

Asn Asp Ile Pro Met Thr Gly Pro Leu Val Ala Gly Gly Leu Leu
1370 1375 1380

Thr Val Cys Tyr Val Leu Thr Gly Arg Ser Ala Asp Leu Glu Leu
1385 1390 1395

Glu Arg Ala Ala Asp Val Lys Trp Glu Asp Gln Ala Glu Ile Ser
1400 1405 1410

Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser Glu Asp Gly Ser
1415 1420 1425

Met Ser Ile Lys Asn Glu Glu Glu Glu Gln Thr Leu Thr Ile Leu
1430 1435 1440

Ile Arg Thr Gly Leu Leu Val Ile Ser Gly Leu Phe Pro Val Ser
1445 1450 1455

Ile Pro Ile Thr Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys Lys
1460 1465 1470

Gln Arg Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Met
1475 1480 1485

Gly Lys Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys
1490 1495 1500

Gly Ile Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu
1505 1510 1515

Gly Thr Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
1520 1525 1530

Met His Lys Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys
1535 1540 1545

Lys Asp Leu Ile Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu
1550 1555 1560

Trp Lys Glu Gly Glu Glu Val Gln Val Leu Ala Leu Glu Pro Gly
1565 1570 1575

Lys Asn Pro Arg Ala Val Gln Thr Lys Pro Gly Leu Phe Lys Thr
1580 1585 1590

Asn Ala Gly Thr Ile Gly Ala Val Ser Leu Asp Phe Ser Pro Gly
1595 1600 1605

Thr Ser Gly Ser Pro Ile Ile Asp Lys Lys Gly Lys Val Val Gly
1610 1615 1620

Leu Tyr Gly Asn Gly Val Val Thr Arg Ser Gly Ala Tyr Val Ser
1625 1630 1635

Ala Ile Ala Gln Thr Glu Lys Ser Ile Glu Asp Asn Pro Glu Ile
1640 1645 1650

Glu Asp Asp Ile Phe Arg Lys Arg Arg Leu Thr Ile Met Asp Leu
1655 1660 1665

His Pro Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro Ala Ile Val
1670 1675 1680

Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu Ala Pro
1685 1690 1695

Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu
1700 1705 1710

Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala Val His Thr Gly
1715 1720 1725

Arg Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg
1730 1735 1740

Leu Leu Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met
1745 1750 1755

Asp Glu Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly
1760 1765 1770

Tyr Ile Ser Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe
1775 1780 1785

Met Thr Ala Thr Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser
1790 1795 1800

Asn Ala Pro Ile Ile Asp Glu Glu Arg Glu Ile Pro Glu Arg Ser
1805 1810 1815

Trp Asn Ser Gly His Glu Trp Val Thr Asp Phe Lys Gly Lys Thr
1820 1825 1830

Val Trp Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Ala
1835 1840 1845

Cys Leu Arg Lys Asn Gly Lys Lys Val Ile Gln Leu Ser Arg Lys
1850 1855 1860

Thr Phe Asp Ser Glu Tyr Val Lys Thr Arg Thr Asn Asp Trp Asp
1865 1870 1875

Phe Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Lys
1880 1885 1890

Ala Glu Arg Val Ile Asp Pro Arg Arg Cys Met Lys Pro Val Ile
1895 1900 1905

Leu Thr Asp Gly Glu Glu Arg Val Ile Leu Ala Gly Pro Met Pro
1910 1915 1920

Val Thr His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly Arg
1925 1930 1935

Asn Pro Lys Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu Pro
1940 1945 1950

Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys Glu Ala Lys Met
1955 1960 1965

Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ser Met
1970 1975 1980

Phe Glu Pro Glu Arg Glu Lys Val Asp Ala Ile Asp Gly Glu Tyr
1985 1990 1995

Arg Leu Arg Gly Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg
2000 2005 2010

Arg Gly Asp Leu Pro Val Trp Leu Ala Tyr Arg Val Ala Ala Glu
2015 2020 2025

Gly Ile Asn Tyr Ala Asp Arg Arg Trp Cys Phe Asp Gly Val Lys
2030 2035 2040

Asn Asn Gln Ile Leu Glu Glu Asn Val Glu Val Glu Ile Trp Thr
2045 2050 2055

Lys Glu Gly Glu Arg Lys Lys Leu Lys Pro Arg Trp Leu Asp Ala
2060 2065 2070

Arg Ile Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Glu Phe
2075 2080 2085

Ala Ala Gly Arg Lys Ser Leu Thr Leu Asn Leu Ile Thr Glu Met
2090 2095 2100

Gly Arg Leu Pro Thr Phe Met Thr Gln Lys Val Arg Asp Ala Leu
2105 2110 2115

Asp Asn Leu Ala Val Leu His Thr Ala Glu Ala Gly Gly Arg Ala
2120 2125 2130

Tyr Asn His Ala Leu Ser Glu Leu Pro Glu Thr Leu Glu Thr Leu
2135 2140 2145

Leu Leu Leu Thr Leu Leu Ala Thr Val Thr Gly Gly Ile Phe Leu
2150 2155 2160

Phe Leu Met Ser Ala Arg Gly Ile Gly Lys Met Thr Leu Gly Met
2165 2170 2175

Cys Cys Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala Gln Ile
2180 2185 2190

Gln Pro His Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe Leu
2195 2200 2205

Ile Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln
2210 2215 2220

Asp Asn Gln Leu Thr Tyr Val Val Ile Ala Ile Leu Thr Val Val
2225 2230 2235

Ala Ala Thr Met Ala Asn Glu Met Gly Phe Leu Glu Lys Thr Lys
2240 2245 2250

Lys Asp Leu Gly Leu Gly Ser Ile Ala Thr Gln Gln Pro Glu Ser
2255 2260 2265

Asn Ile Leu Asp Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu
2270 2275 2280

Tyr Ala Val Ala Thr Thr Phe Val Thr Pro Met Leu Arg His Ser
2285 2290 2295

Ile Glu Asn Ser Ser Val Asn Val Ser Leu Thr Ala Ile Ala Asn
2300 2305 2310

Gln Ala Thr Val Leu Met Gly Leu Gly Lys Gly Trp Pro Leu Ser
2315 2320 2325

Lys Met Asp Ile Gly Val Pro Leu Leu Ala Ile Gly Cys Tyr Ser
2330 2335 2340

Gln Val Asn Pro Ile Thr Leu Thr Ala Ala Leu Phe Leu Leu Val
2345 2350 2355

Ala His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr
2360 2365 2370

Arg Glu Ala Gln Lys Arg Ala Ala Ala Gly Ile Met Lys Asn Pro
2375 2380 2385

Thr Val Asp Gly Ile Thr Val Ile Asp Leu Asp Pro Ile Pro Tyr
2390 2395 2400

Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val
2405 2410 2415

Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala Leu
2420 2425 2430

Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Ile Ser Thr Leu Trp
2435 2440 2445

Glu Gly Asn Pro Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser
2450 2455 2460

Met Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu
2465 2470 2475

Leu Phe Ser Ile Met Lys Asn Thr Thr Asn Thr Arg Arg Gly Thr
2480 2485 2490

Gly Asn Ile Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu
2495 2500 2505

Asn Ala Leu Gly Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly
2510 2515 2520

Ile Gln Glu Val Asp Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg
2525 2530 2535

Gly Glu Thr Asp His His Ala Val Ser Arg Gly Ser Ala Lys Leu
2540 2545 2550

Arg Trp Phe Val Glu Arg Asn Met Val Thr Pro Glu Gly Lys Val
2555 2560 2565

Val Asp Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Cys Gly
2570 2575 2580

Gly Leu Lys Asn Val Arg Glu Val Lys Gly Leu Thr Lys Gly Gly
2585 2590 2595

Pro Gly His Glu Glu Pro Ile Pro Met Ser Thr Tyr Gly Trp Asn
2600 2605 2610

Leu Val Arg Leu Gln Ser Gly Val Asp Val Phe Phe Ile Pro Pro
2615 2620 2625

Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Pro
2630 2635 2640

Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu Asn Leu
2645 2650 2655

Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Ile Lys Val
2660 2665 2670

Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Lys Met Glu Ala Leu
2675 2680 2685

Gln Arg Lys Tyr Gly Gly Ala Leu Val Arg Asn Pro Leu Ser Arg
2690 2695 2700

Asn Ser Thr His Glu Met Tyr Trp Val Ser Asn Ala Ser Gly Asn
2705 2710 2715

Ile Val Ser Ser Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg
2720 2725 2730

Phe Thr Met Arg Tyr Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp
2735 2740 2745

Leu Gly Ser Gly Thr Arg Asn Ile Gly Ile Glu Ser Glu Ile Pro
2750 2755 2760

Asn Leu Asp Ile Ile Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu
2765 2770 2775

His Glu Thr Ser Trp His Tyr Asp Gln Asp His Pro Tyr Lys Thr
2780 2785 2790

Trp Ala Tyr His Gly Ser Tyr Glu Thr Lys Gln Thr Gly Ser Ala
2795 2800 2805

Ser Ser Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro Trp
2810 2815 2820

Asp Val Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr
2825 2830 2835

Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg
2840 2845 2850

Thr Gln Glu Pro Lys Glu Gly Thr Lys Lys Leu Met Lys Ile Thr
2855 2860 2865

Ala Glu Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys Thr Pro Arg
2870 2875 2880

Met Cys Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn Ala
2885 2890 2895

Ala Leu Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys Ser Ala
2900 2905 2910

Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu Leu Val Asp Lys
2915 2920 2925

Glu Arg Asn Leu His Leu Glu Gly Lys Cys Glu Thr Cys Val Tyr
2930 2935 2940

Asn Met Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys
2945 2950 2955

Ala Lys Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg
2960 2965 2970

Phe Leu Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp
2975 2980 2985

Phe Ser Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu
2990 2995 3000

His Lys Leu Gly Tyr Ile Leu Arg Asp Val Ser Lys Lys Glu Gly
3005 3010 3015

Gly Ala Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile
3020 3025 3030

Thr Leu Glu Asp Leu Lys Asn Glu Glu Met Val Thr Asn His Met
3035 3040 3045

Glu Gly Glu His Lys Lys Leu Ala Glu Ala Ile Phe Lys Leu Thr
3050 3055 3060

Tyr Gln Asn Lys Val Val Arg Val Gln Arg Pro Thr Pro Arg Gly
3065 3070 3075

Thr Val Met Asp Ile Ile Ser Arg Arg Asp Gln Arg Gly Ser Gly
3080 3085 3090

Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala
3095 3100 3105

Gln Leu Ile Arg Gln Met Glu Gly Glu Gly Val Phe Lys Ser Ile
3110 3115 3120

Gln His Leu Thr Ile Thr Glu Glu Ile Ala Val Gln Asn Trp Leu
3125 3130 3135

Ala Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser Gly
3140 3145 3150

Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg Phe Ala Ser Ala
3155 3160 3165

Leu Thr Ala Leu Asn Asp Met Gly Lys Ile Arg Lys Asp Ile Gln
3170 3175 3180

Gln Trp Glu Pro Ser Arg Gly Trp Asn Asp Trp Thr Gln Val Pro
3185 3190 3195

Phe Cys Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg
3200 3205 3210

Val Leu Val Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg
3215 3220 3225

Ala Arg Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala
3230 3235 3240

Cys Leu Gly Lys Ser Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe
3245 3250 3255

His Arg Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser Ala
3260 3265 3270

Val Pro Ser His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile
3275 3280 3285

His Ala Lys His Glu Trp Met Thr Thr Glu Asp Met Leu Thr Val
3290 3295 3300

Trp Asn Arg Val Trp Ile Gln Glu Asn Pro Trp Met Glu Asp Lys
3305 3310 3315

Thr Pro Val Glu Ser Trp Glu Glu Ile Pro Tyr Leu Gly Lys Arg
3320 3325 3330

Glu Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala
3335 3340 3345

Thr Trp Ala Lys Asn Ile Gln Ala Ala Ile Asn Gln Val Arg Ser
3350 3355 3360

Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser Met Lys
3365 3370 3375

Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
3380 3385 3390

<210> 9
<211> 10735
<212> DNA
<213> dengue virus

<400> 9
agttgtagt ctacgtggac cgacaagaac agtttcgaat cggaagcttg cttaacgtag 60
ttctaacagt tttttattag agagcagatc tctgatgatc aaccaacgaa aaaagacggg 120
tcgaccgtct ttcaatatgc tgaaacgcgc gagaaaccgc gtgtcaactg tttcacagtt 180
ggcgaagaga ttctcaaaag gattgctctc aggccaagga cccatgaaat tggatgatggc 240
tttcatagca ttcttaagat ttctagccat accccaaca gcaggaattt tggctagatg 300
gggctcattc aagaagaatg gagcgattaa agtggttacgg ggtttcaaga gagaaatctc 360
aaacatgcta aacataatga acaggaggaa aagatccgtg accatgctcc ttatgctgct 420
gccacagcc ctggcgttcc atctgacgac acgaggggga gagccgcata tgatagttag 480
caagcaggaa agaggaaagt cacttttggt caagacctct gcaggtgtca acatgtgcac 540
cctcattgcg atggatttgg gagagtgtg tgaggacacg atgacctaca aatgcccccg 600
gatcactgag gcggaaccag atgacgttga ctgttggtgc aatgccacgg acacatgggt 660
gacctatgga acgtgctctc aaactggcga acaccgacga gacaaacgtt ccgtcgcatt 720

ggccccacac	gtggggcttg	gcctagaaac	aagagccgaa	acgtggatgt	cctctgaagg	780	
tgcttgga	aa	cagatacaaa	aagtagagac	ttgggctctg	agacatccag	gattcacggt	840
gatagccctt	tttctagcac	atgccatagg	aacatccatc	accagaaaag	ggatcatttt	900	
cattttgctg	atgctggtaa	caccatctat	ggccatgcga	tgcgtgggaa	taggcaacag	960	
agacttcgtg	gaaggactgt	caggagcaac	atgggtggat	gtggtactgg	agcatggaag	1020	
ttgcgtcacc	accatggcaa	aaaacaaacc	aacactggac	attgaactct	tgaagacgga	1080	
ggtcacaaac	cctgcagttc	tgcgtaaatt	gtgcattgaa	gctaaaatat	caaacaccac	1140	
caccgattcg	agatgtccaa	cacaaggaga	agccacactg	gtggaagaac	aagacgcgaa	1200	
ctttgtgtgc	cgacgaacgt	tcgtggacag	aggctggggc	aatggctgtg	ggctattcgg	1260	
aaaaggtagt	ctaataacgt	gtgccaagtt	taagtgtgtg	acaaaactag	aaggaaagat	1320	
agttcaatat	gaaaacctaa	aatattcagt	gatagtcacc	gtccacactg	gagatcagca	1380	
ccaggtggga	aatgagacta	cagaacatgg	aacaactgca	accataacac	ctcaagctcc	1440	
tacgtcggaa	atacagctga	ccgactacgg	aacccttaca	ttagattggt	cacctaggac	1500	
agggctagat	tttaacgaga	tggtgttgct	gacaatgaaa	gaaagatcat	ggcttgtcca	1560	
caaacaatgg	tttctagact	taccactgcc	ttggacctct	ggggcttcaa	catcccaaga	1620	
gacttggaac	agacaagatt	tactggtcac	atttaagaca	gctcatgcaa	agaagcagga	1680	
agtagtcgta	ctaggatcac	aagaaggagc	aatgcacact	gcgctgactg	gagcgacaga	1740	
aatccaaacg	tcaggaacga	caacaatttt	cgcaggacac	ctaaaatgca	gactaaaaat	1800	
ggacaaacta	actttaaaag	ggatgtcata	tgtgatgtgc	acaggctcat	tcaagttaga	1860	
gaaagaagtg	gctgagaccc	agcatggaac	tgttctgggtg	caggttaaat	atgaaggaac	1920	
agacgcacca	tgcaagattc	ccttttcgac	ccaagatgag	aaaggagcaa	cccagaatgg	1980	
gagattaata	acagccaacc	ccatagtcac	tgacaaagaa	aaaccagtca	atattgaggc	2040	
agaaccaccc	tttggtgaga	gctacatcgt	ggtaggagca	ggtgaaaaag	ctttgaaact	2100	
aagctggttc	aagaaaggaa	gcagcatagg	gaaaatgttt	gaagcaactg	cccgaggagc	2160	
acgaaggatg	gccattctgg	gagacaccgc	atgggacttc	ggttctatag	gaggagtgtt	2220	
cacgtctatg	ggaaaactgg	tacaccaggt	ttttggaact	gcatatggag	ttttgtttag	2280	
cggagtttct	tggacatga	aaataggaat	agggattctg	ctgacatggc	taggattaaa	2340	

ttcaaggaac acgtcccttt cgatgatgtg catcgcagtt ggcatggtca cactgtacct	2400
aggagtcatg gttcaggcag attcgggatg tgtaatcaac tggaaaggca gagaacttaa	2460
atgtggaagc ggcatttttg tcactaatga agttcacact tggacagagc aatacaaatt	2520
ccaggctgac tcccccaaga gactatcagc agccattggg aaggcatggg aggagggtgt	2580
gtgtggaatc cgatcagcca ctctgtctga gaacatcatg tggaaacaaa tatcaaata	2640
attgaaccac atcctacttg aaaatgacat gaaatttaca gtggtcgtgg gagatgttag	2700
tggaatcttg gcccaaggga aaaaaatgat taggccacaa cccatggaac acaaatactc	2760
gtggaaaagc tggggaaaag ccaaaatcat aggagcggat gtacagaaca ccaccttcat	2820
catcgacggc ccaaacaccc cagaatgcc tgacaatcaa agagcatgga atatttggga	2880
agtagaggac tatggatttg ggattttcac gacaaacata tggttgaaat tgcgtgactc	2940
ctacacccaa gtatgtgacc accggctgat gtcagctgcc attaaggaca gcaaggcagt	3000
ccatgctgac atgggggtact ggatagaaag tgaaaagaac gagacatgga agttggcgag	3060
agcctccttt atagaagtta agacatgcat ctggccaaaa tcccacactc tatggagcaa	3120
tggagtcttg gaaagtgaat tgataattcc aaagatatat ggaggaccaa tatctcagca	3180
caactacaga ccaggatatt tcacacaaac agcagggccg tggcacctag gcaagttgga	3240
actagatttc gatttttgtg aaggtaccac agttgttgtg gatgaacatt gtggaaatcg	3300
aggaccatct ctcagaacca caacagtcac aggaaagata atccatgaat ggtgctgcag	3360
atcttgtacg ctaccccccc tacgtttcaa aggggaagac ggggtgttgg acggcatgga	3420
aatcagacca gtgaaggaca aggaagagaa cctggtcaag tcaatggtct ctgcagggtc	3480
aggagaagtg gacagctttt cactaggact gctatgcata tcaataatga ttgaagaagt	3540
gatgagatcc agatggagca aaaaaatgct gatgactgga acactggctg tgttcctcct	3600
tcttataatg ggacaattga catggagtga tctgatcagg ttatgtatta tggttggagc	3660
caacgcttca gacaagatgg ggatgggaac aacgtaccta gctttaatgg ccactttcaa	3720
aatgagacca atgttcgccg tcgggctatt atttcgcaga ctaacatcta gagaagttct	3780
tcttcttaca attggcttga gcctggtggc atccgtggag ctaccaagtt ccctagagga	3840
gctgggggat ggacttgcaa taggcatcat gatgttgaaa ttattgactg attttcagtc	3900
acaccagcta tgggctactc tgctatcctt gacatttatt aaaacaactt tttcattgca	3960

ctatgcatgg aagacaatgg ctatggtact gtcaattgta tctctcttcc ctttatgcct	4020
gtccacgacc tctcaaaaaa caacatggct tccggtgctg ttgggatctc ttggatgcaa	4080
accactaccc atgtttctta taacagaaaa caaaatctgg ggaaggaaga gttggcccct	4140
caatgaagga attatggctg ttggaatagt tagtattcta ctaagttcac ttttaaaaaa	4200
tgatgtgccg ctagccggcc cattaatagc tggaggcatg ctaatagcat gttatgtcat	4260
atccggaagc tcagctgatt tatcactgga gaaagcggct gaggtctcct gggaggaaga	4320
agcagaacac tcaggcgcct cacacaacat actagtagag gttcaagatg atggaaccat	4380
gaagataaaa gatgaagaga gagatgacac gctcaccatt ctccttaaag caactctgct	4440
ggcagtctca ggggtgtacc caatgtcaat accagcgacc ctttttgtgt ggtatTTTTTg	4500
gcagaaaaag aaacagagat caggagtgtc atgggacaca cccagcccc cagaagtgga	4560
aagagcagtt cttgatgatg gcatctatag aattttgcaa agaggactgt tgggcaggtc	4620
ccaagtagga gtaggagttt tccaagaagg cgtgttccac acaatgtggc acgtcactag	4680
gggagctgtc ctcatgtatc aaggaaaaag gctggaacca agctgggcca gtgtcaaaaa	4740
agacttgatc tcatatggag gaggttggag gtttcaagga tcctggaaca cgggagaaga	4800
agtacaggtg attgctgttg aaccgggaaa aaaccccaaa aatgtacaaa caacgccggg	4860
taccttcaag acccctgaag gcgaagttgg agccatagcc ttagacttta aacctggcac	4920
atctggatct cccatcgtaa acagagaggg aaaaatagta ggtctttatg gaaatggagt	4980
ggtgacaaca agcggaactt acgttagtgc catagctcaa gctaaggcat cacaagaagg	5040
gcctctacca gagattgagg acgaggtgtt taggaaaaga aacttaacaa taatggacct	5100
acatccagga tcgggaaaaa caagaagata ctttcagcc atagtccgtg aggccataaa	5160
aaggaagctg cgcacgctaa tcctagctcc cacaagagtt gtcgcttctg aaatggcaga	5220
ggcactcaag ggagtgccaa taaggatatc gacaacagca gtgaagagtg aacacacagg	5280
aaaggagata gttgacctta tgtgccacgc cactttcacc atgcgcctcc tgtctcccgt	5340
gagagttccc aattataaca tgattatcat ggatgaagca cacttcaccg atccagccag	5400
catagcagcc agaggggtaca tctcaaccgg agtgggtatg ggtgaagcag ctgcgatctt	5460
tatgacagcc actccccag gatcggtgga ggcctttcca cagagcaatg caattatcca	5520
agatgaggaa agagacattc ctgagagatc atggaactca ggctatgact ggatcactga	5580

ttttccaggt aaaacagtct ggtttgttcc aagcatcaaa tcaggaaatg acattgccaa	5640
ctgtttaaga aaaaacggga aacgggtgat ccaattgagc agaaaaacct ttgacactga	5700
gtaccagaaa acaaaaaaca acgactggga ctatgtcgtc acaacagaca tttccgaaat	5760
gggagcaaat ttccgggccg acagggtaat agaccaagg cggtgtctga aaccggtaat	5820
actaaaagat ggtccagagc gcgtcattct agccggaccg atgccagtga ctgtggccag	5880
tgccgcccag aggagaggaa gaattggaag gaacaaaaac aagggaaggatg atcagtatat	5940
ttacatggga cagcctttaa acaatgatga ggaccacgct cattggacag aagcaaagat	6000
gctccttgac aatataaaca caccagaagg gattatccca gccctctatg agccggagag	6060
agaaaagagt gcagctatag acggggaata cagactgcgg ggtgaagcaa ggaaaacgtt	6120
cgtggagctc atgagaagag gggatctacc agtctggcta tcctacaaag ttgcctcaga	6180
aggcttccag tactccgaca gaagggtgtg cttcgatggg gaaaggaaca accaggtgtt	6240
ggaggagaac atggacgtgg agatctggac aaaagaagga gaaagaaaga aactacgacc	6300
tcgctggttg gacgccagaa catactctga cccactggct ctgcgcgagt ttaaagagtt	6360
tgcagcagga agaagaagcg tctcaggtga cctaataatta gaaataggga aacttccaca	6420
acatttgacg caaagggcc cagaatgcttt ggacaacttg gtcattgttc acaattccga	6480
acaaggagga aaagcctata gacatgctat ggaagaactg ccagacacaa tagaaacgtt	6540
gatgctccta gccttgatag ctgtgttgac tgggtggagt acgctgttct tcctatcagg	6600
aagaggtcta ggaaaaacat ctatcggtt actctgcgtg atggcctcaa gcgcactgtt	6660
atggatggcc agtgtggagc cccattggat agcggcctcc atcatactgg agttctttct	6720
gatggtactg cttattccag agccagacag acagcgcact ccacaggaca accagctagc	6780
atatgtggtg ataggtctgt tattcatgat attgacagtg gcagccaatg agatgggatt	6840
attggaaacc acaaagaaag acctggggat tggccatgta gctgctgaaa accaccacca	6900
tgctacaatg ctggacgtag acctacatcc agcttcagcc tggaccctct atgcagtggc	6960
cacaacaatc atcactccta tgatgagaca cacaattgaa aacacaacgg caaatatttc	7020
cctgacagcc atcgcaaacc aagcagctat attgatggga cttgacaagg gatggccaat	7080
atcgaagatg gacataggag ttccacttct cgccttgggg tgctattccc aagtgaatcc	7140
gctgacactg atagcggcag tattgatgct agtagctcat tacgccataa ttggacctgg	7200

actgcaagca aaagctacta gagaagctca aaaaagaaca gcggctggaa taatgaaaaa	7260
tccaactgtc gacgggattg ttgcaataga cttagatccc gtggtttacg atgcaaaatt	7320
tgaaaaacaa ctaggccaaa taatgtttgtt gatacttttg acatcacaga ttcttttgat	7380
gcggactaca tgggccttgt gtgaatccat cacattggct actggacctc tgaccactct	7440
ttgggagggg tctccaggaa aattcttgaa caccacaata gcggtatcca tggcaaacad	7500
tttcaggggg agttatctag caggagcagg tctggccttc tcattaatga aatctctagg	7560
aggaggtagg agaggcacgg gagcccaagg ggaacactg ggagaaaaat ggaaaagaca	7620
actaaaccaa ctgagcaagt cagaattcaa tacttacaag aggagtggga ttatggaggt	7680
ggatagatcc gaagccaaag agggactgaa aagaggagaa acaaccaaac acgcagtatc	7740
gagaggaacg gccaaactga ggtggttcgt ggagaggaac cttgtgaaac cagaagggaa	7800
agtcatagac ctcggttgtg gaagaggtgg ctggtcatat tattgcgctg ggctgaagaa	7860
agtcacagaa gtgaaaggat acacaaaagg aggacctgga catgaggaac caatcccaat	7920
ggcgacctat ggatggaacc tagtaaagct gcactccgga aaagatgtat tttttatacc	7980
acctgagaaa tgtgacaccc ttttgtgtga tattggtgag tcctctccga acccaactat	8040
agaggaagga agaacgttac gtgttctgaa aatggtggaa ccatggctca gaggaacca	8100
attttgcata aaaattctaa atccctatat gccgagcgtg gtagaaactc tggaacaaat	8160
gcaaagaaaa catggaggaa tgctagtgcg aaaccactc tcaagaaatt ccacccatga	8220
aatgtactgg gtttcatgtg gaacaggaaa catttgtgtc gcagtaaaca tgacatctag	8280
aatgttgcta aatcggttca caatggctca caggaagcca acatatgaaa gagacgtgga	8340
cttaggcgct ggaacaagac atgtggcagt agaaccagag gtagccaacc tagatatcat	8400
tggccagagg atagagaata taaaaaatga acataagtca acatggcatt atgatgagga	8460
caatccatac aaaacatggg cctatcatgg atcatatgag gttaagccat caggatcggc	8520
ctcatccatg gtcaatggcg tggtagatt gctcaccaa ccatgggatg ttatcccat	8580
ggtcacacaa atagccatga ctgataccac accctttgga caacagaggg tgtttaaaga	8640
gaaagttgac acgcgcacac caaaagcaaa acgtggcaca gcacaaatta tggaagtgac	8700
agccaggtgg ttatgggggtt tcctttctag aaacaaaaaa cccagaattt gcacaagaga	8760
ggagtttaca agaaaagtta ggtcaaacgc agctattgga gcagtgttcg ttgatgaaaa	8820

tcaatggaac	tcggcaaaaag	aagcagtgga	agacgaacgg	ttctgggaac	ttgtccacag	8880
agagagggag	cttcataaac	aggggaaatg	tgccacgtgt	gtctacaata	tgatggggaa	8940
gagagagaaa	aaattaggag	agttcggaaa	ggcaaaaagga	agtcgtgcaa	tatggtacat	9000
gtggttgga	gcacgcttcc	tagagtttga	agcccttggt	ttcatgaatg	aagatcactg	9060
gttcagtaga	gagaattcac	tcagtggagt	ggaaggagaa	ggactccaca	aacttgata	9120
catactcaga	gacatatcaa	ggattccagg	ggggaacatg	tatgcagatg	acacagccgg	9180
atgggacaca	agaataacag	aggatgatct	ccagaatgag	gctaaaatca	ctgacatcat	9240
ggagcccgaa	catgccctgc	tggctacgtc	aatctttaag	ctgacctacc	aaaataaggt	9300
ggtaaggggtg	cagagaccag	caaaaaatgg	aaccgtgatg	gatgttatat	ccagacgtga	9360
ccagagaggc	agtggacagg	ttggaactta	tggcttaaac	actttcacca	acatggaggc	9420
ccaactgata	agacaaatgg	agtccgaggg	aatcttttta	cccagcgaat	tggaaacccc	9480
aaatctagcc	ggaagagttc	tcgactgggt	ggaaaaatat	ggtgtcgaaa	ggctgaaaag	9540
aatggcaatc	agcggagatg	actgtgtggt	gaaaccaatt	gatgacaggt	tcgcaacagc	9600
cttaacagct	ttgaatgaca	tgggaaaagt	aagaaaagac	ataccacaat	gggaaccttc	9660
aaaaggatgg	aatgattggc	aacaagtgcc	tttctgttca	caccacttcc	accagctaata	9720
tatgaaggat	gggagggaga	tagtggtgcc	atgccgcaac	caagatgaac	ttgtggggag	9780
ggccagagta	tcacaaggcg	cggatggag	cctgagagaa	accgcatgcc	taggcaagtc	9840
atatgcacaa	atgtggcagc	tgatgtat	ccacaggaga	gacctgagac	tggcggctaa	9900
cgctatttgt	tcagccgttc	cagttgattg	ggtcccaacc	agccgcacca	cctggtcgat	9960
ccatgccccat	caccaatgga	tgacaacaga	agacatgtta	tcagtatgga	atagggtctg	10020
gatagaggaa	aacccatgga	tggaggataa	gactcatgtg	tccagttggg	aagaagttcc	10080
atacctagga	aagagggaag	atcagtgggtg	tggatccctg	ataggcttaa	cagcaagggc	10140
cacctgggcc	actaatatac	aagtggccat	aaaccaagtg	agaaggctca	ttgggaatga	10200
gaattatcta	gattacatga	catcaatgaa	gagattcaag	aatgagagtg	atcccgaagg	10260
ggcactctgg	taagtcaaca	cattcacaaa	ataaaggaaa	ataaaaaatc	aaatgaggca	10320
agaagtcagg	ccagattaag	ccatagtacg	gtaagagcta	tgctgcctgt	gagccccgtc	10380
caaggacgta	aaatgaagtc	aggccgaaag	ccacggtttg	agcaagccgt	gctgcctgtg	10440

gctccatcgt ggggatgtaa aaacccggga ggctgcaacc catggaagct gtacgcatgg 10500
 ggtagcagac tagtggttag aggagacccc tccaagaca caacgcagca gcggggccca 10560
 acaccagggg aagctgtacc ctggtggtaa ggactagagg ttagaggaga ccccccgcgt 10620
 aacaataaac agcatattga cgctgggaga gaccagagat cctgctgtct ctacagcatc 10680
 attccaggca cagaacgcca gaaaatggaa tggctgctgtt gaatcaacag gttct 10735

<210> 10
 <211> 3392
 <212> PRT
 <213> dengue virus

<400> 10

Met Ile Asn Gln Arg Lys Lys Thr Gly Arg Pro Ser Phe Asn Met Leu
 1 5 10 15

Lys Arg Ala Arg Asn Arg Val Ser Thr Val Ser Gln Leu Ala Lys Arg
 20 25 30

Phe Ser Lys Gly Leu Leu Ser Gly Gln Gly Pro Met Lys Leu Val Met
 35 40 45

Ala Phe Ile Ala Phe Leu Arg Phe Leu Ala Ile Pro Pro Thr Ala Gly
 50 55 60

Ile Leu Ala Arg Trp Gly Ser Phe Lys Lys Asn Gly Ala Ile Lys Val
 65 70 75 80

Leu Arg Gly Phe Lys Arg Glu Ile Ser Asn Met Leu Asn Ile Met Asn
 85 90 95

Arg Arg Lys Arg Ser Val Thr Met Leu Leu Met Leu Leu Pro Thr Ala
 100 105 110

Leu Ala Phe His Leu Thr Thr Arg Gly Gly Glu Pro His Met Ile Val
 115 120 125

Ser Lys Gln Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr Ser Ala Gly
 130 135 140

Val Asn Met Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Leu Cys Glu
145 150 155 160

Asp Thr Met Thr Tyr Lys Cys Pro Arg Ile Thr Glu Ala Glu Pro Asp
165 170 175

Asp Val Asp Cys Trp Cys Asn Ala Thr Asp Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Ser Gln Thr Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala
195 200 205

Leu Ala Pro His Val Gly Leu Gly Leu Glu Thr Arg Ala Glu Thr Trp
210 215 220

Met Ser Ser Glu Gly Ala Trp Lys Gln Ile Gln Lys Val Glu Thr Trp
225 230 235 240

Ala Leu Arg His Pro Gly Phe Thr Val Ile Ala Leu Phe Leu Ala His
245 250 255

Ala Ile Gly Thr Ser Ile Thr Gln Lys Gly Ile Ile Phe Ile Leu Leu
260 265 270

Met Leu Val Thr Pro Ser Met Ala Met Arg Cys Val Gly Ile Gly Asn
275 280 285

Arg Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val
290 295 300

Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Ile Glu Leu Leu Lys Thr Glu Val Thr Asn Pro Ala Val Leu
325 330 335

Arg Lys Leu Cys Ile Glu Ala Lys Ile Ser Asn Thr Thr Thr Asp Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Ala Thr Leu Val Glu Glu Gln Asp Ala
355 360 365

Asn Phe Val Cys Arg Arg Thr Phe Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Ser Leu Ile Thr Cys Ala Lys Phe Lys
385 390 395 400

Cys Val Thr Lys Leu Glu Gly Lys Ile Val Gln Tyr Glu Asn Leu Lys
405 410 415

Tyr Ser Val Ile Val Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430

Asn Glu Thr Thr Glu His Gly Thr Thr Ala Thr Ile Thr Pro Gln Ala
435 440 445

Pro Thr Ser Glu Ile Gln Leu Thr Asp Tyr Gly Thr Leu Thr Leu Asp
450 455 460

Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Thr
465 470 475 480

Met Lys Glu Arg Ser Trp Leu Val His Lys Gln Trp Phe Leu Asp Leu
485 490 495

Pro Leu Pro Trp Thr Ser Gly Ala Ser Thr Ser Gln Glu Thr Trp Asn
500 505 510

Arg Gln Asp Leu Leu Val Thr Phe Lys Thr Ala His Ala Lys Lys Gln
515 520 525

Glu Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu
530 535 540

Thr Gly Ala Thr Glu Ile Gln Thr Ser Gly Thr Thr Thr Ile Phe Ala
545 550 555 560

Gly His Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Thr Leu Lys Gly
565 570 575

Met Ser Tyr Val Met Cys Thr Gly Ser Phe Lys Leu Glu Lys Glu Val
580 585 590

Ala Glu Thr Gln His Gly Thr Val Leu Val Gln Val Lys Tyr Glu Gly
595 600 605

Thr Asp Ala Pro Cys Lys Ile Pro Phe Ser Thr Gln Asp Glu Lys Gly
610 615 620

Ala Thr Gln Asn Gly Arg Leu Ile Thr Ala Asn Pro Ile Val Thr Asp
625 630 635 640

Lys Glu Lys Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser
645 650 655

Tyr Ile Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe
660 665 670

Lys Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly
675 680 685

Ala Arg Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser
690 695 700

Ile Gly Gly Val Phe Thr Ser Met Gly Lys Leu Val His Gln Val Phe
705 710 715 720

Gly Thr Ala Tyr Gly Val Leu Phe Ser Gly Val Ser Trp Thr Met Lys
725 730 735

Ile Gly Ile Gly Ile Leu Leu Thr Trp Leu Gly Leu Asn Ser Arg Asn
740 745 750

Thr Ser Leu Ser Met Met Cys Ile Ala Val Gly Met Val Thr Leu Tyr
755 760 765

Leu Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Ile Asn Trp Lys
770 775 780

Gly Arg Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asn Glu Val
785 790 795 800

His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Ala Asp Ser Pro Lys Arg
805 810 815

Leu Ser Ala Ala Ile Gly Lys Ala Trp Glu Glu Gly Val Cys Gly Ile
820 825 830

Arg Ser Ala Thr Arg Leu Glu Asn Ile Met Trp Lys Gln Ile Ser Asn
835 840 845

Glu Leu Asn His Ile Leu Leu Glu Asn Asp Met Lys Phe Thr Val Val
850 855 860

Val Gly Asp Val Ser Gly Ile Leu Ala Gln Gly Lys Lys Met Ile Arg
865 870 875 880

Pro Gln Pro Met Glu His Lys Tyr Ser Trp Lys Ser Trp Gly Lys Ala
885 890 895

Lys Ile Ile Gly Ala Asp Val Gln Asn Thr Thr Phe Ile Ile Asp Gly
900 905 910

Pro Asn Thr Pro Glu Cys Pro Asp Asn Gln Arg Ala Trp Asn Ile Trp
915 920 925

Glu Val Glu Asp Tyr Gly Phe Gly Ile Phe Thr Thr Asn Ile Trp Leu
930 935 940

Lys Leu Arg Asp Ser Tyr Thr Gln Val Cys Asp His Arg Leu Met Ser
945 950 955 960

Ala Ala Ile Lys Asp Ser Lys Ala Val His Ala Asp Met Gly Tyr Trp
965 970 975

Ile Glu Ser Glu Lys Asn Glu Thr Trp Lys Leu Ala Arg Ala Ser Phe
980 985 990

Ile Glu Val Lys Thr Cys Ile Trp Pro Lys Ser His Thr Leu Trp Ser
995 1000 1005

Asn Gly Val Leu Glu Ser Glu Met Ile Ile Pro Lys Ile Tyr Gly
1010 1015 1020

Gly Pro Ile Ser Gln His Asn Tyr Arg Pro Gly Tyr Phe Thr Gln
1025 1030 1035

Thr Ala Gly Pro Trp His Leu Gly Lys Leu Glu Leu Asp Phe Asp
1040 1045 1050

Phe Cys Glu Gly Thr Thr Val Val Val Asp Glu His Cys Gly Asn
1055 1060 1065

Arg Gly Pro Ser Leu Arg Thr Thr Thr Val Thr Gly Lys Ile Ile
1070 1075 1080

His Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Phe
1085 1090 1095

Lys Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Val
1100 1105 1110

Lys Asp Lys Glu Glu Asn Leu Val Lys Ser Met Val Ser Ala Gly
1115 1120 1125

Ser Gly Glu Val Asp Ser Phe Ser Leu Gly Leu Leu Cys Ile Ser
1130 1135 1140

Ile Met Ile Glu Glu Val Met Arg Ser Arg Trp Ser Lys Lys Met
1145 1150 1155

Leu Met Thr Gly Thr Leu Ala Val Phe Leu Leu Leu Ile Met Gly
1160 1165 1170

Gln Leu Thr Trp Ser Asp Leu Ile Arg Leu Cys Ile Met Val Gly
1175 1180 1185

Ala Asn Ala Ser Asp Lys Met Gly Met Gly Thr Thr Tyr Leu Ala
1190 1195 1200

Leu Met Ala Thr Phe Lys Met Arg Pro Met Phe Ala Val Gly Leu
1205 1210 1215

Leu Phe Arg Arg Leu Thr Ser Arg Glu Val Leu Leu Leu Thr Ile
1220 1225 1230

Gly Leu Ser Leu Val Ala Ser Val Glu Leu Pro Ser Ser Leu Glu
1235 1240 1245

Glu Leu Gly Asp Gly Leu Ala Ile Gly Ile Met Met Leu Lys Leu
1250 1255 1260

Leu Thr Asp Phe Gln Ser His Gln Leu Trp Ala Thr Leu Leu Ser
1265 1270 1275

Leu Thr Phe Ile Lys Thr Thr Phe Ser Leu His Tyr Ala Trp Lys
1280 1285 1290

Thr Met Ala Met Val Leu Ser Ile Val Ser Leu Phe Pro Leu Cys
1295 1300 1305

Leu Ser Thr Thr Ser Gln Lys Thr Thr Trp Leu Pro Val Leu Leu
1310 1315 1320

Gly Ser Leu Gly Cys Lys Pro Leu Pro Met Phe Leu Ile Thr Glu
1325 1330 1335

Asn Lys Ile Trp Gly Arg Lys Ser Trp Pro Leu Asn Glu Gly Ile
1340 1345 1350

Met Ala Val Gly Ile Val Ser Ile Leu Leu Ser Ser Leu Leu Lys
1355 1360 1365

Asn Asp Val Pro Leu Ala Gly Pro Leu Ile Ala Gly Gly Met Leu
1370 1375 1380

Ile Ala Cys Tyr Val Ile Ser Gly Ser Ser Ala Asp Leu Ser Leu
1385 1390 1395

Glu Lys Ala Ala Glu Val Ser Trp Glu Glu Glu Ala Glu His Ser
1400 1405 1410

Gly Ala Ser His Asn Ile Leu Val Glu Val Gln Asp Asp Gly Thr
1415 1420 1425

Met Lys Ile Lys Asp Glu Glu Arg Asp Asp Thr Leu Thr Ile Leu
1430 1435 1440

Leu Lys Ala Thr Leu Leu Ala Val Ser Gly Val Tyr Pro Met Ser
1445 1450 1455

Ile Pro Ala Thr Leu Phe Val Trp Tyr Phe Trp Gln Lys Lys Lys
1460 1465 1470

Gln Arg Ser Gly Val Leu Trp Asp Thr Pro Ser Pro Pro Glu Val
1475 1480 1485

Glu Arg Ala Val Leu Asp Asp Gly Ile Tyr Arg Ile Leu Gln Arg
1490 1495 1500

Gly Leu Leu Gly Arg Ser Gln Val Gly Val Gly Val Phe Gln Glu
1505 1510 1515

Gly Val Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
1520 1525 1530

Met Tyr Gln Gly Lys Arg Leu Glu Pro Ser Trp Ala Ser Val Lys
1535 1540 1545

Lys Asp Leu Ile Ser Tyr Gly Gly Gly Trp Arg Phe Gln Gly Ser
1550 1555 1560

Trp Asn Thr Gly Glu Glu Val Gln Val Ile Ala Val Glu Pro Gly
1565 1570 1575

Lys Asn Pro Lys Asn Val Gln Thr Thr Pro Gly Thr Phe Lys Thr
1580 1585 1590

Pro Glu Gly Glu Val Gly Ala Ile Ala Leu Asp Phe Lys Pro Gly
1595 1600 1605

Thr Ser Gly Ser Pro Ile Val Asn Arg Glu Gly Lys Ile Val Gly
1610 1615 1620

Leu Tyr Gly Asn Gly Val Val Thr Thr Ser Gly Thr Tyr Val Ser
1625 1630 1635

Ala Ile Ala Gln Ala Lys Ala Ser Gln Glu Gly Pro Leu Pro Glu
1640 1645 1650

Ile Glu Asp Glu Val Phe Arg Lys Arg Asn Leu Thr Ile Met Asp
1655 1660 1665

Leu His Pro Gly Ser Gly Lys Thr Arg Arg Tyr Leu Pro Ala Ile
1670 1675 1680

Val Arg Glu Ala Ile Lys Arg Lys Leu Arg Thr Leu Ile Leu Ala
1685 1690 1695

Pro Thr Arg Val Val Ala Ser Glu Met Ala Glu Ala Leu Lys Gly
1700 1705 1710

Val Pro Ile Arg Tyr Gln Thr Thr Ala Val Lys Ser Glu His Thr
1715 1720 1725

Gly Lys Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met
1730 1735 1740

Arg Leu Leu Ser Pro Val Arg Val Pro Asn Tyr Asn Met Ile Ile
1745 1750 1755

Met Asp Glu Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg
1760 1765 1770

Gly Tyr Ile Ser Thr Arg Val Gly Met Gly Glu Ala Ala Ala Ile
1775 1780 1785

Phe Met Thr Ala Thr Pro Pro Gly Ser Val Glu Ala Phe Pro Gln
1790 1795 1800

Ser Asn Ala Ile Ile Gln Asp Glu Glu Arg Asp Ile Pro Glu Arg
1805 1810 1815

Ser Trp Asn Ser Gly Tyr Asp Trp Ile Thr Asp Phe Pro Gly Lys
1820 1825 1830

Thr Val Trp Phe Val Pro Ser Ile Lys Ser Gly Asn Asp Ile Ala
1835 1840 1845

Asn Cys Leu Arg Lys Asn Gly Lys Arg Val Ile Gln Leu Ser Arg
1850 1855 1860

Lys Thr Phe Asp Thr Glu Tyr Gln Lys Thr Lys Asn Asn Asp Trp
1865 1870 1875

Asp Tyr Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe
1880 1885 1890

Arg Ala Asp Arg Val Ile Asp Pro Arg Arg Cys Leu Lys Pro Val
1895 1900 1905

Ile Leu Lys Asp Gly Pro Glu Arg Val Ile Leu Ala Gly Pro Met
1910 1915 1920

Pro Val Thr Val Ala Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly
1925 1930 1935

Arg Asn Gln Asn Lys Glu Gly Asp Gln Tyr Ile Tyr Met Gly Gln
1940 1945 1950

Pro Leu Asn Asn Asp Glu Asp His Ala His Trp Thr Glu Ala Lys
1955 1960 1965

Met Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ala
1970 1975 1980

Leu Tyr Glu Pro Glu Arg Glu Lys Ser Ala Ala Ile Asp Gly Glu
1985 1990 1995

Tyr Arg Leu Arg Gly Glu Ala Arg Lys Thr Phe Val Glu Leu Met
2000 2005 2010

Arg Arg Gly Asp Leu Pro Val Trp Leu Ser Tyr Lys Val Ala Ser
2015 2020 2025

Glu Gly Phe Gln Tyr Ser Asp Arg Arg Trp Cys Phe Asp Gly Glu
2030 2035 2040

Arg Asn Asn Gln Val Leu Glu Glu Asn Met Asp Val Glu Ile Trp
2045 2050 2055

Thr Lys Glu Gly Glu Arg Lys Lys Leu Arg Pro Arg Trp Leu Asp
2060 2065 2070

Ala Arg Thr Tyr Ser Asp Pro Leu Ala Leu Arg Glu Phe Lys Glu
2075 2080 2085

Phe Ala Ala Gly Arg Arg Ser Val Ser Gly Asp Leu Ile Leu Glu
2090 2095 2100

Ile Gly Lys Leu Pro Gln His Leu Thr Gln Arg Ala Gln Asn Ala
2105 2110 2115

Leu Asp Asn Leu Val Met Leu His Asn Ser Glu Gln Gly Gly Lys
2120 2125 2130

Ala Tyr Arg His Ala Met Glu Glu Leu Pro Asp Thr Ile Glu Thr
2135 2140 2145

Leu Met Leu Leu Ala Leu Ile Ala Val Leu Thr Gly Gly Val Thr
2150 2155 2160

Leu Phe Phe Leu Ser Gly Arg Gly Leu Gly Lys Thr Ser Ile Gly
2165 2170 2175

Leu Leu Cys Val Met Ala Ser Ser Ala Leu Leu Trp Met Ala Ser
2180 2185 2190

Val Glu Pro His Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe
2195 2200 2205

Leu Met Val Leu Leu Ile Pro Glu Pro Asp Arg Gln Arg Thr Pro
2210 2215 2220

Gln Asp Asn Gln Leu Ala Tyr Val Val Ile Gly Leu Leu Phe Met
2225 2230 2235

Ile Leu Thr Val Ala Ala Asn Glu Met Gly Leu Leu Glu Thr Thr
2240 2245 2250

Lys Lys Asp Leu Gly Ile Gly His Val Ala Ala Glu Asn His His
2255 2260 2265

His Ala Thr Met Leu Asp Val Asp Leu His Pro Ala Ser Ala Trp
2270 2275 2280

Thr Leu Tyr Ala Val Ala Thr Thr Ile Ile Thr Pro Met Met Arg
2285 2290 2295

His Thr Ile Glu Asn Thr Thr Ala Asn Ile Ser Leu Thr Ala Ile
2300 2305 2310

Ala Asn Gln Ala Ala Ile Leu Met Gly Leu Asp Lys Gly Trp Pro
2315 2320 2325

Ile Ser Lys Met Asp Ile Gly Val Pro Leu Leu Ala Leu Gly Cys
2330 2335 2340

Tyr Ser Gln Val Asn Pro Leu Thr Leu Ile Ala Ala Val Leu Met
2345 2350 2355

Leu Val Ala His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys
2360 2365 2370

Ala Thr Arg Glu Ala Gln Lys Arg Thr Ala Ala Gly Ile Met Lys
2375 2380 2385

Asn Pro Thr Val Asp Gly Ile Val Ala Ile Asp Leu Asp Pro Val
2390 2395 2400

Val Tyr Asp Ala Lys Phe Glu Lys Gln Leu Gly Gln Ile Met Leu
2405 2410 2415

Leu Ile Leu Cys Thr Ser Gln Ile Leu Leu Met Arg Thr Thr Trp
2420 2425 2430

Ala Leu Cys Glu Ser Ile Thr Leu Ala Thr Gly Pro Leu Thr Thr
2435 2440 2445

Leu Trp Glu Gly Ser Pro Gly Lys Phe Trp Asn Thr Thr Ile Ala
2450 2455 2460

Val Ser Met Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala
2465 2470 2475

Gly Leu Ala Phe Ser Leu Met Lys Ser Leu Gly Gly Gly Arg Arg
2480 2485 2490

Gly Thr Gly Ala Gln Gly Glu Thr Leu Gly Glu Lys Trp Lys Arg
2495 2500 2505

Gln Leu Asn Gln Leu Ser Lys Ser Glu Phe Asn Thr Tyr Lys Arg
2510 2515 2520

Ser Gly Ile Met Glu Val Asp Arg Ser Glu Ala Lys Glu Gly Leu
2525 2530 2535

Lys Arg Gly Glu Thr Thr Lys His Ala Val Ser Arg Gly Thr Ala
2540 2545 2550

Lys Leu Arg Trp Phe Val Glu Arg Asn Leu Val Lys Pro Glu Gly
2555 2560 2565

Lys Val Ile Asp Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr
2570 2575 2580

Cys Ala Gly Leu Lys Lys Val Thr Glu Val Lys Gly Tyr Thr Lys
2585 2590 2595

Gly Gly Pro Gly His Glu Glu Pro Ile Pro Met Ala Thr Tyr Gly
2600 2605 2610

Trp Asn Leu Val Lys Leu His Ser Gly Lys Asp Val Phe Phe Ile
2615 2620 2625

Pro Pro Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser
2630 2635 2640

Ser Pro Asn Pro Thr Ile Glu Glu Gly Arg Thr Leu Arg Val Leu
2645 2650 2655

Lys Met Val Glu Pro Trp Leu Arg Gly Asn Gln Phe Cys Ile Lys
2660 2665 2670

Ile Leu Asn Pro Tyr Met Pro Ser Val Val Glu Thr Leu Glu Gln
2675 2680 2685

Met Gln Arg Lys His Gly Gly Met Leu Val Arg Asn Pro Leu Ser
2690 2695 2700

Arg Asn Ser Thr His Glu Met Tyr Trp Val Ser Cys Gly Thr Gly
2705 2710 2715

Asn Ile Val Ser Ala Val Asn Met Thr Ser Arg Met Leu Leu Asn
2720 2725 2730

Arg Phe Thr Met Ala His Arg Lys Pro Thr Tyr Glu Arg Asp Val
2735 2740 2745

Asp Leu Gly Ala Gly Thr Arg His Val Ala Val Glu Pro Glu Val
2750 2755 2760

Ala Asn Leu Asp Ile Ile Gly Gln Arg Ile Glu Asn Ile Lys Asn
2765 2770 2775

Glu His Lys Ser Thr Trp His Tyr Asp Glu Asp Asn Pro Tyr Lys
2780 2785 2790

Thr Trp Ala Tyr His Gly Ser Tyr Glu Val Lys Pro Ser Gly Ser
2795 2800 2805

Ala Ser Ser Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro
2810 2815 2820

Trp Asp Val Ile Pro Met Val Thr Gln Ile Ala Met Thr Asp Thr
2825 2830 2835

Thr Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr
2840 2845 2850

Arg Thr Pro Lys Ala Lys Arg Gly Thr Ala Gln Ile Met Glu Val
2855 2860 2865

Thr Ala Arg Trp Leu Trp Gly Phe Leu Ser Arg Asn Lys Lys Pro
2870 2875 2880

Arg Ile Cys Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn
2885 2890 2895

Ala Ala Ile Gly Ala Val Phe Val Asp Glu Asn Gln Trp Asn Ser
2900 2905 2910

Ala Lys Glu Ala Val Glu Asp Glu Arg Phe Trp Glu Leu Val His
2915 2920 2925

Arg Glu Arg Glu Leu His Lys Gln Gly Lys Cys Ala Thr Cys Val
2930 2935 2940

Tyr Asn Met Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly
2945 2950 2955

Lys Ala Lys Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala
2960 2965 2970

Arg Phe Leu Glu Phe Glu Ala Leu Gly Phe Met Asn Glu Asp His
2975 2980 2985

Trp Phe Ser Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly
2990 2995 3000

Leu His Lys Leu Gly Tyr Ile Leu Arg Asp Ile Ser Arg Ile Pro
3005 3010 3015

Gly Gly Asn Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg
3020 3025 3030

Ile Thr Glu Asp Asp Leu Gln Asn Glu Ala Lys Ile Thr Asp Ile
3035 3040 3045

Met Glu Pro Glu His Ala Leu Leu Ala Thr Ser Ile Phe Lys Leu
3050 3055 3060

Thr Tyr Gln Asn Lys Val Val Arg Val Gln Arg Pro Ala Lys Asn
3065 3070 3075

Gly Thr Val Met Asp Val Ile Ser Arg Arg Asp Gln Arg Gly Ser
3080 3085 3090

Gly Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu
3095 3100 3105

Ala Gln Leu Ile Arg Gln Met Glu Ser Glu Gly Ile Phe Leu Pro
3110 3115 3120

Ser Glu Leu Glu Thr Pro Asn Leu Ala Gly Arg Val Leu Asp Trp
3125 3130 3135

Leu Glu Lys Tyr Gly Val Glu Arg Leu Lys Arg Met Ala Ile Ser
3140 3145 3150

Gly Asp Asp Cys Val Val Lys Pro Ile Asp Asp Arg Phe Ala Thr
3155 3160 3165

Ala Leu Thr Ala Leu Asn Asp Met Gly Lys Val Arg Lys Asp Ile
3170 3175 3180

Pro Gln Trp Glu Pro Ser Lys Gly Trp Asn Asp Trp Gln Gln Val
3185 3190 3195

Pro Phe Cys Ser His His Phe His Gln Leu Ile Met Lys Asp Gly
3200 3205 3210

Arg Glu Ile Val Val Pro Cys Arg Asn Gln Asp Glu Leu Val Gly
3215 3220 3225

Arg Ala Arg Val Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr
3230 3235 3240

Ala Cys Leu Gly Lys Ser Tyr Ala Gln Met Trp Gln Leu Met Tyr
 3245 3250 3255

Phe His Arg Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser
 3260 3265 3270

Ala Val Pro Val Asp Trp Val Pro Thr Ser Arg Thr Thr Trp Ser
 3275 3280 3285

Ile His Ala His His Gln Trp Met Thr Thr Glu Asp Met Leu Ser
 3290 3295 3300

Val Trp Asn Arg Val Trp Ile Glu Glu Asn Pro Trp Met Glu Asp
 3305 3310 3315

Lys Thr His Val Ser Ser Trp Glu Glu Val Pro Tyr Leu Gly Lys
 3320 3325 3330

Arg Glu Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ala Arg
 3335 3340 3345

Ala Thr Trp Ala Thr Asn Ile Gln Val Ala Ile Asn Gln Val Arg
 3350 3355 3360

Arg Leu Ile Gly Asn Glu Asn Tyr Leu Asp Tyr Met Thr Ser Met
 3365 3370 3375

Lys Arg Phe Lys Asn Glu Ser Asp Pro Glu Gly Ala Leu Trp
 3380 3385 3390

<210> 11
 <211> 10723
 <212> DNA
 <213> dengue virus

<400> 11
 agttgttagt ctacgtggac cgacaaagac agattctttg agggagctaa gctcaacgta 60
 gttctaacag ttttttaatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg 120
 aaaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcgac tgtgcaacag 180

ctgacaaaga gattctcact tggaatgctg cagggacgag gaccattaaa actgttcattg	240
gccctggtgg cgttccttcg tttcctaaca atcccaccaa cagcagggat attgaagaga	300
tggggaacaa ttaaaaaatc aaaagctatt aatgttttga gaggggttcag gaaagagatt	360
ggaaggatgc tgaacatctt gaataggaga cgcagatctg caggcatgat cattatgctg	420
attccaacag tgatggcggt ccatttaacc acacgtaacg gagaaccaca catgatcgtc	480
agcagacaag agaaaggga aagtcttctg tttaaaacag aggatggcgt gaacatgtgt	540
accctcatgg ccatggacct tggatgaattg tgtgaagaca caatcacgta caagtgtccc	600
cttctcaggc agaatgagcc agaagacata gactgttggt gcaactctac gtccacgtgg	660
gtaacttatg ggacgtgtac caccatggga gaacatagaa gagaaaaaag atcagtggca	720
ctcgttccac atgtgggaat gggactggag acacgaactg aaacatggat gtcacagaa	780
ggggcctgga aacatgtcca gagaattgaa acttggatct tgagacatcc aggcttcacc	840
atgatggcag caatcctggc atacaccata ggaacgacac atttccaaag agccctgatt	900
ttcatcttac tgacagctgt cactccttca atgacaatgc gttgcatagg aatgtcaa	960
agagactttg tggaaggggt ttcaggagga agctgggttg acatagtctt agaacatgga	1020
agctgtgtga cgacgatggc aaaaaacaaa ccaacattgg attttgaact gataaaaaca	1080
gaagccaaac agcctgccac cctaaggaag tactgtatag aggcaaagct aaccaacaca	1140
acaacagaat ctcgctgccc aacacaaggg gaaccagcc taaatgaaga gcaggacaaa	1200
aggttcgtct gcaaacactc catggtagac agaggatggg gaaatggatg tggactat	1260
ggaaaggag gcattgtgac ctgtgctatg ttcagatgca aaaagaacat ggaaggaaaa	1320
gttgtgcaac cagaaaactt ggaatacacc attgtgataa cacctcactc aggggaagag	1380
catgcagtcg gaaatgacac aggaaaacat ggcaaggaaa tcaaaataac accacagagt	1440
tccatcacag aagcagaatt gacaggttat ggcactgtca caatggagtg ctctccaaga	1500
acgggcctcg acttcaatga gatggtgttg ctgcagatgg aaaataaagc ttggctggtg	1560
cacaggcaat ggttcctaga cctgccgtta ccatggttgc ccggagcgga cacacaaggg	1620
tcaaattgga tacagaaaga gacattggtc actttcaaaa atccccatgc gaagaaacag	1680
gatgttgttg ttttaggatc ccaagaaggg gccatgcaca cagcacttac aggggcaca	1740
gaaatccaaa tgtcatcagg aaacttactc ttcacaggac atctcaagtg caggctgaga	1800

atggacaagc tacagctcaa aggaatgtca tactctatgt gcacaggaaa gtttaaagtt	1860
gtgaaggaaa tagcagaaac acaacatgga acaatagtta tcagagtgc ataatgaaggg	1920
gacggctctc catgcaagat cccttttgag ataatggatt tggaaaaaag acatgtctta	1980
ggtcgcctga ttacagtcaa cccaattgtg acagaaaaag atagcccagt caacatagaa	2040
gcagaacctc cattcggaga cagctacatc atcataggag tagagccggg acaactgaag	2100
ctcaactggg ttaagaaagg aagttctatc ggccaaatgt ttgagacaac aatgaggggg	2160
gcgaagagaa tggccatttt aggtgacaca gcctgggatt ttggatcctt gggaggagt	2220
tttacatcta taggaaaggc tctccaccaa gtctttggag caatctatgg agctgccttc	2280
agtgggggtt catggactat gaaaatcctc ataggagtca ttatcacatg gataggaatg	2340
aattcacgca gcacctcact gtctgtgaca ctagtattgg tgggaattgt gacactgtat	2400
ttgggagtca tgggtgcaggc cgatagtggg tgcgttgtga gctggaaaaa caaagaactg	2460
aaatgtggca gtgggatttt catcacagac aacgtgcaca catggacaga acaatacaag	2520
ttccaaccag aatccccttc aaaactagct tcagctatcc agaaagccca tgaagagggc	2580
atttgtggaa tccgctcagt aacaagactg gagaatctga tgtggaaaca aataacacca	2640
gaattgaatc acattctatc agaaaatgag gtgaagttaa ctattatgac aggagacatc	2700
aaaggaatca tgcaggcagg aaaacgatct ctgcggcctc agcccactga gctgaagtat	2760
tcattggaaa catggggcaa agcaaaaatg ctctctacag agtctcataa ccagaccttt	2820
ctcattgatg gccccgaaac agcagaatgc cccaacacaa atagagcttg gaattcgttg	2880
gaagtgaag actatggctt tggagtattc accaccaata tatggctaaa attgaaagaa	2940
aaacaggatg tattctgcga ctcaaaactc atgtcagcgg ccataaaaga caacagagcc	3000
gtccatgccg ataatgggtta ttggatagaa agtgcactca atgacacatg gaagatagag	3060
aaagcctctt tcattgaagt taaaaactgc cactggccaa aatcacacac cctctggagc	3120
aatggagtgc tagaaagtga gatgataatt ccaaagaatc tcgctggacc agtgtctcaa	3180
cacaactata gaccaggcta ccatacacaa ataacaggac catggcatct aggtgaagctt	3240
gagatggact ttgatttctg tgatggaaca acagtggtag tgactgagga ctgcggaaat	3300
agaggaccct ctttgagaac aaccactgcc tctggaaaac tcataacaga atggtgctgc	3360
cgatcttgca cattaccacc gctaagatac agaggtgagg atgggtgctg gtacgggatg	3420

gaaatcagac cattgaagga gaaagaagag aatttgggtca actccttgggt cacagctgga	3480
catgggacagg tcgacaactt ttcactagga gtcttgggaa tggcattgtt cctggaggaa	3540
atgcttagga cccgagtagg aacgaaacat gcaatactac tagttgcagt ttcttttgtg	3600
acattgatca cagggaacat gtcctttaga gacctgggaa gagtgatgggt tatggtaggc	3660
gccactatga cggatgacat aggtatgggc gtgacttatc ttgccctact agcagccttc	3720
aaagtcagac caacttttgc agctggacta ctcttgagaa agctgacctc caaggaattg	3780
atgatgacta ctataggaat tgtactcttc tcccagagca ccataccaga gaccattctt	3840
gagttgactg atgcgttagc cttaggcatg atggctctca aaatggtgag aaatatggaa	3900
aagtatcaat tggcagtgac tatcatggct atcttgtgcg tcccaaacgc agtgatatta	3960
caaaacgcat ggaaagtgag ttgcacaata ttggcagtggt tgtccgtttc cccactgctc	4020
ttaacatcct cacagcaaaa aacagattgg ataccattag cattgacgat caaaggcttc	4080
aatccaacag ctatttttct aacaaccctc tcaagaacca gcaagaaaag gagctggcca	4140
ttaaattgagg ctatcatggc agtcgggatg gtgagcattt tagccagttc tctcctaaaa	4200
aatgatattc ccatgacagg accattagtg gctggagggc tcctcactgt gtgctacgtg	4260
ctcactggac gatcggccga tttggaactg gagagagcag ccgatgtcaa atgggaagac	4320
caggcagaga tatcaggaag cagtccaatc ctgtcaataa caatatcaga agatggtagc	4380
atgtcgataa aaaatgaaga ggaagaacaa acactgacca tactcattag aacaggattg	4440
ctgggtgatct caggactttt tcctgtatca ataccaatca cggcagcagc atgggtacctg	4500
tgggaagtga agaaacaacg ggccggagta ttgtgggatg ttccttcacc cccacccatg	4560
ggaaaggctg aactggaaga tggagcctat agaattaagc aaaaagggat tcttgatat	4620
tcccagatcg gagccggagt ttacaaagaa ggaacattcc atacaatgtg gcatgtcaca	4680
cgtggcgctg ttctaattgca taaaggaaag aggattgaac catcatgggc ggacgtcaag	4740
aaagacctaa tatcatatgg aggaggctgg aagttagaag gagaatggaa ggaaggagaa	4800
gaagtccagg tattggcact ggagcctgga aaaaatccaa gagccgtcca aacgaaacct	4860
ggtcttttca aaaccaacgc cggaacaata ggtgctgtat ctctggactt ttctcctgga	4920
acgtcaggat ctccaattat cgacaaaaaa ggaaaagttg tgggtcttta tggtaatggt	4980
gttggttaca ggagtggagc atatgtgagt gctatagccc agactgaaaa aagcattgaa	5040

gacaacccag agatcgaaga tgacattttc cgaaagagaa gactgaccat catggacctc	5100
cacccaggag cgggaaagac gaagagatac cttccggcca tagtcagaga agctataaaa	5160
cgggggtttga gaacattaat cttggccccc actagagttg tggcagctga aatggaggaa	5220
gcccttagag gacttccaat aagataccag accccagcca tcagagctga gcacaccggg	5280
cgggagattg tggacctaata gtgtcatgcc acatttacca tgaggctgct atcaccagtt	5340
agagtgccaa actacaacct gattatcatg gacgaagccc atttcacaga cccagcaagt	5400
atagcagcta gaggatacat ctcaactcga gtggagatgg gtgaggcagc tgggattttt	5460
atgacagcca ctccccggg aagcagagac ccatttcctc agagcaatgc accaatcata	5520
gatgaagaaa gagaaatccc tgaacgttcg tggaattccg gacatgaatg ggtcacggat	5580
tttaaaggga agactgtttg gttcgttcca agtataaaag caggaaatga tatagcagct	5640
tgcctgagga aaaatggaaa gaaagtgata caactcagta ggaagacctt tgattctgag	5700
tatgtcaaga ctagaaccaa tgattgggac ttcgtggtta caactgacat ttcagaaatg	5760
ggtgccattt tcaaggctga gaggggttata gaccccagac gctgcatgaa accagtcata	5820
ctaacagatg gtgaagagcg ggtgattctg gcaggaccta tgccagtgac ccactctagt	5880
gcagcacaaa gaagaggagg aataggaaga aatccaaaaa atgagaatga ccagtacata	5940
tacatggggg aacctctgga aaatgatgaa gactgtgcac actggaaaga agctaaaatg	6000
ctcctagata acatcaacac gccagaagga atcattccta gcatgttcga accagagcgt	6060
gaaaagggtg atgccattga tggcgaatac cgcttgagag gagaagcaag gaaaaccttt	6120
gtagacttaa tgagaagagg agacctacca gtctggttgg cctacagagt ggcagctgaa	6180
ggcatcaact acgcagacag aaggtggtgt tttgatggag tcaagaacaa ccaaactcta	6240
gaagaaaacg tggaagttga aatctggaca aaagaagggg aaaggaagaa attgaaacc	6300
agatggttgg atgctaggat ctattctgac ccactggcgc taaaagaatt taaggattt	6360
gcagccggaa gaaagtctct gaccctgaac ctaatcacag aaatgggtag gctcccaacc	6420
ttcatgactc agaaggcaag agacgcactg gacaacttag cagtgtgca cacggctgag	6480
gcaggtggaa gggcgtacaa ccatgctctc agtgaactgc cggagaccct ggagacattg	6540
cttttactga cacttctggc tacagtcacg ggagggatct ttttattctt gatgagcgga	6600
aggggcatag ggaagatgac cctgggaatg tgctgcataa tcacggctag catcctccta	6660

tggtacgcac aaatacagcc acactggata gcagcttcaa taatactgga gttttttctc	6720
atagttttgc ttattccaga acctgaaaaa cagagaacac cccaagacaa ccaactgacc	6780
tacgttgtca tagccatcct cacagtgggtg gccgcaacca tggcaaacga gatgggtttc	6840
ctagaaaaaa cgaagaaaga tctcggattg ggaagcattg caaccagca acccgagagc	6900
aacatcctgg acatagatct acgtcctgca tcagcatgga cgctgtatgc cgtggccaca	6960
acatttgтта caccaatgтт gagacatagc attgaaaatt cctcagtгaa tgtgtcccta	7020
acagctatag ccaaccaagc cacagtgtta atgggtctcg ggaaaggatg gccattgtca	7080
aagatggaca tcggagttcc ctttctcgcc attggatgct actcacaagt caaccccata	7140
actctcacag cagctctttt cttattggta gcacattatg ccatcatagg gccaggactc	7200
caagcaaaag caaccagaga agctcagaaa agagcagcgg cgggcatcat gaaaaacca	7260
actgtcgatg gaataacagt gattgaccta gatccaatac cttatgatcc aaagtttgaa	7320
aagcagttgg gacaagtaat gctcctagtc ctctgcgtga ctcaagtatt gatgatgagg	7380
actacatggg ctctgtgtga ggctttaacc ttagctaccg ggcccatctc cacattgtgg	7440
gaaggaaatc cagggaggtt ttggaacact accattgcgg tgtcaatggc taacattttt	7500
agagggagtt acttggccgg agctggactt ctcttttcta ttatgaagaa cacaaccaac	7560
acaagaaggg gaactggcaa cataggagag acgcttggag agaaatggaa aagccgattg	7620
aacgcattgg gaaaaagtga attccagatc tacaagaaaa gtggaatcca ggaagtggat	7680
agaaccttag caaaagaagg cattaaaaga ggagaaacgg accatcacgc tgtgtcgcga	7740
ggctcagcaa aactgagatg gttcgttgag agaaacatgg tcacaccaga agggaaagta	7800
gtggacctcg gttgtggcag aggaggctgg tcatactatt gtggaggact aaagaatgta	7860
agagaagtca aaggcctaac aaaaggagga ccaggacacg aagaacccat ccccatgtca	7920
acatatgggt ggaatctagt gcgtcttcaa agtggagttg acgttttctt catcccgcca	7980
gaaaagtgtg acacattatt gtgtgacata ggggagtcac caccaaatcc cacagtggaa	8040
gcaggacgaa cactcagagt ccttaactta gtagaaaatt ggttgaacaa caaactcaa	8100
ttttgcataa aggttctcaa cccatatatg ccctcagtca tagaaaaaat ggaagcacta	8160
caaaggaaat atggaggagc cttagtгagg aatccactct cacgaaactc cacacatgag	8220
atgtactggg tatccaatgc ttccgggaac atagtgtcat cagtgaacat gatttcaagg	8280

atgttgatca acagatttac aatgagatac aagaaagcca cttacgagcc ggatgttgac	8340
ctcgggaagcg gaacccgtaa catcgggatt gaaagtgaga taccaaacct agatataatt	8400
gggaaaagaa tagaaaaaat aaagcaagag catgaaacat catggcacta tgaccaagac	8460
caccataca aaacgtgggc ataccatggt agctatgaaa caaaacagac tggatcagca	8520
tcatccatgg tcaacggagt ggtcaggctg ctgacaaaac cttgggacgt cgtcccatg	8580
gtgacacaga tggcaatgac agacacgact ccatttggac aacagcgcgt ttttaaagag	8640
aaagtggaca cgagaacca agaaccgaaa gaaggcacga agaaactaat gaaaataaca	8700
gcagagtggc tttggaaaga attagggag aaaaagacac ccaggatgtg caccagagaa	8760
gaattcaca gaaaggtgag aagcaatgca gccttggggg ccatattcac tgatgagaac	8820
aagtggaagt cggcacgtga ggctgttgaa gatagtaggt tttgggagct ggttgacaag	8880
gaaaggaatc tccatcttga aggaaagtgt gaaacatgtg tgtacaacat gatgggaaaa	8940
agagagaaga agctagggga attcggcaag gcaaaaggca gcagagccat atggtacatg	9000
tggcttggag cacgcttctt agagtttgaa gccctaggat tcttaaatga agatcactgg	9060
ttctccagag agaactccct gagtggagtg gaaggagaag ggctgcacaa gctaggttac	9120
attctaagag acgtgagcaa gaaagaggga ggagcaatgt atgccgatga caccgcagga	9180
tgggatacaa gaatcacact agaagaccta aaaaatgaag aaatggtaac aaaccacatg	9240
gaaggagaac acaagaaact agccgaggcc attttcaaac taacgtacca aaacaagggtg	9300
gtgcgtgtgc aaagaccaac accaagaggc acagtaatgg acatcatatc gagaagagac	9360
caaagaggta gtggacaagt tggcacctat ggactcaata ctttcaccaa tatggaagcc	9420
caactaatca gacagatgga gggagaagga gtcttttaaaa gcattcagca cctaacaatc	9480
acagaagaaa tcgctgtgca aaactggtta gcaagagtgg ggcgcgaaaag gttatcaaga	9540
atggccatca gtggagatga ttgtgttggtg aaaccttttag atgacagggt cgcaagcgct	9600
ttaacagctc taaatgacat gggaaagatt aggaaagaca tacaacaatg ggaaccttca	9660
agaggatgga atgattggac acaagtggcc ttctgttcac accatttcca tgagttaatc	9720
atgaaagacg gtcgcgtact cgttgttcca tgtagaaacc aagatgaact gattggcaga	9780
gcccgaatct cccaaggagc aggggtggtct ttgcgggaga cggcctgttt ggggaagtct	9840
tacgccccaa tgtggagctt gatgtacttc cacagacgcg acctcaggct ggcggcaaat	9900

gctatttgct cggcagtacc atcacattgg gttccaacaa gtcgaacaac ctggtccata 9960
catgctaaac atgaatggat gacaacggaa gacatgctga cagtctggaa caggggtgtgg 10020
attcaagaaa acccatggat ggaagacaaa actccagtgg aatcatggga ggaaatccca 10080
tacttgggga aaagagaaga ccaatggtgc ggctcattga ttgggttaac aagcagggcc 10140
acctgggcaa agaacatcca agcagcaata aatcaagtta gatcccttat aggcaatgaa 10200
gaatacacag attacatgcc atccatgaaa agattcagaa gagaagagga agaagcagga 10260
gttctgtgggt agaaagcaaa actaacatga aacaaggcta gaagtcaggt cggattaagc 10320
catagtacgg aaaaaactat gctacctgtg agccccgtcc aaggacgtta aaagaagtca 10380
ggccatcata aatgccatag ctggagtaaa ctatgcagcc thtagctcca cctgagaagg 10440
tgtaaaaaat ccgggaggcc acaaaccatg gaagctgtac gcatggcgta gtggactagc 10500
ggttagagga gaccctccc ttacaaatcg cagcaacaat gggggcccaa ggcgagatga 10560
agctgtagtc tcgctggaag gactagaggt tagaggagac ccccccgaac caaaaaacag 10620
catattgacg ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca 10680
gaacgccaga aaatggaatg gtgctgttga atcaacaggt tct 10723

<210> 12
<211> 3391
<212> PRT
<213> dengue virus

<400> 12

Met Asn Asn Gln Arg Lys Lys Ala Lys Asn Thr Pro Phe Asn Met Leu
1 5 10 15

Lys Arg Glu Arg Asn Arg Val Ser Thr Val Gln Gln Leu Thr Lys Arg
20 25 30

Phe Ser Leu Gly Met Leu Gln Gly Arg Gly Pro Leu Lys Leu Phe Met
35 40 45

Ala Leu Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala Gly
50 55 60

Ile Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala Ile Asn Val
65 70 75 80

Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn
85 90 95

Arg Arg Arg Arg Ser Ala Gly Met Ile Ile Met Leu Ile Pro Thr Val
100 105 110

Met Ala Phe His Leu Thr Thr Arg Asn Gly Glu Pro His Met Ile Val
115 120 125

Ser Arg Gln Glu Lys Gly Lys Ser Leu Leu Phe Lys Thr Glu Asp Gly
130 135 140

Val Asn Met Cys Thr Leu Met Ala Met Asp Leu Gly Glu Leu Cys Glu
145 150 155 160

Asp Thr Ile Thr Tyr Lys Cys Pro Leu Leu Arg Gln Asn Glu Pro Glu
165 170 175

Asp Ile Asp Cys Trp Cys Asn Ser Thr Ser Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Thr Thr Met Gly Glu His Arg Arg Glu Lys Arg Ser Val Ala
195 200 205

Leu Val Pro His Val Gly Met Gly Leu Glu Thr Arg Thr Glu Thr Trp
210 215 220

Met Ser Ser Glu Gly Ala Trp Lys His Val Gln Arg Ile Glu Thr Trp
225 230 235 240

Ile Leu Arg His Pro Gly Phe Thr Met Met Ala Ala Ile Leu Ala Tyr
245 250 255

Thr Ile Gly Thr Thr His Phe Gln Arg Ala Leu Ile Phe Ile Leu Leu
260 265 270

Thr Ala Val Thr Pro Ser Met Thr Met Arg Cys Ile Gly Met Ser Asn
275 280 285

Arg Asp Phe Val Glu Gly Val Ser Gly Gly Ser Trp Val Asp Ile Val
290 295 300

Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Phe Glu Leu Ile Lys Thr Glu Ala Lys Gln Pro Ala Thr Leu
325 330 335

Arg Lys Tyr Cys Ile Glu Ala Lys Leu Thr Asn Thr Thr Thr Glu Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Pro Ser Leu Asn Glu Glu Gln Asp Lys
355 360 365

Arg Phe Val Cys Lys His Ser Met Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Gly Ile Val Thr Cys Ala Met Phe Arg
385 390 395 400

Cys Lys Lys Asn Met Glu Gly Lys Val Val Gln Pro Glu Asn Leu Glu
405 410 415

Tyr Thr Ile Val Ile Thr Pro His Ser Gly Glu Glu His Ala Val Gly
420 425 430

Asn Asp Thr Gly Lys His Gly Lys Glu Ile Lys Ile Thr Pro Gln Ser
435 440 445

Ser Ile Thr Glu Ala Glu Leu Thr Gly Tyr Gly Thr Val Thr Met Glu
450 455 460

Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Gln
465 470 475 480

Met Glu Asn Lys Ala Trp Leu Val His Arg Gln Trp Phe Leu Asp Leu
485 490 495

Pro Leu Pro Trp Leu Pro Gly Ala Asp Thr Gln Gly Ser Asn Trp Ile
500 505 510

Gln Lys Glu Thr Leu Val Thr Phe Lys Asn Pro His Ala Lys Lys Gln
515 520 525

Asp Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu
530 535 540

Thr Gly Ala Thr Glu Ile Gln Met Ser Ser Gly Asn Leu Leu Phe Thr
545 550 555 560

Gly His Leu Lys Cys Arg Leu Arg Met Asp Lys Leu Gln Leu Lys Gly
565 570 575

Met Ser Tyr Ser Met Cys Thr Gly Lys Phe Lys Val Val Lys Glu Ile
580 585 590

Ala Glu Thr Gln His Gly Thr Ile Val Ile Arg Val Gln Tyr Glu Gly
595 600 605

Asp Gly Ser Pro Cys Lys Ile Pro Phe Glu Ile Met Asp Leu Glu Lys
610 615 620

Arg His Val Leu Gly Arg Leu Ile Thr Val Asn Pro Ile Val Thr Glu
625 630 635 640

Lys Asp Ser Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Asp Ser
645 650 655

Tyr Ile Ile Ile Gly Val Glu Pro Gly Gln Leu Lys Leu Asn Trp Phe
660 665 670

Lys Lys Gly Ser Ser Ile Gly Gln Met Phe Glu Thr Thr Met Arg Gly
675 680 685

Ala Lys Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser
690 695 700

Leu Gly Gly Val Phe Thr Ser Ile Gly Lys Ala Leu His Gln Val Phe
705 710 715 720

Gly Ala Ile Tyr Gly Ala Ala Phe Ser Gly Val Ser Trp Thr Met Lys
725 730 735

Ile Leu Ile Gly Val Ile Ile Thr Trp Ile Gly Met Asn Ser Arg Ser
740 745 750

Thr Ser Leu Ser Val Thr Leu Val Leu Val Gly Ile Val Thr Leu Tyr
755 760 765

Leu Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys
770 775 780

Asn Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Ile Thr Asp Asn Val
785 790 795 800

His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys
805 810 815

Leu Ala Ser Ala Ile Gln Lys Ala His Glu Glu Gly Ile Cys Gly Ile
820 825 830

Arg Ser Val Thr Arg Leu Glu Asn Leu Met Trp Lys Gln Ile Thr Pro
835 840 845

Glu Leu Asn His Ile Leu Ser Glu Asn Glu Val Lys Leu Thr Ile Met
850 855 860

Thr Gly Asp Ile Lys Gly Ile Met Gln Ala Gly Lys Arg Ser Leu Arg
865 870 875 880

Pro Gln Pro Thr Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala
885 890 895

Lys Met Leu Ser Thr Glu Ser His Asn Gln Thr Phe Leu Ile Asp Gly
900 905 910

Pro Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu
915 920 925

Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu
930 935 940

Lys Leu Lys Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu Met Ser
945 950 955 960

Ala Ala Ile Lys Asp Asn Arg Ala Val His Ala Asp Met Gly Tyr Trp
965 970 975

Ile Glu Ser Ala Leu Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe
980 985 990

Ile Glu Val Lys Asn Cys His Trp Pro Lys Ser His Thr Leu Trp Ser
995 1000 1005

Asn Gly Val Leu Glu Ser Glu Met Ile Ile Pro Lys Asn Leu Ala
1010 1015 1020

Gly Pro Val Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln
1025 1030 1035

Ile Thr Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp
1040 1045 1050

Phe Cys Asp Gly Thr Thr Val Val Val Thr Glu Asp Cys Gly Asn
1055 1060 1065

Arg Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly Lys Leu Ile
1070 1075 1080

Thr Glu Trp Cys Cys Arg Ser Cys Thr Leu Pro Pro Leu Arg Tyr
1085 1090 1095

Arg Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Leu
1100 1105 1110

Lys Glu Lys Glu Glu Asn Leu Val Asn Ser Leu Val Thr Ala Gly
1115 1120 1125

His Gly Gln Val Asp Asn Phe Ser Leu Gly Val Leu Gly Met Ala
1130 1135 1140

Leu Phe Leu Glu Glu Met Leu Arg Thr Arg Val Gly Thr Lys His
1145 1150 1155

Ala Ile Leu Leu Val Ala Val Ser Phe Val Thr Leu Ile Thr Gly
1160 1165 1170

Asn Met Ser Phe Arg Asp Leu Gly Arg Val Met Val Met Val Gly
1175 1180 1185

Ala Thr Met Thr Asp Asp Ile Gly Met Gly Val Thr Tyr Leu Ala
1190 1195 1200

Leu Leu Ala Ala Phe Lys Val Arg Pro Thr Phe Ala Ala Gly Leu
1205 1210 1215

Leu Leu Arg Lys Leu Thr Ser Lys Glu Leu Met Met Thr Thr Ile
1220 1225 1230

Gly Ile Val Leu Leu Ser Gln Ser Thr Ile Pro Glu Thr Ile Leu
1235 1240 1245

Glu Leu Thr Asp Ala Leu Ala Leu Gly Met Met Val Leu Lys Met
1250 1255 1260

Val Arg Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala
1265 1270 1275

Ile Leu Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys
1280 1285 1290

Val Ser Cys Thr Ile Leu Ala Val Val Ser Val Ser Pro Leu Leu
1295 1300 1305

Leu Thr Ser Ser Gln Gln Lys Thr Asp Trp Ile Pro Leu Ala Leu
1310 1315 1320

Thr Ile Lys Gly Leu Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu
1325 1330 1335

Ser Arg Thr Ser Lys Lys Arg Ser Trp Pro Leu Asn Glu Ala Ile
1340 1345 1350

Met Ala Val Gly Met Val Ser Ile Leu Ala Ser Ser Leu Leu Lys
1355 1360 1365

Asn Asp Ile Pro Met Thr Gly Pro Leu Val Ala Gly Gly Leu Leu
1370 1375 1380

Thr Val Cys Tyr Val Leu Thr Gly Arg Ser Ala Asp Leu Glu Leu
1385 1390 1395

Glu Arg Ala Ala Asp Val Lys Trp Glu Asp Gln Ala Glu Ile Ser
1400 1405 1410

Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser Glu Asp Gly Ser
1415 1420 1425

Met Ser Ile Lys Asn Glu Glu Glu Glu Gln Thr Leu Thr Ile Leu
1430 1435 1440

Ile Arg Thr Gly Leu Leu Val Ile Ser Gly Leu Phe Pro Val Ser
1445 1450 1455

Ile Pro Ile Thr Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys Lys
1460 1465 1470

Gln Arg Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Met
1475 1480 1485

Gly Lys Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys
1490 1495 1500

Gly Ile Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu
1505 1510 1515

Gly Thr Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
1520 1525 1530

Met His Lys Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys
1535 1540 1545

Lys Asp Leu Ile Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu
1550 1555 1560

Trp Lys Glu Gly Glu Glu Val Gln Val Leu Ala Leu Glu Pro Gly
1565 1570 1575

Lys Asn Pro Arg Ala Val Gln Thr Lys Pro Gly Leu Phe Lys Thr
1580 1585 1590

Asn Ala Gly Thr Ile Gly Ala Val Ser Leu Asp Phe Ser Pro Gly
1595 1600 1605

Thr Ser Gly Ser Pro Ile Ile Asp Lys Lys Gly Lys Val Val Gly
1610 1615 1620

Leu Tyr Gly Asn Gly Val Val Thr Arg Ser Gly Ala Tyr Val Ser
1625 1630 1635

Ala Ile Ala Gln Thr Glu Lys Ser Ile Glu Asp Asn Pro Glu Ile
1640 1645 1650

Glu Asp Asp Ile Phe Arg Lys Arg Arg Leu Thr Ile Met Asp Leu
1655 1660 1665

His Pro Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro Ala Ile Val
1670 1675 1680

Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu Ala Pro
1685 1690 1695

Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu
1700 1705 1710

Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala Glu His Thr Gly
1715 1720 1725

Arg Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg
1730 1735 1740

Leu Leu Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met
1745 1750 1755

Asp Glu Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly
1760 1765 1770

Tyr Ile Ser Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe
1775 1780 1785

Met Thr Ala Thr Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser
1790 1795 1800

Asn Ala Pro Ile Ile Asp Glu Glu Arg Glu Ile Pro Glu Arg Ser
1805 1810 1815

Trp Asn Ser Gly His Glu Trp Val Thr Asp Phe Lys Gly Lys Thr
1820 1825 1830

Val Trp Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Ala
1835 1840 1845

Cys Leu Arg Lys Asn Gly Lys Lys Val Ile Gln Leu Ser Arg Lys
1850 1855 1860

Thr Phe Asp Ser Glu Tyr Val Lys Thr Arg Thr Asn Asp Trp Asp
1865 1870 1875

Phe Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Lys
1880 1885 1890

Ala Glu Arg Val Ile Asp Pro Arg Arg Cys Met Lys Pro Val Ile
1895 1900 1905

Leu Thr Asp Gly Glu Glu Arg Val Ile Leu Ala Gly Pro Met Pro
1910 1915 1920

Val Thr His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly Arg
1925 1930 1935

Asn Pro Lys Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu Pro
1940 1945 1950

Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys Glu Ala Lys Met
1955 1960 1965

Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ser Met
1970 1975 1980

Phe Glu Pro Glu Arg Glu Lys Val Asp Ala Ile Asp Gly Glu Tyr
1985 1990 1995

Arg Leu Arg Gly Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg
2000 2005 2010

Arg Gly Asp Leu Pro Val Trp Leu Ala Tyr Arg Val Ala Ala Glu
2015 2020 2025

Gly Ile Asn Tyr Ala Asp Arg Arg Trp Cys Phe Asp Gly Val Lys
2030 2035 2040

Asn Asn Gln Ile Leu Glu Glu Asn Val Glu Val Glu Ile Trp Thr
2045 2050 2055

Lys Glu Gly Glu Arg Lys Lys Leu Lys Pro Arg Trp Leu Asp Ala
2060 2065 2070

Arg Ile Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Glu Phe
2075 2080 2085

Ala Ala Gly Arg Lys Ser Leu Thr Leu Asn Leu Ile Thr Glu Met
2090 2095 2100

Gly Arg Leu Pro Thr Phe Met Thr Gln Lys Ala Arg Asp Ala Leu
2105 2110 2115

Asp Asn Leu Ala Val Leu His Thr Ala Glu Ala Gly Gly Arg Ala
2120 2125 2130

Tyr Asn His Ala Leu Ser Glu Leu Pro Glu Thr Leu Glu Thr Leu
2135 2140 2145

Leu Leu Leu Thr Leu Leu Ala Thr Val Thr Gly Gly Ile Phe Leu
2150 2155 2160

Phe Leu Met Ser Gly Arg Gly Ile Gly Lys Met Thr Leu Gly Met
2165 2170 2175

Cys Cys Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala Gln Ile
2180 2185 2190

Gln Pro His Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe Leu
2195 2200 2205

Ile Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln
2210 2215 2220

Asp Asn Gln Leu Thr Tyr Val Val Ile Ala Ile Leu Thr Val Val
2225 2230 2235

Ala Ala Thr Met Ala Asn Glu Met Gly Phe Leu Glu Lys Thr Lys
2240 2245 2250

Lys Asp Leu Gly Leu Gly Ser Ile Ala Thr Gln Gln Pro Glu Ser
2255 2260 2265

Asn Ile Leu Asp Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu
2270 2275 2280

Tyr Ala Val Ala Thr Thr Phe Val Thr Pro Met Leu Arg His Ser
2285 2290 2295

Ile Glu Asn Ser Ser Val Asn Val Ser Leu Thr Ala Ile Ala Asn
2300 2305 2310

Gln Ala Thr Val Leu Met Gly Leu Gly Lys Gly Trp Pro Leu Ser
2315 2320 2325

Lys Met Asp Ile Gly Val Pro Leu Leu Ala Ile Gly Cys Tyr Ser
2330 2335 2340

Gln Val Asn Pro Ile Thr Leu Thr Ala Ala Leu Phe Leu Leu Val
2345 2350 2355

Ala His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr
2360 2365 2370

Arg Glu Ala Gln Lys Arg Ala Ala Ala Gly Ile Met Lys Asn Pro
2375 2380 2385

Thr Val Asp Gly Ile Thr Val Ile Asp Leu Asp Pro Ile Pro Tyr
2390 2395 2400

Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val
2405 2410 2415

Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala Leu
2420 2425 2430

Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Ile Ser Thr Leu Trp
2435 2440 2445

Glu Gly Asn Pro Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser
2450 2455 2460

Met Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu
2465 2470 2475

Leu Phe Ser Ile Met Lys Asn Thr Thr Asn Thr Arg Arg Gly Thr
2480 2485 2490

Gly Asn Ile Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu
2495 2500 2505

Asn Ala Leu Gly Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly
2510 2515 2520

Ile Gln Glu Val Asp Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg
2525 2530 2535

Gly Glu Thr Asp His His Ala Val Ser Arg Gly Ser Ala Lys Leu
2540 2545 2550

Arg Trp Phe Val Glu Arg Asn Met Val Thr Pro Glu Gly Lys Val
2555 2560 2565

Val Asp Leu Gly Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Cys Gly
2570 2575 2580

Gly Leu Lys Asn Val Arg Glu Val Lys Gly Leu Thr Lys Gly Gly
2585 2590 2595

Pro Gly His Glu Glu Pro Ile Pro Met Ser Thr Tyr Gly Trp Asn
2600 2605 2610

Leu Val Arg Leu Gln Ser Gly Val Asp Val Phe Phe Ile Pro Pro
2615 2620 2625

Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Pro
2630 2635 2640

Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu Asn Leu
2645 2650 2655

Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Ile Lys Val
2660 2665 2670

Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Lys Met Glu Ala Leu
2675 2680 2685

Gln Arg Lys Tyr Gly Gly Ala Leu Val Arg Asn Pro Leu Ser Arg
2690 2695 2700

Asn Ser Thr His Glu Met Tyr Trp Val Ser Asn Ala Ser Gly Asn
2705 2710 2715

Ile Val Ser Ser Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg
2720 2725 2730

Phe Thr Met Arg Tyr Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp
2735 2740 2745

Leu Gly Ser Gly Thr Arg Asn Ile Gly Ile Glu Ser Glu Ile Pro
2750 2755 2760

Asn Leu Asp Ile Ile Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu
2765 2770 2775

His Glu Thr Ser Trp His Tyr Asp Gln Asp His Pro Tyr Lys Thr
2780 2785 2790

Trp Ala Tyr His Gly Ser Tyr Glu Thr Lys Gln Thr Gly Ser Ala
2795 2800 2805

Ser Ser Met Val Asn Gly Val Val Arg Leu Leu Thr Lys Pro Trp
2810 2815 2820

Asp Val Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr
2825 2830 2835

Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg
2840 2845 2850

Thr Gln Glu Pro Lys Glu Gly Thr Lys Lys Leu Met Lys Ile Thr
2855 2860 2865

Ala Glu Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys Thr Pro Arg
2870 2875 2880

Met Cys Thr Arg Glu Glu Phe Thr Arg Lys Val Arg Ser Asn Ala
2885 2890 2895

Ala Leu Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys Ser Ala
2900 2905 2910

Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu Leu Val Asp Lys
2915 2920 2925

Glu Arg Asn Leu His Leu Glu Gly Lys Cys Glu Thr Cys Val Tyr
2930 2935 2940

Asn Met Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys
2945 2950 2955

Ala Lys Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg
2960 2965 2970

Phe Leu Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp
2975 2980 2985

Phe Ser Arg Glu Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu
2990 2995 3000

His Lys Leu Gly Tyr Ile Leu Arg Asp Val Ser Lys Lys Glu Gly
3005 3010 3015

Gly Ala Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile
3020 3025 3030

Thr Leu Glu Asp Leu Lys Asn Glu Glu Met Val Thr Asn His Met
3035 3040 3045

Glu Gly Glu His Lys Lys Leu Ala Glu Ala Ile Phe Lys Leu Thr
3050 3055 3060

Tyr Gln Asn Lys Val Val Arg Val Gln Arg Pro Thr Pro Arg Gly
3065 3070 3075

Thr Val Met Asp Ile Ile Ser Arg Arg Asp Gln Arg Gly Ser Gly
3080 3085 3090

Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala
3095 3100 3105

Gln Leu Ile Arg Gln Met Glu Gly Glu Gly Val Phe Lys Ser Ile
3110 3115 3120

Gln His Leu Thr Ile Thr Glu Glu Ile Ala Val Gln Asn Trp Leu
3125 3130 3135

Ala Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser Gly
3140 3145 3150

Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg Phe Ala Ser Ala
3155 3160 3165

Leu Thr Ala Leu Asn Asp Met Gly Lys Ile Arg Lys Asp Ile Gln
3170 3175 3180

Gln Trp Glu Pro Ser Arg Gly Trp Asn Asp Trp Thr Gln Val Pro
3185 3190 3195

Phe Cys Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg
3200 3205 3210

Val Leu Val Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg
3215 3220 3225

Ala Arg Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala
3230 3235 3240

Cys Leu Gly Lys Ser Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe
3245 3250 3255

His Arg Arg Asp Leu Arg Leu Ala Ala Asn Ala Ile Cys Ser Ala
3260 3265 3270

Val Pro Ser His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile
3275 3280 3285

His Ala Lys His Glu Trp Met Thr Thr Glu Asp Met Leu Thr Val
3290 3295 3300

Trp Asn Arg Val Trp Ile Gln Glu Asn Pro Trp Met Glu Asp Lys
3305 3310 3315

Thr Pro Val Glu Ser Trp Glu Glu Ile Pro Tyr Leu Gly Lys Arg
3320 3325 3330

Glu Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala
3335 3340 3345

Thr Trp Ala Lys Asn Ile Gln Ala Ala Ile Asn Gln Val Arg Ser
3350 3355 3360

Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser Met Lys
3365 3370 3375

Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
3380 3385 3390

<210> 13
<211> 10696
<212> DNA
<213> dengue virus

<400> 13
agttgttagt ctacgtggac cgacaagaac agtttcgact cggaagcttg cttaacgtag 60
tgctgacagt tttttattag agagcagatc tctgatgaac aaccaacgga aaaagacggg 120
aaaaccgtct atcaatatgc tgaaacgcgt gagaaaccgt gtgtcaactg gatcacagtt 180
ggcgaagaga ttctcaagag gattgctgaa cggccaagga ccaatgaaat tggttatggc 240
atttatagct ttcctcagat ttctagccat tccaccgaca gcaggagtct tggctagatg 300
gggtaccttt aagaagtcgg gggctattaa ggtcttaaaa ggcttcaaga aggagatctc 360
aaacatgctg agcattatca acaaacggaa aaagacatcg ctctgtctca tgatgatgtt 420
accagcaaca cttgctttcc acttaacttc acgagatgga gagccgcgca tgattgtggg 480
gaagaatgaa agaggaaaat ccctactttt caagacagcc tctggaatca acatgtgcac 540
actcatagcc atggatctgg gagagatgtg tgatgacacg gtcacttaca aatgccccca 600
cattaccgaa gtggagcctg aagacattga ctgctgggtgc aaccttacat cgacatgggt 660
gacttatgga acatgcaatc aagctggaga gcatagacgc gataagagat cagtggcggt 720
agctcccat gttggcatgg gactggacac acgcactcaa acctggatgt cggctgaagg 780
agcttggaga caagtcgaga aggtagagac atggggccctt aggcaaccag ggtttaccat 840
actagcccta tttcttgccc attacatagg cacttccttg acccagaaaag tggttatttt 900
tatactatta atgctggtta ccccatccat gacaatgaga tgtgtaggag taggaaacag 960
agattttgtg gaaggcctat cgggagctac gtgggttgac gtggtgctcg agcacggtgg 1020
gtgtgtgact accatggcta agaacaagcc cacgctggac atagagcttc agaagaccga 1080
ggccacccaa ctggcgaccc taaggaagct atgcattgag ggaaaaatta ccaacataac 1140
aaccgactca agatgtccca cccaagggga agcgatttta cctgaggagc aggaccagaa 1200
ctacgtgtgt aagcatacat acgtggacag aggctgggga aacggttgtg gtttgtttgg 1260

caagggaagc ttggtgacat ggcgcgaaatt tcaatgttta gaatcaatag agggaaaagt	1320
ggtgcaacat gagaacctca aatacaccgt catcatcaca gtgcacacag gagaccaaca	1380
ccaggtggga aatgaaacgc agggagtcac ggctgagata acaccccagg catcaaccgc	1440
tgaagtcatt ttacctgaat atggaaccct cgggctagaa tgctcaccac ggacaggttt	1500
ggatttcaat gaaatgatct cattgacaat gaagaacaaa gcatggatgg tacatagaca	1560
atggttcttt gacttacccc taccatggac atcaggagct acagcagaaa caccaacttg	1620
gaacaggaaa gagcttcttg tgacatttaa aaatgcacat gcaaaaaagc aagaagtagt	1680
tgttcttgga tcacaagagg gagcaatgca tacagcactg acaggagcta cagagatcca	1740
aacctcagga ggcacaagta tctttgcggg gcacttaaaa tgtagactca agatggacaa	1800
attggaactc aaggggatga gctatgcaat gtgcttgagt agctttgtgt tgaagaaaga	1860
agtctccgaa acgcagcatg ggacaatact cattaagggt gagtacaaag gggaagatgc	1920
accctgcaag attcctttct ccacggagga tggacaagga aaagctcaca atggcagact	1980
gatcacagcc aatccagtgg tgaccaagaa ggaggagcct gtcaacattg aggctgaacc	2040
tccttttgga gaaagtaaca tagtaattgg aattggagac aaagccctga aaatcaactg	2100
gtacaagaag ggaagctcga ttgggaagat gttcgaggcc actgccagag gtgcaaggcg	2160
catggccatc ttgggagaca cagcctggga ctttgatca gtgggtggtg ttttgaattc	2220
attagggaaa atggtccacc aaatatattg gagtgcttac acagccctat ttggtggagt	2280
ctcctggatg atgaaaattg gaataggtgt cctcttaacc tggatagggt tgaactcaaa	2340
aaatacttct atgtcatttt catgcatcgc gataggaatc attacactct atctgggagc	2400
cgtggtgcaa gctgacatgg ggtgtgtcat aaactggaaa ggcaaagaac tcaaatgtgg	2460
aagtggaatt ttcgtcacta atgaggtcca cacctggaca gagcaatata aatttcaagc	2520
agactcccc aagagactgg caacagccat tgcaggcgct tgggaaaatg gagtgtgcgg	2580
aattaggtca acaaccagaa tggagaacct cttgtggaag caaatagcca atgaactgaa	2640
ttacatatta tgggaaaaca acattaaatt aacggtagtt gtaggcgaca taactggggt	2700
cttagagcaa gggaaaagaa cactaacacc acaacccatg gagctaaaat attcttgga	2760
aacatgggga aaggcaaaaa tagtgacagc tgaaacacaa aattcctctt tcataataga	2820
tgggccaagc acaccggagt gtccaagtgc ctcaagagca tggaatgtgt gggaggtgga	2880

ggattacggg	ttcggagttt	tcacaaccaa	catatggctg	aaactccgag	aggtgtacac	2940
ccaactatgt	gaccataggc	taatgtcggc	agccgtcaag	gatgagaggg	ctgtacatgc	3000
cgacatgggc	tattggatag	aaagccaaaa	gaatgggagt	tggaagctag	aaaaagcatc	3060
cttcatagag	gtgaaaacct	gcacatggcc	aaaatcacac	actctctgga	gcaatggtgt	3120
gctagagagt	gacatgatta	tcccaaagag	tctagctggg	cccatttcgc	aacacaacca	3180
caggcccg	taccacaccc	aaacggcagg	accctggcac	ttaggaaaaat	tggagctgga	3240
cttcaactat	tgtgaaggaa	caacagttgt	catctcagaa	aactgtggga	caagaggccc	3300
atcattgaga	acaacaacgg	tgtcagggaa	gttgatacac	gaatggtgct	gccgctcgtg	3360
cacacttcct	cccctacgat	acatgggaga	agacggctgc	tggtatggca	tggaaatcag	3420
acccattaat	gagaaagaag	agaatatggt	aaagtctcta	gcctcagcag	ggagtggaaa	3480
ggtggacaac	ttcacaatgg	gtgtcttgtg	tttggcaatc	ctctttgaag	aggtgatgag	3540
aggaaaattt	gggaaaaaac	acatgattgc	aggggttctc	ttcacgtttg	tgctcctcct	3600
ctcagggcaa	ataacatgga	gagacatggc	gcacacactc	ataatgattg	ggtccaacgc	3660
ctctgacaga	atggggatgg	gcgtcactta	cctagctcta	attgcaacat	ttaaaattca	3720
gccattcctg	gctttgggat	tcttcctgag	gaaactgaca	tctagagaaa	atttattgct	3780
gggagttggg	ttggccatgg	cagcaacggt	acgactgcca	gaggacattg	aacagatggc	3840
gaatggaatt	gctttggggc	tcatggctct	taaactgata	acacaatttg	aaacatacca	3900
actatggacg	gcattagttt	ccctaacgtg	ttcaaataca	attttcacgt	tgactgttgc	3960
ctggagaaca	gccactctga	ttttagccgg	aatttcgctt	ttgccagtgt	gccagtcttc	4020
gagcatgagg	aaaacagatt	ggctcccaat	gactgtggca	gctatgggag	ctcaaccctt	4080
accacttttt	attttcagtc	tgaaagatac	actcaaaagg	agaagctggc	cactgaatga	4140
gggggtgatg	gcagttggac	ttgtgagcat	tctagctagt	tctctcctta	ggaatgatgt	4200
gcctatggct	ggaccattag	tggtggggg	cttgctgata	gcgtgctacg	tcataactgg	4260
cacgtcagca	gacctcactg	tagaaaaagc	agcagatgta	acatgggagg	aagaggccga	4320
gcaaacagga	gtgtcccaca	atttaatggt	cacagttgat	gatgatggaa	caatgagaat	4380
aaaagatgac	gagactgaga	acatcttaac	agtgttttta	aaaacagcac	tactaatagt	4440
atcaggcatc	tttccatact	ccatacccg	aacactgttg	gtctggcata	cttggcaaaa	4500

gcaaacccaa agatccggcg tcctatggga cgtacccagc cccccagaga cacagaaagc	4560
ggaactggaa gaaggggtct ataggatcaa acagcaagga atttttggga aaaccaagt	4620
gggggttgga gtacagaaag aaggagtttt ccacaccatg tggcatgtca caagaggggc	4680
agtgttgaca cacaatggga aaagactgga accaaactgg gctagcgtga aaaaagatct	4740
gatttcatac ggaggaggat ggagattgag tgcacaatgg caaaaggggg aggaggtgca	4800
ggttattgcc gtagagcctg ggaagaacct aaagaacttt caaacatgc caggcatttt	4860
tcagacaaca acaggggaaa taggagcaat tgcactggat ttcaagcctg gaacttcagg	4920
atctcccatc ataaacagag agggaaaggt agtgggactg tatggcaatg gagtggttac	4980
aaagaatgga ggctatgtca gtggaatagc gcaaacaat gcagaaccag atggaccgac	5040
accagagttg gaagaagaga tgttcaaaaa gcgaaatcta accataatgg atctccatcc	5100
tgggtcagga aagacgcgga aatatcttcc agctattgtt agagaggcaa tcaagagacg	5160
cttaaggact ctaattttgg caccaacaag ggtagttgca gctgagatgg aagaagcatt	5220
gaaagggctc ccaataaggt atcaaacaac tgcaacaaaa tctgaacaca caggaagaga	5280
gattgttgat ctaatgtgtc acgcaacgtt cacaatgcgc ttgctgtcac cagtcagggt	5340
tccaaactac aacttgataa taatggatga ggcccatttc acagaccag ccagtatagc	5400
ggctagaggg tacatatcaa ctctgttagg aatgggagag gcagccgcaa ttttcatgac	5460
agcaacaccc cctggaacag ctgatgcctt tcctcagagc aacgctcaa ttcaagatga	5520
agagagagac ataccggaac gctcatggaa ttcaggcaat gaatggatta ctgactttgt	5580
tgggaagaca gtgtggtttg tccctagcat caaagccgga aatgacatag caaactgctt	5640
gcggaaaaat ggaaaaaagg ttatttcaact cagcaggaag acctttgaca cagaatatca	5700
aaagaccaa ctgaatgatt gggactttgt ggtgacaaca gacatttcag aaatgggagc	5760
caatttcaa gcagatagag tgatcgacct aagaagatgt ctcaagccgg tgattttgac	5820
agatggacct gagcgggtga tcctggctgg accaatgcca gtcaccgtag cgagcgctgc	5880
gcaaaggaga gggagagttg gcaggaacct acaaaaagaa aatgaccagt acatattcat	5940
gggccagcct ctcaacaatg atgaagacca tgctcactgg acagaagcaa aaatgctgct	6000
ggacaacatc aacacaccag aagggttat accagctctc tttgaaccag aaaggagaa	6060
gtcagccgcc atagacggcg aataccgcct gaagggtgag tccaggaaga ctttcgtgga	6120

actcatgagg	aggggtgacc	tcccagtttg	gctagcccat	aaagtagcat	cagaagggat	6180
caaataataca	gatagaaaat	ggtgctttga	tggagaacgt	aataatcaaa	ttttagagga	6240
gaatatggat	gtggaaatct	ggacaaagga	aggagaaaag	aaaaaactga	gacctaggtg	6300
gcttgatgcc	cgcacttatt	cagatccttt	agcactcaaa	gaattcaagg	attttgcagc	6360
tggcagaaag	tcaatcgccc	ttgatcttgt	gacagaaata	ggaagagtgc	cttcacactt	6420
agcccacaga	acgagaaacg	ccctggataa	tttggatgat	ctgcacacgt	cagaacatgg	6480
cggtagggcc	tacaggcatg	cagtggagga	actaccagaa	acgatggaaa	cactcttact	6540
cctgggactg	atgatcttgt	taacaggttg	agcaatgctc	ttcttgatat	caggtaaagg	6600
gattggaaag	acttcaatag	gactcatttg	tgtaattgct	tccagcggca	tgttatggat	6660
ggctgatgtc	ccactccaat	ggatcgcata	ggctatagtc	ctggagtttt	ttatgatggg	6720
gttgctcata	ccagaaccag	aaaagcagag	aactcccca	gacaaccaac	tcgcatatgt	6780
cgtgataggc	atacttacat	tggctgcaat	agtagcggcc	aatgaaatgg	gactgttgga	6840
aactacaaag	agagatttag	gaatgtctaa	agaaccaggt	gttgtttctc	caaccagcta	6900
tttggatgtg	gacttgcacc	cagcatcagc	ctggacattg	tacgccgtgg	ccacaacagt	6960
aataacacca	atgttgagac	acaccataga	gaattccaca	gcaaagtgtg	ctctggcagc	7020
catagctaac	caggcagtgg	tcctgatggg	tttagacaaa	ggatggccga	tatcgaaaat	7080
ggacttgggc	gtaccactat	tggcactggg	ttgctattca	caagtgaacc	cactaactct	7140
tgcagcggca	gtacttttgc	tagtcacaca	ttatgcaatt	ataggtccag	gattgcaggc	7200
aaaagccacc	cgtgaagctc	agaaaaggac	agctgctgga	ataatgaaga	atccaacggt	7260
ggatggaata	atgacaatag	acctagatcc	tgtaatatat	gattcaaaaat	ttgaaaagca	7320
actaggacag	gtcatgctcc	tggttctgtg	tgcagtccaa	cttttattga	tgagaacatc	7380
atgggccttg	tgtgaagttc	taaccctagc	cacaggacca	ataacaacac	tctgggaagg	7440
atcacctggg	aagttctgga	acaccacgat	agctgtttcc	atggcgaaca	tcttttagagg	7500
gagctattta	gcaggagctg	ggcttgcttt	ttctatcatg	aaatcagttg	gaacaggaaa	7560
gagaggaaca	gggtcacaag	gtgaaacctt	aggagaaaag	tggaaaaaga	aattaaatca	7620
gttatcccgg	aaagagtttg	acctttacaa	gaaatccgga	atcaccgaag	tggatagaac	7680
agaagccaaa	gaagggttaa	aaagaggaga	aataacacac	catgccgtgt	ccagaggcag	7740

cgcaaaactt caatggttcg tggagagaaa catggtcatt cctgaaggaa gagtcataga	7800
cctaggctgt ggaagaggag gctggtcata ttactgtgca ggactgaaaa aagttacaga	7860
agtgcgagga tacacaaaag gcggcccagg acacgaagaa ccagtaccta tgtctacata	7920
cggatggaac atagtcaagt taatgagtgg aaaggatggt ttttatctgc cacctgaaaa	7980
gtgtgatacc ctattgtgtg acattggaga atcttcacca agcccaacag tggaagaaag	8040
cagaaccata agagttttga agatggttga accatggcta aagaacaacc agttttgcat	8100
taaagtattg aaccataca tgccaactgt gattgagcac ttagaaagac tacaaggaag	8160
acatggagga atgcttgtga gaaatccact ctcacgaaac tccacgcacg aaatgtattg	8220
gatatccaat ggtacaggca atatcgtctc ttcagtcaac atggtatcca gattgctact	8280
gaacagattc acaatgacac acaggagacc caccatagag aaagatgtgg atctaggagc	8340
aggaaccga catgtcaatg cggaaccaga aacacccaac atggatgtca ttggggaaag	8400
aataaaaagg atcaaagagg agcatagttc aacatggcac tatgatgatg aaaatcctta	8460
caaacgtgg gcttaccatg gatcctatga agtaaaagcc acaggctcag cctcctccat	8520
gataaatgga gtcgtgaaac tcctcacaaa accatgggat gtggtgcca tggtgacaca	8580
gatggcaatg acagatacaa ctccattcgg ccagcaaaga gtttttaaag agaaagtgga	8640
caccaggaca cctaggccca tgccaggaac aagaaagggt atggagatca cagcggagtg	8700
gctttggagg accctgggaa ggaacaaaag acccagatta tgcacaaggg aggaattcac	8760
aaagaaggtc agaaccaacg cagctatggg cgctgtcttc acagaagaga accaatggga	8820
cagtgcgaga gctgctgttg aggacgaaga attttggaaa cttgtggaca gagaacgtga	8880
actccacaaa ctgggcaagt gtggaagctg cgttttacaac atgatgggca agagagagaa	8940
aaaacttgga gagtttggtg aagcaaaagg cagtagggct atatggtaca tgtggttggg	9000
agccaggtag cttgagttcg aggcgctcgg attcctcaat gaagaccact ggttctcgcg	9060
tgaaaactct tacagtggag tagaaggaga aggactgcac aagctgggat acatcttgag	9120
agatatttcc aagatacccg gaggagccat gtatgctgat gacacagccg gttgggacac	9180
aagaataaca gaagatgacc tgcacaatga ggaaaaaatc acacagcaga tggaccctga	9240
acacaggcag ctagcgaacg ctatattcaa gctcacatac caaaacaaag tgggtcaaagt	9300
ccaacgacca actccaaagg gcacggtaat ggacatcata tctaggaaag accaaagagg	9360

cagtggacag gtgggaactt atggtctgaa cacattcacc aacatggaag cccagctaata	9420
cagacaaatg gaaggagaag gcgtgttgtc aaaggcagac ctcgagaacc cccatccgct	9480
agagaagaaa attacacaat ggttggaaac taaaggagtg gaaaggttaa aaagaatggc	9540
catcagcggg gatgattgcg ttgtgaaacc aatcgacgac agattcgcca atgccctgct	9600
tgccctgaac gatatgggaa aggttagaaa ggacatacct caatggcagc catcaaaggg	9660
atggcatgat tggcaacagg tccccttctg ctcccaccac tttcatgaat tgatcatgaa	9720
agatggaaga aagttggtag ttccctgcag accccaggac gaactaatag gaagagcgag	9780
aatctcccaa ggagcaggat ggagccttag agaaactgca tgtctaggga aagcctacgc	9840
tcaaattgtgg gctctcatgt attttcacag aagagatctt agactagcat ccaacgccat	9900
atgttcagca gtaccagtcc actgggtccc cacgagcaga acgacatggc ctattcatgc	9960
tcaccatcag tggatgacta cagaagacat gcttactgtc tggaacaggg tgtggataga	10020
ggacaatcca tggatggaag acaaaactcc agtcacaacg tgggaagatg ttccatatct	10080
agggaagaga gaagaccaat ggtgcggatc actcataggt ctcaattcca gagcaacctg	10140
ggcccagaac atactcacag caatccaaca ggtgagaagc ctcataaggca atgaagagtt	10200
tctggactac atgccttcga tgaagagatt caggaaggag gaggagtcag agggagccat	10260
ttggtaaaag caggaggtaa actgtcaggc cacattaagc cacagtacgg aagaagctgt	10320
gcagcctgtg agccccgtcc aaggacgtta aaagaagaag tcaggcccaa aagccacggc	10380
ttgagcaaac cgtgctgcct gtagctccgt cgtggggacg taaagcctgg gaggctgcaa	10440
accgtggaag ctgtacgcac ggtgtagcag actagtgggt agaggagacc cctcccatga	10500
cacaacgcag cagcggggcc cgagcactga gggaagctgt acctccttgc aaaggactag	10560
aggttagagg agacccccg caaacaaaaa cagcatattg acgctgggag agaccagaga	10620
tcctgctgtc tcctcagcat cattccaggc acagaacgcc agaaaatgga atggtgctgt	10680
tgaatcaaca ggttct	10696

<210> 14
 <211> 3390
 <212> PRT
 <213> dengue virus

<400> 14

Met Asn Asn Gln Arg Lys Lys Thr Gly Lys Pro Ser Ile Asn Met Leu
1 5 10 15

Lys Arg Val Arg Asn Arg Val Ser Thr Gly Ser Gln Leu Ala Lys Arg
20 25 30

Phe Ser Arg Gly Leu Leu Asn Gly Gln Gly Pro Met Lys Leu Val Met
35 40 45

Ala Phe Ile Ala Phe Leu Arg Phe Leu Ala Ile Pro Pro Thr Ala Gly
50 55 60

Val Leu Ala Arg Trp Gly Thr Phe Lys Lys Ser Gly Ala Ile Lys Val
65 70 75 80

Leu Lys Gly Phe Lys Lys Glu Ile Ser Asn Met Leu Ser Ile Ile Asn
85 90 95

Lys Arg Lys Lys Thr Ser Leu Cys Leu Met Met Met Leu Pro Ala Thr
100 105 110

Leu Ala Phe His Leu Thr Ser Arg Asp Gly Glu Pro Arg Met Ile Val
115 120 125

Gly Lys Asn Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr Ala Ser Gly
130 135 140

Ile Asn Met Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Met Cys Asp
145 150 155 160

Asp Thr Val Thr Tyr Lys Cys Pro His Ile Thr Glu Val Glu Pro Glu
165 170 175

Asp Ile Asp Cys Trp Cys Asn Leu Thr Ser Thr Trp Val Thr Tyr Gly
180 185 190

Thr Cys Asn Gln Ala Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala
195 200 205

Leu Ala Pro His Val Gly Met Gly Leu Asp Thr Arg Thr Gln Thr Trp
210 215 220

Met Ser Ala Glu Gly Ala Trp Arg Gln Val Glu Lys Val Glu Thr Trp
225 230 235 240

Ala Leu Arg His Pro Gly Phe Thr Ile Leu Ala Leu Phe Leu Ala His
245 250 255

Tyr Ile Gly Thr Ser Leu Thr Gln Lys Val Val Ile Phe Ile Leu Leu
260 265 270

Met Leu Val Thr Pro Ser Met Thr Met Arg Cys Val Gly Val Gly Asn
275 280 285

Arg Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val
290 295 300

Leu Glu His Gly Gly Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr
305 310 315 320

Leu Asp Ile Glu Leu Gln Lys Thr Glu Ala Thr Gln Leu Ala Thr Leu
325 330 335

Arg Lys Leu Cys Ile Glu Gly Lys Ile Thr Asn Ile Thr Thr Asp Ser
340 345 350

Arg Cys Pro Thr Gln Gly Glu Ala Ile Leu Pro Glu Glu Gln Asp Gln
355 360 365

Asn Tyr Val Cys Lys His Thr Tyr Val Asp Arg Gly Trp Gly Asn Gly
370 375 380

Cys Gly Leu Phe Gly Lys Gly Ser Leu Val Thr Cys Ala Lys Phe Gln
385 390 395 400

Cys Leu Glu Ser Ile Glu Gly Lys Val Val Gln His Glu Asn Leu Lys
405 410 415

Tyr Thr Val Ile Ile Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430

Asn Glu Thr Gln Gly Val Thr Ala Glu Ile Thr Pro Gln Ala Ser Thr
435 440 445

Ala Glu Val Ile Leu Pro Glu Tyr Gly Thr Leu Gly Leu Glu Cys Ser
450 455 460

Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Ile Ser Leu Thr Met Lys
465 470 475 480

Asn Lys Ala Trp Met Val His Arg Gln Trp Phe Phe Asp Leu Pro Leu
485 490 495

Pro Trp Thr Ser Gly Ala Thr Ala Glu Thr Pro Thr Trp Asn Arg Lys
500 505 510

Glu Leu Leu Val Thr Phe Lys Asn Ala His Ala Lys Lys Gln Glu Val
515 520 525

Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu Thr Gly
530 535 540

Ala Thr Glu Ile Gln Thr Ser Gly Gly Thr Ser Ile Phe Ala Gly His
545 550 555 560

Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Glu Leu Lys Gly Met Ser
565 570 575

Tyr Ala Met Cys Leu Ser Ser Phe Val Leu Lys Lys Glu Val Ser Glu
580 585 590

Thr Gln His Gly Thr Ile Leu Ile Lys Val Glu Tyr Lys Gly Glu Asp
595 600 605

Ala Pro Cys Lys Ile Pro Phe Ser Thr Glu Asp Gly Gln Gly Lys Ala
610 615 620

His Asn Gly Arg Leu Ile Thr Ala Asn Pro Val Val Thr Lys Lys Glu
625 630 635 640

Glu Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser Asn Ile
645 650 655

Val Ile Gly Ile Gly Asp Lys Ala Leu Lys Ile Asn Trp Tyr Lys Lys
660 665 670

Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly Ala Arg
675 680 685

Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Val Gly
690 695 700

Gly Val Leu Asn Ser Leu Gly Lys Met Val His Gln Ile Phe Gly Ser
705 710 715 720

Ala Tyr Thr Ala Leu Phe Gly Gly Val Ser Trp Met Met Lys Ile Gly
725 730 735

Ile Gly Val Leu Leu Thr Trp Ile Gly Leu Asn Ser Lys Asn Thr Ser
740 745 750

Met Ser Phe Ser Cys Ile Ala Ile Gly Ile Ile Thr Leu Tyr Leu Gly
755 760 765

Ala Val Val Gln Ala Asp Met Gly Cys Val Ile Asn Trp Lys Gly Lys
770 775 780

Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asn Glu Val His Thr
785 790 795 800

Trp Thr Glu Gln Tyr Lys Phe Gln Ala Asp Ser Pro Lys Arg Leu Ala
805 810 815

Thr Ala Ile Ala Gly Ala Trp Glu Asn Gly Val Cys Gly Ile Arg Ser
820 825 830

Thr Thr Arg Met Glu Asn Leu Leu Trp Lys Gln Ile Ala Asn Glu Leu
835 840 845

Asn Tyr Ile Leu Trp Glu Asn Asn Ile Lys Leu Thr Val Val Val Gly
850 855 860

Asp Ile Thr Gly Val Leu Glu Gln Gly Lys Arg Thr Leu Thr Pro Gln
865 870 875 880

Pro Met Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala Lys Ile
885 890 895

Val Thr Ala Glu Thr Gln Asn Ser Ser Phe Ile Ile Asp Gly Pro Ser
900 905 910

Thr Pro Glu Cys Pro Ser Ala Ser Arg Ala Trp Asn Val Trp Glu Val
915 920 925

Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu Lys Leu
930 935 940

Arg Glu Val Tyr Thr Gln Leu Cys Asp His Arg Leu Met Ser Ala Ala
945 950 955 960

Val Lys Asp Glu Arg Ala Val His Ala Asp Met Gly Tyr Trp Ile Glu
965 970 975

Ser Gln Lys Asn Gly Ser Trp Lys Leu Glu Lys Ala Ser Phe Ile Glu
980 985 990

Val Lys Thr Cys Thr Trp Pro Lys Ser His Thr Leu Trp Ser Asn Gly
995 1000 1005

Val Leu Glu Ser Asp Met Ile Ile Pro Lys Ser Leu Ala Gly Pro
1010 1015 1020

Ile Ser Gln His Asn His Arg Pro Gly Tyr His Thr Gln Thr Ala
1025 1030 1035

Gly Pro Trp His Leu Gly Lys Leu Glu Leu Asp Phe Asn Tyr Cys
1040 1045 1050

Glu Gly Thr Thr Val Val Ile Ser Glu Asn Cys Gly Thr Arg Gly
1055 1060 1065

Pro Ser Leu Arg Thr Thr Thr Val Ser Gly Lys Leu Ile His Glu
1070 1075 1080

Trp	Cys	Cys	Arg	Ser	Cys	Thr	Leu	Pro	Pro	Leu	Arg	Tyr	Met	Gly
	1085					1090					1095			
Glu	Asp	Gly	Cys	Trp	Tyr	Gly	Met	Glu	Ile	Arg	Pro	Ile	Asn	Glu
	1100					1105					1110			
Lys	Glu	Glu	Asn	Met	Val	Lys	Ser	Leu	Ala	Ser	Ala	Gly	Ser	Gly
	1115					1120					1125			
Lys	Val	Asp	Asn	Phe	Thr	Met	Gly	Val	Leu	Cys	Leu	Ala	Ile	Leu
	1130					1135					1140			
Phe	Glu	Glu	Val	Met	Arg	Gly	Lys	Phe	Gly	Lys	Lys	His	Met	Ile
	1145					1150					1155			
Ala	Gly	Val	Leu	Phe	Thr	Phe	Val	Leu	Leu	Leu	Ser	Gly	Gln	Ile
	1160					1165					1170			
Thr	Trp	Arg	Asp	Met	Ala	His	Thr	Leu	Ile	Met	Ile	Gly	Ser	Asn
	1175					1180					1185			
Ala	Ser	Asp	Arg	Met	Gly	Met	Gly	Val	Thr	Tyr	Leu	Ala	Leu	Ile
	1190					1195					1200			
Ala	Thr	Phe	Lys	Ile	Gln	Pro	Phe	Leu	Ala	Leu	Gly	Phe	Phe	Leu
	1205					1210					1215			
Arg	Lys	Leu	Thr	Ser	Arg	Glu	Asn	Leu	Leu	Leu	Gly	Val	Gly	Leu
	1220					1225					1230			
Ala	Met	Ala	Ala	Thr	Leu	Arg	Leu	Pro	Glu	Asp	Ile	Glu	Gln	Met
	1235					1240					1245			
Ala	Asn	Gly	Ile	Ala	Leu	Gly	Leu	Met	Ala	Leu	Lys	Leu	Ile	Thr
	1250					1255					1260			
Gln	Phe	Glu	Thr	Tyr	Gln	Leu	Trp	Thr	Ala	Leu	Val	Ser	Leu	Thr
	1265					1270					1275			

Cys Ser Asn Thr Ile Phe Thr Leu Thr Val Ala Trp Arg Thr Ala
1280 1285 1290

Thr Leu Ile Leu Ala Gly Ile Ser Leu Leu Pro Val Cys Gln Ser
1295 1300 1305

Ser Ser Met Arg Lys Thr Asp Trp Leu Pro Met Thr Val Ala Ala
1310 1315 1320

Met Gly Ala Gln Pro Leu Pro Leu Phe Ile Phe Ser Leu Lys Asp
1325 1330 1335

Thr Leu Lys Arg Arg Ser Trp Pro Leu Asn Glu Gly Val Met Ala
1340 1345 1350

Val Gly Leu Val Ser Ile Leu Ala Ser Ser Leu Leu Arg Asn Asp
1355 1360 1365

Val Pro Met Ala Gly Pro Leu Val Ala Gly Gly Leu Leu Ile Ala
1370 1375 1380

Cys Tyr Val Ile Thr Gly Thr Ser Ala Asp Leu Thr Val Glu Lys
1385 1390 1395

Ala Ala Asp Val Thr Trp Glu Glu Glu Ala Glu Gln Thr Gly Val
1400 1405 1410

Ser His Asn Leu Met Val Thr Val Asp Asp Asp Gly Thr Met Arg
1415 1420 1425

Ile Lys Asp Asp Glu Thr Glu Asn Ile Leu Thr Val Leu Leu Lys
1430 1435 1440

Thr Ala Leu Leu Ile Val Ser Gly Ile Phe Pro Tyr Ser Ile Pro
1445 1450 1455

Ala Thr Leu Leu Val Trp His Thr Trp Gln Lys Gln Thr Gln Arg
1460 1465 1470

Ser Gly Val Leu Trp Asp Val Pro Ser Pro Pro Glu Thr Gln Lys
1475 1480 1485

Ala Glu Leu Glu Glu Gly Val Tyr Arg Ile Lys Gln Gln Gly Ile
1490 1495 1500

Phe Gly Lys Thr Gln Val Gly Val Gly Val Gln Lys Glu Gly Val
1505 1510 1515

Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu Thr His
1520 1525 1530

Asn Gly Lys Arg Leu Glu Pro Asn Trp Ala Ser Val Lys Lys Asp
1535 1540 1545

Leu Ile Ser Tyr Gly Gly Gly Trp Arg Leu Ser Ala Gln Trp Gln
1550 1555 1560

Lys Gly Glu Glu Val Gln Val Ile Ala Val Glu Pro Gly Lys Asn
1565 1570 1575

Pro Lys Asn Phe Gln Thr Met Pro Gly Ile Phe Gln Thr Thr Thr
1580 1585 1590

Gly Glu Ile Gly Ala Ile Ala Leu Asp Phe Lys Pro Gly Thr Ser
1595 1600 1605

Gly Ser Pro Ile Ile Asn Arg Glu Gly Lys Val Val Gly Leu Tyr
1610 1615 1620

Gly Asn Gly Val Val Thr Lys Asn Gly Gly Tyr Val Ser Gly Ile
1625 1630 1635

Ala Gln Thr Asn Ala Glu Pro Asp Gly Pro Thr Pro Glu Leu Glu
1640 1645 1650

Glu Glu Met Phe Lys Lys Arg Asn Leu Thr Ile Met Asp Leu His
1655 1660 1665

Pro Gly Ser Gly Lys Thr Arg Lys Tyr Leu Pro Ala Ile Val Arg
1670 1675 1680

Glu Ala Ile Lys Arg Arg Leu Arg Thr Leu Ile Leu Ala Pro Thr
1685 1690 1695

Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Lys Gly Leu Pro
1700 1705 1710

Ile Arg Tyr Gln Thr Thr Ala Thr Lys Ser Glu His Thr Gly Arg
1715 1720 1725

Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg Leu
1730 1735 1740

Leu Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met Asp
1745 1750 1755

Glu Ala His Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly Tyr
1760 1765 1770

Ile Ser Thr Arg Val Gly Met Gly Glu Ala Ala Ala Ile Phe Met
1775 1780 1785

Thr Ala Thr Pro Pro Gly Thr Ala Asp Ala Phe Pro Gln Ser Asn
1790 1795 1800

Ala Pro Ile Gln Asp Glu Glu Arg Asp Ile Pro Glu Arg Ser Trp
1805 1810 1815

Asn Ser Gly Asn Glu Trp Ile Thr Asp Phe Val Gly Lys Thr Val
1820 1825 1830

Trp Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Asn Cys
1835 1840 1845

Leu Arg Lys Asn Gly Lys Lys Val Ile Gln Leu Ser Arg Lys Thr
1850 1855 1860

Phe Asp Thr Glu Tyr Gln Lys Thr Lys Leu Asn Asp Trp Asp Phe
1865 1870 1875

Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Lys Ala
1880 1885 1890

Asp Arg Val Ile Asp Pro Arg Arg Cys Leu Lys Pro Val Ile Leu
1895 1900 1905

Thr Asp Gly Pro Glu Arg Val Ile Leu Ala Gly Pro Met Pro Val
1910 1915 1920

Thr Val Ala Ser Ala Ala Gln Arg Arg Gly Arg Val Gly Arg Asn
1925 1930 1935

Pro Gln Lys Glu Asn Asp Gln Tyr Ile Phe Met Gly Gln Pro Leu
1940 1945 1950

Asn Asn Asp Glu Asp His Ala His Trp Thr Glu Ala Lys Met Leu
1955 1960 1965

Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ala Leu Phe
1970 1975 1980

Glu Pro Glu Arg Glu Lys Ser Ala Ala Ile Asp Gly Glu Tyr Arg
1985 1990 1995

Leu Lys Gly Glu Ser Arg Lys Thr Phe Val Glu Leu Met Arg Arg
2000 2005 2010

Gly Asp Leu Pro Val Trp Leu Ala His Lys Val Ala Ser Glu Gly
2015 2020 2025

Ile Lys Tyr Thr Asp Arg Lys Trp Cys Phe Asp Gly Glu Arg Asn
2030 2035 2040

Asn Gln Ile Leu Glu Glu Asn Met Asp Val Glu Ile Trp Thr Lys
2045 2050 2055

Glu Gly Glu Lys Lys Lys Leu Arg Pro Arg Trp Leu Asp Ala Arg
2060 2065 2070

Thr Tyr Ser Asp Pro Leu Ala Leu Lys Glu Phe Lys Asp Phe Ala
2075 2080 2085

Ala Gly Arg Lys Ser Ile Ala Leu Asp Leu Val Thr Glu Ile Gly
2090 2095 2100

Arg Val Pro Ser His Leu Ala His Arg Thr Arg Asn Ala Leu Asp
2105 2110 2115

Asn Leu Val Met Leu His Thr Ser Glu His Gly Gly Arg Ala Tyr
2120 2125 2130

Arg His Ala Val Glu Glu Leu Pro Glu Thr Met Glu Thr Leu Leu
2135 2140 2145

Leu Leu Gly Leu Met Ile Leu Leu Thr Gly Gly Ala Met Leu Phe
2150 2155 2160

Leu Ile Ser Gly Lys Gly Ile Gly Lys Thr Ser Ile Gly Leu Ile
2165 2170 2175

Cys Val Ile Ala Ser Ser Gly Met Leu Trp Met Ala Asp Val Pro
2180 2185 2190

Leu Gln Trp Ile Ala Ser Ala Ile Val Leu Glu Phe Phe Met Met
2195 2200 2205

Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln Asp
2210 2215 2220

Asn Gln Leu Ala Tyr Val Val Ile Gly Ile Leu Thr Leu Ala Ala
2225 2230 2235

Ile Val Ala Ala Asn Glu Met Gly Leu Leu Glu Thr Thr Lys Arg
2240 2245 2250

Asp Leu Gly Met Ser Lys Glu Pro Gly Val Val Ser Pro Thr Ser
2255 2260 2265

Tyr Leu Asp Val Asp Leu His Pro Ala Ser Ala Trp Thr Leu Tyr
2270 2275 2280

Ala Val Ala Thr Thr Val Ile Thr Pro Met Leu Arg His Thr Ile
2285 2290 2295

Glu Asn Ser Thr Ala Asn Val Ser Leu Ala Ala Ile Ala Asn Gln
2300 2305 2310

Ala Val Val Leu Met Gly Leu Asp Lys Gly Trp Pro Ile Ser Lys
2315 2320 2325

Met Asp Leu Gly Val Pro Leu Leu Ala Leu Gly Cys Tyr Ser Gln
2330 2335 2340

Val Asn Pro Leu Thr Leu Ala Ala Ala Val Leu Leu Leu Val Thr
2345 2350 2355

His Tyr Ala Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr Arg
2360 2365 2370

Glu Ala Gln Lys Arg Thr Ala Ala Gly Ile Met Lys Asn Pro Thr
2375 2380 2385

Val Asp Gly Ile Met Thr Ile Asp Leu Asp Pro Val Ile Tyr Asp
2390 2395 2400

Ser Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val Leu
2405 2410 2415

Cys Ala Val Gln Leu Leu Leu Met Arg Thr Ser Trp Ala Leu Cys
2420 2425 2430

Glu Val Leu Thr Leu Ala Thr Gly Pro Ile Thr Thr Leu Trp Glu
2435 2440 2445

Gly Ser Pro Gly Lys Phe Trp Asn Thr Thr Ile Ala Val Ser Met
2450 2455 2460

Ala Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu Ala
2465 2470 2475

Phe Ser Ile Met Lys Ser Val Gly Thr Gly Lys Arg Gly Thr Gly
2480 2485 2490

Ser	Gln	Gly	Glu	Thr	Leu	Gly	Glu	Lys	Trp	Lys	Lys	Lys	Leu	Asn
	2495					2500					2505			
Gln	Leu	Ser	Arg	Lys	Glu	Phe	Asp	Leu	Tyr	Lys	Lys	Ser	Gly	Ile
	2510					2515					2520			
Thr	Glu	Val	Asp	Arg	Thr	Glu	Ala	Lys	Glu	Gly	Leu	Lys	Arg	Gly
	2525					2530					2535			
Glu	Ile	Thr	His	His	Ala	Val	Ser	Arg	Gly	Ser	Ala	Lys	Leu	Gln
	2540					2545					2550			
Trp	Phe	Val	Glu	Arg	Asn	Met	Val	Ile	Pro	Glu	Gly	Arg	Val	Ile
	2555					2560					2565			
Asp	Leu	Gly	Cys	Gly	Arg	Gly	Gly	Trp	Ser	Tyr	Tyr	Cys	Ala	Gly
	2570					2575					2580			
Leu	Lys	Lys	Val	Thr	Glu	Val	Arg	Gly	Tyr	Thr	Lys	Gly	Gly	Pro
	2585					2590					2595			
Gly	His	Glu	Glu	Pro	Val	Pro	Met	Ser	Thr	Tyr	Gly	Trp	Asn	Ile
	2600					2605					2610			
Val	Lys	Leu	Met	Ser	Gly	Lys	Asp	Val	Phe	Tyr	Leu	Pro	Pro	Glu
	2615					2620					2625			
Lys	Cys	Asp	Thr	Leu	Leu	Cys	Asp	Ile	Gly	Glu	Ser	Ser	Pro	Ser
	2630					2635					2640			
Pro	Thr	Val	Glu	Glu	Ser	Arg	Thr	Ile	Arg	Val	Leu	Lys	Met	Val
	2645					2650					2655			
Glu	Pro	Trp	Leu	Lys	Asn	Asn	Gln	Phe	Cys	Ile	Lys	Val	Leu	Asn
	2660					2665					2670			
Pro	Tyr	Met	Pro	Thr	Val	Ile	Glu	His	Leu	Glu	Arg	Leu	Gln	Arg
	2675					2680					2685			
Lys	His	Gly	Gly	Met	Leu	Val	Arg	Asn	Pro	Leu	Ser	Arg	Asn	Ser
	2690					2695					2700			

Thr His Glu Met Tyr Trp Ile Ser Asn Gly Thr Gly Asn Ile Val
2705 2710 2715

Ser Ser Val Asn Met Val Ser Arg Leu Leu Leu Asn Arg Phe Thr
2720 2725 2730

Met Thr His Arg Arg Pro Thr Ile Glu Lys Asp Val Asp Leu Gly
2735 2740 2745

Ala Gly Thr Arg His Val Asn Ala Glu Pro Glu Thr Pro Asn Met
2750 2755 2760

Asp Val Ile Gly Glu Arg Ile Lys Arg Ile Lys Glu Glu His Ser
2765 2770 2775

Ser Thr Trp His Tyr Asp Asp Glu Asn Pro Tyr Lys Thr Trp Ala
2780 2785 2790

Tyr His Gly Ser Tyr Glu Val Lys Ala Thr Gly Ser Ala Ser Ser
2795 2800 2805

Met Ile Asn Gly Val Val Lys Leu Leu Thr Lys Pro Trp Asp Val
2810 2815 2820

Val Pro Met Val Thr Gln Met Ala Met Thr Asp Thr Thr Pro Phe
2825 2830 2835

Gly Gln Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg Thr Pro
2840 2845 2850

Arg Pro Met Pro Gly Thr Arg Lys Val Met Glu Ile Thr Ala Glu
2855 2860 2865

Trp Leu Trp Arg Thr Leu Gly Arg Asn Lys Arg Pro Arg Leu Cys
2870 2875 2880

Thr Arg Glu Glu Phe Thr Lys Lys Val Arg Thr Asn Ala Ala Met
2885 2890 2895

Gly Ala Val Phe Thr Glu Glu Asn Gln Trp Asp Ser Ala Arg Ala
2900 2905 2910

Ala Val Glu Asp Glu Glu Phe Trp Lys Leu Val Asp Arg Glu Arg
2915 2920 2925

Glu Leu His Lys Leu Gly Lys Cys Gly Ser Cys Val Tyr Asn Met
2930 2935 2940

Met Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys Ala Lys
2945 2950 2955

Gly Ser Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Tyr Leu
2960 2965 2970

Glu Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe Ser
2975 2980 2985

Arg Glu Asn Ser Tyr Ser Gly Val Glu Gly Glu Gly Leu His Lys
2990 2995 3000

Leu Gly Tyr Ile Leu Arg Asp Ile Ser Lys Ile Pro Gly Gly Ala
3005 3010 3015

Met Tyr Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile Thr Glu
3020 3025 3030

Asp Asp Leu His Asn Glu Glu Lys Ile Thr Gln Gln Met Asp Pro
3035 3040 3045

Glu His Arg Gln Leu Ala Asn Ala Ile Phe Lys Leu Thr Tyr Gln
3050 3055 3060

Asn Lys Val Val Lys Val Gln Arg Pro Thr Pro Lys Gly Thr Val
3065 3070 3075

Met Asp Ile Ile Ser Arg Lys Asp Gln Arg Gly Ser Gly Gln Val
3080 3085 3090

Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Ala Gln Leu
3095 3100 3105

Ile Arg Gln Met Glu Gly Glu Gly Val Leu Ser Lys Ala Asp Leu
3110 3115 3120

Glu Asn Pro His Pro Leu Glu Lys Lys Ile Thr Gln Trp Leu Glu
3125 3130 3135

Thr Lys Gly Val Glu Arg Leu Lys Arg Met Ala Ile Ser Gly Asp
3140 3145 3150

Asp Cys Val Val Lys Pro Ile Asp Asp Arg Phe Ala Asn Ala Leu
3155 3160 3165

Leu Ala Leu Asn Asp Met Gly Lys Val Arg Lys Asp Ile Pro Gln
3170 3175 3180

Trp Gln Pro Ser Lys Gly Trp His Asp Trp Gln Gln Val Pro Phe
3185 3190 3195

Cys Ser His His Phe His Glu Leu Ile Met Lys Asp Gly Arg Lys
3200 3205 3210

Leu Val Val Pro Cys Arg Pro Gln Asp Glu Leu Ile Gly Arg Ala
3215 3220 3225

Arg Ile Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys
3230 3235 3240

Leu Gly Lys Ala Tyr Ala Gln Met Trp Ala Leu Met Tyr Phe His
3245 3250 3255

Arg Arg Asp Leu Arg Leu Ala Ser Asn Ala Ile Cys Ser Ala Val
3260 3265 3270

Pro Val His Trp Val Pro Thr Ser Arg Thr Thr Trp Ser Ile His
3275 3280 3285

Ala His His Gln Trp Met Thr Thr Glu Asp Met Leu Thr Val Trp
3290 3295 3300

Asn Arg Val Trp Ile Glu Asp Asn Pro Trp Met Glu Asp Lys Thr
3305 3310 3315

Pro Val Thr Thr Trp Glu Asp Val Pro Tyr Leu Gly Lys Arg Glu
3320 3325 3330

Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr Ser Arg Ala Thr
3335 3340 3345

Trp Ala Gln Asn Ile Leu Thr Ala Ile Gln Gln Val Arg Ser Leu
3350 3355 3360

Ile Gly Asn Glu Glu Phe Leu Asp Tyr Met Pro Ser Met Lys Arg
3365 3370 3375

Phe Arg Lys Glu Glu Glu Ser Glu Gly Ala Ile Trp
3380 3385 3390

<210> 15
<211> 10648
<212> DNA
<213> dengue virus

<400> 15
agttgttagt ctgtgtggac cgacaaggac agttccaaat cggaagcttg cttaacacag 60
ttctaacagt ttgtttgaat agagagcaga tctctggaaa aatgaaccaa cgaaaaaagg 120
tggttagacc acctttcaat atgctgaaac gcgagagaaa ccgcgtatca acccctcaag 180
ggttggtgaa gagatttctca accggacttt tttctgggaa aggaccctta cggatgggtgc 240
tagcattcat cacgtttttg cgagtccttt ccatcccacc aacagcaggg attctgaaaa 300
gatggggaca gttgaagaaa aataaggcca tcaggatact gattggattc aggaaggaga 360
taggccgcat gctgaacatc ttgaacggga gaaaaagggtc aacgataaca ttgctgtgct 420
tgattccac cgtaatggcg tttcacttgt caacaagaga tggcgaaccc ctcgatag 480
tggcacaaaca tgaaaggggg agacctctct tgtttaagac aacagagggg atcaacaaat 540
gcactctcat tgccatggac ttgggtgaaa tgtgtgagga cactgtcacg tataaatgcc 600
ccttactggt caataccgaa cctgaagaca ttgattgctg gtgcaatctc acgtctacct 660
gggtcatgta tgggacatgc acccagagcg gagaacggag acgagagaag cgctcagtag 720

ctttaacacc acattcagga atgggattgg aaacaagagc tgagacatgg atgtcatcgg	780
aaggggcttg gaagcatgct cagagagtag agagctggat actcagaaac ccaggattcg	840
cgctcttggc aggatttatg gcttatatga ttgggcaaac aggaatccag cgaactgtct	900
tctttgtcct aatgatgctg gtcgccccat cctacggaat gcgatgcgta ggagtaggaa	960
acagagactt tgtggaagga gtctcaggtg gagcatgggt cgatctgggtg ctagaacatg	1020
gaggatgcgt cacaaccatg gcccagggaa aaccaacctt ggattttgaa ctgactaaga	1080
caacagccaa ggaagtggct ctgttaagaa cctattgcat tgaagcctca atatcaaaca	1140
taaccacggc aacaagatgt ccaacgcaag gagagcctta tctaaaagag gaacaagacc	1200
aacagtacat ttgccggaga gatgtggtag acagagggtg gggcaatggc tgtggcttgt	1260
ttggaaaagg aggagtgtg acatgtgcga agttttcatg ttcggggaag ataacaggca	1320
atttggtcca aattgagaac cttgaataca cagtggttgt aacagtccac aatggagaca	1380
cccatgcagt aggaaatgac acatccaatc atggagttac agccacgata actcccaggt	1440
caccatcggc ggaagtcaaa ttgccggact atggagaact aacactcgat tgtgaacca	1500
ggtctggaat tgactttaat gagatgattc tgatgaaaat gaaaaagaaa acatggcttg	1560
tgcataagca atggtttttg gatctacctc taccatggac agcaggagca gacacatcag	1620
aggttcactg gaattacaaa gagagaatgg tgacatttaa ggttcctcat gccaagagac	1680
aggatgtgac agtgctggga tctcaggaag gagccatgca ttctgccctc gctggagcca	1740
cagaagtgga ctccggtgat ggaaatcaca tgtttgcagg acatctcaag tgcaaagtcc	1800
gtatggagaa attgagaatc aagggaatgt catacacgat gtgttcagga aagttctcaa	1860
ttgacaaaga gatggcagaa acacagcatg ggacaacagt ggtgaaagtc aagtatgaag	1920
gtgctggagc tccgtgtaaa gtccccatag agataagaga tgtgaacaag gaaaaagtgg	1980
ttgggcgtat catctcatcc acccctttgg ctgagaatac caacagtgca accaacatag	2040
agttagaacc cccctttggg gacagctaca tagtgatagg tgttggaaac agtgcattaa	2100
cactccattg gttcaggaaa gggagttcca ttggcaagat gtttgagtcc acatacagag	2160
gtgcaaacg aatggccatt ctaggtgaaa cagcttggga ttttggttcc gttggtggac	2220
tgttcacatc attgggaaag gctgtgcacc aggtttttgg aagtgtgtat acaaccatgt	2280
ttggaggagt ctcatggatg attagaatcc taattgggtt cctagtgttg tggattggca	2340

cgaactcaag gaacacttca atggctatga cgtgcatagc tgttggagga atcactctgt	2400
ttctgggctt cacagttcaa gcagacatgg gttgtgtggt gtcattggagt gggaaagaat	2460
tgaagtgtgg aagcgggaatt tttgtggttg acaacgtgca cacttggaca gaacagtaca	2520
aatttcaacc ggagtcccca gcgagactag cgtctgcaat attgaatgcc caciaaatg	2580
gggtctgtgg aattagatca accacgaggc tggaaaatgt catgtggaag caaataacca	2640
acgagctaaa ttatgttctc tgggaaggag gacatgacct cactgtagtg gctggggatg	2700
tgaaggggggt gttgaccaa ggcaagagag cactcacacc cccagtgaat gatctgaaat	2760
attcatggaa gacatgggga aaagcaaaaa tcttcacccc agaagcaaga aatagcacat	2820
ttttaataga cggaccagac acctccgaat gcccgaatga acgaagagca tggaactttc	2880
ttgaggtgga agactatgga tttggcatgt tcacgaccaa catatggatg aaattccgag	2940
aaggaagttc agaagtgtgt gaccacaggt taatgtcagc ggcaattaaa gatcagaaag	3000
ctgtgcatgc tgacatgggt tattggatag agagctcaaa aaaccagacc tggcagatag	3060
agaaagcatc tcttattgaa gtgaaaacat gtctgtggcc caagaccac acattgtgga	3120
gcaatggagt gctggaaagc cagatgctca ttccaaaatc atatgcgggc cttttttcac	3180
agcacaatta ccgccagggc tatgccacgc aaaccgtggg cccatggcac ttaggcaa	3240
tagagataga ctttggagaa tgccccgga caacagtcgc aattcaggag gattgtgacc	3300
atagaggccc atctttgagg accaccactg catctggaaa actagtcacg caatggtgct	3360
gccgctcctg cacgatgcct cccttaaggt tcttgggaga agatgggtgc tggatatgga	3420
tggagattag gcccttgagt gaaaaagaag agaacatggt caaatcacag gtaacggccg	3480
gacagggcac atcagaaact ttttctatgg gtctgtttgt cctgacctg tttgtggaag	3540
aatgcttgag gagaagagtc actaggaaac acatgatatt gggtgtggtg atcactctt	3600
gtgcatcat cctaggaggc ctcacatgga tggacttact acgagccctc atcatgttg	3660
gggacactat gtctggtaga ataggaggac agatccacct agccatcatg gcagtgttca	3720
agatgtcacc aggatacgtg ctgggtgtgt ttttaaggaa actcacttca agagagacag	3780
cactaatggt aataggaatg gccatgacaa cggtgctttc aattccacat gaccttatg	3840
aactcattga tggaatatca ctggggctaa ttttgctaaa aatagtgaca cttttgaca	3900
acaccaagt gggaacctta gccctttcct tgaccttcat aagatcaaca atgccattg	3960

tcatggcttg	gaggaccatt	atggctgtgt	tgtttgtggt	cacactcatt	cctttgtgca	4020
ggacaagctg	tcttcaaaaa	cagtctcatt	gggtagaaat	aacagcactc	atcctaggag	4080
cccaagctct	gccagtgtac	ctaatagactc	ttatgaaagg	agcctcaaga	agatcttggc	4140
ctcttaacga	gggcataatg	gctgtgggtt	tggttagtct	cttaggaagc	gctcttttaa	4200
agaatgatgt	cccttttagct	ggcccaatgg	tggcaggagg	cttacttctg	gcggcttacg	4260
tgatgagtgg	tagctcagca	gatctgtcac	tagagaaggc	cgccaatgtg	cagtgggatg	4320
aaatggcaga	cataacaggc	tcaagcccaa	tcatagaagt	gaagcaggat	gaagatggct	4380
ctttctccat	acgggacgtc	gaggaaacca	atatgataac	ccttttggtg	aaactggcac	4440
tgataacagt	gtcaggtctc	tacccttgg	caattccagt	cacaatgacc	ttatggtaca	4500
tgtggcaagt	gaaaacacaa	agatcaggag	ccctgtggga	cgtcccctca	cccgctgcca	4560
ctcaaaaagc	cgcactgtct	gaaggagtgt	acaggatcat	gcaaagaggg	ttatttggga	4620
aaactcaggt	tggagtaggg	atacacatgg	aaggtgtatt	tcacacaatg	tggcatgtaa	4680
caagaggatc	agtgatctgc	catgagactg	ggagattgga	gccatcttgg	gctgacgtca	4740
ggaatgacat	gatatcatac	ggtgggggat	ggagacttgg	agacaaatgg	gacaaagaag	4800
aagatgttca	ggtcctcgcc	atagaaccag	gaaaaaatcc	taaacatgtc	caaacgaaac	4860
ccggcctttt	caagacccta	actggagaaa	ttggagcagt	aacattagat	ttcaaaccgg	4920
gaacgtctgg	ttctcccatc	atcaacagga	aaggaaaagt	catcggactc	tatggaaatg	4980
gagtagttac	caaatcaggt	gattacgtca	gtgccataac	gcaagccgaa	agaattggag	5040
agccagatta	tgaagtggat	gaggacattt	ttcgaaagaa	aagattaact	ataatggact	5100
tacaccccg	agctggaaag	acaaaaagaa	ttcttccatc	aatagtgaga	gaagccttaa	5160
aaaggaggct	gcgaaccttg	atcttggctc	ccacgagagt	ggtggcggcc	gagatggaag	5220
aggccctacg	tggactgcca	atccgttatc	agaccccagc	tgtgaaatca	gaacacacag	5280
gaagagagat	tgtagacctc	atgtgtcatg	caaccttcac	aacaagactt	ttgtcatcaa	5340
ccagagttcc	aaattacaac	ctcatagtga	tggatgaagc	acatttcacc	gaccttcta	5400
gtgtcgcggc	tagaggatac	atctcgacca	gggtggaaat	gggagaggca	gcagccatct	5460
tcatgaccgc	aaccctccc	ggagcgacag	atccctttcc	ccagagcaac	agcccaatag	5520
aagacatcga	gagggaaatt	ccggaaaggt	catggaacac	agggttcgac	tggataacag	5580

actaccaagg gaaaactgtg tggtttgttc ccagcataaa agctggaaat gacattgcaa	5640
attgtttgag aaagtcggga aagaaagtta tccagttgag taggaaaacc tttgatacag	5700
agtatccaaa aacgaaactc acggactggg attttgtggt cactacagac atatctgaaa	5760
tgggggccaa ttttagagct gggagagtga tagaccctag gagatgcctc aagccagtta	5820
tcctaacaga tgggccagag agagtcattt tagcagggtcc tattccagtg actccagcaa	5880
gcgctgctca gagaagaggg cgaataggaa ggaaccagc acaagaagac gaccaatacg	5940
ttttctccgg agaccacta aaaaatgatg aagatcatgc ccactggaca gaagcaaaga	6000
tgctgcttga caatatctac accccagaag ggatcattcc aacattgttt ggtccggaag	6060
gggaaaaaac ccaagccatt gatggagagt ttcgcctcag aggggaacaa aggaagactt	6120
ttgtggaatt aatgaggaga ggagaccttc cgggtgtggct gagctataag gtagcttctg	6180
ctggcatttc ttacaaagat cgggaatggg gcttcacagg ggaaaggaat aaccaaattt	6240
tagaagaaaa catggaggtt gaaatttgga ctagagaggg agaaaagaaa aagctaaggc	6300
caagatgggt agatgcacgt gtatacgtg accccatggc tttgaaggat ttaaggagt	6360
ttgctagtgg aaggaagagc ataactctcg acatcctaac agagattgcc agtttgccaa	6420
cttacctttc ctctagggcc aagctcgccc ttgataacat agtcatgctc cacacaacag	6480
aaagaggagg gagggcctac caacacgccc tgaacgaact cccggagtca ctggaaacac	6540
ttatgcttgt agctttacta ggtgctatga cagcaggat cttcctgttt ttcattgcaag	6600
ggaaaggaat agggaaattg tcaatgggtt tgataaccat tgcgggtggct agtggcttgc	6660
tctgggtagc agaaattcaa cccagtgga tagcggcctc aatcatacta gagttttttc	6720
tcatggtact gttgataccg gaaccagaaa aacaaaggac cccacaagac aatcaattga	6780
tctacgtcat attgaccatt ctcaccatta ttggtctcat agcagccaac gagatggggc	6840
tgattgaaaa aacaaaaacg gatthttgggt tttaccagggt aaaaacagaa accaccatcc	6900
tcgatgtgga cttgagacca gcttcagcat ggacgctcta tgcagtagcc accacaattc	6960
tgactcccat gctgagacac accatagaaa acacgtcggc caacctatct ctagcagcca	7020
ttgccaacca ggcggccgtc ctaatggggc ttggaaaagg atggccgctc cacagaatgg	7080
acctcgggtg gccgctgtta gcaatgggat gctatttctca agtgaacca acaactttga	7140
cagcatcctt agtcatgctt ttagtccatt atgcaataat aggtccagga ttgcaggcaa	7200

aagccacaag	agaggcccag	aaaaggacag	ctgctgggat	catgaaaaac	cccacggtgg	7260
acgggataac	agtaatagat	ctagaaccaa	tatcctatga	cccaaaattt	gaaaagcaat	7320
tagggcaggt	catgctactc	gtcttgtgtg	ctggacaact	actcttgatg	agaacaacat	7380
gggctttctg	tgaagtcttg	actttggcca	caggaccaat	cttgaccttg	tgggagggca	7440
acccgggaag	gttttggaac	acgaccatag	ccgtatccac	cgccaacatt	ttcaggggaa	7500
gttacctggc	gggagctgga	ctggcttttt	cactcataaa	gaatgtacaa	acccctagga	7560
ggggaactgg	gaccacagga	gagacactgg	gagagaagtg	gaagagacag	ctaaactcat	7620
tagacagaaa	agagtttgaa	gagtataaaa	gaagtggaat	actagaagtg	gacaggactg	7680
aagccaagtc	tgccctgaaa	gatgggtcta	aaatcaagca	tgcagtatct	agagggtcca	7740
gtaagattag	atggattgtt	gagagaggga	tggtaaagcc	aaaagggaaa	gttgtagatc	7800
ttggctgtgg	gagaggagga	tggctttatt	acatggcgac	gctcaagaac	gtgactgaag	7860
tgaaagggtg	tacaaaagga	ggtccaggac	atgaagaacc	gattcccatg	gctacttatg	7920
gctggaattt	ggtcaaactc	cattcagggg	ttgacgtgtt	ctacaaaccc	acagagcaag	7980
tggacaccct	gctctgtgat	attggggagt	catcttctaa	tccaacaata	gaggaaggaa	8040
gaacattaag	agttttgaag	atggtggagc	catggctctc	ttcaaaacct	gaattctgca	8100
tcaaagtcct	taacccttac	atgccaacag	tcatagaaga	gctggagaaa	ctgcagagaa	8160
aacatggtgg	gaaccttgtc	agatgcccgc	tgtccaggaa	ctccacccat	gagatgtatt	8220
gggtgtcagg	agcgtcggga	aacattgtga	gctctgtgaa	cacaacatca	aagatgttgt	8280
tgaacaggtt	cacaacaagg	cataggaaac	ccacttatga	gaaggacgta	gatcttgggg	8340
caggaacgag	aagtgtctcc	actgaaacag	aaaaaccaga	catgacaatt	attgggagaa	8400
ggcttcagcg	attgcaagag	gagcacaaaag	aaacctggca	ttatgatcag	gaaaacccat	8460
acagaacctg	ggcgtatcat	ggaagctatg	aagctccttc	gacaggctct	gcatcctcca	8520
tggtgaacgg	ggtagtaaaa	ctgctaacaa	aaccttggga	tgtggttcca	atggtgacct	8580
agttagccat	gacagacaca	accccttttg	ggcaacaaag	agtgttcaaa	gagaaggtgg	8640
ataccagaac	accacaacca	aaaccgggta	cacgaatggg	tatgaccacg	acagccaatt	8700
ggctgtgggc	cctccttggg	aagaagaaaa	atcccagact	gtgcacaagg	gaagagttca	8760
tctcaaaagt	tagatcaaac	gcagccatag	gcgcagtctt	tcaggaagaa	cagggatgga	8820

catcagccag tgaagctgtg aatgacagcc ggTTTTggga actggttgac aaagaaaggg	8880
ccctacacca ggaagggaaa tgtgaatcgt gtgtctacaa catgatggga aaacgtgaga	8940
aaaagttagg agagtttggc agagccaagg gaagccgagc aatctggtac atgtggctgg	9000
gagcgcggtt tctggaattt gaagccctgg gttttttgaa tgaagatcac tggtttggca	9060
gagaaaattc atggagtgga gtggaagggg aaggctctgca cagattggga tatatcctgg	9120
aggagataga caagaaggat ggagacctaa tgtatgctga tgacacagca ggctgggaca	9180
caagaatcac tgaggatgac cttcaaaatg aagaactgat cacggaacag atggcccccc	9240
accacaagat cctagccaaa gccattttca aactaaccta tcaaaacaaa gtggtgaaag	9300
tcctcagacc cacaccgaga ggagcgggtga tggatatcat atccaggaaa gaccaaagag	9360
gtagtggaca agttggaaca tatggtttga acacattcac caacatggaa gttcaactca	9420
tccgccaaat ggaagctgaa ggagtcatca cacaagatga catgcagaac caaaagggt	9480
tgaaagaaag agttgagaaa tggctgaaag agtgtggtgt cgacaggtta aagaggatgg	9540
caatcagtgg agacgattgc gtggtgaagc ccctggatga gaggtttggc acttccctcc	9600
tcttcttgaa cgacatggga aaggtaggga aagacattcc gcagtgggaa ccatctaagg	9660
gatggaaaaa ctggcaagag gttccttttt gctcccacca ctttcacaag atcttcatga	9720
aggatggccg ctactagtt gttccatgta gaaaccagga tgaactgata gggagagcca	9780
gaatctcgca gggggctgga tggagcttaa gagaaacagc ctgcctgggc aaagcttacg	9840
cccagatgtg gtcgctcatg tacttccaca gaagggatct gcgttttagcc tccatggcca	9900
tatgctcagc agttccaacg gaatggtttc caacaagcag aacaacatgg tcaatccacg	9960
ctcatcatca gtggatgacc actgaagata tgctcaaagt gtggaacaga gtgtggatag	10020
aagacaacc taatatgact gacaagactc cagtccattc gtgggaagat ataccttacc	10080
tagggaaaag agaggatttg tgggtgtggat ccctgattgg actttcttcc agagccacct	10140
gggcgaagaa cattcacacg gccataacc aggtcagaaa cctgatcgga aaagaggaat	10200
acgtggatta catgccagta atgaaaagat acagcgctcc ttcagagagt gaaggagttc	10260
tgtaattacc aacaacaaac accaaaggct attgaagtca ggccacttgt gccacggctt	10320
gagcaaaccg tgctgcctgt agctccgcca ataatgggag gcgtgaaatc ctagggagg	10380
ccatgcgcca cggaagctgt acgcgtggca tattggacta gcggttagag gagaccctc	10440

ccatcactga caaaacgcag caaaaggggg cccgaagcca ggaggaagct gtactcctgg 10500
 tggaaggact agaggttaga ggagaccccc ccaacacaaa aacagcatat tgacgctggg 10560
 aaagaccaga gatcctgctg tctctgcaac atcaatccag gcacagagcg ccgcaagatg 10620
 gattggtggtt gttgatccaa caggttct 10648

<210> 16
 <211> 3387
 <212> PRT
 <213> dengue virus

<400> 16

Met Asn Gln Arg Lys Lys Val Val Arg Pro Pro Phe Asn Met Leu Lys
 1 5 10 15

Arg Glu Arg Asn Arg Val Ser Thr Pro Gln Gly Leu Val Lys Arg Phe
 20 25 30

Ser Thr Gly Leu Phe Ser Gly Lys Gly Pro Leu Arg Met Val Leu Ala
 35 40 45

Phe Ile Thr Phe Leu Arg Val Leu Ser Ile Pro Pro Thr Ala Gly Ile
 50 55 60

Leu Lys Arg Trp Gly Gln Leu Lys Lys Asn Lys Ala Ile Arg Ile Leu
 65 70 75 80

Ile Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn Gly
 85 90 95

Arg Lys Arg Ser Thr Ile Thr Leu Leu Cys Leu Ile Pro Thr Val Met
 100 105 110

Ala Phe His Leu Ser Thr Arg Asp Gly Glu Pro Leu Met Ile Val Ala
 115 120 125

Lys His Glu Arg Gly Arg Pro Leu Leu Phe Lys Thr Thr Glu Gly Ile
 130 135 140

Asn Lys Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Met Cys Glu Asp
 145 150 155 160

Thr Val Thr Tyr Lys Cys Pro Leu Leu Val Asn Thr Glu Pro Glu Asp
165 170 175

Ile Asp Cys Trp Cys Asn Leu Thr Ser Thr Trp Val Met Tyr Gly Thr
180 185 190

Cys Thr Gln Ser Gly Glu Arg Arg Arg Glu Lys Arg Ser Val Ala Leu
195 200 205

Thr Pro His Ser Gly Met Gly Leu Glu Thr Arg Ala Glu Thr Trp Met
210 215 220

Ser Ser Glu Gly Ala Trp Lys His Ala Gln Arg Val Glu Ser Trp Ile
225 230 235 240

Leu Arg Asn Pro Gly Phe Ala Leu Leu Ala Gly Phe Met Ala Tyr Met
245 250 255

Ile Gly Gln Thr Gly Ile Gln Arg Thr Val Phe Phe Val Leu Met Met
260 265 270

Leu Val Ala Pro Ser Tyr Gly Met Arg Cys Val Gly Val Gly Asn Arg
275 280 285

Asp Phe Val Glu Gly Val Ser Gly Gly Ala Trp Val Asp Leu Val Leu
290 295 300

Glu His Gly Gly Cys Val Thr Thr Met Ala Gln Gly Lys Pro Thr Leu
305 310 315 320

Asp Phe Glu Leu Thr Lys Thr Thr Ala Lys Glu Val Ala Leu Leu Arg
325 330 335

Thr Tyr Cys Ile Glu Ala Ser Ile Ser Asn Ile Thr Thr Ala Thr Arg
340 345 350

Cys Pro Thr Gln Gly Glu Pro Tyr Leu Lys Glu Glu Gln Asp Gln Gln
355 360 365

Tyr Ile Cys Arg Arg Asp Val Val Asp Arg Gly Trp Gly Asn Gly Cys
370 375 380

Gly Leu Phe Gly Lys Gly Gly Val Val Thr Cys Ala Lys Phe Ser Cys
385 390 395 400

Ser Gly Lys Ile Thr Gly Asn Leu Val Gln Ile Glu Asn Leu Glu Tyr
405 410 415

Thr Val Val Val Thr Val His Asn Gly Asp Thr His Ala Val Gly Asn
420 425 430

Asp Thr Ser Asn His Gly Val Thr Ala Thr Ile Thr Pro Arg Ser Pro
435 440 445

Ser Val Glu Val Lys Leu Pro Asp Tyr Gly Glu Leu Thr Leu Asp Cys
450 455 460

Glu Pro Arg Ser Gly Ile Asp Phe Asn Glu Met Ile Leu Met Lys Met
465 470 475 480

Lys Lys Lys Thr Trp Leu Val His Lys Gln Trp Phe Leu Asp Leu Pro
485 490 495

Leu Pro Trp Thr Ala Gly Ala Asp Thr Ser Glu Val His Trp Asn Tyr
500 505 510

Lys Glu Arg Met Val Thr Phe Lys Val Pro His Ala Lys Arg Gln Asp
515 520 525

Val Thr Val Leu Gly Ser Gln Glu Gly Ala Met His Ser Ala Leu Ala
530 535 540

Gly Ala Thr Glu Val Asp Ser Gly Asp Gly Asn His Met Phe Ala Gly
545 550 555 560

His Leu Lys Cys Lys Val Arg Met Glu Lys Leu Arg Ile Lys Gly Met
565 570 575

Ser Tyr Thr Met Cys Ser Gly Lys Phe Ser Ile Asp Lys Glu Met Ala
580 585 590

Glu Thr Gln His Gly Thr Thr Val Val Lys Val Lys Tyr Glu Gly Ala
595 600 605

Gly Ala Pro Cys Lys Val Pro Ile Glu Ile Arg Asp Val Asn Lys Glu
610 615 620

Lys Val Val Gly Arg Ile Ile Ser Ser Thr Pro Leu Ala Glu Asn Thr
625 630 635 640

Asn Ser Ala Thr Asn Ile Glu Leu Glu Pro Pro Phe Gly Asp Ser Tyr
645 650 655

Ile Val Ile Gly Val Gly Asn Ser Ala Leu Thr Leu His Trp Phe Arg
660 665 670

Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ser Thr Tyr Arg Gly Ala
675 680 685

Lys Arg Met Ala Ile Leu Gly Glu Thr Ala Trp Asp Phe Gly Ser Val
690 695 700

Gly Gly Leu Phe Thr Ser Leu Gly Lys Ala Val His Gln Val Phe Gly
705 710 715 720

Ser Val Tyr Thr Thr Met Phe Gly Gly Val Ser Trp Met Ile Arg Ile
725 730 735

Leu Ile Gly Phe Leu Val Leu Trp Ile Gly Thr Asn Ser Arg Asn Thr
740 745 750

Ser Met Ala Met Thr Cys Ile Ala Val Gly Gly Ile Thr Leu Phe Leu
755 760 765

Gly Phe Thr Val Gln Ala Asp Met Gly Cys Val Val Ser Trp Ser Gly
770 775 780

Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Val Asp Asn Val His
785 790 795 800

Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ala Arg Leu
805 810 815

Ala Ser Ala Ile Leu Asn Ala His Lys Asp Gly Val Cys Gly Ile Arg
820 825 830

Ser Thr Thr Arg Leu Glu Asn Val Met Trp Lys Gln Ile Thr Asn Glu
835 840 845

Leu Asn Tyr Val Leu Trp Glu Gly Gly His Asp Leu Thr Val Val Ala
850 855 860

Gly Asp Val Lys Gly Val Leu Thr Lys Gly Lys Arg Ala Leu Thr Pro
865 870 875 880

Pro Val Asn Asp Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala Lys
885 890 895

Ile Phe Thr Pro Glu Ala Arg Asn Ser Thr Phe Leu Ile Asp Gly Pro
900 905 910

Asp Thr Ser Glu Cys Pro Asn Glu Arg Arg Ala Trp Asn Phe Leu Glu
915 920 925

Val Glu Asp Tyr Gly Phe Gly Met Phe Thr Thr Asn Ile Trp Met Lys
930 935 940

Phe Arg Glu Gly Ser Ser Glu Val Cys Asp His Arg Leu Met Ser Ala
945 950 955 960

Ala Ile Lys Asp Gln Lys Ala Val His Ala Asp Met Gly Tyr Trp Ile
965 970 975

Glu Ser Ser Lys Asn Gln Thr Trp Gln Ile Glu Lys Ala Ser Leu Ile
980 985 990

Glu Val Lys Thr Cys Leu Trp Pro Lys Thr His Thr Leu Trp Ser Asn
995 1000 1005

Gly Val Leu Glu Ser Gln Met Leu Ile Pro Lys Ser Tyr Ala Gly
1010 1015 1020

Pro Phe Ser Gln His Asn Tyr Arg Gln Gly Tyr Ala Thr Gln Thr
1025 1030 1035

Val Gly Pro Trp His Leu Gly Lys Leu Glu Ile Asp Phe Gly Glu
1040 1045 1050

Cys Pro Gly Thr Thr Val Ala Ile Gln Glu Asp Cys Asp His Arg
1055 1060 1065

Gly Pro Ser Leu Arg Thr Thr Thr Ala Ser Gly Lys Leu Val Thr
1070 1075 1080

Gln Trp Cys Cys Arg Ser Cys Thr Met Pro Pro Leu Arg Phe Leu
1085 1090 1095

Gly Glu Asp Gly Cys Trp Tyr Gly Met Glu Ile Arg Pro Leu Ser
1100 1105 1110

Glu Lys Glu Glu Asn Met Val Lys Ser Gln Val Thr Ala Gly Gln
1115 1120 1125

Gly Thr Ser Glu Thr Phe Ser Met Gly Leu Leu Cys Leu Thr Leu
1130 1135 1140

Phe Val Glu Glu Cys Leu Arg Arg Arg Val Thr Arg Lys His Met
1145 1150 1155

Ile Leu Val Val Val Ile Thr Leu Cys Ala Ile Ile Leu Gly Gly
1160 1165 1170

Leu Thr Trp Met Asp Leu Leu Arg Ala Leu Ile Met Leu Gly Asp
1175 1180 1185

Thr Met Ser Gly Arg Ile Gly Gly Gln Ile His Leu Ala Ile Met
1190 1195 1200

Ala Val Phe Lys Met Ser Pro Gly Tyr Val Leu Gly Val Phe Leu
1205 1210 1215

Arg Lys Leu Thr Ser Arg Glu Thr Ala Leu Met Val Ile Gly Met
1220 1225 1230

Ala Met Thr Thr Val Leu Ser Ile Pro His Asp Leu Met Glu Leu
1235 1240 1245

Ile Asp Gly Ile Ser Leu Gly Leu Ile Leu Leu Lys Ile Val Thr
1250 1255 1260

His Phe Asp Asn Thr Gln Val Gly Thr Leu Ala Leu Ser Leu Thr
1265 1270 1275

Phe Ile Arg Ser Thr Met Pro Leu Val Met Ala Trp Arg Thr Ile
1280 1285 1290

Met Ala Val Leu Phe Val Val Thr Leu Ile Pro Leu Cys Arg Thr
1295 1300 1305

Ser Cys Leu Gln Lys Gln Ser His Trp Val Glu Ile Thr Ala Leu
1310 1315 1320

Ile Leu Gly Ala Gln Ala Leu Pro Val Tyr Leu Met Thr Leu Met
1325 1330 1335

Lys Gly Ala Ser Arg Arg Ser Trp Pro Leu Asn Glu Gly Ile Met
1340 1345 1350

Ala Val Gly Leu Val Ser Leu Leu Gly Ser Ala Leu Leu Lys Asn
1355 1360 1365

Asp Val Pro Leu Ala Gly Pro Met Val Ala Gly Gly Leu Leu Leu
1370 1375 1380

Ala Ala Tyr Val Met Ser Gly Ser Ser Ala Asp Leu Ser Leu Glu
1385 1390 1395

Lys Ala Ala Asn Val Gln Trp Asp Glu Met Ala Asp Ile Thr Gly
1400 1405 1410

Ser Ser Pro Ile Ile Glu Val Lys Gln Asp Glu Asp Gly Ser Phe
1415 1420 1425

Ser Ile Arg Asp Val Glu Glu Thr Asn Met Ile Thr Leu Leu Val
1430 1435 1440

Lys Leu Ala Leu Ile Thr Val Ser Gly Leu Tyr Pro Leu Ala Ile
1445 1450 1455

Pro Val Thr Met Thr Leu Trp Tyr Met Trp Gln Val Lys Thr Gln
1460 1465 1470

Arg Ser Gly Ala Leu Trp Asp Val Pro Ser Pro Ala Ala Thr Gln
1475 1480 1485

Lys Ala Ala Leu Ser Glu Gly Val Tyr Arg Ile Met Gln Arg Gly
1490 1495 1500

Leu Phe Gly Lys Thr Gln Val Gly Val Gly Ile His Met Glu Gly
1505 1510 1515

Val Phe His Thr Met Trp His Val Thr Arg Gly Ser Val Ile Cys
1520 1525 1530

His Glu Thr Gly Arg Leu Glu Pro Ser Trp Ala Asp Val Arg Asn
1535 1540 1545

Asp Met Ile Ser Tyr Gly Gly Gly Trp Arg Leu Gly Asp Lys Trp
1550 1555 1560

Asp Lys Glu Glu Asp Val Gln Val Leu Ala Ile Glu Pro Gly Lys
1565 1570 1575

Asn Pro Lys His Val Gln Thr Lys Pro Gly Leu Phe Lys Thr Leu
1580 1585 1590

Thr Gly Glu Ile Gly Ala Val Thr Leu Asp Phe Lys Pro Gly Thr
1595 1600 1605

Ser Gly Ser Pro Ile Ile Asn Arg Lys Gly Lys Val Ile Gly Leu
1610 1615 1620

Tyr Gly Asn Gly Val Val Thr Lys Ser Gly Asp Tyr Val Ser Ala
1625 1630 1635

Ile Thr Gln Ala Glu Arg Ile Gly Glu Pro Asp Tyr Glu Val Asp
1640 1645 1650

Glu Asp Ile Phe Arg Lys Lys Arg Leu Thr Ile Met Asp Leu His
1655 1660 1665

Pro Gly Ala Gly Lys Thr Lys Arg Ile Leu Pro Ser Ile Val Arg
1670 1675 1680

Glu Ala Leu Lys Arg Arg Leu Arg Thr Leu Ile Leu Ala Pro Thr
1685 1690 1695

Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly Leu Pro
1700 1705 1710

Ile Arg Tyr Gln Thr Pro Ala Val Lys Ser Glu His Thr Gly Arg
1715 1720 1725

Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Thr Arg Leu
1730 1735 1740

Leu Ser Ser Thr Arg Val Pro Asn Tyr Asn Leu Ile Val Met Asp
1745 1750 1755

Glu Ala His Phe Thr Asp Pro Ser Ser Val Ala Ala Arg Gly Tyr
1760 1765 1770

Ile Ser Thr Arg Val Glu Met Gly Glu Ala Ala Ala Ile Phe Met
1775 1780 1785

Thr Ala Thr Pro Pro Gly Ala Thr Asp Pro Phe Pro Gln Ser Asn
1790 1795 1800

Ser Pro Ile Glu Asp Ile Glu Arg Glu Ile Pro Glu Arg Ser Trp
1805 1810 1815

Asn Thr Gly Phe Asp Trp Ile Thr Asp Tyr Gln Gly Lys Thr Val
1820 1825 1830

Trp Phe Val Pro Ser Ile Lys Ala Gly Asn Asp Ile Ala Asn Cys
1835 1840 1845

Leu Arg Lys Ser Gly Lys Lys Val Ile Gln Leu Ser Arg Lys Thr
1850 1855 1860

Phe Asp Thr Glu Tyr Pro Lys Thr Lys Leu Thr Asp Trp Asp Phe
1865 1870 1875

Val Val Thr Thr Asp Ile Ser Glu Met Gly Ala Asn Phe Arg Ala
1880 1885 1890

Gly Arg Val Ile Asp Pro Arg Arg Cys Leu Lys Pro Val Ile Leu
1895 1900 1905

Thr Asp Gly Pro Glu Arg Val Ile Leu Ala Gly Pro Ile Pro Val
1910 1915 1920

Thr Pro Ala Ser Ala Ala Gln Arg Arg Gly Arg Ile Gly Arg Asn
1925 1930 1935

Pro Ala Gln Glu Asp Asp Gln Tyr Val Phe Ser Gly Asp Pro Leu
1940 1945 1950

Lys Asn Asp Glu Asp His Ala His Trp Thr Glu Ala Lys Met Leu
1955 1960 1965

Leu Asp Asn Ile Tyr Thr Pro Glu Gly Ile Ile Pro Thr Leu Phe
1970 1975 1980

Gly Pro Glu Arg Glu Lys Thr Gln Ala Ile Asp Gly Glu Phe Arg
1985 1990 1995

Leu Arg Gly Glu Gln Arg Lys Thr Phe Val Glu Leu Met Arg Arg
2000 2005 2010

Gly Asp Leu Pro Val Trp Leu Ser Tyr Lys Val Ala Ser Ala Gly
2015 2020 2025

Ile Ser Tyr Lys Asp Arg Glu Trp Cys Phe Thr Gly Glu Arg Asn
2030 2035 2040

Asn Gln Ile Leu Glu Glu Asn Met Glu Val Glu Ile Trp Thr Arg
2045 2050 2055

Glu Gly Glu Lys Lys Lys Leu Arg Pro Arg Trp Leu Asp Ala Arg
2060 2065 2070

Val Tyr Ala Asp Pro Met Ala Leu Lys Asp Phe Lys Glu Phe Ala
2075 2080 2085

Ser Gly Arg Lys Ser Ile Thr Leu Asp Ile Leu Thr Glu Ile Ala
2090 2095 2100

Ser Leu Pro Thr Tyr Leu Ser Ser Arg Ala Lys Leu Ala Leu Asp
2105 2110 2115

Asn Ile Val Met Leu His Thr Thr Glu Arg Gly Gly Arg Ala Tyr
2120 2125 2130

Gln His Ala Leu Asn Glu Leu Pro Glu Ser Leu Glu Thr Leu Met
2135 2140 2145

Leu Val Ala Leu Leu Gly Ala Met Thr Ala Gly Ile Phe Leu Phe
2150 2155 2160

Phe Met Gln Gly Lys Gly Ile Gly Lys Leu Ser Met Gly Leu Ile
2165 2170 2175

Thr Ile Ala Val Ala Ser Gly Leu Leu Trp Val Ala Glu Ile Gln
2180 2185 2190

Pro Gln Trp Ile Ala Ala Ser Ile Ile Leu Glu Phe Phe Leu Met
2195 2200 2205

Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln Asp
2210 2215 2220

Asn Gln Leu Ile Tyr Val Ile Leu Thr Ile Leu Thr Ile Ile Gly
2225 2230 2235

Leu Ile Ala Ala Asn Glu Met Gly Leu Ile Glu Lys Thr Lys Thr
2240 2245 2250

Asp Phe Gly Phe Tyr Gln Val Lys Thr Glu Thr Thr Ile Leu Asp
2255 2260 2265

Val Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu Tyr Ala Val Ala
2270 2275 2280

Thr Thr Ile Leu Thr Pro Met Leu Arg His Thr Ile Glu Asn Thr
2285 2290 2295

Ser Ala Asn Leu Ser Leu Ala Ala Ile Ala Asn Gln Ala Ala Val
2300 2305 2310

Leu Met Gly Leu Gly Lys Gly Trp Pro Leu His Arg Met Asp Leu
2315 2320 2325

Gly Val Pro Leu Leu Ala Met Gly Cys Tyr Ser Gln Val Asn Pro
2330 2335 2340

Thr Thr Leu Thr Ala Ser Leu Val Met Leu Leu Val His Tyr Ala
2345 2350 2355

Ile Ile Gly Pro Gly Leu Gln Ala Lys Ala Thr Arg Glu Ala Gln
2360 2365 2370

Lys Arg Thr Ala Ala Gly Ile Met Lys Asn Pro Thr Val Asp Gly
2375 2380 2385

Ile Thr Val Ile Asp Leu Glu Pro Ile Ser Tyr Asp Pro Lys Phe
2390 2395 2400

Glu Lys Gln Leu Gly Gln Val Met Leu Leu Val Leu Cys Ala Gly
2405 2410 2415

Gln Leu Leu Leu Met Arg Thr Thr Trp Ala Phe Cys Glu Val Leu
2420 2425 2430

Thr Leu Ala Thr Gly Pro Ile Leu Thr Leu Trp Glu Gly Asn Pro
2435 2440 2445

Gly Arg Phe Trp Asn Thr Thr Ile Ala Val Ser Thr Ala Asn Ile
2450 2455 2460

Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu Ala Phe Ser Leu
2465 2470 2475

Ile Lys Asn Val Gln Thr Pro Arg Arg Gly Thr Gly Thr Thr Gly
2480 2485 2490

Glu Thr Leu Gly Glu Lys Trp Lys Arg Gln Leu Asn Ser Leu Asp
2495 2500 2505

Arg Lys Glu Phe Glu Glu Tyr Lys Arg Ser Gly Ile Leu Glu Val
2510 2515 2520

Asp Arg Thr Glu Ala Lys Ser Ala Leu Lys Asp Gly Ser Lys Ile
2525 2530 2535

Lys His Ala Val Ser Arg Gly Ser Ser Lys Ile Arg Trp Ile Val
2540 2545 2550

Glu Arg Gly Met Val Lys Pro Lys Gly Lys Val Val Asp Leu Gly
2555 2560 2565

Cys Gly Arg Gly Gly Trp Ser Tyr Tyr Met Ala Thr Leu Lys Asn
2570 2575 2580

Val Thr Glu Val Lys Gly Tyr Thr Lys Gly Gly Pro Gly His Glu
2585 2590 2595

Glu Pro Ile Pro Met Ala Thr Tyr Gly Trp Asn Leu Val Lys Leu
2600 2605 2610

His Ser Gly Val Asp Val Phe Tyr Lys Pro Thr Glu Gln Val Asp
2615 2620 2625

Thr Leu Leu Cys Asp Ile Gly Glu Ser Ser Ser Asn Pro Thr Ile
2630 2635 2640

Glu Glu Gly Arg Thr Leu Arg Val Leu Lys Met Val Glu Pro Trp
2645 2650 2655

Leu Ser Ser Lys Pro Glu Phe Cys Ile Lys Val Leu Asn Pro Tyr
2660 2665 2670

Met Pro Thr Val Ile Glu Glu Leu Glu Lys Leu Gln Arg Lys His
2675 2680 2685

Gly Gly Asn Leu Val Arg Cys Pro Leu Ser Arg Asn Ser Thr His
2690 2695 2700

Glu Met Tyr Trp Val Ser Gly Ala Ser Gly Asn Ile Val Ser Ser
2705 2710 2715

Val Asn Thr Thr Ser Lys Met Leu Leu Asn Arg Phe Thr Thr Arg
2720 2725 2730

His Arg Lys Pro Thr Tyr Glu Lys Asp Val Asp Leu Gly Ala Gly
2735 2740 2745

Thr Arg Ser Val Ser Thr Glu Thr Glu Lys Pro Asp Met Thr Ile
2750 2755 2760

Ile Gly Arg Arg Leu Gln Arg Leu Gln Glu Glu His Lys Glu Thr
2765 2770 2775

Trp His Tyr Asp Gln Glu Asn Pro Tyr Arg Thr Trp Ala Tyr His
2780 2785 2790

Gly Ser Tyr Glu Ala Pro Ser Thr Gly Ser Ala Ser Ser Met Val
2795 2800 2805

Asn Gly Val Val Lys Leu Leu Thr Lys Pro Trp Asp Val Val Pro
2810 2815 2820

Met Val Thr Gln Leu Ala Met Thr Asp Thr Thr Pro Phe Gly Gln
2825 2830 2835

Gln Arg Val Phe Lys Glu Lys Val Asp Thr Arg Thr Pro Gln Pro
2840 2845 2850

Lys Pro Gly Thr Arg Met Val Met Thr Thr Thr Ala Asn Trp Leu
2855 2860 2865

Trp Ala Leu Leu Gly Lys Lys Lys Asn Pro Arg Leu Cys Thr Arg
2870 2875 2880

Glu Glu Phe Ile Ser Lys Val Arg Ser Asn Ala Ala Ile Gly Ala
2885 2890 2895

Val Phe Gln Glu Glu Gln Gly Trp Thr Ser Ala Ser Glu Ala Val
2900 2905 2910

Asn Asp Ser Arg Phe Trp Glu Leu Val Asp Lys Glu Arg Ala Leu
2915 2920 2925

His Gln Glu Gly Lys Cys Glu Ser Cys Val Tyr Asn Met Met Gly
2930 2935 2940

Lys Arg Glu Lys Lys Leu Gly Glu Phe Gly Arg Ala Lys Gly Ser
2945 2950 2955

Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Phe Leu Glu Phe
2960 2965 2970

Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe Gly Arg Glu
2975 2980 2985

Asn Ser Trp Ser Gly Val Glu Gly Glu Gly Leu His Arg Leu Gly
2990 2995 3000

Tyr Ile Leu Glu Glu Ile Asp Lys Lys Asp Gly Asp Leu Met Tyr
3005 3010 3015

Ala Asp Asp Thr Ala Gly Trp Asp Thr Arg Ile Thr Glu Asp Asp
3020 3025 3030

Leu Gln Asn Glu Glu Leu Ile Thr Glu Gln Met Ala Pro His His
3035 3040 3045

Lys Ile Leu Ala Lys Ala Ile Phe Lys Leu Thr Tyr Gln Asn Lys
3050 3055 3060

Val Val Lys Val Leu Arg Pro Thr Pro Arg Gly Ala Val Met Asp
3065 3070 3075

Ile Ile Ser Arg Lys Asp Gln Arg Gly Ser Gly Gln Val Gly Thr
3080 3085 3090

Tyr Gly Leu Asn Thr Phe Thr Asn Met Glu Val Gln Leu Ile Arg
3095 3100 3105

Gln Met Glu Ala Glu Gly Val Ile Thr Gln Asp Asp Met Gln Asn
3110 3115 3120

Pro Lys Gly Leu Lys Glu Arg Val Glu Lys Trp Leu Lys Glu Cys
3125 3130 3135

Gly Val Asp Arg Leu Lys Arg Met Ala Ile Ser Gly Asp Asp Cys
3140 3145 3150

Val Val Lys Pro Leu Asp Glu Arg Phe Gly Thr Ser Leu Leu Phe
3155 3160 3165

Leu Asn Asp Met Gly Lys Val Arg Lys Asp Ile Pro Gln Trp Glu
3170 3175 3180

Pro Ser Lys Gly Trp Lys Asn Trp Gln Glu Val Pro Phe Cys Ser
3185 3190 3195

His His Phe His Lys Ile Phe Met Lys Asp Gly Arg Ser Leu Val
3200 3205 3210

Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg Ala Arg Ile
3215 3220 3225

Ser Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys Leu Gly
3230 3235 3240

Lys Ala Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe His Arg Arg
3245 3250 3255

Asp Leu Arg Leu Ala Ser Met Ala Ile Cys Ser Ala Val Pro Thr
3260 3265 3270

Glu Trp Phe Pro Thr Ser Arg Thr Thr Trp Ser Ile His Ala His
3275 3280 3285

His Gln Trp Met Thr Thr Glu Asp Met Leu Lys Val Trp Asn Arg
3290 3295 3300

Val Trp Ile Glu Asp Asn Pro Asn Met Thr Asp Lys Thr Pro Val
3305 3310 3315

His Ser Trp Glu Asp Ile Pro Tyr Leu Gly Lys Arg Glu Asp Leu
3320 3325 3330

Trp Cys Gly Ser Leu Ile Gly Leu Ser Ser Arg Ala Thr Trp Ala
3335 3340 3345

Lys Asn Ile His Thr Ala Ile Thr Gln Val Arg Asn Leu Ile Gly
3350 3355 3360

Lys Glu Glu Tyr Val Asp Tyr Met Pro Val Met Lys Arg Tyr Ser
3365 3370 3375

Ala Pro Ser Glu Ser Glu Gly Val Leu
3380 3385